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Abstract 
Introduction and Aims: The progressive nature of heart failure (HF) is reflected by its 
complex pathophysiology, featured by imbalance of damaging and reparative factors. The 
overall aim was to assess the implication of endothelial (dys)function, monocyte subsets, 
different types of endothelial progenitors and plasma microparticles in subjects with HF. A 
special focus was an investigation of possible ethnic differences in these parameters. 
Methods: Parameters of vascular function, monocyte subsets, endothelial progenitors, and 
cellular microparticles were compared between South Asian subjects with systolic HF, and 
those with heart disease without HF and healthy controls. Ethnic differences in HF were 
assessed in three ethnic groups: South Asians, Whites, and African-Caribbeans. 
Additionally, leukocyte counts were compared between subjects with HF with reduced or 
preserved ejection fraction, whose outcome (mortality) was recorded during follow-up. 
Results: South Asian subjects with HF had significantly impaired micro- and 
macrovascular endothelial function, reduced levels of endothelial progenitors, and 
monocytes with reparative potential, but increased levels of microparticles. In HF patients, 
a high count of monocyte microparticles was associated with low ejection fraction. 
There were significant ethnic differences in characteristics of microvascular endothelial 
function, counts of CD14++CD16+ and CD14+CD16++ monocytes and monocyte-derived 
endothelial progenitors. On multivariate analysis, a high monocyte count was a significant 
predictor of death in HF with preserved ejection fraction unlike in those with systolic HF. 
Conclusions: Significant impairment of microvascular endothelial function is present in 
South Asian subjects with HF. High monocyte count is an independent predictor of death 
in HF with preserved ejection fraction. The value of the tested biological markers as 
therapeutic targets should be explored in future studies. 
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CHAPTER I. INTRODUCTION 
 
Heart failure (HF) is a common cardiovascular disorder with a complex aetiology and 
pathogenesis. In the countries members of the European Society of Cardiology there are at 
least 15 million patients who have symptomatic HF.
1-4
 Also there could be a similar 
number of subjects with asymptomatic left ventricular (LV) dysfunction with the overall 
prevalence of HF estimated to be about 4% of the population.
1
 However even these high 
numbers may underestimate the real scale of the problem. Recent guidelines of the 
European Society of Cardiology highlight that the diagnosis of HF is not always reported 
by clinicians, being considered as a condition secondary to the other disorders.
1
 The 
worldwide prevalence of HF is still growing with the ageing population, and better 
immediate survival of patients with acute coronary events.
2-3
 
 
HF is often associated with substantial disability and poor quality of life. At present about 
5% of all acute hospital admissions are related to HF, and about 2% of national health 
budgets are attributable to the costs associated with HF management.
4
 Despite 
improvements in available therapies and revascularization, the mortality of patients with 
HF remains high. Available data suggest that about half of HF patients die within 4 years 
of the diagnosis, with even worse prognosis (i.e. approximately 40% within 1 year) in 
those admitted to hospital with acute decompensation of HF.
3, 5-6
 
 
Evidence exists that there may be epidemiological and pathophysiological differences 
between patients with systolic HF from different ethnic groups.
7
 People of South Asian 
(SA) origin (i.e. those originating from India, Pakistan, and Bangladesh) represent one of 
22 
 
the world biggest ethnic groups and the largest ethnic minority group in the United 
Kingdom.
8
 Importantly, there are significant differences in the pattern of cardiovascular 
morbidity in SA patients.
7
 For example, SA patients with coronary artery disease (CAD) 
have 40-50% higher mortality compared to CAD patients from the white population.
9-10
 
Given that CAD is a major cause of HF this might partly account for the higher prevalence 
of HF in SAs.
11
 HF in SAs develops at a younger age and results in 60% more 
hospitalizations compared to subjects of other ethnic origins.
12
 Additionally, SAs have 
been under-represented in majority of clinical trials on HF.
13
 However, treatments effective 
in white subjects may not be equally effective in patients from other ethnic groups, which 
may affect their prognosis.
14-15
 Given the limited data available on the pathogenesis of HF 
in SAs this high risk community has received a specific focus in the thesis. However the 
possibility of ethnic differences in mechanisms of HF was assessed in the major ethnic 
groups represented in Birmingham, thatare whites, SAs and African-Caribbeans. 
 
Persistently high morbidity and mortality in patients with HF is likely to reflect the 
complex pathophysiology of the disorder. HF is no longer regarded as a purely cardiac 
problem, but rather a systemic disorder associated with various, initially adaptive and 
consequently detrimental, neurohormonal and inflammatory compensatory processes.
16
 
The knowledge of the pathophysiology and management of HF has significantly improved 
during the last decades. However despite modern medical interventions targeting 
neurohormonal activation, mortality and morbidity related to HF remains considerably 
high.
16
 An approach aiming comprehensive neurohormonal blockade has reached its limits 
of effectiveness and new treatment targets have to be identified in relation to the complex 
pathophysiological nature of HF. 
23 
 
 
HF is a functional consequence of a wide range of disorders. A number of diverse and 
potentially modifiable pathological pathways contribute to the development and 
progression of HF. These mechanisms include structural and functional cardiac 
abnormalities, but also vascular damage and endothelial dysfunction, and inflammation.  
 
The prominent regulatory activity of the vascular endothelium in HF was discovered about 
two decades ago, and its assessment in different aspects of cardiovascular medicine in 
general and in HF particularly has been the focus of intense research.
17-19
 Indeed, various 
aspects of endothelial function are affected in HF including vasomotor, haemostatic, 
antioxidant and inflammatory activities. Differences also exist in the pattern of endothelial 
function depending on aetiology, severity and stability of HF in individual patients. 
Accumulating evidence also suggests a prognostic value of different measures of 
endothelial dysfunction in HF. Furthermore, a number of therapeutic interventions and 
regular exercise can improve endothelial function in HF.
20-21
 Healthy subjects of SA origin 
have been shown to have abnormal endothelial function compared with white subjects.
22
 
However the status of endothelial/vascular function in SAs with HF and ethnic differences 
in these parameters in HF have not been explored. These issues were addressed in this 
study aiming to employ a holistic approach to the problem with micro- and macrovascular 
endothelial function addressed as well as arterial stiffness assessed in the study 
populations. 
 
Inflammation is an important mechanism of endothelial dysfunction and part of ischaemia-
induced myocardial damage. Inflammation has also been shown to be implicated in the 
24 
 
progression of HF.
23-24
 Monocytes are a type of blood cells which is actively involved in 
various inflammatory processes in addition to their phagocytic capacity and the role in the 
innate immunity.
25-26
 These cells are equipped with various scavenger receptors (e.g., 
scavenger receptor class A type I [SR-AI, CD204], haptoglobin [CD163]) for removal of 
biological substances from the circulation and tissues.
27-28
 SR-AI is involved in lipid 
accumulation (by macrophages) and atherogenesis, but there are emerging data to 
implicate this receptor in a number of reparative processes, such as clearance of apoptotic 
cells, attenuation of oxidative stress and inflammation.
29-33
 The number of monocytes 
expressing SR-AI is increased in patients with acute coronary syndrome (ACS), but limited 
data are available on monocyte SR-AI expression in HF.
34-35
 
 
Monocytes can also be considered as the largest pool of the circulating progenitor cells, 
with potential to migrate into tissues and differentiate into macrophages and dendritic cells. 
Additionally, monocytes include a proportion of pluripotent progenitors with impressive 
developmental plasticity.
36-37
 Monocytes are actively involved in angiogenesis and repair 
and appear to constitute a major subset of endothelial progenitor cells.
38-40
 This functional 
diversity is partly attributable to the existence of several monocyte subsets.  
 
Indeed, mice have been shown to include a specific monocyte subset able to repopulate 
damaged myocardial tissue in a model of myocardial infarction (MI) and this subset was 
associated with a better myocardial recovery and angiogenesis.
41
 However, humans do not 
have exact equivalents of mouse monocyte markers and subsets, which makes direct 
comparisons between mouse and human monocytes problematic.
25
 Until recently, human 
monocytes were described as two subsets, on the basis of the surface expression of CD14 
25 
 
and CD16. They included the CD14++CD16– subset (comprises about 85% of total 
monocytes) and the CD14+CD16+ subset (usually <15% of total monocytes).
42
 
Importantly, whilst mouse data on Ly-6C
hi
 monocytes appear to concord with those on 
human CD14++CD16– subset, studies on human CD16+ monocytes demonstrate little, if 
any agreement with mouse Ly-6C
lo
 monocytes. This raises the possibility that the profile 
and functions of human monocyte subsets have more differences to their mouse 
counterparts than currently known.
41-43
 
 
“In previous research I have observed that among CD16+ monocytes there were two 
different populations not formally recognised at that time.
40
 These two subsets differed by 
their expression of CD14 (i.e., those expression high or low levels of the marker), and were 
defined as CD14++CD16+ and CD14+CD16+ cells, respectively.
40, 44-45
 This definition of 
monocyte subsets based on three populations was used for the assessment of the 
implication of monocyte subsets in HF. More recently the existence of these three human 
monocyte subsets has been accepted in the consensus on monocyte nomenclature.
46
 
According to this concensus monocyte subsets should be defined as ‘classical’ 
CD14++CD16–, ‘intermediate’ CD14++CD16+, and ‘non-classical’ CD14+CD16+ 
populations. Additionally it was suggested that addition of CCR2 as an additional marker 
might improve the subset discrimination in the future, which was confirmed by my work. 
 
Circulating cellular microparticles, which are small submicron anucleoid phospholipid 
vesicles released from different cells (e.g., platelets, endothelial cells, leukocytes) have 
recently emerged as important messengers of cellular signals.
47
 Indeed, microparticles 
carry surface proteins and contain cytoplasmic material of the parental cells which mediate 
26 
 
numerous biological effects of microparticles on the target cells.
48
 Circulating 
microparticles have been implicated in various cardiovascular disorders, partly due to their 
prothrombotic and proinflammatory properties.
47, 49
 
 
However only scarce data are available at present on the involvement of individual 
monocyte subsets, monocyte-derived angiogenic cells and plasma microparticles in HF and 
information on possible ethnic differences in these parameters is lacking. Accordingly 
these aspects of HF pathophysiology have been addressed in this thesis (Chapter III). 
 
Although the role of different monocyte subsets in cardiovascular pathology is increasingly 
recognised, advances in the field are hampered by the methodological limitations, 
particularly in relation to definition of minor monocyte subsets. Discrimination of CD16-
expressing monocytes based on their CD14/CD16 density is problematic due to a 
substantial overlap in density of these receptors on their surface. This makes accurate 
characterization of phenotype and functional status of individual subsets difficult, and 
results in almost unavoidable contamination with other subsets upon isolation for in vitro 
experiments. Thus there is a pressing need for additional markers or a new highly specific 
marker, which would allow unambiguous discrimination of individual monocyte subsets.  
 
The problem related to definition of monocyte subsets is further amplified by ability of 
monocytes to rapidly change their phenotype during their activation, maturation and 
differentiation towards macrophages, dendritic and other cells. Thus there is a possibility 
of up- or down-regulation on CD14 or CD16 expression on individual subsets, which may 
lead to their wrong assignment to another subset. Although this problem is perhaps less 
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important for analysis of fresh whole blood samples, adding an additional marker or 
discovery of constitutively expressed parameter(s) is desirable for in vitro experiments. 
 
 Accordingly in a separate part of my thesis (Chapter IV) I aimed to identify markers 
which would allow researchers to unequivocally define human monocyte subsets. In that 
chapter I also aimed to shed some further light on the phenotype and functionality of 
monocyte subsets. Additionally, the effect of diurnal variation, physical exercise and delay 
in sample preparation has been addressed in this part of the study. 
 
The clinical importance of HF with preserved ejection fraction (HFpEF) —as contrasted to 
HF with reduced ejection fraction (HFrEF)— is increasingly acknowledged and this 
condition is considered as an emerging problem of cardiovascular medicine.
50
 The 
prevalence of HFpEF is growing rapidly and it is expected to become a dominant form of 
HF in the near future.
51
 Despite the increasing appreciation of the problem and recognition 
of the comparably poor outcome of the two forms of HF, the pathophysiological 
mechanisms of HFpEF are still poorly understood.
52-53
 Specifically, very scarce 
information is available on the role of monocytes and other leukocytes in HFpEF. 
 
From clinical diagnostic point of view these two forms of HF can be clearly discriminated, 
and have different and mutually exclusive diagnostic criteria (i.e., LVEF <50% in HFrEF 
vs. ≥50% in HFpEF according to the current guidelines)
1
. Patients with systolic HF 
predominantly have ischemic background, whilst HFpEF is more linked to hypertension. 
Of note, treatments well established in systolic HF have not necessarily been effective in 
HFpEF. However there is a certain overlap between these conditions. In fact, features of 
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diastolic dysfunction (a hallmark of HFpEF) are present in majority of subjects with 
systolic HF. Also the currently used cut-off level for ‘normal’ LVEF is rather consensus-
based and signs of mild abnormalities of systolic cardiac function have been reported in 
HFpEF.
52
 Although limited data are currently available on the rate of progression from 
HFpEF to HFrEF, it is apparent that a fraction of patients with HFpEF can consequently 
develop HFrEF. 
 
Also, it is still debated on how closely pathological mechanisms of HFpEF are related to 
those with HFrEF. The role of inflammation has been suggested for both conditions, but 
possible difference between the two disorders in monocytes and other leukocytes has not 
yet been assessed. I aimed to address these issues in a separate study presented in Chapter 
V. In that study levels of blood leukocytes and their impact on outcome in HFrEF and 
HFpEF has been evaluated in another population with a high risk of cardiovascular 
disorders in Belarus. 
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CHAPTER II. LITERATURE REVIEW 
 
2.1. Heart failure in South Asians 
2.1.1. Search strategy 
 
Published data for this review were identified by searches of PUBMED (from 1980 - ); 
reference lists from relevant articles as well as authors personal lists. Searches were 
concentrated on the following key words: (a) ‘heart failure’ AND one of the following 
terms ‘South Asian’, ‘South Asians’ – , ‘India’ – , ‘Indian’ – , ‘Pakistan’ – , ‘Pakistani’ , 
‘Bangladesh’, ‘Bangladeshi’ . 
(b) ‘left ventricular systolic dysfunction’ AND one of the following terms ‘South Asian’ , 
‘South Asians’ , ‘India’ , ‘Indian’ , ‘Pakistan’ , ‘Pakistani’ , ‘Bangladesh’ , ‘Bangladeshi’ .  
Total number of identified manuscripts after removal of duplicates – 131. 
 
Manual analysis of these publications selected original clinical studies relevant to 
pathogenetic, diagnostic, prognostic and therapeutic aspects of systolic HF (left ventricular 
[LV] ejection fraction [EF] <50% was used as a threshold) and included data on patients of 
SA origin identified 13 relevant studies.
12, 54-66
 Analysis of references included in these 
publications identified additional 7 papers.
66-72
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2.1.2. Prevalence of heart failure 
 
Data on the prevalence of HF amongst SAs in Europe is sparse with majority of studies 
evaluating hospital admission rates.  
 
Population-based studies on HF prevalence have limited number of participants from the 
Indian subcontinent. For example, in the Echocardiographic Heart of England Screening 
study 1.8% of 6286 randomly selected patients (3960 responders) aged ≥45 years with 
LVEF<40%.
66
 Among patients with LVSD 47% were asymptomatic; 4% of the screened 
population had mildly impaired LV function with EF 40-50%. However, SAs only formed 
0.7% of the sample and no data were provided to characterize HF by ethnic group. 
 
Galasko et al. assessed LV function in 734 patients aged ≥45 years from 7 geographically 
and socioeconomically representative general practices in Harrow and included 216 non-
White subjects, mainly of SA origin (Table 1).
54
 LVSD with EF <45% was documented in 
3.3% of SAs with no differences seen between the SA and White ethnic groups.
 
 
In a hospital based study by Blackledge et al. the crude annual admission rates/ 10 000 
population were significantly higher for both SA men (161 vs.101 for white men) and SA 
women (144 vs. 93 for white women).
12
 Differences in crude incidence rates (first 
admission) were less noticeable (56 vs. 44 for SA and white men, and 43 vs. 41 for SA and 
white women, respectively), indicative of the high rates of repeated hospital admissions 
related to HF attributable to SA origin.
12
 In this study, SAs were on average 8 years 
younger. 
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compared to Whites with a higher proportion of men (56.5%).
12
 This was also the case for 
one study from Canada.
55
In a multiethnic population in Singapore (Chinese 77%, Malay 
14%, Indians 8%) the incidence of hospital admissions for congestive HF was significantly 
higher (by about 35%) in both Malays and Indians than in Chinese.
56 
 
2.1.3. Aetiology of heart failure 
 
CAD is a major cause of HF amongst SAs.
54, 76-77
 Indeed, SAs develop more extensive MI 
at a younger age than the general population.
78
 A history of MI, prior to the first admission 
for HF (10.1%) or the presence of acute MI at time of the first admission for HF (18.8%) 
was much more common in SAs (10.1% and 18.8%, respectively) than in white subjects 
(5.5% and 10.7%, respectively).
55 
 
The high rate of CAD among SAs corresponds to higher prevalence of cardiovascular risk 
factors,
57
 diabetes,
12
 and possibly hypertension.
55, 79-80
 They also display a characteristic 
dyslipidaemia pattern with relatively normal total cholesterol, low HDL cholesterol and 
high triglycerides.
55
 In a recent analysis of 1668 consecutive South East Asian patients 
with congestive HF (EF 28±12%) in Singapore, 50.2% were found to be diabetic and 65% 
had ischaemic cardiomyopathy.
81
 Diabetes was identified as an independent predictor of 
ischaemic cardiomyopathy (odds ratio=1.85, p=0.01) and all-cause mortality (odds 
ratio=1.70, p=0.01) in patients of SA origin.
81
 In contrast, smoking is less common among 
SAs with HF compared to other ethnic groups.
56 
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A non-ischaemicaetiology of HF is perhaps less typical for SAs. For example, 18% of 
white patients and none of the SA subjects have been reported to have alcoholic 
cardiomyopathy as the primary aetiology of LVSD.
54
 This corresponds to a significantly 
lower frequency of heavy alcohol intake found among SAs.
58, 82
 Additionally, atrial 
fibrillation is about twice as common in Whites than in SA patients (31% vs. 15%), 
although SAs are more likely to experience ventricular arrhythmias.
56, 67
 Accordingly, 
white subjects with HF more frequently have atrial arrhythmias, both before or at the time 
of admission for HF.
55
 
 
Of note, the pattern of HF aetiologyin SAs appears to be different between SAs living in 
India and those who have migrated to the UK. In a small study of 125 consecutive patients 
admitted to the Government Medical College in Nagpur (India) with the clinical diagnosis 
of HF, Joshi et al.
68
 found that rheumatic heart disease was the most common aetiology 
(52%) followed by ischaemic and/or hypertensive heart disease (27%), thus reflecting the 
impact of socio-economical differences on the profile of HF morbidity. However, a 
predominantly ischaemicaetiology (i.e., 77%) was reported in Pakistan.
76
 
 
Of note, the approach used to determine aetiology of HF is important for comparison of the 
results from different studies. However such details often omitted in the manuscripts 
reviewed and this should be considered during interpretation of their findings. 
 
Are ethnic differences associated with HF in SA patients related to any specific genetically 
determined defect? At present there is no definitive answer to this question, but 
polygenetic differences are most likely. For example, a deletion of 25 bp in the gene 
36 
 
encoding cardiac myosin binding protein C, a key constituent of the thick filaments 
localized to doublets in the C-zone of the A-band of the sarcomere, is common in Indians 
(2% to 8% of the population), and causes disorganization of sarcomeric structure; there is 
an association with inheritable cardiomyopathies and an increased risk of HF in Indian 
populations (odds ratio = 6.99, p<0.05).
59-60, 83
 
 
In the subanalysis of the large (about 30000 participants) ethnic population-based the 
London Life Sciences Prospective Population (LOLIPOP) study, echocardiograms were 
analysed in a sub-set of 458 healthy individuals. Compared to Whites, SAs had 
significantly higher body mass index, fasting triglycerides and lower HDL-cholesterol, 
whilst blood pressure and fasting glucose levels did not differ significantly between the 
two groups. Although LVEF was similar in both groups, Whites had significantly greater 
left atrial volumes, LV mass and volumes even after indexation for body size. However, 
apparently healthy SAs had significantly lower mitral annular systolic velocity (8.9 cm/s 
vs. 9.5 cm/s, p<0.001) and a higher E/E’ ratio (7.9 vs. 7.0, p<0.001 compared to Whites) 
thus indicating subtle features of reduced systolic and diastolic cardiac performance.
61
 
Additionally, SAs have a greater degree of concentric remodelling with significantly 
higher relative wall thickness. Multivariate models confirm that ethnicity remains 
independently associated with differences in LV volume and mass as well as in left atrial 
volume and relative mass index. It is still a matter of speculation on which specific genetic, 
environmental (e.g., increase stress) or behavioral (e.g., cultural) factors promote these 
differences as well as whether these differences are associated with a higher risk of 
clinically significant HF.
61
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Finally, albumin excretion is much higher in SAs than in Whites independently of older 
age, hypertension and diabetes.
84
 Patients with HF of any cause are known to have elevated 
homocysteine levels, a risk factor for CAD that may contribute to an unfavourable 
prognosis, and several studies in the UK and other western countries have reported 
increased homocysteine levels amongst SAs compared to Whites or African-Caribbeans.
62, 
85
 However, Sosin et al. have recently demonstrated that there were no inter-ethnic 
differences in homocysteine levels nor in serum folate or B12 concentrations.
69 
 
2.1.4. Clinical characteristics of heart failure 
 
Despite the substantially more frequent hospital admissions and higher prevalence of CAD, 
SA patients with HF more often have preserved LV systolic function than Whites (38% vs. 
23%, respectively).
67
 Severe LVSD was found in 28% of Whites compared to 18% of SA 
patients.
58
 Accordingly, a higher prevalence of diastolic dysfunction in SAs has been 
suggested but not well documented.
63
 
 
One may speculate that higher hospitalization rates among SAs may be associated with co-
morbidities such as diabetes mellitus. Even despite presenting at a younger age, SAs have 
more high-risk features at hospital discharge.
12, 81
 For example, SA patients with HF had 
significantly lower levels of hemoglobin and higher levels of urinary albumin excretion.
67, 
84
 Renal damage may partly be associated with a higher prevalence of diabetes mellitus in 
SAs and represent an additional cardiovascular risk factor. SA patients with mild-to-
moderate congestive HF also have higher plasma leptin levels compared to white patients, 
which were associated with insulin resistance.
75
 In contrast, serum adiponectin levels 
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showed no ethnic variation, but were associated with congestive HF and a previous history 
of MI, irrespective of ethnic origin.
75 
 
2.1.5. Drug management of heart failure 
 
There is a dearth of specific data on effectiveness of different drugs for HF in the SA 
population. An analysis of 59 randomized controlled trials in HF revealed marked ethnic 
variations of patients included, with under-representation of SA subjects.
13
 Importantly, 
there was no significant improvement in the representation of the ethnic minorities in large 
clinical trials during the last two decades. Thus, the applicability of recommendations 
developed on white patients to all other ethnic groups can be debated. In clinical practice, 
SAs have been reported to receive beta-blockers, calcium antagonists (i.e., reflecting more 
prominent hypertensive status) and nitrates more often than white patients, whilst loop 
diuretics were less frequently required at admission.
67
 Rates of discharge prescription of 
diuretics, beta-blockers and renin–angiotensin system antagonists did not differ 
significantly.
67
 The rate of revascularisation procedures appears to be higher among SA 
patients, reflecting the higher prevalence of CAD.
67 
 
2.1.6. Hospital admissions 
 
Elderly SAs aged between 60 and 79 years have a five-fold higher risk of presenting with 
HF at hospital than their white counterparts.
70
 Of note, hospital admissions for congestive 
HF were about 35% higher in Indians than in Chinese, but mortality was similar in Indians 
and Chinese.
56 
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The exact reasons for more hospital admissions in SA patients with HF in Europe are not 
clear but may be attributable to more pronounced diastolic HF, adverse co-morbidity (e.g., 
hypertension, diabetes mellitus, and CAD) or poorer compliance with treatment, as well as 
other reasons.
12, 57
 Indeed, only 50.4% of patients with HF in Nagpur (India) were 
compliant with their prescribed diet or drug therapy.
86
 Also, 64.7% of Indo-Asians felt that 
God/fate controlled their health rather than reliance on doctors.
74
 In this study, the majority 
of Indo-Asians (61.8%) were not aware of their primary diagnosis of HF and 3 times more 
often than whites did not have enough information about their drugs.
 
 
2.1.7. Prognosis 
 
Despite a higher age-adjusted prevalence, greater hospitalization rate and worse risk factor 
profile, SA patients with HF appear to have much better prognosis than white patients. 
Unadjusted in-hospital case fatality rates are lower in SA patients than in Whites (i.e., 13% 
vs. 19%).
12, 67
 Indeed, the 30 day, one year, and two year survival rates are also 
consistently better amongst SAs.
12, 67
 Multivariate analysis has also confirmed an 
independent association of SA ethnicity with better prognosis in HF.
12, 67
 Indeed, the better 
prognosis in SA patients may be associated with a lower rate of significant impairment of 
LV contractility, but when patients with preserved LV function were analyzed separately 
similar outcomes were registered irrespective of ethnic origin. 
 
Among factors affecting outcome, age is the most important with a 44% increase in the 
risk of death per decade of life.  Lower systolic blood pressure, renal impairment and 
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history of stroke were the strongest predictors of fatality rate in SAs.
12
 A diagnosis of 
concomitant acute MI was associated with a much poorer event free survival.
12
 Higher 
creatinine and lower hemoglobin levels at admission were each associated with adverse 
outcomes in SAs, although the strength of such association was statistically weaker than 
for white patients.
67
 High glucose concentrations at admission were associated with poor 
outcome and remained independently predictive of adverse events among HF patients 
discharged without any treatment for diabetes.
67
 
 
Interestingly, no significant relation was found between social deprivation and outcome for 
patients with HF in the UK. In fact, patients living in the most disadvantaged areas had 
lower mortality that may reflect the free health service in the UK with ability to provide 
additional support and more often hospitalizations to socially deprived patients.
12
 In 
contrast to data from the United Kingdom, a retrospective sequential chart review of SAs 
and non-SA Whites in Canada hospitalized with a primary diagnosis of congestive HF 
showed in-hospital mortality to be similar in the ethnic groups.
55 
 
In Singapore, mortality from congestive HF was 3.5 times higher in Malays, but was about 
the same in Indians and Chinese. Over the period from 1991 to 1998, mortality from HF 
declined in both Chinese and Indians, but rose in Malays.
56
 Another study of 225 patients 
with HF with LVEF <40% found proportionally more Malay and Indian patients admitted 
for HF than Chinese patients; of this cohort, 67.5% of discharged patients died at 5 years 
and predictors of mortality were female gender, aged ≥70 years, renal impairment, NYHA 
class III or IV, and lack of treatment with angiotensin converting enzyme inhibitors.
65
 
 
41 
 
Prognosis in SA patients with HF failure may also differ in relation to health service 
provision in different countries. For example, data from a tertiary care hospital in Pakistan 
reported that 27.5% patients admitted with HF died and 52% experienced a combined 
event of death or repeat hospitalization for HF during 1-year follow-up.
76, 81
 
 
2.1.8. The developmental origins of adult cardiovascular disease 
 
During the last decades accumulating data led to introduction of a paradigm of the 
developmental origins of adult disease. The concept of epigenetic modifications was 
originally developed by Barker and colleagues based on epidemiological links found 
between lower birthweight and a higher risk of cardiovascular death and type 2 diabetes in 
adulthood.
87-88
 The concept, also known as the thrifty phenotype model states that the fetus 
can trigger in utero adaptations to survive environmental stresses, such as maternal 
undernutrition.
89
 Restriction of the fetal growth is one of many responses, which can 
involve some organs or the whole body. However, the presumable benefits in the deprived 
environment can negatively affect the organism wellbeing in an enriched environment in 
the adulthood. Initial epidemiological associations were confirmed by the followed 
research.
90
  
 
It is important to note that any associations between the birth size and future morbidity are 
continuous across all birth weights and do not have specific cut-off values, thus indicating 
applicability of the hypothesis to babies born with normal size.  
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The model has received a support from extensive mechanistic clinical and experimental 
findings. For example, a prospective study has demonstrated that children born with lower 
weight more often developed insulin resistance in the future.
91-92
 The concept is in 
agreement with experimental studies in which manipulation of animal maternal nutrition 
caused long-term effects on the offspring biology.
93
 In animal maternal undernutrition 
models the offspring showed impaired metabolic homeostasis with insulin resistance, 
hypertension and obesity, as well as features of endothelial dysfunction.
94-96
 Even brief 
periods of maternal undernutrition may result into long-term health consequences.
97
 
 
The Barker’s model was consequently advanced by Gluckman and colleagues who 
suggested that many of the adaptive responses made by the fetus were produced not for 
immediate advantage, but in expectation of the future postnatal environment (either 
favourable or unfavourable, based on maternal-derived signals).
98-99
 The concept declares 
that the risk of adulthood morbidity reflects the degree of mismatch between the 
environment the organism is exposed to during the plastic (i.e., fetal and neonatal) phase of 
life as opposed to the environment the organism is exposed to in the post-plastic stage. The 
greater the degree of mismatch is the higher the risk of disease. Thus the Gluckman’s 
hypothesis also accommodates the postnatal components of the development.
100
 However, 
the relative contribution of the fetal and the postnatal periods of the human development 
are still under debates, and require further research.
100
 Of interest, an animal model of 
prenatal maternal undernutrition revealed a synergistic effect with postnatal exposure to a 
fat rich diet resulting in insulin and leptin resistance, obesity and hypertension.
95
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Of importance, the concepts of developmental origins are not based on the role of the birth 
size per se, whilst the birth size can act as one of indicators of an unfavourable fetal 
environment.
101
 The developmental plasticity appears to be a tightly regulated 
phenomenon by which one genotype can lead to a range of phenotypes. The processes of 
developmental plasticity embrace the commitment of cells to specific lineages, tissue 
differentiation and growth, at least partly via epigenetic changes in gene expression. It has 
been demonstrated that the environmental factors may modulate fetal gene expression by 
two different mechanisms: (i) by transiently and reversibly affecting geneexpression (i.e., a 
normal mechanism of gene promotionand repression), or (ii) via chemical modification 
ofthe DNA or chromatin (i.e., epigenetic modification), for example via DNA methylation 
or histone acetylation.
102-103
 Epigenetic gene modification may mediate changes in 
hypothalamic–pituitary–adrenal axis, glucocorticoid sensitivity, mitochondrial function, 
and (anti) oxidative capacity. This can consequently contribute to the higher risk of 
coronary heart disease, stroke, diabetes, hypertension, and heart failure.
104
 
 
These models of epigenetic changes and developmental origin of adult disease perhaps can 
partly explain some ethnic differences in cardiovascular morbidity and pathogenesis. 
Indeed, very high prevalence of insulin resistance/diabetes, dyslipidemia, and CAD in 
subjects of SA origin can be partly attributable to the developmental gene modulation in 
less developed countries with suboptimal nutrition. These speculations are supported by 
the evidence of impaired endothelial function, seen even in apparently healthy SA subjects, 
and increased leptin levels in HF patients from this ethnic group.
22, 75
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2.1.9. Conclusions 
 
There are substantial ethnic differences for systolic HF, which tend to occur at a younger 
age in SAs and requires more hospital readmissions (Table 2), and could perphaprs be 
partly explain be delovelopmental restrictions (e.g., undernutrition). In contrast, survival 
for such patients appears to be significantly better than for Whites, which might be 
associated with different pattern of HF (e.g., lower rate of severe LVSD). A high 
prevalence of hypertension and diabetes amongst SAs may predispose to diastolic HF (i.e., 
HFpEF). Additionally, the lack of convincing data on clinical effectiveness of currently 
recommended treatments stems from underrepresentation of this ethnic group in 
pharmaceutical clinical trials and racial inequity of access to the health service should also 
be consedered.
105
 
 
Certain heterogeneity in the published data is likely to reflect differences in health service 
systems, differences in study populations (i.e., primary care vs. hospital-based), variations 
in the employed diagnostic thresholds for HF, differences in HF aetiology, etc. Admittedly, 
current knowledge on specific prognosis in SAs with HF is often based upon in-hospital 
cohorts, and more longitudinal community-based studies are needed to establish more 
accurate picture of ethnicity-related prognostication in HF patients. Although HF is an 
important cause of cardiovascular morbidity and mortality, there are still little data on the 
prevalence of systolic HF amongst the minority ethnic communities in Europe.   
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Table 2. Features of heart failure in South Asians vs. Whites 
 South-Asians vs. 
Whites 
Study 
Prevalence Similar Galasko
54
 
Age of presentation Lower Blackledge
12
 
Singh
55
 
Ischaemic aetiology of HF More common Galasko
54
 
History of myocardial infarction 
prior to the first HF admission 
Higher Blackledge
12
 
Diabetes in HF patietns More common Blackledge
12
 
Atrial fibrillation in HF patients Less common Newton
67
 
Hospital re-admissions More common Blackledge
12
 
Newton
67
 
Sosin
70
 
Age-adjusted mortality Lower Blackledge
12
 
 
Of importance, the pathophysiological mechanisms of the ethic differences in systolic HF 
are not clear at present. These differences may be partly linked to the abnormalities in 
vascular endothelial dysfunction in HF (the review of the literature on the role of 
endothelium in HF is provided in Section 1.2.). Also the role of immune system in 
pathogenesis of different cardiovascular disorders is progressively appreciated. Among 
blood cells monocytes could be of particular interest as they could contribute to 
detrimental processes (e.g., inflammation, thrombosis, formation of atherogenic ‘foam’ 
macrophages, atherosclerotic plaque progression and destabilization) but they also seem to 
be crucial for cardiovascular repair.  The literature on the role of monocytes in 
cardiovascular disorders/conditions relevant to HF development and progression is 
discussed in Sections 2.3 and 2.4. 
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2.2. Endothelial function in heart failure 
2.2.1. Pathophysiological insights on endothelial dysfunction 
 
Although the term ‘endothelial dysfunction’ is used throughout the manuscript there is a 
continuum of the quiescent endothelial ‘activation’, endothelial ‘dysfunction’, and 
endothelial ‘damage’.
106-107
 Endothelial ‘activation’ usually refers to physiological 
response to various stimuli (including inflammatory cytokines), such as bleeding, 
infection, etc. aiming to preserve homeostatic stability of the host (protective changes). 
Endothelial ‘activation’ may involve increased expression and shedding of some surface 
adhesion molecules, release of von Willebrand factor (vWF) and fibrinolytic factors. A 
crucial aspect of ‘activation’ is that it is reversible upon cessation of the activating 
agent(s). In contrast, endothelial ‘dysfunction’ refers to the situations of sustained 
excessive (e.g., increased reactive oxygen species [ROS] production) or depressed (e.g., 
impaired vasodilation) endothelial performance. Given that endothelial ‘dysfunction’ could 
follow chronic ‘activation’ (such as by prolonged and inappropriate activation by 
inflammatory cytokines), there is a certain overlap between the two states. In terms of 
blood pressure control, a major pathological feature of endothelial dysfunction (in the 
context of cardiovascular disorders) is a functional deficiency of endothelial NO synthase 
(eNOS). This leads to the reduced bioavailability of nitric oxide [NO] and is usually 
detected by impaired vasomotor responses. Whereas dysfunction may be reversible, 
endothelial ‘damage’ refers to the extreme degree of endothelial dysfunction characterized 
by premature apoptosis/death of endothelial cells. Increased shedding of the circulating 
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endothelial cells and high plasma concentrations of vWF are considered markers of 
endothelial damage. Such damage is unlikely to be reversible.
106
 
 
Although the endothelium serves as a critical regulator of different aspects of vascular 
biology, such as haemostasis and inflammation, its ability to produce NO is pivotal for the 
different endothelial-dependent functions related to the development and progression of 
HF. In addition to the regulation of the haemodynamics, NO acts as a potent modulator of 
myocardial oxygen consumption in the failing heart.
108-109
 Reduced availability of NO in 
HF stems either from its reduced production by eNOS or accelerated NO degradation by 
ROS (Figure 1).
110
 Down-regulation of constitutively expressed eNOS by the endothelium 
is a characteristic feature of endothelial dysfunction and its endomyocardial expression in 
patients with dilated nonischaemic cardiomyopathy was linearly correlated with LV 
contractility.
111
 Paradoxically, the chronic production of NO by inducible NO synthase 
(iNOS) in HF exerts deleterious effects on ventricular contractility and circulatory 
function.
112
 
 
Mice lacking eNOS have abnormal cardiac NO production, impaired myocardial glucose 
uptake and pathologic concentric LV remodelling whilst eNOS overexpression reduced 
severity of HF.
113-115
 Reduced eNOS activity led to the hypertrophic growth of 
cardiomyocytes in vitro and eNOS deficiency in mice was associated with impaired 
myocardial angiogenesis.
116-117
 Whilst eNOS mRNA is reduced in LV tissue of patients 
with end-stage HF, iNOS mRNA is up-regulated and associates with impaired myocardial 
relaxation.
118
 iNOS is located primarily and invariably in the endothelium and vascular 
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Figure 1. Mechanisms and effects of endothelial function in heart failure 
ADMA, asymmetric dimethylarginine, BFR, blood flow reserve, EC, endothelial cell, E-
sel – soluble E-selectin, HF, heart failure, NO, nitric oxide, eNOS, endothelial NO 
synthase, NFκB, nuclear factor κB, P-sel – soluble P-selectin, iNOS, inducible NO 
synthase, ROS, reactive oxygen species, t-PA, tissue type plasminogen activator 
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smooth muscle cells of the myocardial vasculature and its expression appears to be 
associated with the condition of HF per se rather than related to the aetiology of HF.
119
 
 
ROS causes endothelial dysfunction by accelerating NO inactivation. A family of multi-
subunit NADPH oxidases is a major contributor to the increased superoxide anion 
production and oxidative stress in HF.
120
 Depression of the endothelial function and eNOS 
activity may directly lead to the increased NO release, thus maintaining a vicious circle of 
oxidative stress. In a rat model of diastolic HF, the increase in cardiac eNOS expression by 
the eNOS enhancer, AVE3085 (which is an activator of eNOS transcription) was 
accompanied by the reduction in NADPH oxidase, attenuation of cardiac hypertrophy, 
fibrosis and diastolic dysfunction.
121
 
 
Antioxidant capacity is also diminished in HF. For example, in animal experiments activity 
of different superoxide dismutase isoforms are present in the failing myocardium whilst 
gene transfer of extracellular superoxide dismutase significantly improved endothelial 
function.
122-124
 Increased xanthine-oxidase and reduced extracellular superoxide dismutase 
activity is closely associated with increased vascular oxidative stress in HF patients, 
indicating that an increased oxidative burden and loss of vascular oxidative balance as 
possible contributors to endothelial dysfunction in HF.
125
 
 
There are in vivo and in vitro data showing an impaired arginine (eNOS substrate) 
transport in human HF.
126
 Additionally, circulating levels of asymmetric dimethylarginine 
(an endogenous inhibitor of eNOS) and circulating proinflammatory cytokines are 
increased in HF, further contributing to endothelial dysfunction and accelerated apoptosis 
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of endothelial cells.
127
 A strong correlation has been demonstrated between eNOS down-
regulation and endothelial apoptosis.
128
 Of interest, the  beta-blocker carvedilol suppresses 
the caspase cascade and excessive human umbilical vein endothelial cell apoptosis induced 
by the serum of HF patients or addition of tumour necrosis factor-α (TNFα).
129
 
 
Inflammatory changes are common in patients with HF, with numerous studies reporting 
high concentrations of cytokines (e.g., TNF-α andinterleukin [IL]-6) and C-reactive protein 
(CRP).
130-134
 These biomarkers strongly correlate with HF severity and are strongly and 
independently predictive of mortality.
130, 132-135
 In an animal model, as elsewhere, 
inflammation is not an innocent bystander but is rather an active participant in HF 
development and progression.
136
 A dysfunctional endothelium also facilitates a pro-
inflammatory status in HF by release of various inflammatory factors, such as pentraxin 3. 
Endothelial activation of nuclear factor κB (NFκB), a key proinflammatory transcriptional 
factor,is more prominent in patients with severe HF undergoing heart transplantation.
137
 Of 
note, pentraxin 3 levels independently predict cardiac death or HF re-hospitalization.
138
 
However, despite the strong evidence of a detrimental impact of inflammation on HF 
outcome, data onspecific biological therapies against TNF-α (i.e., using etanercept and 
infliximab) have been generally disappointing.
139-140
 
 
2.2.2. Clinical evidence of endothelial dysfunction 
 
Direct evidence of impairment of endothelial dysfunction in the genesis of haemodynamic 
abnormalities in HF has been provided by the infusion of NG-monomethyl-L-arginine, an 
inhibitor of NO production, to volunteers with HF.
141
 Administration of the NG-
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monomethyl-L-arginine increased median pulmonary and systemic vascular resistances 
and arterial pressure, characteristic features of the HF syndrome. Numerous studies have 
demonstrated peripheral endothelium-dependant vasomotor abnormalities in HF assessed 
by brachial artery flow-mediated dilation (FMD) or forearm blood flow changes in 
response to acetylcholine.
142-144
 However, many such studies show weak, if any, 
correlations between these measures of endothelial dysfunction and clinical parameters of 
HF severity, cardiac contractility or wedge pressure.
144-146
 
 
Although the presence of endothelial dysfunction has been uniformly shown in ischaemic 
HF, the evidence is less robust for non-ischaemic HF (NIHF). Both endothelial-dependent 
and endothelial-independent vasodilation are progressively depressed with increasing 
clinical severity in HF related to valvular heart disease, making it difficult to be precise on 
the cause of the vascular dysfunction.
147
 In one small study, HF of non-ischaemic aetiology 
was not associated with abnormalities in FMD, which is in contrast to ischaemic HF.
148
 In 
other studies, patients with ischaemic systolic HF have more prominent endothelial 
dysfunction compared with those with non-ischaemic HF of the same severity.
142, 149
 
 
Although endothelial dysfunction is a feature of HF of any aetiology, multiple co-factors 
typical of ischaemic HF (e.g., atherosclerosis, diabetes, etc.) seem to contribute to systemic 
endothelial impairment per se. In contrast, patients with NIHF could be expected to have 
more localised endothelial dysfunction of cardiac vasculature. The evidence supporting 
this concept will be discussed further below. 
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2.2.3. Endothelial dysfunction of the coronary circulation 
 
Significant impairment of coronary endothelial function has been observed in patients with 
LV dysfunction.
150
 Significant impairment of coronary endothelial function is also present 
in most patients with stable idiopathic dilated cardiomyopathy (IDCM) despite normal 
epicardial coronary arteries, and profound coronary endothelial dysfunction was observed 
in acute-onset IDCM.
151-152
 Of note, the abnormalities of coronary blood flow reserve in 
IDCM correlated with cardiac geometry, NT-pro-BNP levels, but not with FMD of 
peripheral arteries.
153-154
 These findings indicate that in contrast to patients with an 
atherosclerosis-related HF aetiology, many patients with NIHF tend to have localised (i.e., 
coronary/endocardial) rather than systemic endothelial dysfunction. Coronary endothelial 
impairment in IDCM involves both resistance and conductance vessels, but may vary 
substantially in its severity, possibly reflecting individual pathological features of the 
disease (e.g., inflammatory activity).
155
 
 
In one study, the coronary response to acetylcholine correlated with the subsequent 
improvement in LVEF during a 7 month follow-up period.
152
 Furthermore, coronary 
endothelial dysfunction was independently associated with impaired cardiac relaxation in 
160 patients with normal LVEF in the absence of occlusive CAD.
156
 Also, coronary 
endothelial dysfunction in CAD has been associated with future progression of myocardial 
diastolic dysfunction.
157
 These data are supported by findings showing that altered 
myocardial NO balance contributes to hypertrophy-mediated myocardial ischaemia and a 
transition to HF.
158
 Both eNOS activity and expression in cardiac tissue were reduced in 
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ischaemic HF whilst iNOS was increased in human failing hearts.
158-159
 Thus, coronary 
endothelial perturbations may be central to the pathogenesis of HF.  
 
2.2.4. Systemic nature of endothelial dysfunction 
 
Accumulating evidence indicates a systemic nature of endothelial dysfunction in systolic 
HF. Venous endothelial cells in dogs with decompensated HF show evidence of 
inflammatory activation secondary to high vascular stress and peripheral blood flow 
congestion.
160
 On a background of CAD, impaired venous endothelial function in 
ischaemic HF has been associated with elevated CRP levels and over 2-fold higher 
NADPH-dependent superoxide generation.
161
 Endothelium-dependent venodilation by 
dorsal hand veins was also significantly reduced in chronic HF, but particularly so in acute 
decompensated HF and its improvement correlated with the 6-minute walk test distance.
162
 
In contrast, Nightingale et al. reported preserved forearm venous endothelial function in 
patients with chronic NIHF despite arterial endothelial dysfunction.
163
 
 
Resting exhaled NO, a marker of pulmonary endothelial NO release is increased in HF, 
indicating that NO output plays a counter-regulatory role in the impaired blood flow seen 
in chronic HF.
164
 However, HF patients have significantly reduced ability to increase NO 
release during exercise, which parallels any oxygen deficit and is consistent with the 
presence of endothelial dysfunction. The systemic nature of endothelial dysfunction in HF 
is also supported by reports of defective endothelium-dependent dilatory response of the 
microvascular segment.
165-166
 Also, patients with HF have reduced capillary density that is 
inversely related to maximal oxygen consumption.
167
 Indeed, systemic levels of the natural 
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eNOS inhibitor, asymmetric dimethylarginine, are increased in HF patients and 
independently predict a reduced effective renal plasma flow.
168
 
 
Systemic vascular dysfunction in HF also involves impaired arterial elastic properties.
169
 
These changes in HF seem to be secondary toarterial remodelling with hypertrophy of 
vascular wall layer seen in severe chronic HF.
170
 Indeed, the vascular wall hypertrophy 
correlates with both impaired FMD and the arterial response to GTN, thus suggesting that 
increased arterial stiffness may affect the vascular dilatory response irrespective of 
endothelial function.
170
 However, an analysis of the local arterial elastic characteristics 
(e.g., distensibility, compliance) in HF shows their correlation with forearm FMD, but not 
with the response to GTN, indicating that the increased arterial rigidity may be a feature or 
consequence of endothelial dysfunction.
171
 
 
2.2.5. Endothelial dysfunction and clinical outcome 
 
The clinical evidence of vasomotor endothelial dysfunction in HF comes from prospective 
outcome studies. Although these studies are relatively small (Table 3) all invariably show 
an independent significant association of endothelial dysfunction with a negative outcome 
in HF, ranging from mild HF (NYHA class I) with relatively preserved myocardial 
contractility to advanced HF (NYHA class IV) with severely depressed LV function.
172-173
 
 
Both FMD and the arterial response to acetylcholine are significant predictors of a high 
risk of unfavourable events and their predictive value does not seem to be affected by HF 
5
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aetiology. Epicardial endothelial dysfunction is also an independent predictor of 
cardiovascular events and death in patients after cardiac transplantation.
177
 Also, FMD 
significantly predicts the likelihood of response to cardiac resynchronisation therapy 
(CRT), independently of QRS duration, LVEF, or LV dyssynchrony and the improvement 
in FMD 3-months following CRT positively correlates with an increase in 6-minute walk 
distance.
178
 
 
2.2.6. Blood markers of endothelial dysfunction 
 
Most studies showed significant up-regulation of plasma markers of endothelial activation 
(e.g., E-selectin) and damage (e.g., vWF) in chronic HF (Table 4). However, most of these 
studies included patients of mixed aetiology (predominantly ischaemic) with healthy 
individuals serving as controls. Thus it is difficult to differentiate precisely the role of HF 
per se and the influence of co-morbidities (e.g., atherosclerosis, diabetes) as a driving force 
for the up-regulation of these markers. Indeed, Kistorp et al. observed increased levels of 
E-selectin and vWF in HF patients with diabetes but not in those without diabetes.
179
 The 
impact of co-morbidities may also explain lack of correlation between vWF/E-selectin and 
parameters of HF severity (e.g., BNP levels, LVEF, 6-minute walk test or NYHA class) 
and no difference between patients with stable and decompensated HF.
180-181
 Although 
vWF (but not E-selectin) levels were predictive of future adverse cardiovascular outcomes 
in stable HF, the role of co-morbidities is in question, especially given that BNP was of no 
predictive value in the study cohort.
180
 Another index of endothelial damage, circulating 
endothelial cells have been reported to be increased in HF, with no differences between 
acute and chronic HF.
143, 182
 Nonetheless, levels of the circulating endothelial cells 
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correlate with other markers of endothelial damage/dysfunction (FMD, plasma vWF, E-
selectin) and BNP levels but not with LVEF or NYHA class.
143, 182
 
 
Endothelin-1 is produced by the endothelium and vascular smooth muscle cells, and is the 
most potent known vasoconstrictor.
185
 Endothelin-1 overexpression has been shown to 
parallel with other features of endothelial dysfunction and to be implicated in the 
pathogenesis of various cardiovascular disorders.
185
 Unsurprisingly, plasma endothelin-1 
levels are increased in HF patients.
186
 Endothelin-1promotes production of asymmetric 
dimethylarginine in experimental HF, which explains correlation of endothelin-1 levels 
with parameters of endothelial dysfunction in patients with dilated cardiomyopathy.
187-188
 
Inhibition of the endothelin-1 pathway significantly improves vasomotor endothelial 
function and survival in rats with HF.
189
 Endothelium-mediated dilation in HF patients also 
significantly improves after 3 weeks of treatment with low (but not high) doses of 
endothelin A receptor blocker, LU 135252.
190
 However clinical trials on the endothelin 
receptor(s) blockers in HF were disappointing,
191
 but beta-blockers and statins have been 
shown to reduce endothelin-1 production thus possibly contributing their beneficial effects 
in HF.
192-195
 
 
2.2.7. Pharmaceutical agents, nutritional supplements and endothelial function 
 
Excessive activation of the renin-angiotensin system disrupts NO downstream 
signalling.
196
 Accordingly, all available studies indicate that pharmacological blockade of 
renin-angiotensin-aldosterone axis (e.g., angiotensin converting enzyme [ACE] inhibitors 
or spironolactone) improves endothelial function and reduces vWF in HF (Table 5).
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However, the ability to restore endothelial function varies between individual ACE 
inhibitors or depends on their dose (e.g., higher doses are needed for enalapril).
198, 200
 In 
one study, responder status determined by improvement in physical capacity was linked to 
the improvement in endothelial function with ACE inhibitors.
203
 In the African-American 
HF Trial (A-HeFT) improvement in morbidity, mortality, and functional status in HF was 
linked to the restoration in endothelial function.
227
 
 
These clinical findings are supported by experimental data showing that ACE inhibition 
normalizes NO-dependent dilatation in HF models. Beneficial effects of ACE inhibitors on 
the endothelium in HF are mediated via different mechanisms including eNOS up-
regulation, inhibition of endothelial apoptosis and reduced production of vasoconstrictor 
prostanoids.
228-230
 
 
Pleiotropic (i.e., lipid-independent) properties of statins have attracted substantial attention 
of researchers and their endothelial effects were extensively studied. Statins have helped to 
maintain coronary NO production and activity in pacing-induced cardiomyopathy, 
markedly improved endothelium-dependent vasorelaxation, and enhanced myocardial 
neovascularisation.
231-232
 Treatment with statins parallels with improvement of LV function 
and survival via eNOS-mediated mechanisms.
232-233
 In the Controlled Rosuvastatin 
Multinational Trial in Heart Failure (CORONA) trial, therapy with 10mg of atorvastatin 
had no effect on the mortality.
234
 This controversy may stem from a number of factors 
which include the choice of a specific statin and its dose, the population studied or, 
alternatively, longer (almost 3 years) follow-up duration in the CORONA trial. 
 
62 
 
In all but one clinical studies statins resulted in a marked improvement of endothelial 
function, irrespective of HF aetiology (Table 6). However, the treatment of NIHF with the 
highest doses of atorvastatin (80 mg daily) failed to improve endothelial function.
235
 
Endothelial effects of the statins do not seem to depend of their lipid-lowering properties 
and they can improve endothelial function even in HF individuals with normal lipid 
levels.
21, 236
 Lipid-independent effects of statins on the endothelium are also supported by 
failure of ezetimibe to affect endothelial function despite similar reduction in LDL.
237
 
 
Statins seem to have no effect on asymmetric dimethylarginine levels but they significantly 
reduce oxidative stress in HF patients.
194, 238
 Simvastatin increases extracellular superoxide 
dismutase activity, a potential contributor to the statin-induced improvement of endothelial 
function, but this is not seen with ezetimibe therapy.
239
 However, a direct causal relation 
between antioxidant properties of statins and their positive endothelial effects in human HF 
is more difficult to prove and recovery of endothelial function with atorvastatin alone was 
more potent than with its combination with an antioxidant, vitamin E.
240
 
 
Given that endothelial NO is produced from L-arginine, supplementation with this 
aminoacid has been used as a therapeutic option to improve endothelial function in HF. 
Also L-arginine might reduce endogenous NO inhibitor asymmetric dimethylarginine, 
known to be increased in HF.
127
 For example, rats with HF had diminished plasma L-
arginine levels and chronic supplementation with low (but not high) L-arginine doses 
improved aortic endothelium-dependent relaxation ex vivo, but did not affect 
haemodynamics in vivo.
241
 Similarly, in human studies, a lower (e.g., 8 g daily), but not 
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higher (20 g daily) dose of L-arginine have been shown to improve endothelial function.
216, 
218
 In a placebo-controlled study, 6 week treatment with oral L-arginine hydrochloride 
(5.6-12.6 g daily) significantly increased distances during a 6-minute walk test, improved 
arterial compliance and reduced circulating levels of endothelin-1.
243
 Thus, whilst the 
restoration of reduced L-arginine levels may be beneficial in some patients, excessive L-
arginine consumption is unlikely to provide any additional benefits to the endothelium. 
Moreover a significant increase in urea and aspartate transaminase levels was observed in 
patients who received high L-arginine doses.
218
 
 
Vitamin C inhibits endothelial cell apoptosis in congestive HF and studies in this area have 
shown an improvement in endothelial function (Table 5).
244
 Nevertheless given rather 
unsuccessful results of antioxidant vitamin supplementation in clinical trials, they should 
not be routinely recommended in HF patients.
245
 Still, healthy diet habits are essential to 
maintain an appropriate antioxidant status.
246
 Although the number of other medications 
(e.g., allopurinol, sildenafil, etanercept, growth hormone, etc.) have been shown to have 
positive effects on endothelial function, it is currently difficult to speculate on clinical 
relevance of these observations (Table 5).  
 
2.2.8. Exercise and endothelial function 
 
Physical exercise has gained acceptance as a beneficial intervention for patients with HF. 
According to a systematic review of randomized controlled trials, exercise might slow the 
pathophysiological progression of HF.
247
 In chronic HF, regular exercise inhibits 
neurohormonal stimulation, the production of proinflammatory cytokines, reduces levels of 
65 
 
natriuretic peptides, systemic vascular resistance and attenuates the oxidative burden.
247
 
These favourable effects parallel improvement in symptoms, exercise capacity and quality 
of life, whilst patients who do not improve their exercise capacity significantly after an 
exercise training programme have a poorer prognosis.
248
 
 
The shear stress associated with exercise is a critical endothelial stimulus, commonly 
employed to assess endothelial function (i.e., FMD). Accordingly it is natural to expect an 
effect of physical training on the endothelial functional performance. Indeed, regular 
aerobic training of patients with ischaemic and non-ischaemic systolic HF is associated 
with restoration of the vasodilatory endothelial-dependent function (Table 7). In contrast, 
training of isolated muscle groups (e.g., handgrip training) does not seem to have any 
substantial effect on systemic endothelial function.
249
 Physical training in HF has been 
shown to up-regulate eNOS gene expression, accelerate L-arginine transport, and increase 
basal endothelial NO formation.
250-254
 Additionally, in patients with HF, exercise training 
increases vascular endothelial growth factor (VEGF) and mobilises endothelial 
progenitors, presumably an indicator of the desired endothelial regeneration.
255-256
 
 
Intensity of exercise training may also be of importance. Whereas acute bouts of exercise 
have been reported to enhance production of pro-inflammatory cytokines and markers of 
endothelial damage in HF, these effects are not seen when moderate exercise is performed 
regularly.
257-258
 Even in healthy individuals undergoing moderate-intensity exercise, but 
not mild- or high-intensity exercise, there is a significant augmentation of acetylcholine-
induced vasodilation.
259
 Indeed, improvement of FMD after the course of training 
paralleled reverse LV remodelling, prominent improvement in LVEF and reduction in NT-
66 
 
pro-BNP levels, although a causative relationship between these processes is difficult to 
establish.
20
 Also it is still not clear whether exercise-related improvement of endothelial 
function has any independent effect on clinical outcomes. 
 
2.2.9. Genetic predisposition of endothelial dysfunction 
 
In the Genetic Risk Assessment of HF (GRAHF) sub-study of the African-American HF 
Trial, eNOS genotype differed between white and black patients with HF.
260
 In black 
patients the -786T allele was associated with lower LVEF.
260
 The prevalence of allele 
Glu298 was significantly higher in HF patients as genotype Glu298Glu, being associated 
with an increased prevalence of hypertension.
261
 Also HF patients homozygous for eNOS 
promoter polymorphism (thymidine to cytosine transition [T(-786)C]) were found  to have 
a more advanced cardiac autonomic imbalance (i.e., abnormal heart rate variability).
262
 
 
In the GRAHF study, the Glu298Asp polymorphism was associated with reduced 
effectiveness of fixed-dose combination of isosorbide dinitrates and hydralazine which 
only improved the composite score of survival, hospitalization, and quality of life in 
Glu298Glu allele carriers.
260
 McNamara et al. also confirmed poorer event-free survival in 
HF patients with Asp298 variant of eNOS, particularly in those with NIHF.
263
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2.2.10. The endothelium and thrombotic risk 
2.2.10.1. Prothrombotic state in heart failure 
 
Chronic HF is increasingly recognised as a syndrome which confers a considerable 
prothrombotic risk. Whilst the annual incidence of venous thromboembolism is about 0.1% 
in general population, prospective observational studies have shown that thromboembolic 
events would occur in 1.7-2.7% of patients with HF each year.
268
 Indeed, a retrospective 
analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials reported that the 
annual incidence of thrombotic events (including strokes, pulmonary emboli and peripheral 
emboli) in patients with ventricular dysfunction and sinus rhythm was 1.8% in men and 
2.4% in women.
269
 Furthermore, patients with HF generally suffer more severe strokes that 
are associated with high mortality rates.
270
 
 
However, even this high prevalence of thromboembolic events may just represent the tip of 
the iceberg. Indeed, more than 30% of patients with HF, irrespectively of its aetiology, 
may experience ‘silent’ asymptomatic thromboembolic strokes detected by brain magnetic 
resonance imaging.
271 
 
In addition to the risk of venous thromboembolism, patients with HF also have a high [and 
often underestimated] risk of arterial thrombosis. The risk of sudden cardiac death, often 
attributable to acute arterial thrombosis, is 6 - 9 fold higher in those with HF compared to 
the general population.
272
 In the Assessment of Treatment with Lisinopril and Survival 
[ATLAS] study, fresh coronary thrombus was found in more than 30% of such sudden 
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death cases. Both acute MI and unstable angina are independent risk factors for death in 
patients with congestive HF.
273 
 
Why does HF confer a prothrombotic state?  HF is associated with abnormalities of flow 
(low cardiac output, impairment of intracardiac haemodynamics, dilated cardiac chambers, 
stasis of blood in peripheral vascular beds, etc), vascular wall (endothelial damage/ 
dysfunction), and abnormalities of blood constituents (e.g., platelets and haemorrheology). 
Thus HF fulfils all criteria of Virchow's triad of characteristics of a prothrombotic state, 
which promote the risk of thrombosis and, unsurprisingly, the risk of thromboembolic 
complications rises accordingly to the degree of LV contractility impairment.
269
 Given that 
endothelial dysfunction is commonly seen in HF pathophysiology, the contribution of the 
endothelium to thrombosis may be especially important in patients with HF. 
 
2.2.10.2 Vascular endothelium and the maintenance of blood fluidity 
 
The lumen surface of the healthy endothelium is both anticoagulant and antithrombotic. In 
addition to being a passive barrier, endothelial cells directly and actively participate in the 
prevention of venous and arterial thrombosis by regulation of platelet activity and the 
balance of procoagulant factors. 
 
Endothelial cells maintain blood fluidity via different anticoagulant pathways (Figure 2). 
One of the most important is the protein C/protein S pathway.
274
 Stimulation of the 
endothelial cell receptor thrombomodulin by thrombin activates protein C, and activated 
protein C then inhibits coagulation factors VIIIa and Va. To be effective, protein C must 
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form a complex with protein S, which is synthesized by endothelial cells.
275
 The 
interaction of thrombin with thrombomodulin also inhibits thrombin-mediated platelet 
activation and ultimately, clot formation.
276
 Additionally, healthy endothelium inactivates 
thrombin by expressing on their surface heparin-like glycosaminoglycans associated with 
large amounts of antithrombin.
277-278
 Furthermore, endothelial cells possess receptors that 
mediate endocytosis and help to eliminate from the circulation factor Xa, responsible for 
conversion on prothrombin into thrombin
279
. 
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Figure 2. Regulation of haemostasis by the vascular endothelium 
cAMP – cyclic adenosine monophosphate;NO – nitric oxide; PAI-1 –plasminogen 
activator inhibitor type 1;PF1+2 –prothrombin fragments 1+2;TAT –thrombin-
antithrombin III complex;TFPI –tissue factor pathway inhibitor; TM –thrombomodulin; 
t-PA – tissue-type plasminogen activator; vWF – von Willebrand factor. Blue lines 
reflect activities of normal endothelium, red lines show changes associated with 
dysfunctional endothelium 
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In the quiescent state, endothelial cells do not express tissue factor (TF), the key activator 
of extrinsic pathway of coagulation.  In contrast, normal endothelium produces TF 
pathway inhibitor to inactivate TF synthesised by other cells.
280
 The endothelium also 
participates in fibrinolysis by releasing tissue-type plasminogen activator (t-PA) and 
urokinase, thus promoting formation of plasmin able to digest the fibrin network.
281
 
Although endothelial cells also produce plasminogen activator inhibitor type 1 (PAI-1) the 
balance of t-PA and PAI-1 is normally maintained in favour of thrombosis prevention.
282 
 
The antiplatelet properties of the endothelium are largely mediated by prostacyclin and 
NO, which prevents platelet activation by the increase in the cyclic adenosine 
monophosphate contained within platelets. Additionally, endothelial cells possess on their 
luminal surface enzymes (ectonucleotidases) which are able to hydrolyse adenosine 
triphosphate and adenosine diphosphate, both potent platelet activators.
283 
 
2.2.10.3. Endothelium and thrombogenic alterations 
 
The prominent antithrombotic characteristics of healthy endothelial cells are changed 
dramatically in the damaged or dysfunctional endothelium. Indeed, endothelial 
abnormalities are typical amongst patients with HF and represent one of the major 
pathophysiological pathways implicated in the development and progression of HF. For 
example, impaired FMD, increased numbers of circulating endothelial cells shed off 
vascular wall, raised plasma levels of vWF (a marker of endothelial damage) are all 
consistently reported in patients with HF irrespectively of its aetiology (i.e., whether 
ischaemic or non-ischaemic).
143
 Persistent exposure to various cytokines, chemokines and 
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proinflammatory stimuli shifts the balance towards a prothrombotic endothelial cell 
phenotype. Endothelial damage as assessed by plasma vWF levels is predictive of adverse 
outcomes in patients with HF.
180 
 
Endothelial impairment results in dysregulation of all major elements of coagulation 
system. Endothelial activation shifts the balance in favour of platelet aggregation and clot 
formation through the suppression of anticoagulant mechanisms and stimulation of 
procoagulant pathways.  Inflammatory cytokines are abundant in patients with HF (e.g. 
TNF-α, IL-1β) and these modify endothelial physiology and may trigger endothelial 
expression of TF.
284
 Active endothelial production of TF results in downstream activation 
of factor Xa and leads to cleavage of prothrombin to form active thrombin. Indeed, the 
cytokine-mediated expression of TF by endothelial cells and inflammatory cells acts as one 
of the primary initiators of thrombosis in different pathological conditions.
285
 In acute HF, 
elevation of TF levels is significantly correlated with inflammatory burden and is much 
higher in those who died during a 6-month follow-up period.
286
 TF levels have also been 
demonstrated to be predictive of poor prognosis in chronic HF.
287
 
 
Activation of thrombin also promotes development of thrombosis via fibrin formation, as 
well as via a number of fibrin-independent effects. Indeed, thrombin may activate platelets, 
thus enhancing their surface expression of P-selectin and increasing production of platelet 
activation factor. Through protease-activated receptors presenting on endothelial cells, 
thrombin also contributes to endothelial cell activation, vWF release, possible TF 
production, change in endothelial cell shape and increase in endothelial permeability.
288
 
All together, these changes promote inflammation and a procoagulant state in HF.
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Indeed, thrombin activity is substantially increased in patients with HF as demonstrated by 
elevated plasma levels of thrombin-antithrombin complex and prothrombin fragments 
1+2.
289
 In a follow-up of 214 subjects with HF, thrombin-antithrombin complex levels 
were significantly associated with increased risk of death, even after adjustment for other 
prognostic factors (e.g., age, gender, traditional cardiovascular risk factors, NYHA class, 
systolic LV function, renal failure, haemoglobin).
290
 Of note, these prothrombotic markers 
can be significantly reduced by an anticoagulant, warfarin.
291
 However, the clinical utility 
of long-term anticoagulation has not been confirmed as yet in large clinical trials, such as 
the Warfarin and Antiplatelet Therapy in Heart Failure(WATCH) trial.
292
 
 
Platelet abnormalities in HF are also well described and are at least partly attributable to 
the endothelial cell impairment.
293
 Indeed, a dysfunctional endothelium initiates the 
expression of platelet-activating factor which promotes platelet adhesion to endothelial 
cells and up-regulates production of vWF.
293
 The latter is constitutively expressed and 
stored in Weibel–Palade bodies within endothelial cells and physiologically facilitates the 
binding of platelets to exposed extracellular matrix components of damaged vascular wall. 
Impaired endothelial cells also release excessive amounts of vWF, further promoting 
platelet adhesion and activation. Also, patients with HF have increased concentrations of β-
thromboglobulin, platelet surface P-selectin and CD63P.
294
 More recently, endothelium-
derived fractalkine was also found to be a contributor to platelet adhesion andactivation.
295 
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2.2.11. Conclusions and future directions 
 
Endothelial abnormalities are a common feature of HF. Various aspects of the endothelial 
function can be affected, including vasomotor, haemostatic, antioxidant and inflammatory 
activities. Substantial differences exist in the pattern of endothelial function depending on 
aetiology, severity and stability of HF in individual patients. There is considerable 
evidence that in the majority of patients with ischaemic aetiology of HF, endothelial 
dysfunction is systemic in its nature and involves arteries, conductance vessels and 
microvascular beds, coronary, pulmonary and peripheral vessels. There is also minor 
evidence of venous endothelial dysfunction in HF. The pattern of endothelial dysfunction 
is more heterogeneous in NIHF, with fewer features of systemic abnormalities. In fact 
many subjects with NIHF have functionally preserved endothelium in peripheral arteries 
with endothelial dysfunction seen only in coronary vessels. It is possible that coronary 
endothelial dysfunction in these patients mirrors local pathological processes in the heart 
and may reflect their activity.  
 
Endothelial dysfunction undoubtedly has a significant prognostic value in HF but its 
clinical application is hampered by methodological limitations. Some of these methods are 
invasive and some (e.g., FMD) are very operator-dependent. A number of medications 
(including ACE inhibitors and statins) and regular physical activity has been shown to 
improve endothelial function in HF, but there are still no pharmaceutical agents 
specifically targeting the vascular endothelium. In an animal model of HF, endothelial 
dysfunction was successfully corrected by tyrosine phosphatase 1B inhibitors but their 
effects have not yet been tested in human clinical trials.
296
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Major qualitative differences exist between macro- and micro-vascular endothelial cells. 
The latter have distinct morphology, patterns of specific expression of adhesion molecules 
and they vary in their responsiveness towards agonists.
297
 For example, endothelial cell 
thickness varies from<0.1µm in capillaries to 1µm in the aorta. In stable conditions, TF 
plasma inhibitor is primarily associated with the microvascular endothelium, while protein 
C receptor is predominantly expressed on the luminal surface of large vessels, and vWF is 
not only expressed by macrovascular but also lung microvascular endothelial cells.
298-300
 
eNOS activity is also higher in the endothelium of arteries from the renal medulla 
compared with glomeruli and peritubular capillaries.
276
 Admittedly, only limited data are 
available on the performance of the microvascular endothelium in HF. 
 
Moreover, ethnicity is known to affect the risk of HF development. For example, it has 
been shown that patients of SAs origin more often (for about 40%) suffer from CAD with 
higher mortality rates when compared to white population.
301
 Indeed, endothelial 
damage/dysfunction may be an important contributor to the ethnicity-related adverse 
outcomes in HF. Of note, eNOS gene polymorphisms among SA population are associated 
with the risk of arterial hypertension and aneurysmal subarachnoid haemorrhage.
302-303
 
Even healthy SAs have diminished endothelial activity and reduced endothelial progenitor 
cell numbers and function, but increased CRP levels when compared with Whites.
22, 304
 
However, the role of ethnicity in the pathophysiology of HF is still grossly understudied 
with limited data available on possible ethnic differences in endothelial activity in relation 
to the risk of thrombotic and thromboembolic complications. 
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2.3. Monocytes in heart failure 
2.3.1. Inflammation and heart failure 
 
It is widely recognised that inflammation is directly implicated in almost every aspect of 
pathological cardiovascular conditions including HF.
24, 305
 Circulating levels of 
inflammatory cytokines are correlated with short-term and long-term outcomes and, 
according to some reports, with the response to treatment.
131, 305-307
 Abnormal cytokine 
activity, particularly increased concentrations of IL-6 and TNF-α are detected from early 
stages of HF and appear to have value as potential markers for diagnosis, risk stratification, 
and prognosis. TNF-α has been shown to be involved in HF progression as a factor 
promoting myocardial dysfunction and adverse cardiac remodelling.
308
 According to 
animal studies there is an increased cardiac expression of TNF-α in failing myocardium 
associated with progressive LV dysfunction and dilatation.
309-310
 Case-control studies 
revealed up-regulation of inflammatory cytokines (e.g., TNF-α) in both myocardium and 
peripheral monocytes in patients with HF and they have indicated that abnormally high 
circulating cytokine levels predict increased mortality rates.
135, 311
 In fact, pro-
inflammatory shift is obvious from initial stages of HF even before neurohormonal 
activation could be detected, which is a hallmark of more advanced stages of HF. For 
example, significantly risen TNF-α concentrations were seen in subjects with mild HF 
(NYHA II) when compared to normal individuals.
130
 Furthermore, a linear relationship has 
been shown between TNF-α levels and HF functional status.
130, 305
 It is hypothesized that 
sustained increase in cytokines results in cardiomyocyte apoptosis, changes in monocyte 
phenotype transition and activation of matrix metalloproteinases contributing to cardiac 
hypertrophy and adverse LV remodelling.
139-140
 However, reported attempts to utilize 
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inflammatory molecules, such as TNF-α as therapeutic targets for management of severe 
systolic LV dysfunction were rather disappointing and led to an increase in mortality.
312-313
 
 
This controversy could be partly due to the fact that despite its many detrimental effects, 
the cytokines also play an essential regulative role in protective adaptive processes aiming 
to contradict acute or chronic ischaemic injury.
234, 314
 The cutoff cytokine concentration 
associated with the shift from protective to largely deleterious effects is subtle and it is 
likely to fluctuate based on many (patho)physiological variables or even between different 
organs and tissues of the same body. Admittedly, at present the role that TNF-α and other 
cytokines play in HF has not yet been fully clarified and warrants further investigation. 
 
Chronic oxidative stress has been also linked to the establishment and progression of HF. 
Experimental and clinical studies documented an increased generation of ROS, including 
superoxide, hydrogen peroxide, and hydroxyl radicals in the failing heart. Recent findings 
suggest that the number of different pathways could led to increased ROS production in 
HF, which include NADPH and xanthine oxidase pathways, alteration of NOS and the 
mitochondrial electron transport chain.
315
 Experimental data reveal abnormal activation of 
NADPH oxidase in phagocytes in response to neurohormonal activation which promotes 
apoptosis of cardiomyocytes and excessive activation of matrix metalloproteinases 
accompanied by unfavourable remodelling of the failing LV. Furthermore, the critical 
negative consequence of the oxidative burden in HF is its impact on endothelial 
function.
176
 According to clinical studies on HF subjects with severe endothelial 
dysfunction and diminished NO availability the degree of the endothelial dysfunction 
significantly predicts the risk of negative clinical outcomes.
316
 Consequently ROS have 
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been suggested as a possible target of pharmaceutical agents with known pleiotropic anti-
oxidative and anti-inflammatory properties. Several studies have indicated significant role 
of the antioxidant effects of statins on cardiac remodelling, endothelial function in subjects 
with HF.
317-318
 
 
Of note, monocytes represent both a major cellular source and one of the main cellular 
targets of inflammatory cytokines (Table 8). However, the role of monocytes in HF is not 
restricted to cytokine signalling. Growing evidence implicates these cell into various 
cardiovascular disorders associated with HF. Following migration to tissues and under 
appropriate stimulation, monocytes differentiate into different types of macrophages. 
Macrophages are mobile phagocytes specialized in elimination, via various forms of 
endocytosis, invading microorganisms, and debris of cellular, extracellular, and foreign 
origin.
318
 
 
Monocytes are implicated in atherogenesis, the pathological process underlying CAD and 
ischaemic cardiomyopathy.
23
 Their initially protective inflammatory activity may later 
result in chronic arterial damage, endothelial dysfunction and massive release of various 
cytokines, chemokines and growth factors by circulating monocytes and monocyte-derived 
tissue macrophages. As the result, monocytes significantly contribute to smooth muscle 
cell migration into the arterial intima and formation and progression of atherosclerotic 
lesions.
23
 
 
Ischaemia-induced cardiac damage and consequent myocardial remodelling are paralleled 
by intense monocyte infiltration of the damaged tissue, inflammation and impairment of 
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Table 8. Cytokines/chemokines produced by monocytes/macrophages in response to 
vascular inflammation. 
Cytokine Major action in relation to vascular inflammation 
TNFα
135, 306, 308-310, 312 
Induces inflammation 
Induces apoptotic cell death 
Potent chemoattractant for neutrophils 
IL-1α/β
307 
Induces chemokine/cytokine expression 
Promotes the expression of adhesion molecules on endothelial 
cells 
IL-6
130, 305 
Induces chemokine/cytokine production 
Major mediator of the acute phase response 
IL-8
307 
Neutrophil activation and chemotaxis 
SMCs proliferation and migration 
IL-10
130, 305 
Anti-inflammatory cytokine 
Down-regulates the expression of Th1 cytokines. 
Inhibits NFκB activity 
IL-12
317 
Induces cell-mediated immunity 
T cell stimulating factor 
Induces the production of TNF-α and INF-γ 
IL-18
130, 305, 307 
Induces cell-mediated immunity 
Induces INF-γ production 
MIP 1α/β
130, 305, 307
 Granulocyte activation and chemotaxis  
Induce the synthesis and release of pro-inflammatory cytokines 
MCP-1
130, 305, 307 
Monocyte activation and chemotaxis  
Induces SMC accumulation and migration 
 
TNF, tumour necrosis factor α; IL, interleukin; INF, interferon; MIP, monocyte 
inflammatory protein; MCP, monocyte chemoattractant protein; SMC, smooth muscle 
cells.
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LV contractility.
318-319
 For example, Maekawa et al. reported a strong association between 
peripheral monocytosis, LV dysfunction and LV aneurysm formation after MI.
320
 
Accordingly, inhibition of monocyte activation is a tempting therapeutic target in the 
prevention and management of ischaemia-related HF. 
 
2.3.2. Monocyte activation 
 
Before their involvement in the pathogenesis of ACS or HF, monocytes are undergoing 
phenotypic transformation, leading to their activation. CD14, which is a monocyte 
endotoxin receptor (coupled with with Toll-like receptor [TLR]-4) that binds 
lipopolysaccharides (LPS) and initiates monocyte activation. Activated monocytes interact 
with endothelium triggering an inflammatory cytokine cascade.
321-322
 This process is 
enhanced by high levels of CRP or heat shock proteins.
323-329
 
 
Indeed, circulating TLR4-expressing monocytes are ~2.5-fold increased in ACS patients 
and the density of CD14 on the monocyte surface is much higher in patients with 
myocardial necrosis.
330-332
 However it should be kept in mind that that TLR4-mediated 
responsed may be reduced by aging.
333
 In some (but not all) studies, the CD14 gene 
polymorphism has been associated with a history of ACS or MI, indicating its potential 
role in genetic predisposition to the development of ACS and atheromatous plaque 
vulnerability (Table 9).
334-335
 Monocytic TLR4 overexpression in acute MI, demonstrated 
both in the circulation and on ruptured plaque, has been associated with high levels of IL-6 
and TNF-α.
336
 These markers remained elevated for at least 2 weeks after MI onset were 
related to the development of HF.
337
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Table 9. Studies on CD14 gene polymorphism 
Study Patients Polymorphism 
analysed 
Results 
Hubacek
338 
178 patients with 
MI and 135 
control subjects 
-260 C/T The frequency of the T allele was 
higher in MI patients, with higher 
density of the CD14 receptor the T/T 
homozygotes 
Shimada
335 
81 MI patients, 43 
CAD patients, 83 
healthy controls 
-260 C/T The frequencies of T allele and T/T  
homozygotes in MI patients were 
higher than in controls and in patients 
with angina without prior MI 
Heesen
339 
95 healthy blood 
donors 
-260 C/T No differences in CD14 density and 
soluble CD14 levels. 
Arroyo-
Espliguero
334 
194 ACS 
survivors, 140 
CAD patients 
without ACS 
history, 94 
patients with 
normal coronary 
arteries 
-260 C/T Patients with a prior ACS had higher 
frequency of the T/T genotype than 
CAD patients without prior ACS. No 
differences between CAD patients 
without prior ACS and controls. 
Longobardo
340 
213 MI survivors, 
213 healthy 
controls 
-260 C/T No association with acute MI 
Unkelbach
341 
2228 patients 
after diagnostic 
coronary 
angiography 
-159 C/T 
 
No association with MI or CAD in the 
whole cohort. In low coronary risk 
patients (normotensive nonsmokers) 
increased risk for MI in T allele 
homozygotes 
Koch
342 
793 MI patients, 
998 CAD 
patients, 340 
healthy controls 
-159 C/T 
 
Gene polymorphism was not 
associated with CAD or MI 
Agema 
(REGRESS 
trial)
321 
759 patients with 
CAD 
-159 C/T 
 
No association with CAD severity 
Rechciński
343 
57 MI survivors -159 C/T No differences in the first MI age or 
the number of cardiovascular risk 
factors 
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2.3.3. Monocyte-endothelium and monocyte-myocardial interactions 
 
On being activated, monocytes modify their phenotype, thus enhancing their interaction 
with endothelial cells and ability to infiltrate arteries and cardiac tissue. The recruitment of 
circulating monocytes to the vascular subendothelial tissue occurs via a tightly regulated 
multi-step process mediated by a series of cell surface adhesion molecules. Endothelial cell 
activation also results in the up-regulation of a number of endothelial cell adhesion 
molecules, including E-selectin, vascular cell adhesion molecule-1 (VCAM-1) and 
intercellular adhesion molecule 1 (ICAM-1), mediated by the pro-inflammatory cytokines 
(e.g., IL-1β, TNF-α).
344
 
 
In the first step, activated vascular endothelial cells at the site of atherosclerosis express P-
selectin that mediates the tethering and rolling of circulating monocytes. P-selectin binds to 
P-selectin glycoprotein ligand-1 and other glycosylated ligands on monocytes.
345-346
 E-
selectin is also inducibly expressed at sites of atherosclerosis.
347
 P- and E-selectins allow 
the capturing and rolling of leukocytes on the endothelium. They play an important role in 
the signalling pathway through P-selectin glycoprotein ligand-1 in which they activate 
integrins and induce monocyte activation.
348
 An ex vivo model of isolated carotid arteries 
showed that blocking P-selectin with anti-P-selectin antibodies resulted in the reduction of 
monocyte rolling and attachment to the endothelium.
349
 Integrins support both rolling and 
adhesion of leukocytes. Very late antigen-4 (α4β1 integrin) is a monocyte integrin closely 
related to atherosclerosis.
350
 α4β1 mediates interaction with VCAM-1 that is induced on 
cytokine-stimulated endothelium.
351
 In vitroexperimentson monocyte flow along cytokine-
activated endothelial cells (i.e., under shear stress) suggested the involvement of P-selectin, 
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L-selectin, VCAM-1, and very late antigen-4 in monocyte recruitment to the 
endothelium.
352-353
 
 
Increased monocyte expression of Mac-1 (CD11b/CD18), lymphocyte function associated 
antigen-1, and very late antigen-4 promotes monocyte attachment to the endothelium.
354-356
 
Monocyte-associated levels of ICAM-1, VCAM-1, and L-selectin are also elevated from 
the early stages of ACS (either with or without myocardial necrosis).
356-357
 Such 
overproduction of adhesion molecules in ACS may be associated with diminished 
monocyte expression of peroxisome proliferator-activated receptor-γ.
358
 Also, monocytes 
possess receptors facilitating their localisation at sites of injured myocardium.  The ACS-
related up-regulation of monocyte fibronectin receptor very late antigen-5 may be involved 
in their migration to tissues via interaction with fibronectin, the latter being an important 
component of cardiac extracellular matrix.
359 
 
Injured heart muscle also promotes monocyte recruitment.  Indeed, acute MI is associated 
with the rapid induction of mononuclear cell chemoattractants (such as MCP-1 and 
monocyte colony stimulating factor [M-CSF]) that promote monocyte infiltration into the 
injured area, as well as monocyte differentiation to macrophages and proliferation of the 
latter, all critical processes for effective healing of the infracted area.
360
 
 
MCP-1 (gene name CCL2, receptor gene name CCR2) is the most important chemokine 
that regulates migration and infiltration of monocytes/macrophages. Ischaemia rapidly 
stimulates infiltration of infarcted area by MCP-1-positive macrophages, partly via M-CSF 
expression by mature cardiac resident macrophages.
361-362
 MCP-1 production by cultured 
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human cardiac cells has been shown to beupregulated by inflammatory cytokines and 
downregulated by hypoxia.
363
 Cardiac overexpression of MCP-1 induces macrophage 
infiltration, neovascularization, expression of the wide range of cytokines and chemokines 
(e.g., TNF-α, IL-1β, IL-6, IL-8, IL-10, transforming growth factor-β), and the 
accumulation of cardiac myofibroblasts, thereby affecting LV remodelling.
361-362, 364-366
 
 
Of note, plasma MCP-1 levels are increased as early as 3 hours after the onset of chest 
pain, reach their maximum at 24 hours and remain elevated at least for 7 days.
364, 366
 
Interestingly, the majority of studies on MCP-1 genetic polymorphism failed to find any 
association with the risk of MI (Table 10). However, in the Framingham Heart Study 
Offspring Cohort, the MCP-1-2578G allele was significantly related to a higher prevalence 
of MI (with an adjusted odds ratio 2.0).
367 
 
Stress-induced expression of MCP-1 contributes significantly to the development of 
coronary collaterals during the early phase of acute MI.
368
 Nonetheless, excessive MCP-1 
production may have adverse effects. In 2270 patients with ACS enrolled in the OPUS-
TIMI-16 trial, MCP-1 levels were independently associated with an increased risk of death 
or MI during 10 months of follow-up.
369
 Similarly, MCP-1 levels measured in 4244 post-
ACS patients in the A to Z trial were predictive of the recurrence of cardiovascular events 
(hazard ratio 2.16) and mortality after 4 months (hazard ratio 1.76).
370
 Interestingly, MCP-
1levels appear to have little prognostic importance in patients with stable CAD.
371
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Table 10. Studies on MCP-1 gene polymorphism 
Study Patients Polymorphism 
analysed 
Results 
Iwai
372 
2,266 subjects, 
including 34 MI 
survivors 
-2138 A/T No significant association with MI 
or atherosclerosis 
Jemaa
373 
319 MI patients,  
467 healthy 
controls 
-2518 G/A Patients with MI had significantly 
higher frequency of the AG+GG 
genotypes compared to controls 
McDermott
367
 
(Framingham 
Heart Study 
Offspring 
Cohort) 
1797 subjects -2518 G/A The MCP-1-2578G allele was 
associated with higher serum MCP-
1 levels and higher MI prevalence 
Bjarnadottir
374 
460 MI survivors, 
1842 disease free 
controls 
-2518 G/A,  
-2076 A/T  
plus -190 G/A 
polymorphism 
of CCR2 gene 
No difference in the frequencies of 
any of the polymorphisms studied 
between the cases and the controls 
Cermakova
375
 139 MI patients, 
359 healthy 
controls 
-2518 G/A No relationship was observed 
between circulating MCP-1 levels 
and carriage of the G allele 
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MCP-1may be a potential target for intervention, but data from preclinical data have been 
controversial. In experimental studies, a genetically determined lack of MCP-1 synthesis or 
anti-MCP-1 therapy were associated with more favourable myocardial remodelling, better 
survival and contractility preservation, attenuated interstitial fibrosis and reduced infarct 
size, but also with delayed replacement of injured cardiomyocytes with granulation tissue 
and defective macrophage differentiation.
362, 376-377
 In contrast, two rodent studies show 
that cardiac MCP-1 overexpression or myocardial MCP-1 injection reduced infarct area 
and scar formation and prevented LV dysfunction after MI.
365, 378
 Of note, MCP-1 
treatment stimulated neovascularization independently from the involvement of bone 
marrow-derived endothelial progenitors.
365, 378
 Thus the time and extent of MCP-1 
availability may be of importance. 
 
2.3.4. Monocytes and inflammation and plaque destabilisation 
 
Monocytes are actively involved in initiation of the inflammatory cascade in ACS and HF 
(Figure 3). Activated monocytes promote the synthesis of proinflammatory molecules, 
such as IL-6 and TNF-α, partly mediated by TLR4 stimulation and Mac-1 expression – as 
discussed above.
328
 Unstable angina and MI are also associated with increased levels of 
TLR4, and downstream molecules, such as IL-12 and B7-1.
330
 The anti-inflammatory 
cytokine IL-10 is also up-regulated in response to TNF-α in ACS, suggesting a control 
mechanism for inflammation.
379
 
 
Catecholamines are directly involved in the regulation of IL-10 expression in monocytes, 
but not in T-cells, after acute stressful conditions.
379
 Furthermore, circulating monocytes in 
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Figure 3. Implication of monocytes in acute coronary syndrome. 
LFAA – lymphocyte function associated antigen, VLAAA – very late after activation 
antigen, PPAR - peroxisome proliferator-activated receptor, COX – cyclooxigenaze, MG-
CSF – monocyte-granulocyte colony stimulating factor, FSAP – factor VII activating 
protease 
 
 
ACS produce equal amounts of TNF-α, but less IL-10 (after stimulation with LPS in vitro) 
as compared with healthy controls.
380-381
 Thus, the production of proinflammatory 
cytokines is not counterbalanced by anti-inflammatory cytokines such as IL-10.
 
 
Monocytes are involved in the destabilization of atherosclerotic plaques by their 
production of matrix metalloproteinases. Indeed, catecholamines potentiate LPS-induced 
synthesis of matrix metalloproteinase 1 and matrix metalloproteinase 9 in circulating 
monocytes and monocyte-derived macrophages.
382
 Oxidized LDL also stimulates 
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monocyte expression of the urokinase receptor and consequent urokinase-mediated matrix 
metalloproteinase 9 generation.
383
 The scavenger receptor CD204 and a chemokine, CXCL 
16 are responsible for the uptake of oxidized LDL and phosphatidylserine, and 
transforming the macrophage into a foam cell.  
 
In other studies, increased monocyte expression of extracellular matrix metalloproteinase 
inducer and cyclooxygenase-2 enhance the production of matrix metalloproteinase 1 and 
matrix metalloproteinase 9 in acute MI.
384-385
 In animal models of acute MI, strong 
monocyte myeloperoxidase activity correlates with progressive LV dilation and LV 
function impairment.
386
 Also, human monocytes stimulated with TNF-α release 
angiotensin II, which further stimulates matrix metalloproteinase 1 synthesis.
387
 
 
2.3.5. Monocyte scavenger receptors 
 
Various scavenger receptors represent an important part of the monocyte receptor system, 
which is involved in detecting of different substances and their elimination from blood and 
tissues (e.g., accumulation of lipids into the atherosclerotic plaques).
388-389
 
 
The main scavenger receptors expressed on circulating monocytes express are SR-AI 
(CD204) and CD36. These receptors have a high-affinity to oxidized phospholipid 
components of the oxidized LDL.
390
 Mice studies showed absence of lipid accumulation in 
aortas of mice that lacked both CD36 and apoE.
391
 Scavenger receptor-dependent lipid 
accumulation and progression of atherosclerosis is supported by findings of an abundance 
of oxidized phospholipids that serve as binding partners for CD36/CD204 in the plaque 
region of blood vessels, along with absence of oxidized phospholipids in the nonplaque 
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region. Recent experimental studies suggest that CD36 has both a proatherogenic and a 
prothrombotic role in the cardiovascular system. The enrichment of oxidized phospholipids 
in the plaque allows CD36 to penetrate the plaque, whereas removal of CD36 decreases the 
progression of atherosclerosis.
392
 
 
Macrophage/foam cells produce cytokines that activate neighbouring smooth muscle cells, 
resulting in extracellular matrix formation, fibrosis, and plaque instability.
393
 In one study 
12,625 genes were analysed in peripheral blood mononuclear cells in ACS patients in the 
acute and chronic stable phases.
394
 Gene expression profiles revealed that amongst 
different immune response factors and the receptor activity markers, CD204 was the most 
markedly increased in the acute phase of ACS. Recurrence of cardiovascular events was 
significantly lower in the ‘CD204 low’ group compared to patients with high CD204 
expression.
394
 The number of CD204-expressing monocytes is much higher amongst 
patients with ACS compared to those with chronic CAD and this was associated with a 
higher rate of residual mural thrombus in acute MI patients.
34
 
 
Of interest emerging data also indicate that CD204 may be implicated in a number of 
reparative processes, such as clearance of apoptotic cells, attenuation of oxidative stress 
and inflammation.
29-33
 However, information on monocyte CD204 expression in HF not 
available at present. 
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2.3.6. Monocyte counts in myocardial infarction and heart failure 
 
Recent data show that monocyte counts correlate with mortality in patients with acute 
MI.
395
 Peripheral monocytosis occurs 2 to 3 days after MI onset, reflecting the mobilisation 
of monocytes and macrophages into the necrotic myocardium and this is associated with 
the extent of myocardial damage, creatine kinase release and fibrinogen levels.
396-397
 An 
increase in procoagulant activity of circulating monocytes after successful PCI in MI has 
been correlated with an increase in systemic IL-6 levels.
398
 
 
How do monocytes relate to clinical parameters and prognosis post-MI?  Monocyte counts 
on the first few days after acute MI treated with primary PCI correlated with markers of 
effective myocardial reperfusion, such as myocardial blush Grade 2-3 and ST-segment 
resolution on the ECG.
399
 Amongst all white blood cells, only monocytes were 
significantly and independently associated with the contractile recovery of the infarcted 
area at 6 months.
399
 Of note, patients with MI complicated by HF or LV aneurysm had 
much higher peak monocyte counts than those without these complications. Indeed, 
predischarge left ventriculography revealed that peak monocyte count negatively 
correlated with LVEF and positively correlated with LV end-diastolic volume (indicating 
their role in myocardial remodelling) and cardiac events, including readmission for HF, 
recurrent MI and cardiac deaths (including sudden deaths).
320
 In another study, peripheral 
monocytosis was associated with non-recovery of LV performance in patients with LV 
dysfunction complicating acute MI.
400
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Interestingly, patients who experienced hostility and stressful events in ACS often had 
more pronounced monocytosis.
401
 In the study by Horne et al., 3227 stable subjects 
monocyte count was independent predictor of future MI development or death.
402
 
 
Despite the well recognised contribution of monocytes to the pathogenesis of different 
cardiovascular disorders scarce information is available on their numbers in patients with 
HF.
 
 
2.3.7. Drug treatment and monocyte activity 
 
The significant role of monocytes in cardiovascular disorders makes them a potential target 
for pharmaceutical treatment (Table 11). However only a limited number of studies is 
currently available on effects of drug therapy on monocyte characteristics, with the most of 
the agents tested being routinely used in ACS and/or in HF. 
 
Anticoagulants. Abciximab (but not heparin) reduced platelet mass attached to monocytes 
in acute MI patients through the reduction of Mac-1 expression but did not affect the 
number of MPAs.
403
 Combination of reteplase and abciximab was much more effective in 
MPA reduction than reteplasealone.
404
 Implantation of heparin-coated stents in ACS 
accelerates normalisation of platelet-leukocyte aggregate levelscompared to balloon 
angioplasty alone.
405 
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Table 11. Effects of drug treatment on monocytes 
Drug Species Disorder/Model Effects on monocytes 
Abciximab
403 
Human MI Reduced Mac-1 expression and 
platelet mass attached to monocytes; 
no effect on MPA number 
Reteplase and 
abciximab
404 
Human MI Reduced MPA number more 
effectively that reteplase alone 
Heparin-coated 
stents
405 
Human ACS Restored MPAs quicker compared to 
angioplasty alones 
Kaptopril, 
idrapril, 
fosinopril, 
losartan
406 
Human Healthy 
volunteers 
Decreased monocyte TF expression 
Enalapril
407 
Human MI Reduced MCP-1 levels 
Perindopril, 
candesartan
408 
Human MI No effects on MCP-1 levels 
Clopidogrel
409 
Human ACS Decreased MPA number 
Atorvastatin
410 
Human ACS Reduced MCP-1 levels 
Atorvastatin
411 
Human MI Reduced monocyte cyclooxygenese-2 
Cerivastatin
383 
Human Healthy 
volunteers 
Decreased expression of urokinase 
receptor on monocytes 
Celecoxib
385
 Human MI Reduced monocyte secretion of IL-6 
and matrix metalloproteinase 9 
Dobutamine
412 
Human Monocyte 
culture 
Inhibited LPS-induced production of 
MCP-1 
Eplerenone
413 
Rat MI Prevented LV dilation and improved 
LV function via mineralocorticoid 
receptor blockade 
 
ACE inhibitors and angiotensin II receptor antagonists. Captopril, idrapril, fosinopril and 
losartan decreased monocyte TF expression in vitro.
406
 In a small randomized, double-
blind, placebo-controlled study 4 week treatment with enalapril (5 mg daily) significantly 
reduced MCP-1 levels in MI patients.
407
 However, no effect of perindopril or candesartan 
on MCP-1 levels was found in acute MI.
408 
 
Antiplatelet drugs. Both loading dose (300mg) and continuous administration of 
clopidogrel decreased MPA numbers in ACS.
409 
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Statins. Atorvastatin reduced MCP-1 levels in ACS and monocyte cyclooxygenase-2 
expression in acute MI.
410-411
 Another statin, cerivastatin was able to decrease expression 
of urokinase receptors on monocytes.
383 
 
Other drugs. Ininvitro studies celecoxib dramatically reduced monocyte secretion of IL-6 
and matrix metalloproteinase 9 and dobutamine successfully inhibited LPS-induced 
production of MCP-1.
385, 412
 In animal MI models, eplerenone effectively preventedLV 
dilation and improved LV function via mineralocorticoid receptor blockade.
413 
 
2.3.8. Monocyte subsets 
 
Circulating monocytes are not a homogeneous population of cells - whether defined 
phenotypically and functionally - and include several subpopulations, which play complex 
roles in atherogenesis, each with their own potential for promotion of plaque formation. A 
substantial part of our knowledge on the role of monocyte subsets in atherogenesis derives 
from studies of mouse monocytes which include two major subsets: Ly-6C
hi
 monocytes 
and Ly-6C
lo
 monocytes.  
 
Counts of Ly-6C
hi 
monocytes are increased dramatically in hypercholesterolemic apoE-
deficient mice consuming a high-fat diet, actively adhere to activated endothelium, 
infiltrate atherosclerotic lesions, and became lesional macrophages.
414
 Ly-6C
lo
 monocytes 
enter atherosclerotic lesions less frequently, but they are prone to developing into plaque 
cells expressing the dendritic cell-associated marker CD11c, and appear to have enhanced 
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atherogenic activity, indicating that phagocyte heterogeneity within plaques is linked to 
distinct sub-populations of infiltrating monocytes.  
 
Plaque recruitment of Ly-6C
lo
 cells is CCR5 (but not CX3CR1)-dependent whilst Ly-6C
hi
 
monocytes unexpectedly required CX3CR1 (normally expressed at low levels on these 
cells) in addition to CCR2 and CCR5 to accumulate within plaques.
415
 Genetic deletion of 
CCR2, CX3CR1 or their ligands markedly reduces atherosclerotic lesion size in animal 
models of atherosclerosis.
416
 Moreover, double deletion of CX3CL1 and CCR2 expression 
in mice has an additive effect and dramatically reduces macrophage accumulation in the 
artery wall and development of atherosclerosis.
416
 Recently, a triple inhibition of CCL2, 
CX3CR1, and CCR5 in hypercholesterolemic mice led to a marked and additive 90% 
reduction in atherosclerosis.
417
 Of interest, in this study the lesion size strongly correlated 
with the absolute number of circulating monocytes, but particularly so with the Ly-6
lo 
subset.
417
 
 
Oxidized LDL promotes conversion of CD11c- monocytes to CD11c+ cells and a high fat 
diet significantly increases the proportion of Ly-C6
lo 
CD11c+ monocytes in apoE-deficient 
mice resulting in an increased proportion of circulating CD11c+ monocytes with abundant 
lipids in the cytoplasm and ‘foam’ cellsphenotype.
418
 This formation of CD11+ circulating 
‘foam’ cells was associated with CD204 expression on their surface and was accompanied 
by abundant accumulation of CD11c+ cells in the atherosclerotic plaques.
418
 
 
Whilst human monocytes do not have direct equivalents of markers used for discrimination 
of mouse monocyte subsets, it is clear that monocyte subpopulations also exist in humans. 
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At present, human monocyte subsets are characterised by surface expression of CD14 
(LPS and apoptotic cell receptor) and CD16 (Fc γ receptor type III) with about 85% of 
circulating monocytes being CD14++CD16– cells and about 15% of monocytes being 
represented by minor CD16+ populations (normally below 15%). CD14++CD16– cells 
monocytes are considered to be counterparts of the Ly-C6
hi 
mouse monocytes and 
CD14+CD16+ cells – of the Ly-C6
lo
 mouse subset.
25
 
 
A proportion of CD14+CD16+ monocytes has been previously shown to positively 
correlate with serum cholesterol and triglyceride levels, and negatively correlate with HDL 
cholesterol levels in patients with hypercholesterolemia and they are increased in those 
with developed CAD.
419-420
 Also, CD14++CD16– monocytes from patients with familial 
hypercholesterolemia preferentially take up native LDL whereas CD14+CD16+ monocytes 
exhibit an increased uptake of oxidized LDL via CD36, an increased expression of CD11c 
and macrophage markers and a higher adherence to activated endothelial cells in response 
to oxidized or native LDL stimulation.
421
 Given that recent data show that mouse Ly-6C
lo
 
monocytes (analogous of CD16+ human monocytes) ‘patrol’ arterial endothelial surface, it 
seems possible that CD16+ monocytes exert a specific role in the handling of oxidized 
LDL deposits on the vessel wall.
418, 422
 Indeed, monocytes isolated from patients with CAD 
also have increased CX3CR1 expression.
423
 
 
However, the acknowledgment ofthe substantial role of monocytes and their subsets in 
atherogenesis raises important issue of the interactions of these cells with recognised 
cardiovascular risk factors. At present it is commonly accepted that cardiovascular risk 
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factors exert atherogenic properties mainly through the damage of vascular wall and 
modulation of lipid metabolism. 
 
The presence and number of cardiovascular risk factors is significantly and differentially 
associated with counts of monocyte subsets.
424
 There is a significant correlation between 
the ‘classical’ inflammatory CD14++CD16– monocytes and the number of risk factors 
present in patients with CAD suggesting novel mechanisms linking cardiovascular risk 
factors and chronic inflammation in atherosclerosis.
424
 
 
Despite the growing evidence of important and diverse roles of monocyte subsets in 
cardiovascular disorders only scarce data are available in relation to HF. Recently 
Barisione et al. suggested that in a small study that CD14++CD16+ cells was increased in 
30 patients with chronic stable HF compared with 26 healthy controls.
425
 However, the 
study participants differed not only by the presence of HF but also by the presence of 
CAD, hypertension, diabetes, and other morbidities commonly seen in patients with HF 
and which could drive the between the two groups. Clearly more data are needed in 
relation to this area. 
 
2.3.9. Angiogenesis and heart failure 
 
Angiogenesis is a physiological process characterised by the growth of new blood vessels 
from preexisting ones.
426
 More recently the term arteriogenesis has been additionally 
introduced, defined as an outgrowth of pre-existing arterioles into large conductance 
97 
 
collateral arteries.
426
 Both processes have been implicated in the pathophysiology of 
various cardiovascular disorders including CAD and HF.
426
 
 
Among of the pro-angiogenic factors vascular endothelial growth factor (VEGF) is perhaps 
best characterized and featured by high (as compared to other growth factors) specificity 
for the vascular endothelium.
427
 VEGF triggers a potent signalling cascade within 
endothelial cells and represents a major contributor to angiogenesis, inducing accelerated 
formation of the capillary network in affected tissues. In in vitro studies stimulation with 
VEGF led to proliferation of bovine capillary endothelial cells followed by formation of 
tubular structures.
427
 
 
Abnormal levels of angiogenic factors, such as VEGF have been reported in HF 
patients.
287, 428
 VEGF levels are reduced in congestive HF but they are up-regulated in 
acute HF.
429-430
 VEGF did not independently predict outcome in chronic HF, and a 
pathophysiological role of angiogenic factors in human HF is unclear.
287
 However, 
treatment with VEGF reduced myocardial apoptosis, promoted capillary growth, preserved 
myocardial contractility and prolonged survival in animal studies.
431-432
 
 
More recently, the angiopoietins, another family of growth factors specific for the vascular 
endothelium has been characterised.
433
 The angiopoietins are growth factors acting through 
interaction with their surface cellular receptors, Tie-1 and Tie-2.
434
 These receptors are 
tyrosine kinases similar to VEGF receptors.
434
 However the actions of the angiopoietins 
appear to be quite different from those of VEGF, although they act in a complementary and 
coordinated way, playing a key role in vascular development. Angiopoietin-1 is also a 
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chemotaxin and - in conjunction with VEGF - recruits endothelial cells to initiate and 
accelerate angiogenesis. In the presence of VEGF angiopoietin-2promotes a rapid increase 
in capillary diameter, remodelling of the basal lamina and new vessel growth. In contrast, 
if VEGF is inhibited, angiopoietin-2 leads to endothelial cell death and vessel 
regression.
428, 434
 Chong et al. demonstrated increased levels of VEGF, angiopoietin-2 and 
Tie-2, but normal levels of angiopoietin-1, in both stable and decompensated HF thus 
indicating a potential role for these angiogenic factors in the pathophysiology of HF.
312
 
 
Increased levels of angiogenic factors in HF cannot be considered as a direct proof of 
enhanced angiogenesis in HF per se. Further evidence of abnormal angiogenesis in HF is 
coming from animal models indicating that impaired angiogenesis may lead to HF.
435
 For 
example, STAT3-deficiency in mice was associated with reduced density of myocardial 
capillary network leading to enhanced interstitial fibrosis, dilation of cardiac chambers and 
premature death.
435
 Also VEGF was able to improve collateral circulation, facilitating 
recovery of global and regional cardiac contractility in a model of temporal coronary artery 
occlusion.
436
 
 
2.3.10. Monocytes and angiogenesis 
 
Current data suggest a potential implication of monocytes in vascular tissue repair. It has 
been shown that macrophage depletion markedly delays wound healing, impairs cardiac 
remodelling and increases mortality after myocardial injury, thus identifying the 
macrophages as key players in myocardial healing.
437
 Indeed, in animal models the lack of 
macrophages was accompanied by premature development of myocardial dysfunction.
438
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In contrast, appropriate macrophage activation might be important for cardiovascular 
repair, removal of apoptotic/necrotic tissues and other debris, and thus 
monocyte/macrophage depletion may not necessarily be an effective approach for the 
prevention of HF.
438
 Indeed, these studies revealed a favourable role of monocytes in the 
prevention of excessive ischaemia-induced myocardial remodelling, probably due to their 
role in angiogenesis. 
 
Angiogenesis stimulated by tissue hypoxia is mediated by activation of expression of 
hypoxia-inducible factor-1α and it usually results into the development of new 
capillaries.
439-440
 Angiogenesis is a tightly regulated process that occurs in the context of a 
fine-tuned balance between pro-angiogenic and anti-angiogenic factors.
440
 In various 
cardiovascular injury models, including MI and stroke angiogenesis positively correlates 
with macrophage levels at the site of damage.
440-441
 These findings are supported by the 
observation of an up-regulated DNA synthesis by endothelial cells at sites of macrophage 
accumulation in damaged tissues. Additionally, macrophages isolated from sites of tissue 
injury have been shown to induce angiogenesis in vitro, similarly to media taken from the 
macrophage culture.
442-443
 Taken together, the available data imply that activated 
macrophages are able to influence angiogenesis, mainly via expression of pro-angiogenic 
factors (e.g., VEGF) and orchestrating activity of other cell types involved in 
angiogenesis.
444-445
 Finallyemerging data suggest that some monocyte populations have a 
potential to directly differentiate into endothelial cells, which is discussed in the following 
section. 
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2.3.11. Endothelial progenitors in heart failure 
 
According to a changing paradigm, in addition to endothelium-resident cells, endothelial-
progenitor cells (EPCs) derived from the bone marrow play a significant role in 
angiogenesis and endothelial repair.
38
 EPCs are defined as circulating cells of myeloid 
origin sharing stem cell surface markers (e.g., CD34) and an endothelial marker (usually 
VEGF receptor 2 [KDR]).
39
 The surface marker CD133 is detected on an immature subset 
of EPCs and it was suggested as an additional marker of human angioblast-like EPCs to 
distinguish these from mature endothelial or monocytic cells. Accordingly, the combined 
phenotype of CD34+CD133+KDR+ cells was used in many studies alongside to 
CD34+KDR+ definition of EPCs.
39
 
 
Conflicting reports have been published on the numbers of circulating CD34+ 
haematopoietic progenitors in HF with some studies observing reduction or no change in 
their levels irrespectively of HF aetiology (Table 12).
446
 HF severity rather than its 
aetiology appears to be the main factor affecting levels of CD34+ cells. Indeed, CD34+ 
cells have been shown to be increased in mild HF and depressed in severe HF compared to 
HF free controls.
447
 Others studies confirmed a significant inverse correlation between 
CD34+ and CD34+CD133+ counts and NYHA functional class and their progressive 
reduction from NYHA class I-II to NYHA class III HF independently of aetiology.
448-449
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Table 12. Studies assessing circulating endothelial progenitor cells in heart failure 
Study Study design and 
definition of heart failure 
Definition of 
EPCs 
Outcome 
Valgimigli
449
 Case-control, observational 
Objective ventricular 
impairment 
[NYHA I-IV] 
 
CD34+CD133 
+KDR+ 
↑ EPCs in early 
stages of HF 
Nonaka-
Sarukawa
447
 
Case-control observational 
[NYHA I-IV] 
 
CD34 + ↓ EPC in 
advanced HF 
Michowitz
450
 Prospective observational 
Primary end point: survival 
[NYHA II-IV] 
 
‘Early’ EPC 
colonies 
(flk-1+, Tie-2+, 
CD31+) 
The number of 
colonies was an 
independent 
predictor of 
mortality  
Geft
451
 Case-control observational 
[NYHA I-IV] 
CD34 + Number of 
apoptotic EPCs 
positively 
correlated with 
NYHA class 
 
Fritzenwanger
448
 Case-control, observational 
[NYHA I-IV] 
 
CD34 + 
CD133 + 
Number of 
EPCs inversely 
correlated with 
NYHA class. 
NYHA, New York Heart Association; EPC, endothelial progenitor cells; VEGF, vascular 
endothelial growth factor, HF, heart failure; EC, endothelial cell. 
 
 
It is likely that a reduction in CD34+ cell levels is secondary to HF rather than an element 
of HF pathogenesis itself and it probably reflects bone marrow depression and anaemia 
common in severe HF. These hypotheses are supported by observations that implantation 
of ventricular assist devices was associated with a transient increase in CD34+ cells in 
parallel with a reduction in BNP levels.
452
 Also CD34+ cell numbers in HF were not 
affected by physical exercise testing, and transcoronary transplantation of CD34+ cells into 
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patients with a history of an anterior MI did not have any effect on endothelial function.
453-
454
 
 
Numbers of ‘early’ EPCs, counted in culture are reduced in HF, being inversely related to 
NYHA class, but not to VEGF, NT-pro-BNP or CRP levels.
449-450
 The migratory activity 
of ‘early EPCs’ is significantly impaired in HF (particularly of ischaemic aetiology), 
correlate with endothelial dysfunction and can be normalised by physical exercise.
446, 453
 
Functional impairment of circulating progenitors in HF is also supported by increased 
numbers of ‘late’ apoptotic progenitors, particularly in severe HF, which correlated 
inversely with LVEF and positively with NYHA class.
451
 In 107 patients with chronic HF, 
‘early EPCs’ were independent predictors of all-cause mortality.
450
 NT-pro-BNP dose-
dependently increased the numbers, proliferative and functional capacity of human ‘early’ 
EPCs in vitro.
455
 Systemic BNP administration to mice led to a significant increase in bone 
marrow Sca-1/Flk-1+ endothelial progenitors and improvement in blood flow and capillary 
density in the ischaemic limbs.
455
 
 
CD34+KDR+ cells seem to be only significantly reduced in patients with very severe 
HF.
449, 453
 Indeed, numbers of CD34+KDR+ cells in HF are unaffected by physical 
exercise or implantation of ventricular assist devices.
452-453
 However, in one randomized 
study 3 months treatment with high doses of rosuvastatin increased CD34+KDR+ cells and 
their integrative capacity, which paralleled a significant improvement in FMD and 
LVEF.
194
 Additionally, implantation of CD133+ cells in the infarcted zone in 7 candidates 
for cardiac transplantation was associated with improvement of NYHA class, LVEF, 
reduction in NT-pro-BNP levels, and risk of sudden death by 24 months after treatment.
456
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However, the last study was small, lacked a control group and two of the seven patients 
died during the period of the observation – thus, larger controlled trials are essential to 
draw any robust conclusion on clinical perspectives of such therapies in HF.  
 
In summary, the biological and pathological roles of altered production of angiogenic 
factors are still not entirely clear. They may reflect a degree of compensatory angiogenesis 
in patients with ischaemic HF but it is more plausible that these changes reflect an ongoing 
process of vascular remodelling in response to the haemodynamic changes. The potential 
of these pathways as therapeutic targets is still to be determined.  
 
2.3.12. Monocytes as endothelial progenitor cells 
 
Admittedly, the origin as well as the phenotypic and functional characteristics of EPCs 
remains poorly understood. Several cell types obtained either from bone marrow, 
peripheral blood or tissue-resident stem cells have potential to differentiate into endothelial 
cells, with CD14+ myeloid monocytic cells being a common source of EPCs. Moreover, 
EPC phenotype may change during the process of maturation, which begins in the bone 
marrow and continues in the circulation. Early in the circulation EPCs loose CD133 and 
they increasingly express endothelial markers. More recently EPCs were re-defined 
according to their in vitro angiogenic potency as endothelial cell colony-forming units 
(with limited potential for proliferation), and endothelial colony-forming cells (with almost 
unlimited ability to proliferate in culture).
457
 The authors concluded that endothelial 
colony-forming cells are the ‘true’ EPCs able to differentiate into functional endothelial 
cells and form perfused vessels in vivo. It becomes apparent that EPCs represent a 
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heterogeneous population in terms of origin and their angiogenic properties. This 
heterogeneity should be cautiously taken into consideration in future cell therapy studies 
and studies aiming to identify novel pharmacological target molecules related to 
angiogenesis.  
 
Much attention has also been attracted to the capacity of monocytes to act as potential 
EPCs.
458-459
 Circulating monocytes can differentiate into different types of phagocytes, 
such as macrophages, dendritic cells, osteoclasts, microglia and Kupffer cells.
460
 Until 
recently, the differentiation potential of monocytes was believed to be restricted to cells 
with phagocytic or antigen-presenting properties. However, several lines of evidence 
suggest that circulating CD14+ monocytes are able to (trans)differentiate into various non-
phagocytes, including cells of mesodermal and neuroectodermal lineages.
459
 Curiously, 
this phenomenon was probably first described almost 150 years ago, in 1867 when 
Cohnheim and co-workers showed that peripheral blood monocytes participated in tissue 
renewal in different organs.  
 
The ability of circulating cells of hematopoietic origin to differentiate into endothelial cells 
at sites of vascular remodellingwas initially reported by Crosby et al.
461
 who demonstrated 
that blood-derived cells represent ~10% of endothelial cells in mice neovasculature 
developed in response to ischaemia. At almost the same time another group   revealed that 
under appropriate in vitro conditions CD14+ cells can differentiate into endothelial-like 
cells with characteristic endothelial features.
462
 Also macrophages were shown to infiltrate 
the myocardium in response to cardiac MCP-1 overexpression and to form erythrocyte-
containing vascular-like tubes.
463
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Injection of human CD14+ cells improves healing and vascularisation of the ischaemic 
limbs in diabetic mice.
464
 Transplantation of CD14+KDR+ cells into balloon-injured 
femoral arteries of nude mice significantly contributed to efficient reendothelialization, 
whilst CD14+KDR– monocytes failed to produce any effect.
465
 Experimental work shows 
that monocytes may include subpopulations of multipotent cells capable of in vitro 
differentiation into various somatic cell types.
37
 These cells, but not ‘classical’ monocytes, 
were able to successfully restore LV function after experimental MI.
466 
 
The number of circulating CD14+KDR+ cells has been found to be increased in acute MI. 
CD14+KDR+ but not CD14+KDR– cells stimulated organization of human microvascular 
endothelial cells into capillary-like structures.
467
 Human activated macrophages delivered 
to rats early after MI accelerated vascularization, tissue repair, and improved cardiac 
remodelling and function.
468
 In mice, M-CSF reduced the infarct area and improved LV 
remodelling after MI through the recruitment of CXCR4+ cells into the infarcted 
myocardium.
469 
 
However, it was noted that cells of the monocytic origin lacked some endothelial cell 
antigens and couldthemselves be subsequently colonized by endothelial cell. Indeed, 
Harraz et al. reported that CD14+CD34+ monocytes have the potential to be incorporated 
into the vascular endothelium in mouse ischaemic limbs and to transdifferentiate into 
endothelial cells (or other cells types) depending on the environmental cues.
470
 
Furthermore, under angiogenic stimulation (e.g., with VEGF) monocytes can develop an 
endothelial phenotype with expression of specific surface markers and even to form 
tubular-like structures in vitro, thus suggesting possible implication in vasculogenesis.
471
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Finally, Kuwana et al. described a primitive cell population termed as monocyte-derived 
multipotential cells (MOMC) and they introduced a concept of the multipotential nature of 
circulating monocytes.
472
 This cell population contains progenitors that can differentiate 
into several distinct mesenchymal cell types, including bone, cartilage, fat, skeletal and 
cardiac muscle cells, as well as neurons. MOMCs can be generated in vitroby culturing 
circulating CD14+ monocytes on fibronectin in the presence of soluble factors derived 
from circulating CD14+ cells. MOMCs express several endothelial markers, including 
vascular endothelial cadherin and VEGF type 1 receptor, and have the ability to take up 
acetylated LDL. More recently, the same group have demonstrated that transplantation of 
the MOMCs promoted the neovessel formation with over 40% of the newly formed vessels 
incorporated human endothelial cells derived from MOMCs.
473
 These findings indicate 
that humanMOMCs can proliferate and differentiate along the endothelial lineage in a 
specific permissive environment and thus could represent an autologous transplantable cell 
source for therapeutic vasculogenesis.  
 
These data clearly demonstrate the intimate relationship between monocytes and 
endothelial cells suggesting that specific monocyte population(s) may be recruited for 
vasculogenesis and may represent a population of endothelial precursors. However, it 
remains to be determined how EPCs are implicated in the pathophysiology of HF and how 
can EPC activity be manipulated in beneficial ways. 
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2.3.13. Monocyte-platelet aggregates 
 
The adhesion of leukocytes to platelets deposited at the site of vascular injury may 
represent an important mechanism by which leukocytes contribute to haemostasis and 
thrombosis. Indeed, the risk of graft occlusion after reconstructive surgery amongst 
patients with peripheral vascular disease is much higher in those with more active 
leukocyte-platelet adhesion in the early postoperative period.
474
 The number of monocyte-
platelet aggregates (MPA) is also markedly increased after hip and knee artroplasty.
475-476
 
Such an increased formation of MPAs has been associated with high levels of P-selectin, 
CD40 ligand, TF and Mac-1 expression on monocytes; a correlation with beta-
thromboglobulin levels suggestsa role of MPAs in augmenting blood coagulability after 
major joint surgery.
477
 Patients with essential thrombocythemia, a disorder characterised by 
a high risk of thrombosis, also had increased MPA levels.
478
 
 
MPAs form when platelets are activated and undergo degranulation. Activated platelets 
express on their surface high levels of P-selectin that binds to the leukocyte receptor, P-
selectin glycoprotein ligand-1.
479
 In vivo data confirm that P-selectin augments platelet-
leukocyte aggregation.
479
 In experimental models, the infusion of recombinant human P-
selectin glycoprotein ligand-1 reduced myocardial reperfusion injury in an animal model of 
vascular injury.
480
 Platelet derived microparticles, which are shed from platelets upon their 
activation, also interact with monocytes in a mechanism dependent upon CD62P, similar to 
that seen with MPA formation.
481
 Additionally, platelet adhesion to monocytes may occur 
through calcium independent mechanisms, involving neither P-selectin glycoprotein 
ligand-1 nor P-selectin.
482
 Thrombospondin is also reported to be involved in the cross-link 
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between platelets and monocytes in early vascular injury via an interaction with 
glycoprotein IV on the surface of both cells.
483
 In fact, MPAs is a good marker of platelet 
activation (e.g., in ACS) being even superior to surface P-selectin expression as the latter is 
rapidly released into circulation by degranulated platelets whilst MPAs continues to be 
detected in the circulation.
484
 
 
An important question relates to the biological role of MPAs. They may simply reflect the 
physiological mechanism of elimination of activated platelets from the circulation and just 
represents a stage of platelet adherence to monocyte prior to their phagocytosis. As early as 
in 1966, Poole
485
 demonstrated the phagocytosis of platelets by monocytes in organised 
arterial thrombi using electron microscopy. That means that high levels of MPAs seen in 
ACS may perhaps reflect disproportionally high number of activated platelets in the 
circulation in relation to the relatively small area of local vascular injury. Alternatively, 
monocytes may be attracted to remove excessive activated platelets.  
 
However, the role of MPAs might be even more complicated. Elstad et al. have suggested 
that P-selectin may prime monocytes to increase platelet-activating factor synthesis, thus 
representing a vicious circle leading to progressive and uncontrolled platelet activation.
345
 
Additionally, conjugation with platelets activates expression of Mac-1 on monocytes, 
which amplifies interactions with platelets via fibrinogen bivalently linking Mac-1 with its 
platelet glycoprotein IIb/IIIa.
486-487
 The importance of MPAs for the vascular thrombosis is 
further supported by the observation that monocytes constitute16% of platelet thrombus-
bound leukocytes, which represents an almost 4-fold enrichment as compared with their 
proportion in circulating blood.
488
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The conjugation of leukocytes with platelets is promoted by different conditions associated 
with inflammation and endothelial dysfunction (e.g., diabetes).
489-490
 Incubation of human 
blood with CRP doubles MPA formation and injection of LPS to mice increased MPA 
count 4-fold.
491
 MPAs —but not platelet aggregates with lymphocytes and neutrophils— 
are increased in patients with diabetes.  Indeed, more severe diabetes (for example, 
complicated by proliferative retinopathy and nephropathy) is associated with an even 
higher numbers of MPAs.
490
 The increased association of monocytes with platelets accords 
with the data of enhanced of thromboxane A2 by monocytes in diabetic patients.
492
 The 
number of circulating MPAs increases with age and correlates with reduced synthesis of 
NO by platelets.
493
 
 
Not surprisingly, MPA formation is increased in patients with CAD (Table 13). Patients 
with stable CAD have increased circulating MPAs compared with controls (15.3% 
vs.6.3%, respectively).
494
 However, destabilisation of atherosclerotic plaques complicated 
by atherothrombosis results in a profound (3-fold) increase in total and TF-positive MPAs 
found in blood of ACS patients compared to stable CAD.
483, 495
 For example, Furman et al. 
examined 61 patients with acute MI and compared them with 150 control subjects and 
reported that intensive formation of MPAs in MI starts very early and may be detected 
within 4 hours of symptom onset, even prior the increase in creatinine kinase levels.
496
 
However, utility of MPA count for diagnostic purposes in ACShas to be tested with direct 
comparison to cardiac troponins, and it has important limitations relevant to a labour 
intensive procedure for MPA enumeration by flow cytometry and the lack of exclusive 
cardiac specificity. 
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Table 13. Monocyte tissue factor expression and monocyte-platelet aggregates in 
patients with cardiovascular risk factors and cardiovascular disorders 
Study Condition Controls Monocyte effects 
Puccetti
497
 Hypercholesterolemia Healthy Increased TF 
expression 
Ichikawa
498
 Diabetes mellitus Healthy Increased TF 
expression 
Kaplar
490
 Diabetes mellitus with 
angiopathy 
Diabetes 
mellitus without 
angiopathy 
Increased MPAs 
Hölschermann
499
 Smoking pre-
menopausal women 
Non-smoking 
pre-menopausal 
women 
Increased TF 
expression 
Furman
494
 Stable CAD Healthy Increased MPAs 
Kälsch
500
 Unstable angina Stable CAD No effect on TF 
binding and MPAs 
Brambilla
495
 Acute coronary 
syndrome 
Stable CAD, 
healthy 
Increased TF-positive 
MPAs 
Sarma
482
 Acute coronary 
syndrome 
Stable CAD Increased MPAs 
Furman
496
 Myocardial infarction Stable CAD Increased MPAs 
Freeburn
501
 Myocardial infarction Stable CAD Increased MPAs 
Vieira
502
 Deep vein thrombosis Healthy Increased TF 
expression 
Hölschermann
503
 Cerebral venous 
thrombosis (women) 
Healthy Increased TF 
expression 
Arellano-
Rodrigo
504
 
Essential 
thrombocythemia with 
history of thrombosis 
Healthy Increased TF 
expression, increased 
MPAs 
Kornberg
478
 Polycythemiavera Healthy Increased TF 
expression 
Bunescu
476
 Hip arthroplasty Prospective 
study 
Increased MPAs 
 
CAD – coronary artery disease, MPA – monocyte-platelet aggregates, TF – tissue factor 
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Given the clear association of MPAs with the onset of atherothrombosis, these may 
perhaps be appealing targets for antitrombotic treatment. However, only limited data are 
available on the effects of medical therapy on MPA levels. Of note, anticoagulation has 
little impact on monocyte-platelet interactions.
505
 In a recent randomized study of 60 
patients undergoing percutaneous coronary intervention (mostly with stable CAD) 
anticoagulation with a combination of unfractioned heparin and eptifibatide was associated 
with higher MPA counts compared with bivalirudin, but this difference disappeared after 
pretreatment with clopidogrel.
479
 In one in vitrostudy, the formation of MPAs was 
markedly enhanced in the presence of glycoprotein IIb/IIIa antagonist, MK-852.
506
 In 
contrast to anticoagulants, antiplatelet therapy reduced MPAs by 46% within 4 days.
505
 
This effect has been correlated with a concomitant decrease in monocyte Mac-1 
expression.
505
 
 
2.3.14. Conclusions 
 
There is a convincing evidence that monocytes possess high developmental plasticity, and 
are able to trans-differentiate into other non-phagocytic cell types under diverse 
microenvironments. Recent literature —mostly based onin vitro data— supports the 
hypothesis that monocytes include a population of potent progenitor cells actively involved 
in postnatal vasculogenesis, although, it is not certain whether monocytes can become fully 
functional endothelial cells. There is also a convincing evidence to support a significant 
role of monocytes in angiogenesis —a significant step in the process of tissue repair— 
following ischaemic myocardial injury. Increased monocyte activation seen at the sites of 
post-ischaemic injury is more likely to reflect an attempt for tissue repair rather than a 
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deteriorating immune overreaction. Thus, induction rather than inhibition of monocyte 
activation might be a potential therapeutic target.  
 
However the available data do not sufficiently establish a causative relation between 
altered monocyte-derived pathways and progression of HF. It is not clear whether this is a 
pathway leading to HF or a consequence of the systemic nature of HF. In the first case, 
mobilization of monocytes could be a potential therapeutic target whilst in the second case, 
monocyte number and function could be an excellent disease marker. Moreover it must be 
elucidated whether monocytes can differentiate to a fully functional endothelial cells or 
their contribution in angiogenesis and/or vasculogenesis is restricted to production of 
vascular growth factors. There is also a need to identify appropriate stimuli to lead 
monocyte differentiation to progenitor cells, and such stimuli have to be cell-specific and 
organ specific in order to limit their action towards the desired direction. Brain natriuretic 
peptides, granulocyte-colony stimulating factor and erythropoietin that have been used up 
to now as progenitor cell activators are neither cell nor organ specific. 
 
There is a big gap in research due to the lack of in vivo evidence supporting the ability of 
monocytes/macrophages infiltrating the dysfunctional vascular wall/myocardium to act as 
potent progenitor cells. Perhaps, certain stimuli are required for monocytes/macrophages to 
trans-differentiate into functional progenitor cells. Such stimuli might not be present in the 
dysfunctional tissue and may need to be externally applied. Alternatively, only a subset of 
monocytes may possess a capacity to trans-differentiate into progenitor cells. In my 
opinion it will be some time before monocyte-derived progenitor cells-based therapies can 
be applied in clinical practice. Nonetheless, much progress has been made during the last 
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years in the understanding of monocyte role in cardiovascular disease. I believe that their 
presence in sites of vascular or myocardial injury is not a catastrophic immune 
overreaction but a desperate attempt for tissue repair. 
 
Finally, anti-inflammatory treatment-strategies for the management of HF are now more 
than appealing theories; however, the initial trials that tested therapies targeting 
inflammation in the overall HF population have had disappointing results. As it has been 
underlined in a recent statement issued by the Translational Research Committee of the 
Heart Failure Association of the European Society of Cardiology, the most successful trials 
have been those where small very carefully selected groups of patients were treated. 
Indeed, the idea of a common inflammatory pathway that underlies all different forms of 
HF appears to be unlikely.
507
 It is probably more realistic to design specific anti-
inflammatory approaches for different types and/or stages of HF. Thus determination of 
the specific inflammatory pathways in different forms of HF is essential. The use of 
specific inhibitors of inflammation appears to be a promising treatment option; however, 
sufficient knowledge of basic mechanisms, detailed pre-clinical studies and justified 
patient selection for clinical trials are required for the development of successful anti-
inflammatory approaches in the management of HF. 
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2.4. Circulating microparticles in cardiovascular disease 
2.4.1. Definition of microparticles 
 
The extremely complex and multifactorial nature of many cardiovascular disorders, 
including atherogenesis and HF is well recognised.
508
 For example, in atherogenesis in 
addition to accumulation of lipids by ‘foam’ cells, plaque formation and progression, there 
are numerous interactions between various cell types inside the vascular wall (e.g., 
macrophages, smooth muscle cells) and in the blood (e.g., leukocytes and platelets). These 
interactions orchestrate alterations of the extracellular matrix, the migration of leucocytes 
through endothelium, inflammatory burden, plaque neovascularisation, growth and 
destabilisation, and ultimately, the development of atherothrombotic complications.
508
  
One relatively recent advance in this area is the discovery of circulating microparticles and 
their strong association with endothelial damage, platelet activation, hypercoagulability, 
and regulation of inter-cellular interactions, which links the presence of cardiovascular risk 
factor, atherogenesis and thrombosis.
509-510
 
 
Microparticles are defined as small (0.1 – 1 µm diameter) anucleoid phospholipid vesicles 
released from different cells, platelets, erythrocytes, leukocytes, endothelial cells.
511-513
 
Microparticles carry surface proteins and include cytoplasmic material of the parental cells. 
Microparticle membrane includes negatively charged phospholipids, mainly 
phosphatidylserine. Microparticles are distinguished from exosomes (which are smaller 
vesicles [40-100 nm] derived from endoplasmic membranes), and apoptotic bodies (which 
are larger particles [>1.5 µm] that contain nuclear components).
514
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2.4.2. Endothelial cell microparticles – a marker of vascular damage/dysfunction 
 
Circulating endothelial cell microparticles (EMPs) can be identified and measured by 
detection of antigens constitutively expressed by mature endothelial cells (e.g., CD31 
[platelet-derived growth factor], CD105 [endoglin], CD144 [vascular endothelium 
cadherin], CD146, etc).
515
 During the process of vesiculation, EMPs may also acquire 
inducible endothelial markers such as CD54 [ICAM-1], CD62E [E-selectin] and CD106 
[VCAM-1], TF and annexin V [an apoptotic marker]). The presence of these antigens on 
the microparticle surface affects their biological activity and may serve as a basis of EMP 
classification: for example, CD54+, CD62E+ and CD106+ EMPs predominantly reflect 
inflammatory endothelial cell activation, whilst TF+ EMPs reflect prothrombotic changes 
of endothelial cells, and annexin V+ EMPs characterise endothelial apoptosis.
516
 However, 
the expression of these antigens may not be exclusive and at present it is unclear if the 
process of microparticle formation occurs randomly from the surface of dysfunctional 
endotheliocytes or whether it is actively regulated so that EMP immunophenotype may be 
different from the antigen profile of the ‘maternal’ cells. Additionally, analysis of the 
antigenic composition of EMP using a proteomic approach reveals the presence of the 
wide range of proteins, such as metabolic enzymes, proteins involved in adhesion and 
fusion processes, cytoskeleton associated proteins and nucleosome indicating a potential 
role of EMPs as messengers of signals of dysfunctional endothelium.
517
 
 
Indeed, irrespective of their antigen characteristics, EMP values reflect the presence of 
endothelial dysfunction (Figure 4). There are strong associations between high levels of 
EMPs (CD31+, CD51+, CD144+) and various vascular structural and functional 
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Figure 4.Endothelial microparticles in atherogenesis and atherothrombosis. 
Cardiovascular risk factors and resulting endothelial dysfunction are accompanied by 
release of microparticles from endothelial cells. The pattern of the circulating EMPs 
appears to reflect functional state of parental endotheliocytes and various EMP subtypes 
trigger specific pathophysiolocical responses. For example, endothelium may release 
microparticles expressing adhesion molecules facilitating recruitment of inflammatory 
cells, whist microparticles from apoptotic endothelial cells seem to promote 
angiogenesis. Different types of EMPs play their own unique roles in the development 
and progression of atherosclerosis and their levels are independent predictors of 
atherosclerotic disease and future cardiovascular events. ACS – acute coronary 
syndromes, CRP – C-reactive protein, EC – endothelial cells, EMP – endothelial 
microparticles, ICAM – intracellular adhesion molecule, TF – tissue factor, VCAM -
vascular cell adhesion molecule 
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abnormalities, for example, impairment of FMD, accelerated pulse wave velocity, and high 
CRP levels.
518-520
 Annexin V+CD31+ EMPs correlate with vasodilatory endothelial 
dysfunction and have been shown to have a potential as a marker of coronary endothelial 
function independent of classical cardiovascular risk factors.
521-522
 Furthermore, 
therapeutic improvement of endothelial function has been associated with a reduction of 
circulating EMP levels.
523
 
 
Patients with different cardiovascular risk factors have significant up-regulation of EMPs 
before the development of CAD. For example, various EMP types (CD144+, CD31+, 
CD51+ and annexin V+) are increased in diabetic patients, and appear to be good 
predictors of CAD (Figure 4). Also, EMP numbers in diabetes were closely correlated with 
the presence of non-calcified coronary plaques more prevalent in patients with ACS.
524
 
Significant correlation of HbA1c and CD31+ and CD51+ EMPs indicates that poor 
glycaemia control may directly promote vesiculation from endothelial cells.
518
 
 
Another line of evidence on the pathophysiological links between EMP formation and 
vascular dysfunction/damage is provided by studies on hypertension, both systemic and 
pulmonary (Table 14). Indeed, hypertension causes increased shear stress and direct 
mechanical damage of arteries. EMPs appear to be very sensitive to hemodynamic changes 
in hypertension, and their numbers are increased even in mild hypertension and rise further 
in proportion to blood pressure elevation, even in the presence of multiple risk factors.
525
 
Moreover, EMP generation is strongly associated with abnormalities of arterial elastic 
properties in hypertension.
526
 Persistent arterial elastic abnormalities correlate to EMPs 
even after blood pressure normalisation.
527-528
 In contrast, pulmonary hypertension is 
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Table 14. The influence of circulating microparticles in patients with cardiovascular 
risk factors and cardiovascular disease 
Condition Endothelial MP Platelet MP Leukocyte MP 
Hypertension ↑CD31+CD42- MP
525
 ↑CD41+ MP
525
 NA 
Hypercholest
erolaemia 
NA ↑CD42a+CD42b+ 
MP
529
 
NA 
Diabetes ↑CD144+ MP
516, 521
 
↑CD51+ MP
518
 
↑CD31+CD42- MP
518
 
↑CD41+ MP
530
 
↑CD42a+ MP
531
 
↑CD42b+ MP
532
 
↑CD42b+CD61+MP
533
 
↑CD31+CD42+ MP
518
 
↑CD42a+ MP in those 
with retinopathy
534
 
↑CD14+ MP
531
 
↑annexin V+ MP
531
 
↑CD45+ MP
518
 
↑CD14+ MP in patients 
with retinopathy
535
 
↑annexin V+ in patients 
with retinopathy
535
 
Smoking NA ↔CD61+ MP
536
 NA 
Obesity ↑CD31+CD42b-MP
537
 ↑CD31+CD42b+MP
537
 NA 
Coronary 
artery disease 
↑CD51+ MP
538
 
↑CD31+CD42- MP
538
 
↑CD144+ MP
519
 
↑CD31+annexin+ MP 
in patients with LV 
dysfunction
521
 
CD31+annexin V+ 
MP correlated with 
endothelial 
dysfunction
522
 
↑CD62P+ MP
539
 
↑CD63+ MP
539
 
↑CD61+ MP (after 
PCI)
540
 
 
NA 
Peripheral 
artery disease 
NA ↑CD42a MP
541-542
 
↑CD62P+ MP
539
 
↑CD63+ MP
539
 
NA 
Carotid 
atherosclerosis 
CD105+ MP 
associated with 
inward carotid 
remodelling
543
 
↑CD41+CD61+ MP
544
 ↑CD11a+ MP in 
subclinical 
atherosclerosis
545
 
Acute 
coronary 
syndrome 
↑CD31+CD42- MP
538
 
↔CD51+ MP
538
 
CD54+ MP were 
associate with 
persistent coronary 
occlusion
546
 
↑CD41+CD61+ MP
547
 
↑CD41+ MP
539
 
↑CD41+ MP
539
 
↑CD41+ MP
548
 
CD15+ MP were 
associate with persistent 
coronary occlusion
546
 
Stroke ↑CD54+ MP
549
 
↑CD105+ MP
549
 
↑CD144+ MP
549
 
↑Annexin V+ MP
549
 
↑CD62E+ MP
550
 
↑CD41+CD61+ MP
551
 
↑CD42b+ MP
552
 
NA 
MP – microparticles, NA – data not available, ↑ - increased, ↔ - not changed.
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associated with the rise of microparticles of different origin (eg, from platelets, endothelial 
cells, leucocytes), but only EMPs predict the hemodynamic severity of pulmonary 
hypertension.
553
 In one study, elevated CD62E+ EMPs but not leukocyte microparticles 
predicted adverse clinical events (ie, combination of death and re-admission for right HF or 
worsening of right HF symptoms) in patients with pulmonary hypertension during 12-
month follow-up.
554
 
 
Additionally, EMPs may represent a ‘link’ between endothelial dysfunction and arterial 
thrombosis. Microparticles released from endothelial cells in vivo have been shown to 
carry TF on their surface.
555
 Although in vivo role of this phenomenon has not yet been 
assessed and EMPs are unlikely to compete with monocyte-derived microparticles as a 
main microparticle-related source of circulating TF.
556
 EMPs generation is stimulated by 
plasminogen activator inhibitor-1 and may trigger platelet aggregation via von Willebrand 
factor.
557-558
 A recent prospective study of 488 consecutive patients with various 
cardiovascular risk factors demonstrated during a mean follow-up of three years that EMP 
count is a significant (but weak) independent predictor of future cardiovascular events 
(hazard ratio: 1.35, 95% CI: 1.09 to 1.65, p = 0.005).
559
 
 
2.4.3. Platelet microparticles – beyond a marker of platelet activation 
 
Platelets microparticles (PMPs) may also be generated by megakaryocytes, and are 
typically identified by the expression of constitutive platelets markers such as CD41, 
CD42b or CD61.
511, 560-562
 PMPs express various antigens from the platelet surface such as 
glycoproteins I, IIa, IIb, IIIa, vWF, P-selectin, thrombospondin and chemokine receptors 
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(e.g., CXCR4).
511, 560-562
 Immunophenotypic PMP characteristics, their phospholipid 
composition and cholesterol content may therefore reflect the functional state of platelets 
shedding microparticles as well as nature of a stimulator of their release.
563
 
 
About 25% of the procoagulant activity of stimulated platelet suspensions is associated 
with microparticles released upon platelet activation and their surface may be 
approximately 50- to 100-fold more procoagulant than the surface of activated platelets per 
se.
564-565
 Low amounts of PMPs are continuously shed from platelets but this process is 
highly accelerated following platelet activation or intensive physical activity.
566-568
 Release 
of PMPs appears to be an active process with different platelet receptors (e.g., tetraspanin, 
αIIbβ3 integrin) implicated into its regulation.
569
 PMPs bind to the subendothelial matrix 
acting as a catalytic centre for further platelet binding at sites of endothelial injury.
570
 For 
example, Siljander and colleagues showed that PMPs are involved in the formation of 
fibrin fibrils.
571
 Thrombogenic properties of PMPs have since been confirmed in 
experimental studies and high PMP levels are strongly associated with different thrombotic 
conditions (Figure 5). In a mouse model of venous thrombosis, for example, the injection 
of microparticles increased the extent of thrombosis, whereas leukocyte microparticles 
were negatively correlated with thrombus weight.
572
 PMPs were also significantly 
increased in patients with acute pulmonary embolism and were the main source of 
procoagulant microparticles.
573
 In valvular atrial fibrillation, which carries a very high risk 
of thromboembolism, the numbers of PMPs are more than 3-fold increased.
574
 
 
Interestingly, the biological roles of PMP spread beyond their participation in thrombotic 
processes.
575
 PMPs actively interact with endothelial and blood cells and they are 
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Figure 5. Platelet microparticles in atherogenesis and atherothrombosis. 
ACS – acute coronary syndromes, CAD – coronary artery disease, EPC – endothelial 
progenitor cells, ICAM – intracellular adhesion molecule, PAD – peripheral artery 
disease, PE – pulmonary embolism, PMP – platelet microparticles. 
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intimately involved in the regulation of their function.
576
 For example, PMPs can activate 
EMPs, trigger up-regulation of cell adhesion molecules on them, induce apoptosis of 
endothelial progenitors, and can activate and aggregate neutrophils in vitro.
577-579
 
Arachidonic acid released from PMPs can activate ICAM-1 on monocytes, as well as the 
adhesion molecules, P- and E-selectins on endothelial cells.
560, 577, 580-582
 Also, PMPs 
participate in the regulation in leukocyte interactions and amplify leukocyte-mediated 
tissue injury in thrombotic and inflammatory disorders.
579, 583
 PMPs have been shown to 
contain active caspase 3 and seem to serve as a messenger triggering apoptosis of 
macrophages.
584
 They may also participate in the regulation of inflammatory responses and 
induce angiogenesis in vitro, probably through the activation of endothelial cells.
585-587
 
PMPs differ in size which can affect the pattern of plasma membrane receptors, adhesion 
molecules, chemokines, growth factors, protein composition and membrane function.
588
 
 
PMPs are significantly up-regulated in patients with different cardioavascular risk factors 
(e.g., hypertension, hyperlipidemia, diabetes, obesity) and a combination of these risk 
factors appears to have a cumulative effect on PMP production.
525, 530, 536-537, 589
 PMP seem 
not to be elevated in patients who smoke.
537
 In diabetes, PMPs may be associated with the 
high rate of thrombotic events, atherosclerosis and retinopathy, because PMP levels 
correlated with platelet activation (e.g., platelet P-selectin expression).
530, 532-534
 
Unfortunately, there is only limited information on the effect of cardiovascular treatment 
on PMP levels. In one study, eicosapentaenoic acid but not pitavastatin reduced PMPs in 
hyperlipidemic and diabetic patients.
529
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2.4.4. Leukocyte microparticles – regulators of cellular interactions 
 
Microparticles are also released by all major types of white blood cells: monocytes, 
granulocytes and lymphocytes. TF-expressing monocyte-derived microparticles (MMP) 
constitute the second largest pool of thrombogenic microparticles in addition to PMPs.
381, 
590-591
 Exposure to endotoxemia increases procoagulant microparticles (predominantly TF+ 
monocyte microparticles) in vivo and in vitro.
592-595
 MMPs bind to activated platelets 
triggering the formation of fibrin.
381, 590
 Experimental data also show that active generation 
of MMPs results in disruption of endothelial cell integrity and increases endothelial 
thrombogenicity (e.g., increased endothelial expression of TF and reduced expression of 
anticoagulant TF pathway inhibitor and thrombomodulin).
593
 Procoagulant TF-bearing 
leukocyte microparticles are incorporated into evolving thrombi, suggesting their role in 
thrombus development and propagation.
572
 Moreover, granulocytes and monocytes transfer 
TF-positive microparticles to platelets, thus enhancing their procoagulant activity and 
initiating clot formation.
572
 Leukocyte microparticles can also activate platelets by Akt 
phosphorylation and P-selectin interaction.
596
 
 
Non-thrombotic regulatory functions of leukocyte microparticles are also recognised. 
Gasser et al. have reported that leukocyte microparticles may specifically adhere to 
monocytes and that endothelial cells are involved in cell signalling and inflammatory 
responses.
597
 Polymorphonuclear cell microparticles can induce IL-6 release from 
endothelial cells suggesting their involvement in the pro-inflammatory transformation of 
the endothelium.
598
 Stimulated T cells generate microparticles that induce the production 
of TNF-α and IL-1β by monocytes, in keeping with a role in the inflammatory 
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processes.
599
  The mutual regulatory effects of microparticle-mediated signals are reflected 
by correlation between levels of microparticles of different origin. For example, monocyte 
microparticles are increased in diabetes and correlate with PMPs, as well as with markers 
of platelet activation (CD62P, CD63, P-selectin).
535
 Elevated microparticles of different 
origin including PMPs, EMPs, and monocyte microparticles, are increased in patients with 
spontaneous deep vein thrombosis and correlate with D-dimer levels, a marker of fibrin 
turnover.
600
 
 
Microparticles released from neutrophils carry selectins, integrins, complement regulators 
on their surface, Fc-receptors typical of parental cells, and contain enzymes able to degrade 
the extracellular matrix, such as matrix metalloproteinase 9 and elastase.
597
 The pattern of 
microparticles generated by monocytes (and probably by other cells) depends on the 
stimuli that produced them.
601
 However, not only blood- or endothelial cell-derived 
microparticles may be found in the circulation. For example, tumour-derived TF-bearing 
microparticles were also associated with venous thromboembolism in cancer patients and 
may be essential in the pathogenesis of cancer-associated thrombosis.
602-606
 
 
Taken together, the currently available data indicate the presence of various regulatory 
roles of the different types of circulating microparticles that may be involved in 
thrombosis, endothelial perturbations and inflammation, processes related to the 
development and progression of cardiovascular disorders.   
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2.4.5. Microparticles and atherogenesis 
 
EMPs are significantly increased in patients with CAD.
521, 539
 Although formation of 
microparticles might be a passive shedding of membrane microvesicles from dysfunctional 
endothelial cells, they may represent a potentially clinically relevant pathway involved in 
activation of various physiological reparative processes. For example, experimental 
muscular ischaemia triggers an intensive generation of apoptotic annexin V+ 
microparticles by endothelial cells.
607
 Microparticles isolated from ischaemic muscles 
induce a more potent differentiation of bone marrow mononuclear cells into endothelial-
like cells compared to microparticles from non-ischaemic limbs.
607
 Microparticles from 
apoptotic endothelial cells and endothelial cells activated by inflammatory factors 
accelerate differentiation of bone marrow mononuclear cells and enhance their in vivo 
angiogenic capacity.
607
 However, Koga et al. have shown that high levels of EMPs were 
good predictors for CAD, even stronger compared to traditional risk factors.
519
 This 
discrepancy may either stem from inability of microparticle-mediated angiogenesis to 
adequately balance progressive ischaemia or the presence of other not currently known 
mechanisms than link excessive budding of endothelial cells and atherogenesis. 
 
However some available data show that EMPs may at least partly be responsible for 
prothrombotic state typical of CAD. Indeed, microparticles released by dysfunctional 
endothelium bind platelets and promote platelet activation in patients with coronary 
atherosclerosis.
608
 Additionally, local endothelial damage during percutaneous coronary 
interventions is associated with temporary platelet activation and accompanied by prompt 
(within about 15 minutes) shedding of PMPs, especially in those undergoing coronary 
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stenting.
609
 Importantly, this process occurs even despite optimal antiplatelet therapy and 
the lack of classical signs of platelets activation (e.g., normal soluble P-selectin levels).
609
 
 
The systemic nature of atherosclerosis is reflected by microparticle perturbations observed 
in patients with different plaque location. Patients with carotid plaques have higher levels 
of large PMPs than subjects without carotid atherosclerosis, even after adjustments for 
cardiovascular risk factors.
610
 High levels of CD11a+ leukocyte microparticles and 
CD105+ EMPs were associated with inward carotid remodelling in individuals with the 
greatest intima-media thickness even before atherosclerosis was detectable.
543
 PMP levels 
significantly correlate with both intima-media thickness and the presence of intracranial 
stenosis, but cannot predict subclinical atherosclerosis burden in asymptomatic 
subjects.
552,545
 PMP shedding is also amplified in patients with peripheral artery disease 
closely following a degree of platelet hyperreactivity.
539, 541
 In patients with an 
arteriosclerotic arterial obliterans PMPs are further increased by vascular surgery in 
parallel with levels of proinflammatory cytokines (e.g., IL-6).
542
 
 
Microparticles are also produced within atherosclerotic plaques themselves, predominantly 
by cells of leukocytic origin.
611
 Demonstration of the presence of immunoglobulins 
encapsulated inside plaque-derived microparticles suggests their potential 
immunomodulating role. The vast majority (more that 90%) of the immunoglobulin G-
containing microparticles were CD14+ indicating their monocyte\macrophage origin.
611
 
Although detailed biological roles of plaque-derived microparticles are poorly understood 
they may probably serve as regulatory messengers involved in orchestration of 
immune/inflammatory responses in an atherosclerotic plaque. Additionally, microparticles 
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isolated from human atherosclerotic lesions express the CD40 ligand, activate endothelial 
cells and appear to stimulate intra-plaque neovascularization, plaque progression and 
destabilization.
612
 Furthermore, certain types of microparticles may promote vascular 
inflammation and expression of inflammatory cytokines (e.g., TNF-α) by endothelial 
cells.
613
 Importantly, even stable human atherosclerotic plaques shed membrane 
microparticles with procoagulant potential (mainly of monocytic and lymphocytic origin) 
in the process of apoptosis.
614
 However, although these microparticles are likely to 
facilitate atherogenesis and are associated with a prothrombotic state much more data are 
needed to establish their pathophysiological and clinical significance. Important issues are 
to establish links between different types of microparticles, biological mechanisms of their 
release and clinically relevant consequences directly attributed to their activity. 
 
2.4.6. Microparticles and (athero)thrombosis 
 
PMPs are associated with ACS and their levels are substantially increased in ACS patients 
with or without of myocardial necrosis. PMPs have also been reported to be independent 
predictors of thrombotic events.
547-548, 615
 However, being involved in the initiation of the 
atherothrombotic cascade their levels do not reflect the severity of myocardial damage and 
similar PMP levels were seen in patients with unstable angina and MI.
546
 Indeed, PMP 
elevation in acute atherothrombosis parallels with co-existing activation of platelets which 
peaks during the first 1-2 days after the event.
544, 616
 
 
In contrast to PMPs, the number of EMPs progressively increases from patients with 
unstable angina to those with acute MI and further from patients with uncomplicated MI 
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course to those with recurring MI.
538
 Considering the relation between EMP formation, 
endothelial dysfunction and atherogenesis, it is interesting to see that high EMP levels in 
ACS are associated with the presence of ‘high-risk’ angiographic lesions including 
eccentric plaque location, multiple irregular plaques as well as lesions with thrombi.
617
 Of 
note, being linked to the different parameters marking ‘high-risk’ lesions EMP levels do 
not directly correspond the severity of coronary stenosis and, in fact, higher in patients 
with moderate stenosis than in those with severe lesions. One may speculate that maximal 
release of microparticles by the endothelium may occur at the stage of active plaque 
formation and remodelling and remit following the stabilisation of mature plaques. In fact 
this explanation would correspond to the known higher vulnerability of relatively small 
atherosclerotic plaques.
618
 Active intraplaque generation of CD105+ EMPs, TF+ 
microparticles and CD11a+ microparticles and their relevance to the plaque destabilisation 
is supported be the observation that their concentrations are significantly higher within the 
occluded coronary artery than in the peripheral circulation.
619
 Furthermore, in a study of 
123 patients with ST-elevation MI, coronary occlusion prior to angiography was associated 
with the highest EMP numbers.
546
 Although the details of the role of EMPs in the 
development of atherothrombotic events are still poorly understood the interaction between 
EMPs is probably involved. Indeed, the levels of EMP aggregates with platelets are 
diminished during the first hours of MI and return to values close to those observed in 
stable CAD at approximately 48 h after the onset of MI.
608
 The coincidence of the temporal 
dynamics of EMP-platelet aggregates with the time-frame of excessive platelet activation 
on the background of increased numbers of free EMPs indirectly indicates their preferable 
participation in platelet clot formation. Increased EMPs were also predictive of recurrent 
MI compared to those with an uncomplicated MI course.
538
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Some controversy exists about dynamics of TF+ microparticles (mainly of monocytic 
origin) in ACS. One study showed no apparent increase in TF+ microparticles.
620-621
 
However, Huisse et al. reported that failure of thrombolysis with tenecteplase to restore 
coronary circulation in patients with ST-elevation MI was associated with high levels of 
TF+ microparticles, which correlated with the levels of thrombin-antithrombin 
complexes.
622
 This controversy is likely to reflect the background antithrombotic therapy 
and the clinical status of patients included in the studies. Of note, a prospective study of 
286 patients with ACS (a mean follow up of 3.26 years) revealed that plasma TF activity 
(mainly attributed to circulating TF+ microparticles) was an independent predictor of 
survival, with hazard ratio of 9.27 (95% confidence interval 1.24-69.12, p = 0.03).
623
 
 
Accumulating data also indicate that microparticles are involved in the development of 
cerebrovascular events. Microparticle numbers correspond to the severity, lesion volume 
and outcome in patients with stroke.
624
 PMPs are prominently increased in patients with 
cerebral vaso-occlusive conditions, especially during transient ischaemic attacks, in those 
with lacunar infarcts, small vessel disease, and multi-infarct dementia.
552
 The degree of 
PMP up-regulation in acute-phase cerebral infarction may vary substantially, depending on 
its aetiology and it is more prominent in small-vessel occlusions and large-artery 
atherosclerosis when compared to patients with cardioembolic strokes.
552
 However, even 
among the last category of patients (e.g., among patients with prosthetic heart valves) PMP 
elevation is significantly associated with the development of adverse events.
625
 Although 
only limited data are currently available on the role of microparticles in stroke, increased 
levels of PMP in acute stroke seem to persist in the convalescent phase of the disease.
626
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Cerebral ischaemic episodes and infarct volumes in acute stroke are also significantly 
associated with high levels of EMPs.
549
 Various types of EMPs appear to play differential 
role in the pathogenesis of different forms of cerebrovascular atherosclerosis. CD62E+ 
EMPs dominate in patients with extracranial stenosis whilst CD31+ and CD31+anexin V+ 
EMPs represent a predominant type of EMPs in those with intracranial stenosis.
550
 High 
levels of CD105+ and CD144+ EMPs on admission with stroke are significantly associated 
with negative clinical outcomes.
549
 However, not all types of EMPs allowed discriminating 
acute ischaemic stroke from conditions mimicking stroke and details of the specific roles 
of different subsets of EMPs in the development of stroke is a subject of future research.
627
 
 
2.4.7. Microparticles in heart failure 
 
Only scarce information is currently available on the role of microparticles in HF. CD144+ 
EMP are significantly up-regulated in Japanese subjects with systolic HF being 
progressively higher in subjects with more severe forms of the disease.
628
 A 30-month 
follow-up of these patients revealed that high EMP count was significantly and 
independently associated with higher incidence of a composite endpoint of cardiovascular 
events (MI, stroke, re-hospitalization for HF, and cardiovascular death). 
 
Bulut et al. reported that reduction in total and endothelial microparticles after 
immunoadsorption in 13 patients with severe HF paralleled improvement in endothelial 
function and LVEF.
629
 Also cardiac transplantation in subjects with terminal HF was 
followed by significant reduction in CD62+ EMP.
630
 However the causal relationship 
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between the decrease in circulating microparticles and other favourable cardiovascular 
changes is still to be established. 
 
Data on the implications of other microparticle types (e.g., PMP or MMP) in HF are scanty 
but may be of potential clinical interest. 
 
2.4.8. Conclusions 
 
Most of the currently available clinical studies on human microparticles are observational 
in their nature with only few studies assessing prognostic role of different microparticle 
types and effects of interventions. These data prove associations of microparticle count 
with different cardiovascular disorders but do not necessarily imply direct 
pathophysiological links. Robust experimental studies based on the evaluation of the 
delivery of different microparticles types in various models of cardiovascular disorders are 
often missing and are highly desirable. Nevertheless microparticles are undoubtedly 
involved in pathogenesis of cardiovascular disorders and highlight potential areas of 
investigation rather than provide definitive answers to numerous questions.  More research 
is clearly needed to shed further light on this intriguing area. 
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CHAPTER III. ETHNIC DIFFERENCES IN ENDOTHELIAL AND VACULAR 
FUNCTION IN HEART FAILURE 
3.1. Introduction to the chapter 
 
As it was discussed in the Literature review section, HF remains a common pathological 
condition associated with significant ethnic differences in clinical presentation, course and 
prognosis.
631-632
 Subjects of SA origin represent a large ethnic group featured by a unique 
and unfavourable pattern of high prevalence of CAD, diabetes, associated with 
development of HF at younger age and an increased risk of HF-related hospital 
admissions.
8, 301
 Indeed, HF in SAs develops at a younger age and results in 60% more 
hospitalizations compared to subjects of white origin.
12
 In addition, there are pathological 
differences between subjects with HF from different ethnic groups although the 
pathophysiological mechanisms of such differences are still poorly understood.
7, 9
 
 
Given that prevalence of systolic LV impairment does not seem to vary substantially 
among different ethnic groups it is reasonable to speculate that the known clinical and 
prognostic ethnicity-related differences in HF may be partly attributable to extracardiac 
factors, such as endothelial (dys)function, systemic inflammation, and capacity of the 
reparative mechanisms.
633
 Indeed, the endothelium plays a critical role in the regulation of 
vascular tone, recruitment of leukocytes (and other inflammatory processes), maintenance 
of the balance between the pro- and anticoagulant states, and many other 
pathophysiological processes.
191
 Impairment of endothelial function is associated with 
negative outcome in various cardiovascular disorders but it seems particularly important in 
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subjects with HF. Indeed, impairment of endothelial response to hyperaemia or 
acetylcholine is a significant independent predictor of negative outcomes (including death, 
and re-hospitalization) in HF, irrespectively of its aetiology.
172-176, 178
 Additionally EMPs 
have recently emerged as a novel marker of the endothelial (dys)function, which strongly 
reflects the degree of endothelial activation and damage and EMP levels have been shown 
to be up-regulated in subjects with HF.
49, 634
 Although previous research has mostly 
focused on subjects with clinically apparent cardiovascular morbidity, it was also shown 
that even healthy SAs had worse parameters of endothelial function compared to healthy 
white subjects.
22
 However, the state of endothelial function in SAs with HF has not been 
specifically studied. 
 
The progressive nature of HF reflects a complex pathophysiology of the disorder, with 
features of an imbalance between inflammatory and reparative processes.
305
 Monocytes 
play important roles in both.
25
 Monocytes are not uniform and include subsets with 
profoundly different functional properties which might be implicated in both HF 
progression and repair (discussed in more details in the Chapter II).
635
 
 
There are scarce data on the specific monocyte subsets in HF. In a small study, Mon2 
subset was increased in European patients with chronic stable HF compared with healthy 
controls and their counts correlated with worsening NYHA class and reduced LV 
contractility.
425
 However in addition to the presence of HF per se, the influence of co-
morbidities and cardiovascular risk factors needs to be considered and dictates the need for 
an appropriate ‘disease controls’ group which was missing the that study. 
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The reparative properties of monocytes may also be relevant in HF. Scavenger receptor 
class A type I (SR-AI, also CD204) is involved in lipid accumulation (by macrophages) 
and atherogenesis, but there are emerging data that implicate this receptor in a number of 
reparative processes, such as clearance of apoptotic cells, attenuation of oxidative stress 
and inflammation.
29-33
 The number of monocytes expressing SR-AI is increased in patients 
with ACS, but data on monocyte SR-AI expression in HF are not available at present.
34-35
 
Circulating levels of MPAs have been shown to be a good marker of monocyte activation, 
and they are up-regulated in various cardiovascular and thrombotic disorders.
636
 Also, 
circulating cellular MMP and PMP are increasingly recognised as important messengers of 
cellular signals in cardiovascular disorders.
637
 However, scarce data are currently available 
on the levels of MPAs, MMPs and PMPs in HF. 
 
Continuous cardiac and vascular remodelling in HF reflects the need for adaptation to 
haemodynamic changes, as well as to the ischaemic background common in HF subjects. 
The role of EPCs in angiogenesis and vascular remodelling is progressively acknowledged 
and accumulating data indicate their relevance in the context of HF.
38
 
 
EPC counts have been shown to be abnormal in HF subjects and depend upon HF 
severity.
447, 449
 A large proportion of EPCs has been found to be of monocytic origin.
38
 
Monocytes include cells able to acquire an endothelial phenotype in culture.
462
 Indeed, 
cultures of ‘early’ EPCs are largely comprised of monocytes (e.g., over 97% them are 
CD14+ cells) and the colony formation is strictly dependent upon monocytes presence.
638-
641
 A proportion of circulating CD14+ monocytes express low levels of CD34 and these 
CD14+CD34+ cells were able to improve carotid re-endothelialization after balloon injury 
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in animals.
642
 Also, potent angiogenic properties were demonstrated for monocytes 
expressing KDR (VEGF receptor type 2).
465
 However, the numbers of CD34+ and KDR+ 
angiogenic monocytes, total or attributable to individual monocyte subsets have not been 
studied in HF. 
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3.2. Aims and hypotheses 
 
The aims of this thesiswere to assess possible ethnic differences in endothelial function, 
monocyte subsets, EPCs and plasma microparticles in systolic HF and to investigate the 
status of these parameters in SA patients with HF vs. control subjects with normal LV 
contractility. 
 
In this thesis, I hypothesised the presence of ethnic differences in endothelial macro- and 
micro-vascular function between HF subjects of SA, white and African-Caribbean (AC) 
origin. Macrovascular function was quantified by FMD of the brachial artery in response to 
reactive hyperaemia, whilst arterial stiffness was assessed by quantification of the pulse 
wave velocity (PWV). Microvascular function was quantified by forearm laser Doppler 
flowmetry using skin iontophoresis with acetylcholine and sodium nitroprusside. I also 
contrasted these measures of localised endothelial function by measuring the numbers of 
EMPs, which may arise from any vascular bed.
637
 
 
I also hypothesised that there would be significant HF-associated changes and ethnic 
differences in monocyte subsets (and their expression of SR-AI), MMPs and PMPs, which 
may account for some of the observed clinical ethnicity-related differences in HF.
12, 54
 To 
test this hypotheses I studied ethnic differences in monocytes subsets, MMPs, PMPs in HF 
subjects of SA, AC and white origin. The SA patients with HF were also compared against 
matched ‘disease controls’ and ‘healthy controls’ of SA origin.  
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The next hypothesis of this thesis was that SA subjects with HF would have abnormal 
parameters of endothelial progenitors compared with matched patients with preserved LV 
contractility and secondly, there would be significant ethnic differences in these parameters 
between HF subjects of SA, AC and white ethnic origin. 
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3.3. Study population 
3.3.1. Interethnic comparisons in heart failure 
 
Fifty subjects of SA origin were compared with 50 age- and sex-matched Whites, and 28 
subjects of AC ethnic origin with HF. All HF subjects had LVEF <40% confirmed by 
echocardiography (described below) and were clinically stable at the time of assessment 
with no hospitalisation or therapy changes in the preceding 3 months. Subjects with atrial 
fibrillation, cancer, rheumatoid arthritis, or haemodynamically significant valvular heart 
disease, or taking hormone replacement therapy, were excluded. 
 
Subjects with HF from different ethnic groups were generally well matched for 
demographic features (Table 15). The majority of the patients had an ischaemic aetiology 
of HF (82% of SAs, 80% of Whites, 79% of ACs, p=0.71). A higher proportion of subjects 
of AC origin had a history of hypertension compared to Whites (p=0.012) and mean 
diastolic blood pressure was higher in ACs (p=0.04). Whites had less diabetes than both 
SAs and ACs (p<0.001). Additionally ACshad higher body mass index (p=0.01) and lower 
leucocyte counts (p=0.02). The higher prevalence of diabetes associated with increased 
body mass index in ACs could reflect more features of metabolic syndrome, compared to 
other ethnic groups. The three ethnic study groups were matched for most medications 
(Table 15), with the exception of statins which were more commonly taken by SAs. 
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Table 15. Demographic, clinical and echocardiographic characteristics of 
subjectswith heart failure 
 South Asian White  African-Caribbean p 
Age, years 66.5±11.1 68.8±8.91 69.3±10.3 0.42 
Male, % 88 84 86 0.85 
NYHA class: I/II/III, % 22/38/40 24/44/32 8/46/46 0.20 
 
Past Medical History 
Ischaemic aetiology, %  82 80 79 0.71 
Previous myocardial 
infarction, % 
66 70 46 0.08 
Previous stroke, % 8 6 7 0.90 
Hypertension, % 72 58‡ 86 0.03 
Diabetes, % 62* 30‡ 64 0.001 
Smoking, % 14 16 10 0.93 
Chronic obstructive 
pulmonary disease, % 
26 20 18 0.47 
ICD/CRTP/CRTD 6 7 4 0.93 
Systolic BP, mm Hg 130±19.4 130±18.1 136±22.8 0.34 
Diastolic BP, mm Hg 74.7±11.1† 74.7±9.67‡ 80.5±10.6 0.04 
Body mass index, kg/m
2
 26.9±4.57† 27.7±4.03 30.4±6.80 0.01 
Haemoglobin, g/dl 13.2±1.62 13.9±2.13 12.9±1.72 0.08 
Leukocytes, 10
6
/ml  7.20±1.89† 7.32±2.07‡ 6.03±2.29 0.02 
Creatinine, µmol/l 102±29.7† 99±29.8‡ 125±39.3 0.003 
Glomerular filtration rate, 
ml/min/1.73m
2
 
67.7±20.8 64.7±18.5 64.4±22.2 0.74 
Glucose, mmol/l 6.84±2.27 5.46±0.99 6.91±3.50 0.16 
Total cholesterol, mmol/l 4.00±1.03 4.16±1.05 4.04±1.01 0.82 
HDL cholesterol, mmol/l 1.22±0.42 1.27±0.46 1.39±0.41 0.52 
 
Echocardiographic parameters 
LV end diastolic volume, ml 159±52.9 162±59.0 201±99.9 0.11 
LV end systolic volume, ml 111±48.4 115±48.6 150±75.4 0.07 
LV ejection fraction, % 30.5±11.3 29.7±7.68 30.3±7.26 0.94 
E/E' ratio 11.7±8.00 12.4±4.86 13.9±6.12 0.60 
Left atrium diameter, mm 4.06±0.83 4.40±0.72 4.46±1.20 0.28 
Interventricular septum, mm 11.8±2.4 11.5±3.2 13.5±4.7 0.16 
Posterior wall, mm 9.4±2.3* 9.3±2.3‡ 12.6±5.9 0.004 
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 South Asian White  African-Caribbean p 
 
Medications 
Aspirin, % 86 92 96 0.55 
Clopidogrel, % 14 14 17 0.99 
Warfarin, % 10 4 4 0.36 
ACE inhibitors, % 84 80 89 0.45 
Loop diuretics, % 62 72 93 0.06 
Thiazide diuretics, % 4 16 12 0.16 
Spironolactone, % 26 26 43 0.25 
Digoxin, % 12 16 7 0.53 
Nitrates, % 26 26 25 0.96 
Statins, % 84* 64 79 0.02 
Calcium channel blockers, 
% 
18 18 18 0.99 
Beta-blockers, % 56 68 57 0.52 
 
BP - blood pressure, E/E' ratio - early filling (E) to early diastolic mitral annular velocity 
(E') ratio, LV – left ventricular. Values expressed as Mean±Standard Deviation. *p<0.05 
between SAs and Whites, †p <0.05 between SAs and ACs, ‡ p <0.05 between Whites and 
ACs, *p<0.05 between SAs and Whites. ICD/CRTP/CRTD – Implantable cardioverter-
defibrillator/cardiac resynchronisation therapy-pacemaker/cardiac resynchronisation 
therapy-defibrillator. 
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3.3.2. Comparison of heart failure subjects to controls without hear failure 
 
Fifty SA subjects with HF were compared with two age- and sex- matched control groups 
of 40 SA ‘disease controls’ (subjects with CAD diagnosed during elective coronary 
angiography but with normal LV systolic function [LVEF >50%]) and 40 ‘healthy 
controls’ with no vascular, metabolic, neoplastic or inflammatory disease revealed by 
careful history, examination and routine laboratory tests. 
 
The groups were well-matched for age, sex, body mass index and smoking (Table 16). 
‘Disease controls’ and HF subjects had lower haemoglobin and HDL-cholesterol, a higher 
leukocyte count and creatinine than the ‘healthy controls’. 
 
All study subjects fasted for 12 hours and abstained from smoking, alcohol, tea and coffee 
for 24 hours prior to the study. The subjects were advised to omit their medications on the 
study day and the evening before, as a more prolonged treatment omission was deemed 
unethical. All scans were performed in a quiet, darkened, temperature controlled room 
after resting for 15-20 minutes. Ethical approval was granted by the local research ethics 
committee and written informed consent was obtained from all participants. 
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Table 16. Demographic, clinical and echocardiographic characteristics of subjects 
with heart failure 
 Healthy controls Disease controls Heart failure p value 
Age, years 61.3±13.7 64.2±9.52 66.5±11.1 0.11 
Male, % 80% 90% 88 0.76 
Clinical parameters 
Systolic BP, mm Hg 134±14.5 134±19.5 130±19.4 0.54 
Diastolic BP, mm Hg 80.0±8.88† 75.0±13.7 74.7±11.1 0.03 
Body mass index, kg/m
2
 25.9±4.08 26.2±3.66 26.9±4.57 0.71 
Smoking, % 12 10 14 0.71 
Haemoglobin, g/dl 14.3±1.49*† 13.3±2.02 13.2±1.62 0.006 
Leucocytes, 10
6
/ml  6.25±1.17*† 7.58±1.52 7.20±1.89 0.001 
Creatinine, µmol/l 83.9±22.4† 91.2±28.3 102±29.7 0.02 
Glomerular filtration rate, 
ml/min/1.73m
2
 
75.5±15.0 75.8±17.6 67.7±20.8 0.11 
Glucose, mmol/l 5.56±1.30 6.86±2.59 6.84±2.27 0.22 
Total cholesterol, mmol/l 4.63±1.09 4.06±1.00 4.00±1.03 0.06 
HDL cholesterol, mmol/l 1.52±0.37*† 1.18±0.31 1.22±0.42 0.016 
Echocardiographic parameters 
LV end diastolic volume, ml 89.1±32.4† 109±21.6‡ 159±52.9 0.00 
LV end systolic volume, ml 34.5±17.2† 44.9±11.7‡ 111±48.4 0.00 
LV ejection fraction, % 62.2±10.9† 58.6±7.00‡ 30.5±11.3 0.00 
E/E' ratio 8.50±3.50 10.2±3.97 11.7±8.00 0.16 
Left atrium diameter, mm 3.64±0.42 3.88±0.62 4.06±0.83 0.12 
 
BP - blood pressure, E/E' ratio - early filling (E) to early diastolic mitral annular velocity 
(E') ratio, LV – left ventricular. Values expressed as Mean±Standard Deviation. *p<0.05 
between healthy controls and disease controls, †p <0.05 between healthy controls and heart 
failure group, ‡ p <0.05 between disease controls and heart failure group. 
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3.4. Methods 
3.4.1. Assessment of macrovascular endothelial function: flow-mediated dilation of 
brachial artery 
 
FMD was assessed according to the published guidelines.
643
 High resolution ultrasound 
scanning of the right brachial artery was performed with a 10 MHz probe 3-5cm above the 
antecubital fossa, with subjects lying flat and the probe kept in the same position 
throughout the study. Anterior to posterior wall diameters (leading edge to leading edge) 
were recorded simultaneously with synchronization by the R-wave on electrocardiogram. 
For every stage the arterial diameter was calculated as an average of 5 measurements of 3 
consecutive cardiac cycles. Endothelium-dependent dilation was assessed by response to 
reactive hyperaemia (i.e., FMD). The sphygmomanometer cuff placed around the right 
upper arm was inflated to 30-40mmHg above the systolic blood pressure for 5 minutes 
following by prompt deflation and recording of brachial artery images for 5 minutes with 
the maximal response used for the analysis. Once the baseline brachial artery diameter and 
flow was restored, the endothelium-independent dilation was assessed 3 minutes after 
sublingual administration of 0.4mg glycerol trinitrate (GTN, 
NitrolingualHohenlockstedt, Germany). The endothelium-dependent and endothelium-
independent responses were estimated as a percentage of the brachial diameter changes 
compared to baseline levels (Standard Operating Procedure 103 ‘Flow-mediated dilation’). 
 
For the purpose of the technique validation and assessment of intra-observer variability I 
repeated measurements of flow-mediated- and GTN-mediated dilation on 5 different days 
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(in addition to the original measurement made on the day of the study, i.e., 6 measurements 
in total). This was done on two study subjects. Intra-observer coefficients of variability 
(CV) for FMD were 2.30%, and 2.28% for the two subjects with average value 2.29%. 
Intra-observed CV for GTN-mediated dilation was 2.19%, and 2.96% for the two subjects 
with average value 2.58% (Table 17). 
 
For the assessment of inter-observer CV the measurements of the parameters were 
performed by another member of the department experienced with the technique who was 
unaware of the subjects’ details. Measurements done on 10 subjects showed inter-observer 
CV 2.36% for FMD and 3.48% for GTN-mediated dilation (Table 18). 
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Table 17. Intra-observer variability of measurements of macrovascular endothelial 
function (brachial artery) with ultrasound 
Subject Day Baseline 
diameter, 
mm 
Diameter 
after 
reactive 
hyperaemia, 
mm 
FMD, % Diameter 
after GTN, 
mm 
GTN-
mediated 
dilation, % 
Subject 
1 
Day 1 3.56 4.31 21.01 3.90 9.55 
Day 2 3.57 4.33 21.3 3.91 9.52 
Day 3 3.54 4.31 21.8 3.89 9.89 
Day 4 3.56 4.32 21.3 3.91 9.83 
Day 5 3.57 4.3 20.4 3.91 9.52 
Day 6 3.54 4.31 21.8 3.87 9.32 
Mean±SD 3.56±0.01 4.31±0.01 21.3±0.49 3.90±0.02 9.61±0.21 
CV, % 0.38 0.24 2.30 0.41 2.19 
Subject 
2 
Day 1 5.42 6.05 11.6 6.05 11.6 
Day 2 5.43 6.04 11.2 6.04 11.2 
Day 3 5.43 6.06 11.6 6.06 11.6 
Day 4 5.44 6.05 11.2 6.06 11.4 
Day 5 5.43 6.03 11.0 6.03 11.0 
Day 6 5.41 6.04 11.6 6.06 12.0 
Mean±SD 5.43±0.01 6.05±0.01 11.4±0.26 6.05±0.01 11.5±0.34 
CV, % 0.19 0.17 2.28 0.21 2.96 
Average CV, % 0.29 0.21 2.29 0.31 2.58 
 
CV, coefficient of variability; FMD, flow-mediated dilation; GTN, glycerol trinitrate. 
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Table 18. Inter-observer variability of measurements of macrovascular endothelial 
function (brachial artery) with ultrasound 
Subject Baseline 
diameter, mm 
Diameter 
after reactive 
hyperaemia, 
mm 
FMD, % Diameter 
after GTN, 
mm 
GTN-
mediated 
dilation, % 
Operator 1 
1 4.8 5.25 9.37 5.27 9.8 
2 4.36 4.78 9.63 4.85 11.24 
3 4.43 4.78 7.9 4.81 8.58 
4 3.56 4.31 21.01 3.9 9.55 
5 5.42 6.05 11.62 6.05 11.62 
6 4.66 4.97 6.65 4.94 6.04 
7 4.13 4.47 8.23 4.9 18.64 
8 4.55 4.87 7.03 4.92 7.03 
9 4.4 4.82 9.55 4.86 10.45 
10 4.38 4.56 4.11 4.63 5.71 
Operator 2 
1 4.73 5.18 9.51 5.19 9.73 
2 4.34 4.77 9.91 4.86 11.98 
3 4.5 4.88 8.44 4.84 7.56 
4 3.59 4.4 22.56 3.96 10.31 
5 5.1 5.72 12.16 5.74 12.55 
6 4.68 4.99 6.62 4.96 5.98 
7 4.1 4.43 8.05 4.83 17.80 
8 4.58 4.9 6.99 4.92 7.42 
9 4.4 4.83 9.77 4.84 10.00 
10 4.4 4.57 3.86 4.64 5.45 
Inter-observer 
CV, % 0.90 0.99 2.36 0.84 3.48 
 
CV, coefficient of variability; FMD, flow-mediated dilation; GTN, glycerol trinitrate. 
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3.4.2. Assessment of microvascular endothelial function: laser Doppler flowmetry 
 
Assessment of microvascular endothelial function has been performed using Laser Doppler 
perfusion monitor (DRT system with MIC1-e iontophoresis controller, Moor Instruments, 
Axminster, UK) with upper forearm iontophoresis (0.1mA for 60 sec.) of 1% acetylcholine 
(Sigma-Aldrich, Dorset, UK) to evaluate endothelial-dependent response, and 1% sodium 
nitroprusside (Sigma-Aldrich, Dorset, UK) to evaluate endothelium-independent 
response.
644
 Maximum percentage changes in perfusion were calculated using mean 
baseline perfusion (during 1 minute of baseline scanning) and maximum perfusion during 
the tests, and the analysis was performed off-line using software provided by the 
equipment manufacturer (Standard Operating Procedure 107 ‘Measurement of 
microvascular endothelial function’). 
 
For the purpose of the method validation, the study has been repeated on different days in 
two healthy subjects (Subject 1 and Subject 2) (Table 19). Inter-observer CV of the 
response to acetylcholine was 9.79% in Subject 1 and 12.5%, with average 11.2%; CV of 
the response to sodium nitroprusside was 12.4% in Subject 1 and 22.6% in Subject 2, with 
average 17.5%. Intra-assay variability (blinded analysis of stored data) gave the same 
results due to automatic nature of analysis of the stored data. A relatively high inter-
observer variability in response to acetylcholine and sodium nitroprusside is apparently 
due to substantial physiological variability of the skin blood flow, also reported by other 
authors.
645
 In contrast, the baseline values of the skin perfusion showed high variability 
(which is commonly acknowledged in literature) due to its high sensitivity to numerous 
factors (e.g., some variations in temperature, blood pressure, etc). 
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Table 19. Inter-assay variability of parameters of microvascular endothelial function 
assessed by laser Doppler flowmetry 
 
Perfusion 
before Ach, 
PU 
Perfusion 
after Ach, 
PU 
Response 
to Ach, 
% 
Perfusion 
before SNP, 
PU 
Perfusion 
after SNP, 
PU 
Response 
to SNP, 
% 
Subject 
1 
Day 1 12.9 116.6 804 12.4 121.1 877 
Day 2 24.2 211.7 775 8 70.7 784 
Day 3 30.5 276.8 808 31.5 230.8 633 
Day 4 26.3 256.9 877 11 100.3 812 
Day 5 15.9 172 982 26.2 253.8 869 
Mean± 
SD 
22.0± 
7.34 
207± 
64.8 
849.2± 
83.1 
17.8± 
10.4 
155± 
81.8 
795± 
98.6 
CV, % 33.4 31.3 9.79 58.4 52.8 12.40 
Subject 
2 
Day 1 21.6 321.1 1387 18.2 139.7 668 
Day 2 15.2 201.7 1227 12.2 71.6 487 
Day 3 16.4 227.4 1287 16.5 122.1 640 
Day 4 17.1 217.8 1174 33 213.2 546 
Day 5 15.9 172 982 26.3 253.8 865 
Mean± 
SD 
17.2± 
2.53 
228± 
56.1 
1211± 
151 
21.2± 
8.33 
160± 
73.0 
641± 
145 
CV, % 14.7 24.6 12.50 39.3 45.6 22.60 
Average CV, % 24.1 28.0 11.2 48.9 49.2 17.5 
 
Ach, acetylcholine; CV, coefficient of variability; MPAs, monocyte-platelet aggregates; PU, 
perfusion units; SD, standard deviation; SNP, sodium nitroprusside. 
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3.4.3. Assessment of arterial stiffness 
 
Carotid-femoral PWV, carotid-radial PWV, and aortic augmentation index were measured 
using Sphygmocor device (Sphygmocor, Atcor medical, Sydney, Australia). Radial artery 
waveforms were recorded over 10 seconds using a high-fidelity hand-held applanation 
tonometer to perform pulse wave analysis and calculate aortic augmentation index using an 
inbuilt modern Sphygmocor CVMS software system (Version 8). Carotid-femoral PWV 
(predominantly arteries of elastic type) and carotid-radial PWV (predominantly arteries of 
muscular type) were obtained by making sequential ECG-gated tonometer recordings at 
the carotid, femoral, and radial arteries. The straight-line distances between the sternal-
notch and waveform measurement sites were determined, and path length taken as the 
difference between the two distances (according to the manufacture recommendations). 
 
Intra-observer CV for PWV was calculated on the basis of four consecutive measurements 
done on the same day, which were performed on two different healthy subjects twice on 
each. My average intra-observer CV was 5.29% (Table 20). Inter-observer CV for PWV 
was calculated on the basis of five measurements performed on different days in two 
healthy subjects. My inter-observer CV was 6.58% and 2.73% for the two subjects, with 
average CV 4.66%. Intra-observer CV for the aortic augmentation index was 7.99%. Inter-
observer CV for the aortic augmentation index was 5.29% and 11.12% for the two 
subjects, with average CV 8.21%. 
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Table 20. Intra- and inter-assay variability of measurement of pulse wave velocity 
Intra-assay variability assessment 
 
Subject 1 Subject 2 
 
Day 1 Day 2 Day 1 Day 2 
Measurement 1 10.5 9.8 8 7.8 
Measurement 2 9.3 9.2 8.6 8.3 
Measurement 3 9 9 7.8 7.7 
Measurement 4 10.4 9.5 8.7 7.5 
Mean±SD 9.80±0.76 9.38±0.35 8.28±0.44 7.83±0.34 
Intra-assay CV, % 7.76 3.73 5.34 4.34* 
Inter-assay variability assessment 
 
Subject 1 Subject 2 
Day 1 10.5 8.4 
Day 2 9 8 
Day 3 9.6 8 
Day 4 9.8 7.8 
Day 5 9 8.1 
Mean±SD 9.58±0.63 8.06±0.22 
Inter-assay CV, % 6.58 2.73* 
Pulse wave velocity units – m/sec; *Average intra-assay CV, 5.29; Average inter-assay CV, 
% 4.66 
151 
 
3.4.4. Echocardiography 
 
Cardiac function was assessed by two-dimensional echocardiography (Phillips iE33 
ultrasound machine, Bothel, WA, USA) according to the current guidelines.
646-648
 Modern 
off-line QLAB software [Xcelera, Phillips Ultrasound Quantification Module, USA] was 
used for quantification of parameters of cardiac structure and function. LV volumes and 
LVEF were measured using the modified Simpson’s biplane method.
648
 For diastolic 
function assessment, transmitral flow was obtained in the apical 4-chamber position, where 
the pulsed Doppler sample volume cursor was placed in parallel with the blood flow 
direction. Mitral early inflow velocity (E and A) was measured by conventional Doppler 
measurement technique. Early diastolic lateral mitral annular velocity (E') was measured 
by Tissue Doppler imaging with E/E' ratio calculated as a parameter of diastolic function. 
Left atrial diameter, thickness of posterior wall and interventricular septum were measured 
in M-mode. 
 
3.4.5. Flow cytometry 
3.4.5.1. Quantification and characterisation of monocyte subsets, monocyte-platelet 
aggregates and endothelial progenitors 
 
Flow cytometric analysis was performed using the BD FACSCalibur flow cytometer 
(Becton Dickinson, Oxford, UK [BD]). Following 20 minutes of supine rest, blood 
samples were collected into ethylene-diamine tetra-acetic acid (EDTA)-containing tubes. 
Within 1 hour 100µl of blood was incubated with fluorochrome-conjugated antibodies for 
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15 minutes in the dark. Red blood cells were lysed with 2ml of BD lysing solution® for 10 
minutes, washed in PBS, followed by immediate flow cytometric analysis. Anti-CD16-
Alexa Fluor 488 (clone DJ130c, AbDSerotec, Oxford, UK) and anti-CD14-PE (clone 
MфP9, BD) antibodies were used to define monocyte subsets. Anti-CD42a-PerCP (clone 
Beb1, BD) antibodies were used to characterize monocyte interaction with platelets and 
anti-CD204-APC (clone 351520, R&D Systems, Abingdon, UK [R&D]) antibodies were 
used to assess CD204 expression on monocyte subsets. Monoclonal antibodies for CD204 
were conjugated to APC using LL-APC-XL conjugation kit (Innova Biosciences, UK). 
Anti-CD34-PerCP antibodies (clone 351520, BD), anti-KDR-APC antibodies clone ,R&D 
Systems, Abingdon, UK [R&D]) and anti-VEGF receptor 1 (VEGFR1)-APC antibodies 
(R&D) were used to enumerate CD34+KDR+ EPCs, CD34+ and KDR+ monocytes.  
 
Monocyte subsets were defined as CD14++CD16– cells (Mon1), CD14++CD16+ cells 
(Mon2) and CD14+CD16+ cells (Mon3) (Figure 6). Absolute counts of individual 
monocyte subsets and EPCs (cells/µl) were calculated using total monocyte count obtained 
with haematoanalyser (Bayer Advia 120,Siemens, Newbury, Berks, UK) and proportions 
of individual monocyte subsets determined by flow cytometry. MPAs were defined as 
events positive to both monocyte markers (as above) and a platelet marker CD42a 
(glycoprotein IX). ‘Classical’ EPCs were defined as CD34+/KDR+ mononuclear cells (i.e., 
monocytes plus lymphocytes) (Figure 7). Monocyte-derived EPCs were defined as CD34+ 
and KDR+ monocytes (total and attributable to the individual subsets).SR-AI and 
VEGFR1 expression was measured by its median fluorescent intensity (MFI) on individual 
monocyte subsets 
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Figure 6. Analysis of monocyte subpopulations by flow cytometry 
Analysis of monocyte subpopulations by flow cytometry A. Selection of monocyte cluster 
on the basis of forward and side scatter optic properties (aiming to include all monocytes in 
a sample); B. Exclusion of granulocytes; C. Exclusion of lymphocytes; D. Selected 
monocytes and their subsets: Mon1 (CD14++CD16- monocytes), Mon2 (CD14++CD16+ 
monocytes), and Mon3 (CD14+CD16++ monocytes); E. Individual monocyte subsets are 
gated according to their CD34 and KDR expression for enumeration of KDR+ and CD34+ 
monocyte subsets; F. VEGF receptor 1 expression is assessed on individual monocyte 
subsets. 
. 
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Figure 7. Analysis of CD34+KDR+ endothelial progenitor cells 
A. Selection of mononuclear cells (i.e., monocytes plus lymphocytes) on the basis of 
forward and side scatter optic properties; B. Gating of the CD34+KDR+ endothelial 
progenitor cells (EPCs) 
 
 
The analysis was performed according to the approved SOP (Standard Operating 
Procedure 197 ‘Enumeration of monocytes sub-populations by flow cytometry’). In order 
to obtain intra-assay CV for the method I was given 6 fresh blood samples taken from 2 
volunteers whilst I was blinded to any information on the mixture of the 6 samples 
provided. The blind samples were given and CV calculations were done by Dr Andrew D 
Blann, Consultant Clinical Scientist and Consultant Statistician responsible for the 
laboratory quality control in the department. The analysis showed that intra-assay CV 
derived from the results on percentage of the different subpopulations of monocytes (i.e., 
Mon1, Mon2, Mon3) gave a mean CV of 4.75%. The CV of the monocyte count on the 
Advia was 6.65%. CV for the cumulative analysis of monocyte subset enumeration was 
6.8%. CVs of sub-analyses of the Mon1, Mon2 and Mon3 populations according to their 
VEGFR1/CD34 expression were variable: 8.5% for Mon1, 9.0% for Mon2, and 17.9% for 
Mon3. Higher variability for the analysis of minor monocyte subsets is attributable to the 
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scarcity of these subsets, and partial overlap between the two subsets when their traditional 
(as above) definition was used (i.e., on the basis of CD14 and CD16 expression only). My 
further work aiming to develop an unequivocal and more robust approach of enumeration 
of the monocyte subsets and further validation of the protocol is provided in Chapter IV. 
 
3.4.5.2. Quantification of plasma microparticles 
 
A venous blood sample was taken from the antecubital vein into citrated vacutainers 
(Becton Dickinson, Oxford, UK). Samples were centrifuged at 2880g for 15min and 
plasma was stored at -70°C. Quantification of microparticles was performed by flow 
cytometry (FACSCalibur, Becton Dickinson, Oxford, UK). For batched analysis 50 µl of 
defrosted citrated plasma were incubated with fluorochrome-labeled monoclonal anti-
CD144-PE antibody (clone 123413, R&D Systems, Abingdon, UK), anti-CD14-PerCP 
antibody (clone 134620, R&D) and anti-CD42b-APC (clone HIP1, BD) for 20 minutes in 
the dark at room temperature. After that 25 µl of CytoCount beads (DakoCytomation, 
Glostrup, Denmark) and 200 µl of phosphate buffered saline were added. Acquired events 
were plotted according to their forward and side scatter characteristics in log-scales and 
gated to include events smaller than 1 µm (defined using latex microbeads, Sigma-Aldrich, 
Dorset, UK), but to exclude electronic noise. The size of the region was kept the same for 
all study samples. 
 
The EMPs were defined as CD144+ events, MMPs were defined as CD14+ events and 
PMPs as CD42+ events in the microparticle gate. The degree of positivity to the individual 
markers was defined using species-, immunoglobulin-, protein mass-matched isotype 
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controls (clone 20116, R&D Systems, Abingdon, UK). A minimum of 100,000 
microparticles were collected for analysis per sample. Absolute counts of the 
microparticles were obtained using their proportion to count beads and expressed as the 
numbers of events per µl of plasma. The analysis was performed according to the approved 
Standard Operating Procedure 197 ‘Enumeration of microparticles by flow cytometry’. 
Intra-observer and inter-observer variability of microparticle analysis was 3.5% and 
11.7%, respectively. 
 
3.4.6. Statistical analysis and power calculation 
 
Data are expressed as mean ± standard deviation (SD) for normally distributed data; or 
median with first and third quartiles (Q1-Q3) for non-normally distributed data. Study data 
were analysed by one way analysis of variance (ANOVA). A post-hoc Tukey test was 
performed to assess inter-group differences where appropriate. Log transformation of non-
normally distributed variables was performed prior to ANOVA. A χ2 test was used for the 
comparison of the categorical variables between three groups. When such comparisons 
showed significant differences pair-wise χ2 tests were performed to establish any 
differences between individual groups. A p-value (two tailed) of <0.05 was considered 
statistically significant. SPSS 17 (SPSS, Inc, Chicago, Illinois, USA) statistical software 
was used to perform the statistical analyses. Multivariable linear regression analysis has 
been performed in order to determine clinical and demographic factors associated with the 
study parameters in HF subjects. Regression analysis was started from univariate analysis 
in order to assess unadjusted predictive value of the demographic and clinical variables and 
ethnicity for parameters of vascular and cardiac function, and monocytes/microparticles. 
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Those variables which showed a significant predictive value on the univariate analysis 
were consequently included into a stepwise multivariate regression model.   
 
On the basis on previous work of the department on the study parameters (arterial stiffness, 
endothelial damage/dysfunction) a sample size of 25 subjects in each group would have an 
80% power to detect a difference of 0.5 standard deviations in FMD.
649
 For further 
confidence I aimed to recruit 50 subjects per group for the inter-ethnic comparisons and 40 
subjects per each control group. 
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3.5. Results 
3.5.1. Endothelial function and arterial stiffness in heart failure 
3.5.1.1. Flow-mediated dilation 
 
(a) Comparison of HF subjects vs. controls. 
SAs with HF had significantly lower FMD compared to ‘disease controls’ and ‘healthy 
controls’ (p=0.033 and p<0.001, respectively)(Table 21). No significant difference in the 
baseline diameter of brachial artery and endothelium-independent response to GTN was 
observed between the groups (p=0.53). 
 
(b) Inter-ethnic comparisons in HF.  
SAs and ACs with HF had similar values of FMD (p=0.98), which were significantly 
lower compared to Whites (p<0.001 and p=0.01, respectively)(Table 22, Figure 8). No 
significant difference in the baseline diameter of brachial artery and endothelium-
independent response to GTN was observed between the groups (p=0.77). 
 
3.5.1.2. Microvascular function 
 
SAs with HF had significantly lower endothelium-mediated microvascular response to 
acetylcholine compared to ‘disease controls’ and ‘healthy controls’ (p<0.001, for 
both)(Table 21). SAs had significantly lower response to acetylcholine compared to Whites 
and ACs (p<0.001)(Table 22, Figure 9). There was no significant difference in response 
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toacetylcholine between subjects of white and AC origin (p=0.88). There was no ethnic 
difference in baseline skin perfusion (p=0.81).  
 
Table 21. Characteristics of endothelial and vascular function in South Asian subjects 
with heart failure compared to controls 
 Healthy controls 
(n=40) 
Disease controls 
(n=40) 
Heart failure 
(n=50) 
p 
Flow mediated dilation 
BA diameter, mm 4.08±0.73 4.35±0.52 4.16±0.68 0.19 
BA FMD, % 11.7±4.65*† 7.22±3.69‡ 4.76±4.78 <0.001 
BA response to GTN, % 12.1±4.33 11.3±4.18 11.0±5.25 0.53 
Microvascular function 
LD baseline, PU 26.2 (17.6-35.6) 24.1 (19.1-34.3) 20.8 (14.5-27.3) 0.07 
LD acetylcholine, % 543±254*† 390±290‡ 129±93.1 0.001 
LD sodium nitroprusside, % 350 (163-706) 252 (108-517) 258 (169-452) 0.26 
Arterial stiffness 
PWV (femoral), m/sec 7.19±2.08* 7.83±2.85 8.63±3.11 0.06 
PWV (radial), m/sec 7.61±1.40 7.51±1.08 7.81±1.45 0.69 
Augmentation index, % 28.8±12.1 26.0±11.0 25.1±14.3 0.59 
Endothelial microparticles 
EMP, per µl 9470  
(6107-11025)† 
9724  
(5831-11136)‡ 
10929  
(6225-19600) 
0.04 
BA - brachial artery, EMP – endothelial microparticles, FMD - flow-mediated dilation, 
GTN – glycerol trinitrate, LD – laser Doppler, PWV – pulse wave velocity, PU – perfusion 
units. Values expressed as Mean±Standard Deviation or Median (Q1-Q3). *p<0.05 
between healthy controls and disease controls (p=0.07 for EMPs), †p <0.05 between 
healthy controls and HF group, ‡ p <0.05 between disease controls and HF group (p=0.08 
for EMPs). 
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Table 22. Parameters of endothelial and vascular function in subjects with heart 
failure 
 South Asian 
(n=50) 
White 
(n=50) 
African-Caribbean 
(n=28) 
p 
Flow-mediated dilation 
BA diameter, mm 4.16±0.68 4.15±0.68 4.47±0.84 0.14 
BA FMD, % 4.76±4.78* 8.49±4.63‡ 4.55±3.56 <0.001 
BA response to GTN, % 11.0±5.25 11.5±4.73 10.9±4.93 0.77 
Microvascular function 
LD baseline, PU 20.8 (14.5-27.3) 19.2 (15.2-30.1) 19.8 (15.4-25.5) 0.81 
LD acetylcholine, % 129±93.1*† 265±151 281±159 <0.001 
LD sodium nitroprusside, % 258 (169-452) 249 (152-493) 273 (109-744) 0.67 
Arterial stiffness 
PWV (femoral), m/sec 8.63±3.11 8.11±3.11 9.35±2.33 0.23 
PWV (radial), m/sec 8.15 (6.60-8.72) 7.10 (6.30-7.60) 7.70 (6.90-8.87) 0.88 
Augmentation index, % 25.1±14.3† 25.9±14.1‡ 15.2±16.5 0.02 
Endothelial microparticles 
EMP, per µl 10929 
(6225-19600)† 
8527 
(6984-10818) 
8786 
(6415-11381) 
0.04 
 
BA - brachial artery, EMP – endothelial microparticles, FMD - flow-mediated dilation, 
GTN – glycerol trinitrate, LD – laser Doppler, PWV – pulse wave velocity, PU – perfusion 
units. Values expressed as Mean±Standard Deviation or Median (Q1-Q3). *p<0.05 
between SAs and Whites (p=0.075 for EMPs), †p <0.05 between SAs and ACs, ‡ p <0.05 
between Whites and ACs. 
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Figure 8. Ethnic differences in flow mediated dilation in heart failure 
 
 
Figure 9. Ethnic differences in microvascular endothelial function in heart failure 
LD acetylcholine – response to iontophoresis of acetylcholine measure by laser Doppler 
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3.5.1.3. Arterial stiffness 
 
(a) Comparison of HF subjects vs. controls. 
Carotid-femoral PWV was significantly higher in SAs with HF compared to healthy 
individuals (p=0.048)(Table 21). No significant difference in carotid-radial PWV and 
augmentation index was found.  
 
(b) Inter-ethnic comparisons in HF.  
No significant ethnic difference in PWV (carotid-femoral and carotid-radial) in HF 
subjects was evident (Table 22). Aortic augmentation index was significantly lower 
amongst AC subjects compared to other ethnic groups (p=0.044 compared to SAs; p=0.033 
compared to Whites). 
 
3.5.1.4. Endothelial microparticles 
 
(a) Comparison of HF subjects vs. controls. 
The median EMP count was significantly different among the three SA groups (Kruskal 
Wallis test, p=0.04) but not significantly different between the individual groups (posthoc 
tests, p=0.08 and p=0.07 between ‘healthy controls’ vs. HF subjects, and ‘healthy controls’ 
vs. ‘disease controls’, respectively) (Table 21).  
 
(b) Inter-ethnic comparisons in HF.  
EMPs were significantly different between the three HF ethnic groups (Kruskal Wallis test, 
p=0.04) but were not significantly different on post-hoc testing for the individual inter-
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group comparisons (SAs vs. ACs [p=0.07] and SAs vs. Whites [p=0.10]) (Table 22, Figure 
10). 
 
 
Figure 10. Ethnic differences in endothelial microparticles in heart failure 
 
3.5.1.5. Multivariable analysis 
 
Using linear regression analysis, FMD in HF subjects (n=128) was significantly associated 
with age, NYHA class, history of hypertension, glucose and total cholesterol levels, and 
carotid-femoral PWV (Table 23). The microvascular endothelial function in HF 
significantly correlated with diabetes, glucose and HDL levels, smoking and ethnicity. 
Carotid-femoral PWV was significantly associated with age, diabetes, systolic and 
diastolic blood pressure, glomerular filtration rate, glucose levels, and FMD. LVEF was 
the only parameter significantly correlated with carotid-radial PWV. Ethnicity and NYHA 
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class were associated with aortic augmentation index. Ethnicity was not correlated with the 
carotid-femoral PWV, carotid-radial PWV. On univariate analysis, EMP count was 
significantly associated with ethnicity, LVEF and systolic blood pressure.  
 
After adjustment for other significant clinical and demographic variables in a multivariable 
analysis, ethnicity was significantly associated with microvascular endothelial function 
(i.e., response to acetylcholine) (Table 24). Although a significantly higher proportion of 
SA patients with HF received statins compared with Whites, statin use was not 
significantly associated with parameters of endothelial function and arterial stiffness (Table 
25). 
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Table 23. Univariate linear regression analysis of predictors of parameters of 
endothelial function and arterial stiffness 
Predictor β R
2
 p 
 Flow-mediated dilation 
Age -0.29 0.08 0.001 
NYHA class 0.23 0.04 0.011 
History of hypertension -0.19 0.04 0.038 
Glucose -0.48 0.23 0.004 
Total cholesterol 0.24 0.06 0.03 
Carotid-femoral PWV -0.22 0.05 0.018 
Diabetes -0.15 0.02 0.099 
Ethnicity 0.39 0.15 0.005 
 Laser Doppler, response to acetylcholine 
Diabetes -0.21 0.04 0.02 
Glucose levels -0.43 0.18 0.01 
HDL cholesterol 0.27 0.07 0.039 
Smoking 0.28 0.08 0.002 
Ethnicity 0.42 0.18 <0.001 
 Carotid-femoral PWV 
Age 0.38 0.14 <0.001 
Diabetes 0.29 0.08 0.002 
Systolic blood pressure 0.35 0.12 <0.001 
Diastolic blood pressure 0.19 0.04 0.042 
Glomerular filtration 
rate 
-0.20 0.04 0.046 
Glucose 0.032 0.10 0.067 
Flow-mediated dilation -0.22 0.05 0.018 
Ethnicity 0.07 0.01 0.46 
 Carotid-radial PWV 
Ejection fraction -0.36 0.13 0.007 
Ethnicity -0.006 0.00 0.96 
 Augmentation index 
NYHA III class -0.27 0.07 0.013 
Ethnicity -0.24 0.06 0.028 
 Endothelial microparticles 
Ejection fraction -0.23 0.05 0.04 
Systolic blood pressure -0.21 0.04 0.02 
Ethnicity 0.25 0.07 0.005 
 PWV, pulse wave velocity 
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Table 24. Multivariable analysis of predictive value of ethnicity for parameters of 
endothelial function and arterial stiffness 
Parameter β R
2
 p 
Flow-mediated dilation -0.06 0.39 0.49 
Laser Doppler, response to acetylcholine 0.49 0.41 0.003 
Endothelial microparticles 0.20 0.23 0.06 
Augmentation index -0.21 0.09 0.35 
 
 
 
Table 25. Predictive value of statins for parameters of endothelial function and 
arterial stiffness (univariate regression analysis) 
Parameter β R
2
 p 
Flow-mediated dilation -0.044 0.00 0.63 
Laser Doppler, response to acetylcholine -0.33 0.00 0.72 
Pulse wave velocity (femoral) 0.13 0.02 0.16 
Pulse wave velocity (radial) 0.074 0.01 0.51 
Augmentation index 0.14 0.02 0.21 
Endothelial microparticles 0.12 0.01 0.20 
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3.5.2. Monocyte subsets and monocyte-platelet aggregates in heart failure 
3.5.2.1. Monocyte subsets and monocyte-platelet aggregates 
 
(a) Comparison of HF subjects vs. controls. 
SAs with HF had lower numbers and percentage of Mon3 compared to ‘disease controls’ 
and ‘healthy controls’ (p=0.036 and p=0.014, respectively for Mon3 numbers; p=0.07 and 
p=0.005 for Mon3 percentage)(Table 26). No significant difference in Mon1, Mon2 and 
MPA counts was found between the study groups (p=0.90, p=0.78 and p=0.67, 
respectively). 
 
(b) Inter-ethnic comparisons in HF.  
Whites had significantly higher Mon2 counts and percentages compared with SAs and ACs 
(p=0.004 and p=0.002, respectively for Mon2 counts, p=0.006 and p=0.009, respectively 
for Mon2 percentages)(Table 27, Figure 11). ACs had the highest count of Mon3 (p=0.015 
vs. SAs and p=0.052 vs. Whites) and the highest percentages of Mon3 (p<0.001 vs. SAs 
and p<0.001 vs. Whites)(Figure 12). No significant differences in Mon1 counts were 
observed between the study groups. No significant difference in Mon1, and MPAs was 
found between the study groups (p=0.20, p=0.73, respectively). 
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Table 26. Monocytes, monocyte-platelet aggregates and microparticles in South Asian 
subjects with heart failure compared to controls 
 Heart failure Disease controls Healthy controls p 
Monocyte subsets 
Mon1, per µl 342±118 333±125 329±139 0.90 
Mon2, per µl 18.0 (9.37-31.7) 15.7 (12.7-30.6) 22.4 (15.2-28.9) 0.78 
Mon3, per µl 26.8 (15.6-43.7)*† 34.0 (25.9-41.0) 36.9 (26.2-60.7) 0.019 
Mon1, % 85.0±8.27 84.1±6.64 81.4±9.56 0.18 
Mon2, % 4.73 (2.95-8.14) 5.04 (3.18-8.17) 5.20 (4.09-7.84) 0.73 
Mon3, % 7.47 (4.49-10.9)*† 9.31 (7.52-11.3) 9.91 (6.33-15.9) 0.023 
MPA, per ul 61.2 (35.5-123) 70.0 (39.6-121) 65.9 (44.1-114) 0.67 
CD204 expression 
CD204 (all 
monocytes), MFI 
11.5 (8.33-26.0) 11.3 (9.18-16.6) 29.9 (9.26-39.0) 0.30 
CD204 (Mon1), MFI 10.5 (7.82-26.0) 10.4 (8.50-14.9) 33.5 (9.02-42.8) 0.15 
CD204 (Mon2), MFI 41.5 (25.3-55.5) 48.5 (31.5-72.3) 50.5 (35.4-58.2) 0.30 
CD204 (Mon3), MFI 26.5±18.3 25.9±12.3 23.9±15.5 0.78 
CD204 (Mon1), % 22.2 (9.46-66.6) 20.2 (14.1-37.7) 71.2 (22.4-82.3) 0.14 
CD204 (Mon2), % 74.4±19.8 76.6±19.3 81.6±14.9 0.25 
CD204 (Mon3), % 53.9±21.5 53.1±18.3 51.4±22.9 0.89 
Microparticles 
Monocyte MPs, per µl 1106  
(583-2816)*† 
602  
(449-1085) 
457 (303-622) 0.001 
Platelet MPs, per µl 36368  
(25524-55991)*† 
 
28851  
(25294-37091)‡ 
23141  
(16725-28749) 
0.001 
MFI, median fluorescent intensity, MP, microparticles.*p<0.05 between HF and disease 
control groups, †p <0.05 between HF and healthy control groups, ‡ p <0.05 between 
disease controls and healthy controls. 
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Table 27. Monocytes, monocyte-platelet aggregates and microparticles in subjects 
with heart failure 
 
South Asians Whites 
African-
Caribbeans p 
Monocyte subsets 
Mon1, per µl 342±118 344 (256-446) 282 (185-397) 0.20 
Mon2, per µl 18.0 (9.37-31.7)* 27.3 (18.8-57.8)‡ 19.9 (9.67-38.3) 0.003 
Mon3, per µl 26.8 (15.6-43.7)† 27.6 (18.8-47.2)‡ 43.9 (26.065.9) 0.026 
Mon1, % 87.2 (80.6-91.5) 85.3 (81.1-87.0) 82.0 (77.4-85.6) 0.10 
Mon2, % 4.73 (2.95-8.14)* 7.32 (5.63-10.8)‡ 5.29 (2.69-9.97) 0.005 
Mon3, % 7.47 (4.49-10.9)† 7.51±3.94‡ 13.8±7.38 <0.00
1 
MPA, per µl 61.2 (35.5-123) 69.6 (41.8-133) 55.8 (40.1-150) 0.73 
CD204 expression 
CD204 (all 
monocytes), MFI 
11.5 (8.33-26.0) 10.4 (8.15-37.0) 11.3 (8.24-54.0) 0.88 
CD204 (Mon1), MFI 10.5 (7.82-26.0) 8.94 (7.41-39.4) 10.7 (7.06-62.4) 0.87 
CD204 (Mon2), MFI 41.5 (25.3-55.5) 29.5 (21.6-57.6) 35.6 (19.2-62.0) 0.58 
CD204 (Mon3), MFI 26.5±18.3† 16.6 (10.8-24.4) 14.5 (8.88-23.9) 0.08 
CD204 (Mon1), % 22.2 (9.46-66.6) 15.9 (9.66-71.2) 24.8 (10.3-81.9) 0.77 
CD204 (Mon2), % 74.4±19.8 69. 9±18.2 72.1±20.9 0.54 
CD204 (Mon3), % 53.9±21.5† 46.8±20.5 38.8±16.9 0.014 
Microparticles 
Monocyte MPs, per µl 1106 (583-2816)* 761 (566-987) 890 (664-1482) 0.054 
Platelet MPs, per µl 36368  
(25524-55991)*† 
28288  
(24783-34986) 
30045  
(23201-40674) 
0.016 
 
MFI, median fluorescent intensity, MP, microparticles.*p<0.05 between SAs and Whites, 
†p <0.05 between SAs and ACs (p=0.057 for platelet MPs), ‡ p <0.05 between Whites and 
ACs. 
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Figure 11. Ethnic differences in CD14++CD16+ monocytes (Mon2) in heart failure 
 
 
Figure 12. Ethnic differences in CD14+CD16+ monocytes (Mon3) in heart failure 
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3.5.2.2. Monocyte CD204 expression 
 
(a) Comparison of HF subjects vs. controls:  
HF subjects had similar monocyte CD204 expression when compared with controls (Table 
26). 
 
(b) Inter-ethnic comparisons in HF.  
SAs had significantly higher proportion of Mon3 expressing CD204 compared with ACs 
(p=0.011) and similar trend compared with Whites (p=0.088) (Table 27). 
 
3.5.2.3. Monocyte-derived and platelet-derived microparticles 
 
(a) Comparison of HF subjects vs. controls. 
MMP count was significantly increased in the HF group compared to ‘disease controls’ 
and ‘healthy controls’ (p=0.014 and p=0.001, respectively) (Table 26). PMPs were 
incrementally increased from ‘healthy controls’ to ‘disease controls’ (p=0.016) and further 
from ‘disease controls’ to patients with HF (p=0.035) (Figure 13). 
 
(b) Inter-ethnic comparisons in HF. 
SA subjects had more MMPs than Whites (p=0.008). There was a non-significant trend 
towards higher PMP levels in SAs compared with Whites (p=0.079) and ACs (p=0.057) 
(Table 27). 
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Figure 13. Platelet microparticles in heart failure subjects vs. control groups 
 
 
3.5.2.4. Multivariate analysis 
 
On univariate linear regression analysis, ethnicity was predictive of Mon2 and Mon3 in HF 
patients (Table 28). After the adjustment for age and diabetes in multivariate analysis, 
white origin was independently predictive of high Mon2 counts, whilst AC origin was 
independently predictive of high Mon3 count and percentages and low granulocyte counts. 
SA origin was predictive of high MMP and PMP counts. 
 
High MMP count was significantly predictive of LVEF in HF patients, before and after 
adjustment for age (β -0.23 for both; p=0.035 and p=0.042, respectively). 
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Table 28. Predictive value of ethnicity on monocyte subsets, and microparticles 
Parameter Compa- 
rative 
ethnicity 
Unadjusted Adjusted* 
β R
2
 p β R
2
 p 
Mon2,  
per µl 
Whites 0.29 0.09 0.005 0.25 0.11 0.02 
ACs -0.29 0.77 -0.05 0.66 
Mon3,  
per µl 
Whites 0.42 0.07 0.68 0.094 0.10 0.38 
ACs 0.28 0.007 0.31 0.003 
Mon2,  
% 
Whites 0.24 0.06 0.016 0.19 0.09 0.081 
ACs -0.12 0.90 -0.04 0.72 
Mon3, 
 % 
Whites -0.04 0.20 0.65 0.01 0.23 0.93 
ACs 0.43 <0.001 0.48 <0.001 
MMPs,  
per µl 
Whites -0.37 0.12 <0.001 -0.36 0.12 <0.001 
ACs -0.25 0.009 -0.25 0.009 
PMPs,  
per µl 
Whites -0.27 0.08 0.007 -0.30 0.09 0.005 
ACs -0.27 0.007 -0.27 0.007 
ACs, African-Caribbeans, MMPs, monocyte microparticles, PMP, microparticles.  
*Adjusted for age and diabetes. B, coefficient of regression, MMP, monocyte 
microparticles, PMP, platelet microparticles, SE, standard error, β, adjusted coefficient of 
regression.
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3.5.3. Endothelial progenitor cells in heart failure 
3.5.3.1. Endothelial progenitor cells in heart failure in South Asians 
 
SAs with HF had significantly reduced total numbers of CD34+ monocytes compared to 
‘disease controls’ (p=0.015) and ‘healthy controls’ (p=0.003) (Table 29, Figure 14). Also, 
CD34+ Mon1 were reduced in HF compared with ‘disease controls’ (p=0.037); CD34+ 
Mon2 were lower in HF compared to ‘disease controls’ (p=0.02) and showed similar trend 
when compared to ‘healthy controls’ (p=0.06). The CD34+ Mon3 counts were not 
significantly different between the three groups. 
 
A different trend was seen for the numbers of KDR+ monocytes. Total KDR+ monocytes 
and KDR+ Mon1 were increased in ‘disease controls’ compared with ‘healthy controls’ 
(p=0.021 and p=0.005, respectively); however, KDR+ Mon1 counts were reduced in HF 
subjects (p=0.036 vs. ‘disease controls’) (Figure 15). There were no significant differences 
in KDR+ Mon2 and KDR+ Mon3 between HF and control groups. 
 
VEGFR1 expression on Mon1 and Mon2 was significantly reduced in HF compared to 
‘disease controls’ (p=0.035, and p=0.001, respectively), whilst VEGFR1 expression on 
Mon3 was not significantly different. Levels of CD34+KDR+ EPCs were reduced in HF 
vs. ‘healthy controls’ (p<0.0001) and ‘disease controls’ (p=0.018) (Figure 16). 
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Table 29. Endothelial progenitors and monocyte expression of VEGF receptor 1 in 
South Asian subjects with heart failure compared to controls 
 Heart failure Disease controls Healthy controls p 
CD34+ monocytes,  
per µl 
9.37  
(6.20-20.7)*† 
18.0  
(12.8-36.9) 
19.0  
(11.7-24.2) 
0.015 
CD34+ Mon1,  
per µl 
7.35  
(4.79-17.2)* 
14.8  
(10.1-32.3) 
13.0  
(7.65-18.6) 
0.012 
CD34+ Mon2,  
per µl 
0.82  
(0.54-1.97)*† 
2.12  
(1.09-4.08) 
1.69  
(1.08-3.36) 
0.031 
CD34+ Mon3,  
per µl 
1.15  
(0.71-2.33) 
1.96  
(1.23-2.30) 
2.02  
(0.92-3.27) 
0.14 
KDR+ monocytes,  
per µl 
1190  
(767-2531)* 
3068  
(1009-6246)‡ 
993  
(744-1935) 
0.021 
KDR+ Mon1, 
 per µl 
410  
(161-1503)* 
1234  
(340-3296)‡ 
275  
(169-578) 
0.004 
KDR+ Mon2,  
per µl 
469  
(242-1200) 
915  
(255-2730) 
417  
(201-770) 
0.17 
KDR + Mon3,  
per µl 
162  
(77.5-231) 
219  
(104-382) 
229  
(138-517) 
0.24 
VEGFR1 (Mon1),  
MFI 
12.6±5.82* 16.2±6.54 14.4±5.93 0.045 
VEGFR1 (Mon2),  
MFI 
30.9±14.4* 46.0±21.5 36.0±15.6 0.001 
VEGFR1 (Mon3),  
MFI 
11.3±3.34 13.5±5.31 11.3±4.18 0.055 
CD34+KDR+ EPC,  
per µl 
915  
(441-1580)*† 
1567  
(902-2574) 
2292  
(1066-5775) 
0.001 
 
EPC, endothelial progenitor cells, KDR, kinase domain receptor, MFI, median fluorescent 
intensity, VEGFR1, vascular endothelial growth factor receptor 1. *p<0.05 between HF 
and disease control groups, †p <0.05 between HF and healthy control groups (p=0.06 for 
CD34+ Mon2), ‡ p <0.05 between disease controls and healthy controls. 
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Figure 14. CD34+ monocytes in heart failure vs. control groups 
CAD, coronary artery disease (‘disease’ controls) 
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Figure 15. KDR+ monocytes in heart failure vs. control groups 
CAD, coronary artery disease (‘disease’ controls) 
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Figure 16. CD34+KDR+ endothelial progenitor cells (EPCs) in heart failure vs. 
control groups 
CAD, coronary artery disease (‘disease’ controls) 
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3.5.3.2. Inter-ethnic comparisons in heart failure 
 
Whites had significantly less KDR+ Mon3 than ACs (p=0.033), but significantly more 
CD34+ Mon2 than both SAs (p=0.001) and AC (p=0.048). There were no ethnic 
differences in other study parameters (Table 30). 
 
Table 30. Endothelial progenitors and monocyte expression of VEGF receptor 1 in 
subjects with heart failure 
 South Asians Whites African-Caribbeans p 
KDR+ monocytes,  
per µl 
1190  
(767-2531) 
1603  
(623-4668) 
2454  
(856-6549) 
0.46 
KDR+ Mon1,  
per µl 
410  
(161-1503) 
565  
(196-1958) 
1018  
(427-3938) 
0.30 
KDR+ Mon2,  
per µl 
469  
(242-1200) 
758  
(283-2078) 
661  
(284-1623) 
0.50 
KDR + Mon3,  
per µl 
162  
(77.5-231) 
96.8  
(29.5-185)‡ 
215  
(98.5-643) 
0.01 
CD34+ monocytes,  
per µl 
9.37  
(6.20-20.7) 
14.1  
(8.96-42.0) 
12.0  
(7.41-27.7) 
0.10 
CD34+ Mon1,  
per µl 
7.35  
(4.79-17.2) 
10.5  
(6.45-27.6) 
9.11  
(4.70-19.5) 
0.27 
CD34+ Mon2,  
per µl 
0.82  
(0.54-1.97)* 
2.38  
(1.12-5.70)‡ 
1.37  
(0.56-2.73) 
<0.001 
CD34+ Mon3,  
per µl 
1.15 
(0.71-2.33) 
1.23  
(0.73-2.34) 
2.53  
(1.05-4.07) 
0.05 
VEGFR1 (Mon1),  
MFI 
12.6±5.82 15.2±9.07 15.5±8.22 0.21 
VEGFR1 (Mon2),  
MFI 
30.9±14.4 33.9±18.9 36.7±21.4 0.43 
VEGFR1 (Mon3),  
MFI 
11.3±3.34 12.0±9.56 11.5±4.01 0.88 
CD34+KDR+ EPC,  
per µl 
915  
(441-1580) 
1229  
(697-1810) 
1673  
(583-2874) 
0.29 
 
EPC, endothelial progenitor cells, KDR, kinase domain receptor, MFI, median fluorescent 
intensity, VEGFR1, vascular endothelial growth factor receptor 1. *p<0.05 between SAs 
and Whites, ‡ p <0.05 between Whites and ACs. 
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3.5.3.3. Regression analysis 
 
On univariate linear regression analysis, endothelial progenitors were not significantly 
associated with LVEF or E/E’ (Table 31). On univariate analysis, VEGFR1 expression by 
Mon2 showed a trend towards predictive value for LVEF (p=0.054), but after adjustment 
for ethnicity this parameter was significantly predictive of LVEF (β=-0.25. p=0.039). After 
adjustment for ethnicity and age, this was of borderline significance (β=-0.24. p=0.051). 
 
Table 31. Predictive value of the endothelial progenitors and monocyte angiogenic 
characterisctics for cardiac geometry and function 
 Ejection fraction E/E’ 
β R
2
 p β R
2
 p 
EPC -0.17 0.03 0.17 -0.06 0.00 0.68 
CD34+ monocytes -0.06 0.00 0.65 0.06 0.00 0.63 
CD34+ Mon1 -0.06 0.00 0.60 0.07 0.01 0.59 
CD34+ Mon2 -0.07 0.01 0.58 -0.02 0.00 0.91 
CD34+ Mon3 0.07 0.01 0.57 0.12 0.01 0.38 
KDR+ monocytes -0.16 0.03 0.20 -0.04 0.00 0.79 
KDR+ Mon1 -0.16 0.03 0.20 -0.01 0.00 0.97 
KDR+ Mon2 -0.16 0.03 0.21 -0.05 0.00 0.72 
KDR + Mon3 -0.15 0.02 0.25 -0.06 0.00 0.69 
VEGFR1 (Mon1) -0.21 0.04 0.081 0.06 0.00 0.66 
VEGFR1 (Mon2) -0.23 0.05 0.054 -0.03 0.00 0.82 
VEGFR1 (Mon3) -0.13 0.02 0.29 0.01 0.00 0.96 
 
EPC, endothelial progenitor cells, KDR, kinase domain receptor, VEGFR1, vascular 
endothelial growth factor receptor 1. 
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On univariate regression analysis, AC ethnicity was predictive of the numbers of KDR+ 
Mon3 in HF (p=0.03) (Table 32). On multivariate analysis, AC ethnicity remained 
independently predictive of KDR+ Mon3 count even after adjustment for age, HF 
aetiology and history of diabetes (β=0.021, p=0.045). 
 
Table 32. Predictive value of ethnicity on endothelial progenitors and monocyte 
angiogenic characteristics 
 South Asians Whites African-Caribbeans 
β R
2
 p β R
2
 p β R
2
 p 
EPC -0.14 0.02 0.22 0.11 0.01 0.30 0.04 0.00 0.71 
CD34+ monocytes -0.15 0.02 0.17 0.13 0.02 0.19 -0.02 0.00 0.88 
CD34+ Mon1 -0.12 0.01 0.28 0.09 0.01 0.37 0.01 0.00 0.93 
CD34+ Mon2 -0.12 0.02 0.27 0.14 0.02 0.15 -0.08 0.01 0.43 
CD34+ Mon3 -0.12 0.01 0.29 0.12 0.01 0.23 -0.03 0.00 0.76 
KDR+ monocytes -0.10 0.01 0.37 0.05 0.00 0.61 0.08 0.01 0.46 
KDR+ Mon1 -0.09 0.01 0.44 -0.02 0.00 0.82 0.17 0.03 0.10 
KDR+ Mon2 -0.11 0.01 0.35 0.12 0.01 0.25 -0.05 0.00 0.65 
KDR + Mon3 -0.10 0.01 0.40 -0.05 0.00 0.62 0.22 0.05 0.03 
VEGFR1 (Mon1) -0.17 0.03 0.12 0.10 0.01 0.30 0.08 0.01 0.40 
VEGFR1 (Mon2) -0.09 0.01 0.40 0.03 0.00 0.79 0.10 0.01 0.30 
VEGFR1 (Mon3) -0.05 0.00 0.66 0.05 0.00 0.62 -0.01 0.00 0.89 
 
EPC, endothelial progenitor cells, KDR, kinase domain receptor, VEGFR1, vascular 
endothelial growth factor receptor 1. 
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3.6. Discussion 
 
3.6.1. Endothelial function and arterial stiffness 
 
This study shows for the first time significant ethnic differences in endothelial function in a 
cohort of 128 subjects with systolic HF. The White ethnic group had significantly higher 
values of FMD of the brachial artery compared to other ethnic groups, with no difference 
seen between SA and AC subjects. 
 
The impact of endothelial dysfunction on pathogenesis and outcome of systolic HF is well 
recognised. Numerous studies have demonstrated peripheral endothelium-dependent 
vasomotor abnormalities in HF as assessed by brachial artery FMD or forearm blood flow 
changes in response to acetylcholine.
142-144
 Direct evidence for endothelial dysfunction in 
the genesis of haemodynamic abnormalities in HF has been provided by the infusion of 
NG-monomethyl-L-arginine, an inhibitor of NO production, into volunteers with HF.
141
 
Also, there is an independent significant association of endothelial dysfunction with a 
negative outcome in HF, whether in mild HF (NYHA class I) with relatively preserved 
myocardial contractility or in more advanced HF (NYHA class IV) with severely 
depressed LV function.
172-173
 The predictive value of FMD for the outcome does not seem 
to be affected by HF aetiology. 
 
In this study I found that SAs with HF had significantly worse macrovascular endothelial 
function than HF-free control subjects, a finding that accords with well recognised 
macrovascular endothelial abnormalities in Whites with HF.
175
 However, in the inter-
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ethnic comparison non-White ethnic groups had differences in the proportion of patients 
having diabetes mellitus, a potent contributor to endothelial dysfunction.
650
 When the study 
results were adjusted for important clinical and demographic co-variables, such as age, 
NYHA class, diabetic status, ethnicity was no longer associated with FMD in HF patients. 
This analysis indicates that ethnicity-related differences in co-morbidities/risk factors 
accompanying HF rather than ethnicity itself may determine the status of macrovascular 
endothelial dysfunction. 
 
In contrast to robust evidence of macrovascular endothelial dysfunction in HF, only 
limited data are available on the status of microvascular endothelial function in such 
subjects.
651-652
 In my study, I show significant impairment of the cutaneous vascular 
response to acetylcholine in SAs with HF. I also show for the first time that SAs with HF 
have significant impairment of microvascular endothelial function compared to other 
ethnic groups, with SA ethnicity being associated with microvascular endothelial 
dysfunction, even after adjustment for age, presence of hypertension and diabetes, blood 
pressure and glucose levels. It might be plausible to speculate that these abnormalities of 
endothelium-dependant regulation of microvascular flow could account for the 
unexplained discrepancy between the distinctly more prominent HF symptoms in SA 
subjects (e.g., much higher hospitalisation rate) despite relatively preserved LV 
contractility as compared to white HF subjects.
12, 67
 
 
Most but not all studies have shown the ability of statins to improve FMD in subjects with 
systolic HF.
193, 235, 238, 242
 Of note, the study with the longest controlled period of treatment 
with statins in HF (i.e., for 12 weeks) failed to significantly improve FMD.
235
 These 
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observations suggest that beneficial effects of statins on vasomotor endothelial function in 
HF may wear off during longer-term treatment. Also, there are no published data on the 
effects of statins on microvascular endothelial function in HF patients. In my study, 
treatment with statins was not associated with parameters of macrovascular (i.e., FMD), 
and microvascular (i.e., response to acetylcholine) endothelial function. Thus, despite a 
higher proportion of SA subjects with HF received statins compared with Whites, this is 
unlikely to significantly affect the ethnic differences seen in the study, particularly given 
that Whites had higher FMD than SAs. 
 
In contrast to measures of endothelial function, parameters of arterial stiffness did not 
differ between SA subjects with HF and matched ‘disease controls’. No significant ethnic 
difference in PWV was observed, but aortic augmentation index was slightly lower in ACs. 
Ethnicity was associated with differences in the aortic augmentation index (but not in 
PWV). However, its significance failed to be independent of other factors affecting aortic 
stiffness. 
 
EMPs have emerged as a novel marker of endothelial dysfunction related to the 
pathogenesis of various cardiovascular disorders.
637
 Recently, EMPs were shown to be of 
significant predictive value for negative clinical outcomes in HF.
628
 However, I was unable 
to identify any data on EMP count in subjects with systolic HF as compared to individuals 
with normal cardiac contractility. In this study, I observed a trend towards increased values 
of EMPs in subjects with HF compared to control groups as well as increased EMP values 
in SAs with HF compared with other ethnic groups. Whilst ethnicity tended to be 
associated with EMP count in HF on linear regression, this was not significant after the 
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adjustments (p=0.06). It is therefore unclear whether ethnicity affects EMPs as a marker of 
endothelial dysfunction, but given the strong trend towards higher EMPs in SAs with HF 
observed in this study, further investigations are probably warranted. 
 
It has been previously shown that subjects of SA origin present with symptoms of 
congestive HF on average 8 years earlier than Whites.
12
 Additionally SAs with HF have 
about 60% more hospital admissions in general and 5-fold higher risk of presenting with 
HF at hospital among the elderly without signs of more severe LV impairment.
12, 70
 A 
higher prevalence of diastolic dysfunction in SAs has been suggested but not well 
documented.
63
 Accordingly it is unclear at present which factors could be responsible for 
more HF symptoms in SAs. 
 
It is increasingly recognised that endothelial dysfunction could be a significant contributor 
to the development of HF with preserved EF and it may also affect the symptoms of 
systolic HF.
1
 Even healthy SAs have worse parameters of endothelial function compared to 
healthy Whites.
22
 The results of the present study show that SA ethnicity is associated with 
more severe endothelial dysfunction, even after adjustment for the cardiovascular risk 
factors including diabetes. It is thus tempting to speculate that more prominent endothelial 
dysfunction may be at list partly responsible for the more symptomatic status in SAs with 
HF. Further research would be needed to prove the concept. 
 
Despite the higher age-adjusted prevalence, greater hospitalization rate and worse risk 
factor profile, SA subjects with HF appear to have better prognosis than Whites. The 30 
day, 1-year, and 2-year survival rates are consistently better amongst SA.
12, 67
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Multivariable analysis has also confirmed an independent association of SA ethnicity with 
more favourable prognosis in HF.
12, 67
 Again it is plausible that better prognosis in SAs 
may reflect the situation that earlier presentation with HF due to symptoms associated with 
vascular disease related toendothelial dysfunction leads to earlier and timely initiation of 
the treatment. Additionally the study results identify microvascular endothelial dysfunction 
as a potential target for the therapeutic interventions in SAs with HF. 
 
3.6.2. Monocyte subsets 
 
This study shows for the first time significant ethnic difference in monocyte subsets in HF. 
The counts and proportion of Mon3, which have been suggested to have a reparative 
potential were significantly higher in HF subjects of AC origin.
41
 These observations may 
reflect an implication of monocyte subsets in the ethnicity-related differences in 
pathogenesis and clinical outcomes of HF. 
 
The progressive nature of HF reflects an imbalance between detrimental (e.g., 
inflammation) and reparative processes.
305
 Monocytes are actively involved in both 
processes by release a diverse range of cytokines and angiogenic factors orchestrating 
recruitment and activity of other cell types.
25, 653
 Individual monocyte subsets have been 
shown to be featured by different profiles of the cytokines and growth factors produced. 
For example, Mon1 actively produce various inflammatory cytokines, Mon3 have clearly 
attenuated inflammatory properties, whilst Mon2 shows the highest of all monocytes 
expression of IL-10 and receptors to angiogenic factors (the differences between monocyte 
subsets are addressed in Chapter IV of the thesis).
635
 
187 
 
 
The findings of higher Mon3 levels in AC subjects with HF could account for reported 
ethnicity-related differences in HF. Although some studies showed an increased net 
mortality in Black vs. White patients with HF this difference disappears after adjustment 
for worse medication adherence and lower socio-economic status among Blacks.
654-655
 
Despite a higher prevalence of cardiovascular disease and risk factors for HF, Black 
patients have similar prevalence of reduced LVEF as compared with Whites.
656-657
 
However, the mortality after hospitalization for HF was 32% lower for Blacks during 
short-term follow-up and 16% lower during long-term follow-up than for Whites. It is 
possible that these observations may reflect ‘better’ intrinsic protective/reparative potential 
in this ethnic group, which may be partly attributable to higher Mon3 levels seen in AC 
subjects in my study. These hypotheses are perhaps further supported by the reported 
reparative properties of this subset.
635
  
 
In this study I also show significant ethnic difference in SR-AI expression on Mon3 subset, 
with higher levels seen in SA subjects. These findings may offer a further explanation why 
SA subjects with HF have a better prognosis than Whites despite a higher rate of an 
ischaemic aetiology, a recognised risk factor of adverse prognosis, and on average 8-years 
younger age of presentation with HF.
12, 67
 Indeed, emerging data indicate that SR-AI is 
critical for the number of reparative processes, such as clearance of apoptotic cells, 
attenuation of oxidative stress and inflammation.
29-33
 
 
In contrast to the previous report of increased Mon2 levels in European patients with HF 
(compared with healthy controls), there were no significant HF-related changes in this 
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monocyte subset in subjects of SA origin.
425
 Nonetheless, my results indicate significant 
ethnic variations for this subset with white subjects having the highest values, which 
possibly explain the discrepancy.  
 
A feature of HF is the continuous cardiac remodelling associated with adaptation to the 
shifts in haemodynamics, tissue ischaemia and endothelial dysfunction.
658
 Mon2 has the 
maximal (of all monocytes) expression of receptors to angiogenic factors, such as 
angiopoietin and VEGF. In patients with stroke, the Mon2 subset is increased whereas 
Mon3 is decreased, but both subsets were positively associated with a favourable prognosis 
(in contrast to Mon1).
44
 Contrary, a recent small study showed a negative correlation 
between Mon2 count and LVEF and other parameters of HF severity, but this was not seen 
in our larger study population of SA patients with HF.
425
 Thus, the clinical relevance of 
Mon2 subset should be explored further taking into account ethnic origin of the study 
population. 
 
3.6.3. Microparticles derived from monocytes and platelets 
 
It has been shown that patients with systolic HF have increased levels of EMPs which 
independently predicted future risk of cardiovascular events.
628
 In this study I show for the 
first time that patients with HF also have significantly increased levels of both MMPs and 
PMPs. Initially PMPs attracted attention of researchers and clinicians as markers and 
contributors of thrombosis.
637
 However, their biological roles apparently spread far beyond 
their participation in thrombotic processes. For example, PMPs regulate activity of 
endothelial and other blood cells.
576
 They can activate endothelial cells and neutrophils and 
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amplify leukocyte-mediated tissue injury in thrombotic and inflammatory disorders.
577, 579, 
583
 Also, excessive generation of MMPs leads to disruption of endothelial integrity and 
prothrombotic activation of the endothelium.
593
 
 
The present study indicates that although both MMPs and PMPs are increased in HF, only 
MMPs levels are independently and negatively predictive of LVEF. Although detailed 
mechanisms of such association are to be clarified in the future, several factors are likely to 
be implicated. Firstly, MMPs can impair endothelial function as discussed above. 
Secondly, high MMP levels parallel monocyte activation and may reflect an accompanying 
excessive inflammatory burden.
47
 Thirdly, microparticles are increasingly acknowledged 
as messengers of biological information and direct regulators of various 
(patho)physiological processes and may thus be directly implicated in the pathogenesis of 
HF.
48
 
 
3.6.4. Endothelial progenitor cells 
 
In this study, I show for the first time significant abnormalities in monocyte-derived 
CD34+ and KDR+ EPCs in patients with systolic HF. The study also demonstrates the 
presence of significant ethnic differences in some populations of monocyte-derived EPCs, 
which may be related to the observed ethnic differences in clinical characteristics and 
prognosis in HF. 
 
EPCs play a significant role in endothelial repair and angiogenesis.
38
 Given that ischaemic 
aetiology is dominant among patients with systolic HF and local tissue hypoperfusion is 
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common in HF subjects irrespective of aetiology it is not surprising that abnormal numbers 
and activity of endothelial progenitors were seen in HF subjects.
449
 The origin as well as 
the phenotypic and functional characteristics of EPCs still remains insufficiently 
understood and several cell types derived from the bone marrow, peripheral blood and 
tissue-resident cells may obtain endothelial phenotype under appropriate stimulation.
38
 
However CD14+ myeloid monocytic cells have been showen to be a major type of 
circulating angiogenic cells.
640
 
 
Despite similar numbers of total monocytes in the study groups, the numbers of CD34+ 
monocytes were 2-fold lower in HF subjects than in both control groups with normal LV 
contractility. Importantly, these changes were only attributable to Mon1 and Mon2 subsets. 
The changes in CD34+ monocytes were similar to that seen in circulating CD34+KDR+ 
EPCs, which were also reduced in HF patients. The pattern of changes of KDR+ 
monocytes was different from that seen for CD34+ monocytes. Of note, KDR+ Mon1 were 
4.5-fold increased in patients with CAD with normal LVEF (‘disease controls’) than in 
healthy volunteers. 
 
How could the differences seen between the CD34+ and KDR+ cells be explained? 
CD14+KDR+ cells support vascular repair via release of angiogenic factors rather than 
through differentiation into functional endothelial cells per se. Indeed, transplantation of 
CD14+KDR+ monocytes (but not CD14+KDR– cells) into murine balloon-injured femoral 
arteries significantly promoted reendothelialization.
465
 However, CD14+KDR+ cells in 
vitro stimulated the organization of human microvascular endothelial cells into capillary-
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like structures rather conversion to endothelial cells themselves.
467
 Also these cells were 
able to improve LV function after experimental MI.
466 
 
In contrast to KDR+ monocytes, CD34+ monocytes were reported to incorporate into the 
endothelium of blood vessels in ischaemic tissues and to transdifferentiate into endothelial 
cells.
470
 This accords with in vitro findings that under angiogenic stimulation (e.g., with 
VEGF) monocytes can develop a typical endothelial phenotype with expression of specific 
surface markers.
471
 Thus different types of monocyte-derived angiogenic cells may have 
different implications for vascular repair (for example, by providing an appropriate 
proangiogenic environment or by differentiation to endothelial cells). At present, it is 
difficult to confidently speculate on whether the down-regulation of monocyte-derived 
EPCs in HF patients is related to the pathogenesis of HF per se, or whether it is secondary 
to HF and reflects bone marrow depression common in severe HF.  
 
In my study, counts of monocyte-derived EPCs did not correlate with parameters of 
cardiac geometry and function, raising the question of the clinical importance of these 
cells. However, higher VEGFR1 expression on the Mon2, a subset with a reported 
reparative potential showed some association with lower LVEF. 
 
The study also highlights for the first time apparent differences between three major 
monocyte subsets in terms of their contribution to the pool of monocytic angiogenic cells 
in HF. Whilst HF was associated in with down-regulation of CD34+ and KDR+ monocytes 
derived from ‘classical’ Mon1 and CD34+ Mon2, endothelial progenitors derived from 
‘non-classical’ monocytes Mon3 were not significantly affected. These observations 
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provide further evidence of differential roles of monocyte subsets in cardiovascular 
disorders.
659-660
 Although detailed pathological implication and prognostic value of the 
abnormalities in monocyte-derived EPCs seen in this study are still to be clarified, they 
may potentially become novel therapeutic targets in the future. In this respect, the 
preliminary clinical success of transplantation of even unselected bone marrow 
mononuclear cells gives basis for some cautious optimism.
661
 
 
Although the main focus of this thesis were subjects of SAs origin, significant ethnicity-
related differences in characteristics of cardiovascular health have also been reported for 
Black Africans and ACs.
662-664
 The pathophysiological background of these differences 
could be partly related to the worse profile of inflammatory markers and vascular 
dysfunction seen in even in relatively healthy AC subjects. Indeed, ACs with no vascular 
disease had higher fasting insulin, TNF-α, and IL-6 levels, greater carotid intima-media 
thickness and attenuated small vessel reactivity compared with Whites.
665
 In accordance 
with previous data AC subjects in my study also tended to have higher blood pressure.
665
 
 
3.6.5. Potential limitations 
 
One limitation is the relatively small number of AC subjects. There were difficulties in 
finding AC subjects that met strict inclusion criteria and many of them were reluctant to 
participate in this research.  
 
This study is also limited by its cross-sectional design and it did not aim to assess clinical 
and prognostic implications of the found ethnic differences in endothelial function. The 
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study control groups were of SA origin aiming to focus on this high-risk ethnic group. 
However it is difficult to speculate whether the observations (both positive and negative) 
could be characteristic of HF in general, particularly given the number of significant ethnic 
differences in HF patients reported above. 
 
The healthy controls were defined from careful clinical history and examination, but as 
angiography was not performed in these healthy subjects (for ethical reasons), there is a 
possibility that some of them could have subclinical CAD. 
 
Admittedly ethnic minority groups are also heterogeneous and significant differences 
can be seen even within these groups (e.g., depending on environmental factors). For 
example, ACs from the UK had greater carotid intima media thickness, decreased 
endothelium dependent vasodilatation, higher homocysteine and lower folate levels than 
age- and sex-matched ACs in Jamaica.
666-670
 This was associated with higher insulin 
resistance despite no significant differences in body mass index or the waist to hip ratio, 
suggesting a role of a nutritionally enriched environment, as a significant contributor to 
cardiovascular morbidity irrespectively of ethnicity. 
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3.7. Conclusions 
 
There are significant ethnicity-related differences in both micro- and macrovascular 
endothelial function in systolic HF. SA ethnicity is associated with microvascular 
endothelial dysfunction in this disorder. 
 
Patients with systolic HF of SA origin have significantly reduced numbers and proportions 
of Mon3, a monocyte subset with reparative potential, and increased levels of PMPs, 
MMPs, and EMPs. Among different types of microparticles, only MMPs were 
independently predictive of reduced LVEF. 
 
Circulating counts of monocyte-derived EPCs are significantly altered in HF, but their 
levels are not significantly associated with echocardiographic parameters of cardiac 
geometry and function. 
 
There are significant ethnicity-related differences in monocyte-derived EPCs, monocyte 
subsets, their expression of scavenger receptor SR-AI in patients with systolic HF. 
 
The study observations may contribute to understanding of the role of the endothelium, 
different monocyte populations and blood microparticles in the complex pathophysiology 
of HF. Additionally these findings may provide some insight to the known clinical 
ethnicity-related differences in HF and could be useful for developing future strategies of 
HF management. 
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CHAPTER IV. DEFINITION AND CHARACTERISATION OF HUMAN 
MONOCYTE SUBSETS 
4.1. Introduction 
 
Until recently, monocytes were divided into two subsets: ‘classical’ CD14+CD16– 
monocytes and ‘non-classical’ CD14lowCD16+ subsets. However it was observed that the 
immunophenotypic pattern of CD16+ cells includes both cells with low and high CD14 
surface levels and that the expression of important surface antigens varies between these 
cells (sometimes defined as CD14+CD16+ and CD14++CD16+ respectively).
40, 44-45
 
However, because there is an overlap between these two subsets when they are defined just 
by CD14 and CD16 expression, an unequivocal discrimination and accurate 
characterisation of these subsets is problematic. As a result only scarce data are currently 
available on biological and functional characteristics of the individual monocyte subsets. 
 
Given that the work reported in this part of the thesis was done when a substantial part of 
data from Chapter 3 had been collected, the newly developed protocol of monocyte 
analysis could not be used retrospectively for subjects investigated in the previous chapter. 
Thus the new protocol on monocyte flow cytometric characterisation is described in this 
chapter. 
 
196 
 
4.2. Aims and hypotheses 
 
The aim of this part of the study was to develop an approach of objective discrimination of 
the three human monocyte subsets, and to provide some insight on the phenotypic, and 
functional properties of the monocyte subsets and to assess effects of the diurnal variation 
and exercise on monocyte subsets and MPAs. 
 
I also hypothesized that monocyte subsets and MPAs would be affected by physical 
exercise, and undergo diurnal circadian variations. 
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4.3. Study population 
4.3.1. Overall comments 
Assessment of blood monocytes has been done on young healthy volunteers. The risk of 
presence of subclinical atherosclerosis in healthy volunteers was considered low based on 
lack of symptoms in young active individuals, profile of risk factors for arthrosclerosis, 
lack of any suggestive signs or symptoms during the exercise (in 12 participants). 
Additionally a fraction of those volunteers undergone measurement of carotid intima-
media thickness (a surrogate parameter for early atherosclerosis) as part of a parallel study 
ongoing in the department.  
 
The study was approved by the Warwickshire Research Ethics Committee (reference 
number 08/H1211/23, dated 04.09.2008). Additional amendments have been granted by 
the same committee to allow substudies on monocyte subsets in healthy volunteers 
(amendment 1, dated 12.11.2008, amendment 3, dated 24.04.2009, and amendment 5, 
dated 14.05.2009). 
 
The immunophenotypic analysis of bone marrow cells was performed on anonymised 
samples provided by the Clinical Immunology Service (Professor M.T. Drayson). These 
samples were the residue of normal bone marrow taken and sent for routine clinical testing 
for lymphoma staging; these residues would normally have been incinerated. All 
participants signed an informed consent for analysis of their bone marrow cell 
immunophenotype and the Clinical Immunology Service has ethics approval for use of 
these samples for research and development 
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4.3.2. Immunophenotypic characterisation 
 
Peripheral vein blood samples were collected from 20 carefully selected non-fasting 
healthy volunteers (aged 30.3±6.4 years, 8 male, body mass index 23.2±2.9 kg/m
2
) 
between 11.00 and 12.00h, which were processed within 30 minutes of collection. Bone-
marrow samples were obtained from 11 individuals with suspected peripheral lymphomas 
(otherwise healthy and with no bone-marrow involvement). 
 
4.3.3. Effects of physical exercise 
 
The effects of exercise on the dynamics of total monocyte count, monocyte subsets and 
MPAs, as well as monocyte expression of CD14, CD16, CCR2 were assessed in 12 healthy 
volunteers (age 35.3±7.62 years, 8 male). Treadmill exercise was performed using Case 16 
exercise testing system (Marquette Medical Systems Inc, Milwaukee, WI, USA) according 
to Bruce protocol with the volunteers exercising to exhaustion, as previously described.
671
 
Venous blood samples were taken immediately pre-exercise, 15 minutes, 60 minutes and 
24 hours post-exercise (four samples in total). The choice of time points for the post-
exercise sampling was based on preliminary results from two volunteers with samples 
obtained at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours and 24 hours. In this 
pilot exercise, the highest monocyte counts were seen at 15 minutes and lowest at 1 hour 
and these time-points were selected for the for the rest of the participants. All participants 
were asked to abstain from other strenuous physical activity for the period of the study. 
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4.3.4. Diurnal variation 
 
Possible diurnal variations in monocyte subsets and MPAs were assessed in 16 healthy 
volunteers (age 36±8.7 years, 7 male). Blood samples were taken at 6 hourly intervals, 
starting at 6 a.m. and finishing 6 a.m. on the following day (5 samples in total). 
 
4.3.5. Time-delay analysis 
 
Effects of delay in sample preparation on parameters of monocyte subsets and MPAs were 
assessed in 12 samples. The samples were reprocessed at 1, 2, and 4 hours after collection 
in order to quantify temporal changes in the study parameters once ex vivo (4 samples in 
total). The samples were kept at room temperature with slow rotation. 
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4.4. Methods: Flow cytometry 
4.4.1. Equipment and software 
 
Flow cytometric analysis was performed using the BD FACSCalibur flow cytometer 
(Becton Dickinson, Oxford, UK [BD]). VenturiOne, Version 3.1 software (Applied 
Cytometry, Sheffield, UK) was employed for data analysis. 
 
4.4.2. Absolute count of monocyte subsets 
 
Mouse anti-human monoclonal fluorochrome-conjugated antibodies anti-CD16-Alexa 
Fluor 488 (clone DJ130c, AbDSerotec, Oxford, UK), anti-CD14-PE (clone MфP9, BD), 
anti-CD42a-PerCP (clone Beb1, BD) and anti-CCR2-APC (clone 48607, R&D) were 
mixed with 50µl of fresh EDTA-anticoagulated whole blood or bone marrow in BD 
TruCount tubes (BD) containing a strictly defined number of fluorescent count beads. 
After incubation for 15 minutes red blood cells were lysed by 450µl of BD lysing 
solution® (BD) for 15 minutes followed by dilution in 1.5 ml of PBS and immediate flow 
cytometric analysis. Monocytes were selected by gating strategies based on forward and 
side scatter properties to select monocytes (Figure. 17a), side scatter properties versus 
CD14 expression to exclude granulocytes (Figure. 17b), and ungated CD14 versus CD16 
expression to exclude natural killer lymphocytes (Figure. 17c). Monocyte subsets were 
defined as CD14++CD16–CCR2+ cells (Mon1), CD14++CD16+CCR2+ cells (Mon2) and 
CD14+CD16+CCR2– cells (Mon3) (Figures 17 and 18). 
 
201 
 
 
 
Figure 17. Gating strategies and presentation of monocyte subsets 
(a) selection on monocyte region on forward scatter (FSC) vs. side scatter (SSC) plot, (b) 
separation of mononuclear cells from granulocytes, (c) selection of CD14– lymphocytes to 
separate CD16+CD14– natural killer lymphocytes from CD16+ monocyte subsets, (e) 
separation of monocyte subsets, that must correspond to regions Monos on (a) and Mon on 
(b) but must not include lymphocytes from (c), (g) separation of CD16+ monocyte subsets 
on the basis of their CCR2 expression, (h) CCR2 expression of Mon1 subset, (d) and (f) 
location of on Mon3 and Mon2, respectively, on CD14 vs. CD16 plot. Mon 1 – 
CD14++CD16–CCR2+ monocytes, Mon 2 – CD14++CD16+CCR2+ monocytes, Mon 3 – 
CD14+CD16+CCR2– monocytes. 
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Figure 18. Gating strategies and presentation of bone marrow monocytes 
(a) selection on monocyte region on forward scatter (FSC) vs. side scatter (SSC) plot, (b) 
separation of CD16+ monocyte subsets on the basis of their CCR2 expression.  
 
 
Absolute counts of monocyte subsets (cells/µl) were obtained by calculating the number of 
monocytes proportional to the number of count beads according to the manufacturers 
recommendations. MPAs were defined as events positive to both monocyte markers (as 
above) and the platelet marker CD42a (glycoprotein IX) (Figures 17 and 18).  
 
My intra-assay CV was performed on blood samples taken from two healthy subjects (four 
samples from each) (Table 33). Intra-assay CV was: total monocyte count – 2.31%, Mon1 
– 1.91%, Mon2 – 5.23%, Mon3 – 8.29% (average for monocyte counts – 4.44%), MPAs – 
6.11%. My inter-assay CV was performed on blood samples taken from one healthy 
subject on six consequent days (Table 34). Inter-assay CV was: total monocyte count – 
3.36%, Mon1 – 3.68%, Mon2 – 13.01%, Mon3 – 9.16% (average for monocyte counts – 
7.30%), MPAs – 8.28%. The method is described in theStandard operating procedure 201 
‘Monocyte subsets, monocyte-platelet aggregates by flow cytometry’. 
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Table 33. Intra-assay variability of measurement of monocyte subsets and monocyte-
platelet aggregates 
 
Total 
monocytes 
(per µl) 
Mon1 
(per µl) 
Mon2 
(per µl) 
Mon3 
(per µl) 
MPA 
(per µl) 
Subject 
1 
Sample 1 470 397 28.7 44.4 38.7 
Sample 2 459 390 29.0 40.6 33.3 
Sample 3 454 383 26.9 43.9 35.2 
Sample 4 447 381 28.4 37.7 35.5 
Mean±SD 457±9.85 387±7.32 28.6±0.96 42.2±3.13 35.4±2.20 
CV, % 2.16 1.89 3.37 7.42 6.24 
Subject 
2 
Sample 1 213 169 10.8 33.1 21.0 
Sample 2 211 163 12.7 35.8 21.5 
Sample 3 222 169 12.3 40.7 23.8 
Sample 4 221 170 11.7 39.3 21.5 
Mean±SD 217±5.34 169±3.25 12.0±0.85 37.6±3.44 21.5±1.28 
CV, % 2.46 1.92 7.09 9.17 5.97 
Intra-assay CV 
(average), % 
2.31 1.91 5.23 8.29 6.11 
 
CV, coefficient of variability; MPAs, monocyte-platelet aggregates; SD, standard 
deviation. 
 
Table 34. Inter-assay variability of measurement of monocyte subsets and monocyte-
platelet aggregates 
 
Total 
monocytes 
(per µl) 
Mon1 
(per µl) 
Mon2 
(per µl) 
Mon3 
(per µl) 
MPA 
(per µl) 
Day 1 470 397 28.7 44.4 38.7 
Day 2 447 384 26.1 36.6 32.5 
Day 3 443 380 25.3 37.7 31.2 
Day 4 455 398 21.7 35.0 35.1 
Day 5 456 387 31.0 37.8 36.7 
Day 6 425 360 30.5 35.2 37.5 
Mean±SD 
449± 
15.1 
384± 
14.1 
27.2± 
3.54 
37.8± 
3.46 
35.3± 
2.92 
Inter-assay CV, % 3.36 3.68 13.0 9.16 8.28 
 
CV, coefficient of variability; MFI, media fluorescent intensity, MPAs, monocyte-platelet 
aggregates; SD, standard deviation. 
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4.4.3. Expression of surface antigens on monocyte subsets 
 
For analysis of surface antigens, 100µl of whole blood or bone marrow was incubated with 
mouse anti-human monoclonal fluorochrome-conjugated antibodies for 15 minutes in the 
dark. Red blood cells were lysed with 2ml of BD lysing solution® for 10 min, washed in 
PBS followed by immediate flow cytometric analysis. Anti-CD16-Alexa Fluor 488 (clone 
DJ130c, AbDSerotec, Oxford, UK) and anti-CD14-PerCP-Cy5.5 (clone M5E2, BD) were 
used for definition of monocyte subsets into CD14++CD16– monocytes (Mon1), 
CD14++CD16+ monocytes (Mon2) and CD14+CD16+ monocytes (Mon3). PE-conjugated 
antibodies were used against TLR4 (clone 285219, R&D), integrin β2/CD18 (ICAM 
receptor), clone 212701, R&D Systems Europe Ltd, Abingdon, UK [R&D]), CXCR4 
(SDF-1 receptor), clone 12G5, R&D), CD34 (clone 8G12, BD), VEGF receptor 1 (clone 
49560, R&D), ferritin (monoclonal antibody by AbdSerotec, Oxford, UK, clone F317B2 
conjugated to PE using LL-PE-XL conjugation kit from Innova Biosciences, UK),  CD64 
(clone 276426, R&D). APC-conjugated antibodies were used against IL6 receptor (clone 
17506, R&D), integrin α4/CD49d (VCAM-1 receptor), clone 7.2R, R&D), CD163 (clone 
215927, R&D), KDR (VEGF receptor 2, clone 89106, R&D), Tie2 (clone 83715, R&D), 
CD115 (clone 61708, R&D), CD204 (clone 351520, R&D) and ApoB (clone 369717, 
R&D). Monoclonal antibodies for last two antigens were conjugated to APC using LL-
APC-XL conjugation kit [Innova Biosciences, UK]. 
 
My inter-assay CV for a surface marker expression (CCR2) on Mon1 – 3.69%, on Mon2 – 
4.15%, on Mon3 – 4.07% (average for monocyte CCR2 expression – 3.97%). Inter-assay 
CV for a surface marker expression (CCR2) on Mon1 – 10.24%, on Mon2 – 4.85%, on 
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Mon3 – 4.86% (average for monocyte CCR2 expression – 6.65%)(Table 35). The method 
is described in more details in Standard operating procedure 201 ‘Monocyte subsets, 
monocyte-platelet aggregates by flow cytometry’. 
 
Table 35. Intra- and inter-assay variability of measurement of monocyte surface 
expression of CCR2 
 
CCR2 (Mon1) 
MFI 
CCR2 (Mon2) 
MFI 
CCR2 (Mon3) 
MFI 
Intra-assay variability assessment 
Subject 
1 
Sample 1 140 106 15.1 
Sample 2 135 107 15.1 
Sample 3 129 106 15.8 
Sample 4 122 97.0 14.1 
Mean±SD 132±7.76 106±4.73 15.1±0.68 
CV, % 5.88 4.46 4.53 
Subject 
2 
Sample 1 86.5 85.8 13.8 
Sample 2 85.8 91.3 12.9 
Sample 3 88.1 92.0 12.8 
Sample 4 85.1 85.7 13.6 
Mean±SD 86.1±1.28 88.6±3.40 13.2±0.48 
CV, % 1.50 3.84 3.61 
Intra-assay CV 
(average), % 
3.69 4.15 4.07 
Inter-assay variability assessment 
Day 1 140 106 15.1 
Day 2 116 102 15.3 
Day 3 114 108 15.0 
Day 4 123 97.7 13.5 
Day 5 106 98.0 15.4 
Day 6 110 96.3 15.1 
Mean±SD 118±12.1 101±4.92 14.9±0.73 
Inter-assay CV, % 10.2 4.85 4.86 
 
CV, coefficient of variability; MFI, median fluorescent intensity, MPAs, monocyte-platelet 
aggregates; SD, standard deviation. 
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4.4.4. Assessment of intracellular activation of NFκB pathway 
 
Stimulation of monocyte receptors (including Toll-like receptors and CD14) by a variety of 
stimuli results in activation of the nuclear factor κB (NFκB) pathway.  Phosphorylation and 
disintegration of IκBs by the specific inhibitory κB kinases (IKK) is followed by 
translocation of cytoplasmic NFκB into the nucleus. Here, it binds to the promoter region 
of various genes, including cytokines (e.g., TNF-α, and IL-1β), cyclooxygenase-2, 
inducible NO-synthase, and matrix metalloproteases, thereby activating their 
transcription.
672-673
 
 
The IKK complex consists of two catalytic subunits of which IKKβ, but not IKKα, plays 
an essential role in NFκB activation mediated by lipopolysaccharides, TNFα, or IL-1. 
IKKβ is 20-fold more active than IKKα.
674-675
 Because the activated (translocated into 
nuclei) form of NFκB is identical to its resting cytoplasmic form, determination of NFκB 
total levels inside a cell is not informative. Several methods of NFκB assessment in 
isolated nuclei are associated with multistep procedures of cell isolation and preparation 
which are likely to cause some degree of artificial activation.
676
 For this study, I developed 
a method of direct measurement of intracellular levels of IKKβ as a surrogate cytoplasmic 
marker of activation of NFκB pathway, aiming to assess proinflammatory shift in 
monocyte phenotype and function. 
 
To assess intracellular levels of IKKβ, 100µl of fresh whole blood was incubated with 
monoclonal mouse-antihuman antibodies against CD16-Alexa Fluor 488 (clone DJ130c, 
AbDSerotec, Oxford, UK) and CD14-PerCP-Cy5.5 (clone M5E2, BD) for 15 min 
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following by lysing of red blood cells with 2ml of BD PharmLyse™ for 10 min and 
washing in staining buffer. The resulting pellet was resuspended in 
Fixation/Permeabilization solution (BD) for 20 minutes and, following centrifugation, in 2 
ml of BD Perm/Wash™ buffer for 10 minutes. Following further centrifugation the pellet 
was incubated for 30 minutes with monoclonal mouse anti-human APC-conjugated (LL-
APC-XL conjugation kit [Innova Biosciences, UK]) antibodies against IKKβ (clone 
10A9B6, Abcam, Cambridge, UK), washed and resuspended in 200µl of 2% PBS/2% 
paraformaldehyde solution (PharmFix, BD) for immediate flow cytometric analysis.  
 
Intra-assay CVs for the method were 5.52% for Mon1, 5.75% for Mon2, and 4.60% for 
Mon3 (Table 36). Inter-assay CVswere9.2% form Mon1, 9.7% for Mon2, 11.4%for Mon3 
(Standard operating procedure 202 ‘Intracellular I-Kappa-Kinase Beta (IKKβ)’). 
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Table 36. Intra- and inter-assay variability of measurement of intracellular monocyte 
IKKβ levels 
 
Mon1, MFI Mon2, MFI Mon3, MFI 
Intra-assay variability assessment 
Subject 
1 
Sample 1 66.28 65.6 60.47 
Sample 2 72.47 74.71 63.24 
Sample 3 76.24   73.11 63.8 
Mean±SD 71.7±4.1 71.1±4.0 62.5±2.3 
CV, % 5.7 5.6 2.3 
Subject 
2 
Sample 1 77.6 81.0 80.0 
Sample 2 69.6 70.3 67.5 
Sample 3 70.9 73.9 74.4 
Mean±SD 72.7±3.51 75.1±4.4 74.0±5.1 
CV, % 4.8 5.9 6.9 
Intra-assay CV 
(average), % 
5.25 5.75 4.60 
Inter-assay variability assessment 
Day 1 59.8 63.1 65.3 
Day 2 55.4 57.6 54.7 
Day 3 59.4 73.7 60.6 
Day 4 71.1 74.9 70.7 
Day 5 70.1 75.3 78.7 
Day 6 64.3 66.4 68.0 
Mean±SD 63.4±5.8 68.5±6.6 68.0±7.8 
Inter-assay CV, % 9.2 9.7 11.4 
 
CV, coefficient of variability; MFI, media fluorescent intensity. 
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4.4.5. Monocyte phagocytic activity 
 
The phagocytic activity of monocyte subsets was assessed in 15 healthy individuals using 
novel commercially available pHrodoE.Coli BioParticles Phagocytosis Kit for Flow 
Cytometry (Invitrogen, California, UK). The assay is based on the fluorescence of 
pHrodo™ E. coli BioParticles® conjugates, which are inactivated, unopsonized 
Escherichia coli filled with the fluorochrome with minimal fluorescence at neutral pH (eg, 
in blood) that dramatically increases in acidic condition (i.e., inside phagocytome). The 
assay was run according to the manufacture recommendations with CD16-Alexa Fluor 488 
(as above) and CD14-APC (clone MфP9, BD) used to discriminate monocyte subsets. 
Expression of the surface markers, IKKβ levels and phagocytic activity are presented as 
median fluorescent activity (MFI). 
 
Intra-assay CVs for the method are for Mon1 - 5.4%, for Mon2 - 7.1%, for Mon3 - 1.4% 
(average for the three monocyte subsets – 4.63% (Table 37. Standard operating procedure 
206 ‘Assessment of monocyte phagocytic activity by Flow Cytometry’). 
 
Table 37. Intra-assay variability of measurement of monocyte phagocytic activity 
Subsets Sample 1 Sample 2 Sample 3 Intra-assay CV* 
Mon1, MFI 155.38 139.49 147.22 5.4% 
Mon2, MFI 155.38 137.00 138.24 7.1% 
Mon3, MFI 56.23 54.74 55.73 1.4% 
Average intra-assay CV is 4.63% 
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4.4.6. Cell sorting and stimulation experiments 
 
Thirty mlof citrate-anticoagulated blood were collected from 3 healthy volunteers. 
Peripheral blood mononuclear cells were isolated by Ficoll-Paque density gradient 
centrifugation, as previously described.
677
 Monocyte subsets were further isolated by 
magnetic sorting of the PBMC fraction using VarioMACS (MiltenyiBiotec, Düsseldorf, 
Germany) and direct or indirect labeling with microbead-conjugated antibodies. The whole 
procedure is schematically illustrated (Figure 19). 
 
Monocyte subsets obtained by cell sorting were resuspended at a density of 1x10
6
cells⁄ml, 
in culture medium consisting of RPMI-1640 supplemented with 2 mM L-glutamine, 100 
µg/ml gentamycin and 100 µg/ml penicillin. Cell suspensions were incubated in gently 
shaking polystyrene tubes, at 37
o
C, in a 5% CO2 humidified atmosphere, in the presence or 
absence of 1 µg/ml LPS endotoxin. Cells were harvested 24 hours post stimulation. 
Intracellular staining for 6 inflammatory markers (IL-1β, MCP-1, IL-6, IL-10, TNF-α and 
IKKβ) was performed as described above. Allophycocyanin (APC) conjugated antibodies 
were used for intracellular staining of IL-10, TNF-α and IKKβ while phycoerythrin (PE) 
conjugated markers were utilized for the intracellular staining of IL-1 β, MCP-1 and IL-6 
(all BD, Oxford, UK). The MFI of stained cells was assessed by the FACScalibur 
cytometer (BD, Oxford, UK). Experiments were conducted in triplicates and mean values 
were compared. Optimal time points and LPS concentrations were retrieved through a set 
of preliminary experiments where 2, 4 and 24 hours of stimulation and 0.1, 1 and 10 µg/ml 
of LPS were evaluated. 
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Figure 19. Schematic illustration of monocyte isolation by magnetic sorting 
After density gradient centrifugations cells were either processed for CD14++CD16– 
isolation (root A) or CD14++CD16+/CD14+CD16+ isolation (root B). For root A, 
Monocyte Isolation Kit I was used (MiltenyiBiotec, Dusseldorf, Germany). For step B1, 
CD16+Monocyte isolation Kit (MiltenyiBiotec, Dusseldorf, Germany) was used with the 
following modification: instead of CD16-microbeads, CD16-FITC conjugated antibody 
was used (MiltenyiBiotec, Dusseldorf, Germany). Cells were then indirectly labelled with 
anti-FITC microbeads and CD16 presenting cells were positively selected. Anti-FITC 
microbeads were removed (step B2) using the anti-FITC multisort Kit (MiltenyiBiotec, 
Dusseldorf, Germany) in order cells to be relabelled (step B3) with CD14 microbeads 
(MiltenyiBiotec, Dusseldorf, Germany). 
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4.4.7. Statistical analysis 
 
Data are expressed as mean±SD for normally distributed parameters and median 
(interquartile range) for non-normally distributed parameters. Statistical significance of 
differences between monocyte subsets was determined by ANOVA with Tukey’s post-hoc 
test for normally distributed parameters and Friedman test with Dunns post-hoc test or 
Tukey’s post-hoc test of arithmetically transformed variables for non-normally distributed 
parameters. For comparisons of values in the presence or absence of endotoxin stimulation, 
paired-sample t-test was utilized.  
 
Statistical significance of the changes in different monocyte subsets and MPAs during 
diurnal variation analysis, exercise test and time-delay analysis was assessed using 
repeated measures ANOVA. Greenhouse-Geisser correction was applied when sphericity 
assumption was not met. Pairwise comparisons were made using Sidak’s adjustment. 
Friedman test was utilized for non-normally distributed parameters. A value of p<0.05 
(two-tailed) was considered statistically significant. Statistical analysis was performed with 
SPSS18.0 software and GraphPad Prism 4.0 software (La Jolla, CA, USA). A power 
calculation determined the need for at least 12 subjects in order to have 80% power to 
detect changes of ≥0.5 standard deviation, based upon our preliminary work on monocyte 
subsets and the assessment of biological fluctuations in circulating blood cells. 
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4.5. Results 
4.5.1. Discrimination of monocyte subsets 
 
During the screening of various parameters I have found that two distinct populations of 
CD16+ monocytes can be reliably discriminated on the basis of their expression of CCR2 
(MCP-1 receptor) (Figure 17). CD14++CD16+ monocytes were positive for CCR2 (MFI 
152.5±55.6) whilst CD14+CD16+ cells expressed minimal if any levels of CCR2 (MFI 
18.4±1.90, p<0.0001) (Table 38). CD14++CD16– monocytes had maximal density of 
CCR2 on their surface (MFI 241.5 ±49.2, p<0.0001 vs. the 2 other monocyte subsets).  
 
To simplify further characterisation of monocyte subsets in the manuscript, I classified 
them as Mon1 (CD14++CD16–CCR2+), Mon2 (CD14++CD16+CCR2+) and Mon3 
(CD14+CD16+CCR2–) subsets. On the CD14 vs. CD16 plot, there is a small area which 
may include proportions of both Mon2 and Mon3 subsets (Figures. 17d vs. 17f). 
Accordingly, CCR2 is essential for determining the absolute count of the three monocyte 
subsets. However, the two markers (CD14 and CD16) were enough to characterise surface 
antigen profile, providing that a small gap was left between Mon2 and Mon3 regions to 
prevent contamination from another subset. 
 
In healthy subjects, the Mon1 subset constituted 84.6±5.77% of all monocytes (360.1±87.0 
cells/µl); whilst Mon2, 5.90±3.40% (24.5±14.8 cells/µl); and Mon3, 9.51±3.74% 
(38.9±12.7 cells/µl) (Table 38). Although all Mon2 express CD16, CD16 density on this 
subset was 3.5-fold lower compared to Mon3 (p<0.0001). Mon2 represented the monocyte 
subset with largest size (on the basis of forward scatter 
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Table 38. Comparative characteristics of monocyte subsets 
Parameter Mon1 Mon2 Mon3 p 
Count, cell/µl 360.1±87.0 24.5±14.8 38.9±12.7  
% of all 
monocytes 
84.6±5.77 5.90±3.40 9.51±3.74  
Aggregates with 
platelets, % 
10.4±2.30* 16.0±5.65
‡
 11.95±2.56 <0.001 
Forward scatter 696±20.0*
†
 715±20.3
‡
 673±18.6 <0.001 
Side scatter 360±82.1
†
 357±29.9
‡
 279±27.0 <0.001 
CCR2, MFI 241.5 ±49.2*
†
 152.5±55.6
‡
 18.4±1.90 <0.001 
CD14, MFI 1737±296
†
 1820±400
‡
 146±63.8 <0.001 
CD16, MFI 7.02±1.02*
†
 37.0±5.94
‡
 128.1±49.5 <0.001 
CD64, MFI§ 369.9±91.5
†
 349.5±106.8
‡
 61.2±45.4 <0.001 
CD115+, % 77.5 (37.6-87.4)*
†
 99.1 (93.5-99.8)
 ‡
 87.2 (58.3-93.6) <0.001 
CD115, MFI 13.6±6.24* 34.8±14.9
‡
 20.1±9.89 <0.001 
CD204+, % 24.5±14.9* 56.9±16.7
‡
 61.1±14.29 <0.001 
CD204, MFI 5.84±2.32*
†
 11.5±3.91 14.6±6.66 <0.001 
CD163+, % 98.6±1.27
†
 99.7±0.32
‡
 70.3±13.7 <0.001 
CD163, MFI 201.8±79.1*
†
 289.2±90.3
‡
 24.3±14.9 <0.001 
Integrin β2, 
MFI§ 
53.8±18.8
*
 100.2±26.5
‡
 57.8±21.3 <0.001 
Integrin α4+, % 74.7 (59.8-82.2)*
†
 94.7 (91.1-96.7)
 ‡
 99.1 (98.2-99.4) <0.01 
Integrin α4, MFI 14.4±3.12*
†
 30.2±8.07
‡
 58.0±6.78 <0.001 
CXCR4+, % 91.0 (79.3-96.2)*
†
 95.6 (92.0-97.9)
 ‡
 51 (42.9-58.9) <0.01 
CXCR4, MFI 21.8 (16.0-39.3)*
†
 31.3 (24.8-47.5)
 ‡
 9.95 (8.40-12.6) <0.01 
Tie2+, % 25.1±5.46 53.7±8.87 31.9±13.9 <0.001 
Tie2, MFI 6.2±0.75* 10.4±1.67
‡
 7.0±2.24 <0.001 
VEGFR1+, % 18.2 (14.5-52.0) 69.6 (62.3-85.3) 28.3 (20.75-33.23) <0.001 
VEGFR1, MFI 6.15 (5.65-9.88)*
†
 14.1 (12.0-19.6)
 ‡
 5.50 (4.90-6.28) <0.001 
KDR+, % 5.00 (3.38-7.23)*
†
 8.25 (5.65-10.9)
 ‡
 2.80 (2.23-4.58) <0.001 
CD34+, % 0.45 (0.2-1.0)*
†
 1.45 (0.83-3.3) 2.40 (1.8-3.7) <0.001 
Ferritin+, % 9.58±7.41*
†
 18.8±9.94
‡
 4.0±2.55 <0.001 
Ferritin, MFI 4.8±0.96*
†
 5.7±1.24
‡
 2.9±0.51 <0.001 
ApoB+, % 28.8±14.7* 46.7±17.5
‡
 28.4±10.4 0.001 
ApoB, MFI 6.3±2.32* 9.3±3.37
‡
 6.3±1.56 0.001 
TLR4+, % 18.4 (14.3-32.2) * 63.2 (46.4-75.2)
‡
 21.4 (18.4-29.9) <0.001 
TLR4, MFI 6.50  (5.60-7.70) *
†
 12.4 (8.93-15.9)
 ‡
 5.20 (4.53-6.18) <0.001 
IL-6 receptor, 
MFI§ 
62.3±10.0
†
 58.9±8.95
‡
 30.6±5.92 <0.001 
IKKβ, MFI 61.1±16.7
† 
47.7±9.70 42.6±5.91 0.013 
Phagocytic 
activity, MFI 
101.0±25.9
†
 90.3±20.9
‡
 35.0±13.5 <0.001 
*
Significant difference between Mon1 and Mon2 (p<0.05); 
†
Significant difference between 
Mon1 and Mon3 (p<0.05); 
‡
 Significant difference between Mon2 and Mon3 (p<0.05). 
§
Apparently all monocytes expressed this marker.
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characteristics) followed by Mon1, with Mon3 representing the smallest subset (p<0.05 for 
all subsets, Table 38). Mon1 and Mon2 subsets had similar granularity, which was 
significantly higher compared to Mon3 (p<0.0001). 
 
4.5.2. Immunophenotypic characteristics of monocyte subsets 
 
The Mon2 subset had statistically significant differences in surface expression of various 
receptors compared to other subsets. They had the highest density of TLR4 (more than 2-
fold compared to other subsets), integrin β2/CD18 (ICAM receptor, about 2-fold higher 
compared to other subsets), CXCR4, Tie2, CD163, KDR, VEGF receptor 1 (more than 2-
fold), CD115 (macrophage colony-stimulating factor (M-CSF) receptor) (for all these 
parameters, p<0.05). The Mon2 subset also had the highest density of ferritin and ApoB on 
their surface (p<0.05 compared to other subsets). Additionally, the Mon2 subset had the 
highest proportion of aggregates with platelets (16.0±5.65%, compared to 10.4±2.30% of 
Mon1 and 11.95±2.56% of Mon3).  
 
Given that Mon1 comprised about 85% of all monocytes, most circulating MPAs were 
derived from this subset. Mon1 and Mon2 subsets expressed similar levels of CD14, IL6 
receptor, CD64, which were much higher than on the surface of Mon3 (p<0.0001). The 
density of surface expression of integrin α4/CD49d (VCAM-1 receptor) and CD204 (SR-
AI) were lowest on Mon1, significantly higher on Mon2 and maximal on Mon3. Mon3 
included the highest (about 2.4%) proportion of cells expressing CD34. 
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4.5.3. Bone marrow monocytic cells 
 
Compared to the blood, the total monocyte count in bone marrow was increased 3-fold 
(420±88.4 cell/µL vs. 1294±832 cell/µL, respectively, p<0.001), whilst the count of bone 
marrow Mon2 was >10-fold higher compared to blood Mon2 (24.5±14.8cell/µL in the 
blood vs. 276±363cell/µL in the bone marrow, p<0.001) (Table 39). Accordingly, as 
compared to the blood the proportion of Mon2 in bone marrow was 2.5-fold higher 
(5.90±3.40% vs. 15.6±15.4%, respectively, p<0.001), the proportion of Mon1 lower 
(84.6±5.77% vs. 75.6±15.6%, respectively, p=0.001) and of Mon3 very similar 
(9.51±3.56% vs. 8.80±3.73%, respectively, p=0.97) (Table 39). In addition to the three 
subsets defined above, bone marrow uniformly included a population of CD14+CD16– 
cells, located on the plots closely to Mon1 and not seen (at any significant numbers) in the 
blood (Figure 18). This population included on average 229±154 cells/µL of bone marrow 
and constituted 15.7±7.47% in relation to the total count of other monocyte subsets. 
Although the exact functional role of these cells is not clear, given their exclusivity to bone 
marrow, they might represent a pool of monocyte progenitors undergoing maturation.  
 
All three bone marrow monocyte subsets expressed more integrin β2/CD18 (especially 
Mon2) and CD204 (especially Mon3) and less IL-6 receptor and CXCR4 than their 
circulating counterparts (Table 39). In the bone marrow, Mon1 expressed less TLR4; bone 
marrow Mon2 carried less CD14 and more CD16, than blood monocytes. A higher 
proportion of Mon3 expressed CD34. Bone marrow and blood monocytes expressed 
similar levels of VEGF receptor 1 (all subsets) and TLR4 (Mon2 and Mon3). 
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Although expression of angiogenic markers, Tie2 and KDR in bone marrow were 
significantly higher on all three monocyte subsets, the maximal levels of these parameters 
were typical of Mon2. Tie2 was expressed on 64.7%, and KDR on 58.6% of bone marrow 
Mon2. Compared to peripheral blood, the bone marrow Mon2 and Mon3 included larger 
proportions of CD34+KDR+ cells commonly defined as endothelial progenitors (0.2% vs. 
1.69% for Mon2 and 0.6% vs. 7.21% for Mon3, respectively). 
 
For all three bone marrow subsets, the proportion of monocytes carrying the surface 
platelet marker CD42a (i.e., MPAs) was about 3-fold higher than in peripheral blood. 
Again, the bone marrow Mon2 had the highest proportion of MPAs (45.3±19.6%) 
compared to bone marrow Mon1 (33.9±19.2%) and bone marrow Mon3 (32.3±20.7%, 
p<0.001). The rate of aggregation with platelets for monocyte progenitors was much lower 
compared to other subsets (12.1 [10.4-14.6]%). 
2
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4.5.4. Functional characteristics of monocyte subsets 
 
Mon1 had significantly higher levels of IKKβ (MFI 61.1±16.7) compared to the two other 
monocyte populations (p<0.05). IKKβ levels were similar in Mon2 and Mon3 subsets 
(MFI 47.7±9.70 and 42.6±5.91, respectively). Mon1 and Mon2 had much higher 
phagocytic activity compared with Mon3 (p<0.001, Tables 38 and 40). There was no 
significant difference in the phagocytic activity of Mon1 and Mon2. 
 
Stimulation with 1 µg/ml LPS produced dissimilar alterations of the intracellular 
phenotype in monocyte subsets [Tables 41 and 42]. Mon1 and Mon2 had a comparable 
degree of LPS-stimulated TNFα production (p=0.16). Mon1 had a higher LPS-stimulated 
increase in expression in IL1β (p<0.001), IL6 (p=0.001), MCP-1 (p<0.001) and IKKβ 
(p<0.01), whilst Mon2 had maximal increase in IL10 production among all monocyte 
subsets (p<0.05). LPS had no effect on the intracellular expression of cytokines and IKKβ 
in Mon3. 
 
Table 40. Summary of comparative characteristics of the 3 monocyte subsets 
 Mon1 Mon2 Mon3 
Size (forward scatter) ++ +++ + 
Granularity (side scatter) ++ ++ + 
CD14 ++ ++ + 
CD16 - + ++ 
CCR2 +++ ++ + 
TLR4 + ++ + 
IL6 receptor ++ ++ + 
integrin β2/CD18 ++ ++ + 
integrin α4/CD49d + ++ +++ 
CXCR4 ++ +++ + 
VEGF receptor 1 ++ +++ + 
Tie2 + ++ + 
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CD163 ++ +++ + 
CD115 + ++ + 
CD64 ++ ++ + 
CD204 + ++ +++ 
Apolipoprotein B + ++ + 
Ferritin ++ +++ + 
Aggregation with platelets + ++ + 
NFκB ++ + + 
Phagocytic activity ++ ++ + 
TLR4 - Toll-like receptor 4, IL6 – interleukin 6, VEGF – vascular endothelial growth 
factor, NFκB – nuclear factor κB. 
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Table 41. Baseline values and mean fold change of MFI after LPS stimulation of 
monocyte subsets 
Monocyte 
Subset 
Intracellular 
marker 
Baseline 
MFI 
Post stimulation 
MFI 
Proportional 
change in MFI p 
Mon1 
TNF-α 7.9±0.4 13.3±0.9 1.7±0.02 0.002 
IL-1β 16.0±1.5 254.4±15 15.9±0.6 0.001 
IL-6 12.8±1.2 21.1±2.4 1.7±0.04 0.007 
IL-10 124.5±12.6 178.4±15.9 1.4±0.02 0.001 
MCP-1 32.8±3.5 67.2±9.7 2.0±0.07 0.011 
IKKβ 14.4±0.5 28.9±1.0 2.0±0.01 0.000 
Mon2 
TNF-α 11.8±0.8 18.9±0.7 1.6±0.07 0.001 
IL-1β 6.4±0.1 8.1±0.1 1.3±0.03 0.002 
IL-6  6.3±0.1 7.9±0.1 1.3±0.02 0.000 
IL-10 59.2±3.4 115.2±7.2 1.9±0.02 0.002 
MCP-1 5.9±0.02 7.8±0.1 1.3±0.02 0.001 
IKKβ 19.9±1.2 33±1.4 1.7±0.09 0.003 
Mon 3 
TNF-α 20.4±0.3 18.8±0.3 0.92±0.03 0.029 
IL-1β 7.5±1.2 6.8±0.2 0.92±0.13 0.426 
IL-6 6.5±0.1 6±0.7 0.93±0.11 0.446 
IL-10  125.9±3.7 104.5±43.1 0.83±0.35 0.489 
MCP-1 6.3±0.1 6±0.1 0.95±0.02 0.041 
IKKβ 28.8±4.9 24.3±0.3 0.86±0.13 0.257 
IL, interleukin ,MFI, median fluorescence intensity, MCP-1, monocyte chemoattractant 
protein-1, TNF, tumor necrosis factor, p values baseline vs. post stimulation values. 
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Table 42. Comparison of the response to LPS stimulation between monocyte subsets 
Intracellular 
marker 
Proportional change MFI p 
Mon 1 Mon 2 Mon3 
Mon1 vs. 
Mon2 
Mon1 vs. 
Mon3 
Mon2 vs. 
Mon3 
TNF-α 1.7±0.02 1.6±0.07 0.92±0.03 0.16 <0.001 <0.001 
IL-1β 15.9±0.6 1.3±0.03 0.92±0.13 <0.001 <0.001 0.845 
IL-6 1.7±0.04 1.3±0.02 0.93±0.11 0.001 <0.001 0.005 
IL10 1.4±0.02 1.9±0.02 0.83±0.35 0.07 0.034 0.002 
MCP-1 2.0±0.07 1.3±0.02 0.95±0.02 <0.001 <0.001 <0.001 
IKKβ 2.0±0.01 1.7±0.09 0.86±0.13 <0.01 0.001 <0.001 
IL, interleukin ,MFI, median fluorescence intensity, MCP-1, monocyte chemoattractant 
protein-1, TNF, tumor necrosis factor, p values baseline vs. post stimulation values. NB. 1 
= no effect. 
 
4.5.5. Effects of physical exercise 
 
The participants of this substudy performed incremental treadmill exercise for 13.1±2.03 
minutes (Bruce protocol), equivalent to VO2max 46.8±8.40 mL/kg/min. Total monocyte 
count and numbers of Mon1 increased significantly by 15 minutes after the exercise 
(p=0.021 and p=0.009, respectively) followed by a significant reduction at 1 hour (p=0.012 
and p=0.055, respectively) (Table 43, Figure 20). Although Mon2 and Mon3 numerically 
followed the same trend, only the reduction in Mon3 by 1 hour after the exercise reached 
the level of significance (p=0.008). No significant changes in relative proportions of the 
monocyte subsets were detected (Table 43). 
 
The total MPA count and numbers of MPAs associated with Mon1 dropped significantly 
by 15 minutes after exercise (p=0.044 and p=0.040, respectively) with even lower numbers 
seen by 1 hour (p=0.014 and p=0.024, respectively) when compared to the pre-exercise 
values (Table 43). The reduction in MPAs associated with Mon2 reached the level 
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significance by 1 hour after the exercise (p=0.035). No significant changes in MPAs 
associated with Mon3 were observed. 
 
Expression of CD14 on Mon1 reduced significantly by 1 hour after exercise (p=0.013), 
with no significant changes seen in CD14 expression on Mon2 and Mon3. Physical 
exercise did not affect CD16 and CCR2 expression on any monocyte subsets. Monocyte 
and MPA parameters measured at 24 hours after the exercise did not differ significantly 
from baseline values. 
 
Table 43. Effect of exercise on monocyte subsets and monocyte-platelet aggregates 
 Pre-
exercise 
15 min 1 hour 24 hours p 
Total monocytes, cells/µl 420±47.0 478±51.0* 397±48.6† 444±48.1 0.013 
Mon1, cells/µl 348±39.4 397±42.4* 337±42.8† 374±40.7 0.032 
Mon2, cells/µl 25.9±6.40 26.3±6.81 20.2±6.76 22.6±5.26 0.079 
Mon3, cells/µl 46.2±6.05 55.3±6.31 39.2±6.08† 48.1±7.20 0.008 
Mon1, % 83.0±1.69 81.8±1.69 84.7±1.98 83.9±1.73 0.29 
Mon2, % 5.92±1.12 5.70±1.00 4.98±1.20 5.31±1.05 0.29 
Mon3, % 11.1±0.92 12.5±1.03 10.4±1.27 10.7±1.16 0.12 
MPA, per µl 106±26.0 73.7±14.8* 57.9±17.2* 104±26.4 0.021 
MPA with Mon1, per µl 81.2±22.3 52.1±11.8* 40.4±11.8* 80.6±21.8 0.019 
MPA with Mon2, per µl 12.1±4.01 8.90±2.57 7.86±3.41* 9.59±3.14 0.16 
MPA with Mon3, per µl 12.3±3.14 12.2±2.85 9.74±3.08 13.9±3.85 0.23 
CD14 (Mon1), MFI 1365±63.7 1252±60.8 1169±62.6* 1336±48.8 0.006 
CD14 (Mon2), MFI 1254±131 1072±97.0 1068±103 1195±112 0.17 
CD14 (Mon3), MFI 173±17.0 150±12.5 152±19.1 167±13.1 0.094 
CD16 (Mon1), MFI 11.9±0.50 11.9±0.51 11.6±0.57 12.0±0.45 0.53 
CD16 (Mon2), MFI 74.1±5.63 75.6±4.88 73.0±5.95 70.3±4.50 0.86 
CD16 (Mon3), MFI 147±15.7 146±14.3 135±13.6 144±13.8 0.34 
CCR2 (Mon1), MFI 123±5.67 125±7.44 106±8.34 119±15.1 0.25 
CCR2 (Mon2), MFI 97.0±3.77 98.9±3.34 92.5±5.19 99.0±8.27 0.58 
CCR2 (Mon3), MFI 13.6±0.48 13.9±0.55 12.8±0.35 13.9±0.62 0.30 
 
 *p<0.05 compared with the pre-exercise values, †p<0.05 compared with values 15 min. 
after exercise (except, p=0.055 for Mon1) 
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Figure 20. The dynamics of monocytes and monocyte-platelet aggregates 
after the exercise 
MPA, monocyte-platelet aggregates 
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4.5.6. Diurnal variation 
 
Significant diurnal variations have been observed in the numbers and relative proportions 
of Mon2, which peaked at 6pm and were lowest at 6am (p=0.011 and p=0.001, 
respectively) (Table 44, Figure 21). Moreover, surface expression of CCR2 on Mon2 
followed the same pattern. No significant diurnal variation was observed in monocyte 
expression of CD16 and CD14. 
 
There were trends towards variations in total monocyte and Mon1 counts (peak at 12am., 
nadir at 12pm., p=0.003 and p=0.002, respectively; pairwise comparisons were not 
significant) and Mon3 counts (peak at 12am, nadir at 6am, p=0.076). 
 
 
Figure 21. The diurnal variation of Mon2 monocyte subset 
Mon2, CD14++CD16+CCR2 monocytes 
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Table 44. Diurnal variation of monocyte subsets and monocyte-platelet aggregates 
 6 a.m. 12 p.m. 6 p.m. 12 a.m. 6 a.m. p  
Total monocytes,  
cells/µl 
477±118 450±91.7 467±109 543±147 466±121 0.003 
Mon1, cells/µl 407±113 367±93 379±109 448±143 389±109 0.002 
Mon2, cells/µl 30.5±15.5 37.0±21.4 42.1±21.4* 40.9±18.4* 31.9±18.1 0.011 
Mon3, cells/µl 39.5±14.6 45.6±13.7 45.5±14.2 50.8±14.1 44.7±12.8 0.076 
Mon1, % 84.9±5.00 81.0±7.43 80.4±7.63 75.7±21.0 83.1±5.10 0.24 
Mon2, % 6.84±3.91 8.67±5.35* 9.61±5.57* 8.19±4.38 7.07±3.45 0.001 
Mon3, % 8.30±2.32 10.3±2.91 10.0±3.08 9.91±4.00 9.87±2.96 0.093 
MPA, per µl 78.9±43.8 96.8±48.2 77.4±45.7 100±38.0 91.2±50.3 0.083 
MPA with Mon1,  
per µl 
66.1±39.2 80.2±43.1 62.4±41.4 81.5±35.4 77.3±41.2 0.13 
MPA with Mon2,  
per µl 
8.54±5.78 12.0±9.21 10.6±5.71 13.6±9.51 11.1±11.4 0.13 
MPA with Mon3,  
per µl 
9.48±18.2 4.60±2.77 4.40±3.63 5.32±3.62 4.37±2.92 0.38 
CD14 (Mon1), 
MFI 
1071±194 1187±194 1053±282 1162±152 1193±205 0.061 
CD14 (Mon2), 
MFI 
564±419 626±442 599±439 639±440 633±443 0.18 
CD14 (Mon3), 
MFI 
89.4±48.8 89.4±33.1 91.7±35.4 98.3±40.1 98.9±40.0 0.28 
CD16 (Mon1), 
MFI 
11.5  
(9.56-1276) 
11.8  
(10.4-1406) 
12.1  
(9.50-1234) 
12.8  
(10.5-1456) 
11.7  
(10.2-1460)
0.13 
CD16 (Mon2), 
MFI 
40.5±30.0 40.2±24.6 40. 8±24.9 39.1±23.8 40.5±26.0 0.50 
CD16 (Mon3), 
MFI 
171±60.6 176±61.2 175±71.0 168±64.6 177±53.9 0.39 
CCR2 (Mon1), 
MFI 
159±29.5 171±31.9 163±43.9 163±39.5 162±34.0 0.64 
CCR2 (Mon2), 
MFI 
113±17.8 119±20.0 123±19.8 116±17.3 112±15.9 0.048 
CCR2 (Mon3), 
MFI 
15.9±1.41 16.0±1.92 16.2±1.40 16.1±1.29 16.0±1.96 0.79 
 
MPA, monocyte-platelet aggregates, MFI, median fluorescent intensity. *p<0.05 compared 
with the baseline values (except, p=0.051 for CCR2 (Mon2)), †p<0.05 compared with 
previous time-point. 
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4.5.7. Time-delay analysis 
 
A delay of up to 2 hours in sample analysis after venipuncture did not significantly affect 
counts and relative proportions of monocyte subsets (Table 45). By 4 hours, the proportion 
of Mon2 significantly increased (p=0.004) and this was driven by a reduction in the 
proportion of Mon1 (p=0.001). Mon3 counts (but not percentage) also tended to increase 
(p=0.021, with no pairwise significant differences). 
 
MPA counts were more sensitive to the delay in sample processing. There was a numerical 
trend towards an increase by 1 hour, and MPAs significantly increased by 2 hours and 
further by 4 hours (p=0.025 and p=0.016, respectively) (Figure 22). A similar trend was 
seen for MPAs associated with all individual monocyte subsets, with MPA numbers 
approximately doubling by 2 hour and further doubling by 4 hours (Table 45). 
 
CD14 and CD16 expression on Mon1 significantly increased by 2 hours (p=0.031 and 
p=0.002, respectively) and further by 4 hours (p=0.006 and p=0.007, respectively). 
Monocyte CCR2 expression was not affected by delay in sample preparation (Table 45). 
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Table 45. Effects of delayed sample processing on monocyte subsets and monocyte-
platelet aggregates 
 Immediately 1 hour delay 2 hour delay 4 hour delay p 
Total monocytes, 
cells/µl 
386±60.4 401±63.3 406±76.8 416±65.7 0.58 
Mon1, cells/µl 330±52.0 339±52.1 339±62.8 325±49.7* 0.84 
Mon2, cells/µl 24.3±6.72 34.8±10.1 31.5±9.40 50.9±13.8* 0.042 
Mon3, cells/µl 31.8±5.92 34.3±6.83 38.0±7.65 40.1±8.29 0.021 
Mon1, % 86.6±1.32 85.5±1.55 84.4±1.49 79.7±2.73 0.014 
Mon2, % 5.58±0.99 5.82±1.10 6.33±1.06 10.7±1.81* 0.004 
Mon3, % 8.50±1.04 8.71±1.03 9.28±1.17 9.54±1.22 0.32 
MPA, per µl 52.0±21.4 79.8±24.0 137±20.8* 271±59.8* 0.02 
MPA with 
Mon1, per µl 
35.9±14.6 58.3±17.9 104±16.4* 201±45.1* 0.03 
MPA with 
Mon2, per µl 
7.58±4.05 9.74±4.26 14.7±3.90 38.9±11.4* 0.006 
MPA with 
Mon3, per µl 
8.50±2.94 11.7±3.30 18.3±3.37* 31.0±7.80* 0.008 
CD14 (Mon1), 
MFI 
950±119 1205±75.3 1464±83.1* 1967±186* <0.005 
CD14 (Mon2), 
MFI 
1084±145 1302±73.3 1503±98.3 1903±315 0.067 
CD14 (Mon3), 
MFI 
169±18.2 185±21.8 209±21.3 276±51.0 0.096 
CD16 (Mon1), 
MFI 
13.2±0.53 13.6±0.56 14.1±0.57* 17.3±0.86* 0.001 
CD16 (Mon2), 
MFI 
59.1±1.65 58.3±1.37 59.2±2.29 61.4±4.08 0.58 
CD16 (Mon3), 
MFI 
167±13.6 166±19.6 185±13.4 203±22.3 0.087 
CCR2 (Mon1), 
MFI 
121±16.7 129±14.9 125±12.9 146±12.9 0.30 
CCR2 (Mon2), 
MFI 
103±7.51 105±4.17 104±6.11 110±3.78 0.56 
CCR2 (Mon3), 
MFI 
15.1±0.74 14.7±0.44 13.3±0.63 14.3±0.86 0.23 
MPA, monocyte-platelet aggregates, MFI, median fluorescent intensity. *p<0.05 compared 
with the baseline values (except, p=0.067 for Mon2). 
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Figure 22. Effect of the delay in the sample processing on monocyte-platelet aggregate 
number 
MPA, monocyte-platelet aggregates 
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4.6. Discussion 
 
In this section I show that three human monocyte subsets can be reliably discriminated on 
the basis of varying expression of CD14, CD16 and CCR2 and they comprise three 
phenotypically and functionally distinct subsets. 
 
Mon1 is characterised by high expression of CD14, IL6 receptor, CD64, CCR2 and 
CD163, but low expression of VCAM-1 receptor and CD204 and absent CD16. Mon2 is 
characterised by maximal expression of ICAM-1 receptor, Tie2, CXCR4, CD163, VEGF 
receptor 1, KDR, ferritin, ApoB and CD115. Compared to Mon1, Mon2 have up-regulated 
CD16, VCAM1 receptor and CD204. In contrast, Mon3 had maximal expression of CD16, 
VCAM1 receptor and CD204, but diminished levels of CD14, IL6 receptor, CD64, CCR2 
and CD163. On the basis of these findings, Mon1 appear to correspond to Ly-6C
hi
 mouse 
monocytes and Mon3 to Ly-6C
lo 
monocytes.
25
 However, it is not clear which mouse 
monocyte subset may correspond to the human Mon2. 
 
Important questions arise about the developmental origins and functional differences 
between the three monocyte populations. Experimental findings show that the two mouse 
monocyte subsets do not arise from distinct lineages. Rather, Ly-6C
lo
 monocytes (Mon3 
analogue) are a product of the Ly-6C
hi
 monocyte subset (Mon1 analogue).
678
 In this study I 
show that all three human monocyte subsets are already present in bone marrow, although 
the relative proportion of the Mon2 subset is much higher in bone marrow than in blood. 
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In accordance with previous studies showing that inflammatory activity of Mon3 is 
significantly lower compared to ‘classical’ monocytes (CD14++CD16–), I observed 
significantly lower levels of IKKβ in Mon3 compared to Mon1. Intriguingly, the 
observation that IKKβ levels in Mon2 are similar to Mon3 and significantly lower 
compared to Mon1 suggests that the functional role of Mon2 is distinct from pro-
inflammatory Mon1.  
 
Monocyte subpopulations significantly differed in their ability to produce cytokines in 
response to LPS. Mon1 had the highest LPS-stimulated expression of IL1β, IL6, MCP-1 
and IKKβ, whilst Mon2 exerted the maximal of all subset increases in IL10 expression. In 
accordance with previous data, Mon3 were apparently unresponsive to LPS.
679-680
 Of note, 
in it was previously shown that CD14+CD16+ monocytes (i.e., Mon3) could produce 
inflammatory cytokines in response to viral rather than bacterial stimulation.
680
 These 
observations further confirm significant functional differences of the three monocyte 
subsets. Recently it has been demonstrated that in a similar manner to mice Ly-6C
lo
 
monocytes, the human CD14+CD16+ subset ‘patrols’ the endothelium in a lymphocyte 
function-associated antigen (LFA)-1 dependent manner.
680
 Given the relatively small 
levels of CD18 (β-chains) expressed by Mon3 in our study, it is likely that α-chain of the 
ICAM-1 receptor (ie, LFA-1, CD11a) is critical for the ‘patrolling’ activity. However, 
expression of LFA-1 on monocyte subsets has not been assessed in this study, which 
should be considered as a study limitation. 
 
Divergent directions of phenotypic change on Mon2 compared to Mon1 (including 
increase in size, increased expression of various markers such as ICAM-1 receptor, Tie2, 
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CXCR4, CD163, VEGF receptor 1, KDR, ferritin and ApoB) and Mon3 (reduced size and 
granularity, down-regulation of most markers discussed above, but specific maximal up-
regulation of CD204, VCAM-1receptor  and CD16) may indicate that Mon2 and Mon3 
represent developmentally independent subsets rather than different stages of monocyte 
maturation. Although only few studies separately analysed CD14++CD16+ and 
CD14+CD16+monocytes, dynamics in their counts appear to be discordant.
44-45
 The 
CD14++CD16+ subset is increased, whereas CD14+CD16+ cells are decreased in numbers 
after stroke, although both subsets (in contrast to CD14++CD16– monocytes) were 
positively associated with a favourable prognosis.
44
 CD14++CD16+ but not CD14+CD16+ 
monocytes, are increased in severe asthma.
45
 CD14++CD16+ are associated negative 
prognosis in chronic kidney disease.
681 
 
These clearly distinct characteristics of monocyte populations raise the important question 
as to what the role may be of this ‘mysterious’ Mon2 subset? To address this, we must 
consider them in context of previous findings. Expression of a marker seen on 
macrophages (CD16) and high density of M-CSF receptor (CD115) may indicate their 
transformation towards tissue-resident cells (e.g., macrophages). Mon2 uniformly express 
maximal levels of receptors to proangiogenic factors (Tie2 [an angiopoietin receptor], 
KDR, CXCR4 and VEGF receptor 1). It has been reported that CD14+ cells include a 
subset of pluripotent cells able to differentiate into various cell lineages (e.g., epithelial, 
neuronal, neuronal and hepatic) under appropriate microenvironments and that multipotent 
cells of monocytic origin successfully restored LV function after experimental MI.
37, 466
 
Bone marrow and peripheral blood-derived CD14+Tie2+CD34– cells (thus, phenotypically 
corresponding to Mon2) were shown to transdifferentiate into endothelial lineage cells and 
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contribute to neovascularisation in vivo in response to MCP-1.
642
 Of note the similarity of 
Mon2 to bone marrow monocytic cells and their higher proportion in bone marrow may 
imply their direct bone marrow origin rather than their development from Mon1. 
 
M-CSF treatment of infarcted mice significantly reduced infarct size and improved LV 
function.
469
 Immunohistochemistry revealed that M-CSF increased macrophage infiltration 
and neovascularization of infarcted myocardium. This paralleled the mobilization of 
CXCR4+ cells into the peripheral circulation and their homing into the infarct area which 
showed marked SDF-1 expression.
469
 These effects were abrogated by the CXCR4 
antagonist AMD3100.  
 
Interesting parallels can be drawn in relation to Mon2 which expressed maximal levels of 
the unique M-CSF receptor (CD115) and CXCR4. Also in accordance with these findings, 
cardiac MCP-1 overexpression in mice with bone marrow replaced by Tie2/LacZ mice was 
associated with effective prevention of cardiac dysfunction and remodelling after MI, by 
myocardial mobilisation of Tie2 monocytes.
365
 These angiogenic/reparative MCP-1 
responsive (CCR2+Tie2+) monocytes probably correspond to the Mon2 subset. Of note, 
no increase in CD34+KDR+ EPCs was observed in this model.
365
 These cells exhibit the 
potential to differentiate in vitro into cells with endothelial characteristics and significantly 
contributed to efficient re-endothelialization in a mouse model of vascular injury.
465
 Taken 
together, although these various studies employed different markers to describe 
angiogenic/reparative monocytes, all of them appear to correspond to the Mon2 subset.  
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Of importance, Tie2-expressing peripheral blood monocytes are selectively recruited to 
spontaneous and orthotopic tumours, to promote angiogenesis in a paracrine manner, and 
they account for most of the proangiogenic activity of myeloid cells in tumours.
682-683
 High 
Mon2 expression of CD163 (a scavenger receptor known to exert anti-inflammatory 
properties) and high surface density of ferritin (iron-binding protein involved in control of 
oxidative burden). Taken together with previous data on high IL10 expression on 
CD14++CD16+ monocytes the findings may indicate that the reparative properties of 
Mon2 may even go beyond their putative  angiogenic potential.
684-688 
 
Interestingly there was an unexpected observation of a higher rate of MPAs in bone 
marrow than in peripheral blood. Generally such aggregates are believed to reflect platelet 
activation, an unlikely scenario in bone marrow.
636
 Although exact significance of this 
phenomenon is unclear it might indicate the role of platelets in monocyte maturation in 
bone marrow. However, these observations could be biased by the slightly longer 
processing time of bone marrow samples than blood samples.   
 
Also this study shows for the first time the presence of significant diurnal variation in the 
Mon2 subset. The highest levels of this subset were observed at 6pm, possibly reflecting 
increased day-time activity of the participants. Also this variation may partly be related to 
the ‘biological clock’, e.g., being affected by well recognised and clinically important 
variations in glucocorticoid levels. Indeed, glucocorticoids (e.g., cortisol) play a significant 
role in regulation of vascular reactivity and inflammation.
689-691
 Glucocorticoids modulate 
different aspects of monocyte structure, metabolism and function (predominantly 
inhibitory effects).
692-694
 These effects are mediated by corticosteroid receptors expressed 
235 
 
by monocytes/macrophages.
695
 Acute administration of glucocorticoids has also been 
reported to reduce circulating monocyte levels.
696
 Apparently scarce information is 
available on mechanisms of cortisol-mediated down-regulation of monocyte mobilization 
from bone-marrow and regulation of their homing to tissues, which might be partly related 
to the cortisol-mediated effects on adhesion molecules.
697
 However, in my study the 
pattern of diurnal monocyte variation did not strictly follow the classical pattern of cortisol 
variation (i.e., peak levels in the early morning and lowest levels at about midnight - 4 
am).
698
 This suggests the presence of other regulatory mechanisms of monocyte 
mobilisation to the circulation. For example, sleep per se and irrespectively of diurnal 
variation was shown to down-regulate proportions of IL-10 producing monocytes (i.e., 
predominantly Mon2), which appear to correspond to my data showing a significant 
reduction of Mon2 at night time (6 am) as compared with day-time (6 pm, p=0.001).
699
 
 
Although Mon1 and Mon3 showed a trend towards diurnal variation, their changes were 
relatively small and are thus unlikely to have a significant biological role, at least in 
healthy volunteers. 
 
Another novel observation in this study is the prompt increase in monocyte count and the 
contrasting reduction in MPAs following exercise. One possibility is that some MPAs 
could disaggregate under enhanced flow/shear stress conditions seen during exercise. 
However, this is perhaps unlikely given that MPA numbers continued to decrease further 
by 1 hour after the exercise, when baseline haemodynamics should be restored. An 
alternative explanation is that the exercise facilitated preferential migration to tissues of 
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monocytes aggregated with platelets. This is supported by published data showing the role 
of platelets in the regulation and acceleration of monocyte homing.
700-701
 
 
The study also shows significant post-exercise reduction in CD14 expression on Mon1. 
CD14 is intimately involved in monocyte antibacterial and inflammatory responses.
26
 
Thus, this observation may shed further light on the potential mechanism for the 
beneficial/anti-inflammatory effects of exercise but also their immunodepressive effects.
702
 
 
Monocyte subsets appear to respond differentially to physical activity. In the study by 
Simpsonet al., the proportion of CD14++CD16+monocytes increased by 27% immediately 
after exercise, but reduced by 49% after just one hour, indicating fairly prominent 
dynamics of the ‘proinflammatory’ CD16+ monocytes.
703
 Moreover, monocyte expression 
of surface receptors differs between various subsets.
703
 Also, moderate-intensity treadmill 
exercise predominantly increased CD16+ monocytes, and revealed significant inter-subset 
differences and significant changes in CD62L, CD11b, CXCR2, and HLA-DR 
expression.
704
 Indeed, physically active individuals had a lower percentage of 
CD14++CD16+ monocytes, a lower unstimulated monocyte production of TNF-α and 
lower CRP levels compared to sedentary individuals.
705
 The advantage of the present study 
is its accurate and objective discrimination of the three monocyte subsets which further 
increases our knowledge on immediate monocyte responses to exercise in healthy 
individuals.
 
 
Finally, the time-delay substudy shows that a delay in sample processing of up to 2 hours 
has little effect on the accuracy of monocyte subsetcounting. More prolonged delays tend 
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to shift monocyte proportions from Mon1 to Mon2 (and possibly Mon3). These findings 
are also of interest from the point of view of monocyte biology, given that they may 
highlight a propensity for ‘classical’ monocytes (Mon1) to express CD16, a typical feature 
of the minor monocyte subsets. It is unclear whether these changes reflect Mon1 
differentiation to macrophages (known to express CD16) or their ability to differentiate 
into other monocyte subsets. In order to answer this question, more detailed analysis of 
isolated Mon1 will be required.
706
 In contrast to monocyte subsets, analysis of MPA counts 
should not be performed later than one hour from sample collection as further delay 
significantly affect the results due to a progressive increase in MPA numbers. Analysis of 
monocyte CD14 and CD16 expression should also be performed within one hour. 
 
Of note, the number of participants in this study was relatively small, leaving a possibility 
of “significant” changes/differences detected by chance alone. This needs to be kept in 
mind interpreting the results, and further research with more mechanisctic insight into 
monocyte subset functionality would be useful. 
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4.7. Postscript 
 
After I had completed the immunophenotypic part of the study with the manuscript being 
under submission a consensus on monocyte subset nomenclature was published. 
Interestingly, the consensus agreed about the existence of the three monocyte subsets 
defined in the study.
42, 46
 
 
4.8. Conclusions 
 
In conclusion, in this chapter of the thesis I demonstrate that human monocytes include 
three major functionally and phenotypically different subsets which can be unequivocally 
discriminated on the basis of their CCR2 expression. These subsets are defined as 
CD14++CD16-CCR2+ cells (Mon1), CD14++CD16+CCR2+ cells (Mon2) and 
CD14+CD16+CCR2– cells (Mon3). Thus, previous monocyte work might need to be re-
evaluated in the light of this newly characterised Mon2 cell population.  
 
Mon2 undergoes significant diurnal variations. A single episode of exercise causes a 
temporal increase in monocytes with a contrasting significant reduction in MPA numbers. 
Analysis of monocyte subset counts should be performed within 2 hours of blood sampling 
whereas measurement of MPAs and monocyte CD14 and CD16 expression should be 
performed within 1 hour. 
 
The functional roles of the Mon2 subset need further investigation, both in health and in 
diseases in which monocytes play a pivotal role, such as atherosclerosis. Also, Mon2 may 
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correspond to a population of angiogenic/pluripotent progenitor monocytes, as described in 
previous studies. 
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CHAPTER V. BLOOD LEUKOCYTES IN PATIENTS WITH HEART 
FAILURE: IMPACT ON PROGNOSIS 
 
5.1. Introduction 
 
HF with preserved ejection fraction (HFpEF) is an emerging problem of cardiovascular 
medicine.
50
 Whilst the prevalence of HF with reduced ejection fraction (HFrEF) has been 
relatively stable over the last two decades, the prevalence of HFpEF is growing rapidly and 
it is expected to become a dominant form of HF in the near future.
51
 Despite the increasing 
appreciation of the problem and recognition of the comparably poor outcome of the two 
conditions, the pathophysiological mechanisms of HFpEF are still poorly understood.
52-53
 
 
Different types of leukocytes play important roles in the pathogenesis and prognosis of 
HFrEF via their contribution to inflammation, extracellular matrix remodelling, and 
reparatory processes.
660
 In a number of studies, relative lymphopenia, and particularly T-
helper deficit were strong predictors of higher risk of death in severe HFrEF and acute 
decompensated HF.
707-713
 In patients with moderate-to-severe chronic HFrEF, low 
lymphocyte count was a much stronger predictor of mortality than LVEF.
714
 Lymphocyte 
abnormalities, such as increase in Th17 population and reduction in Treg lymphocytes has 
been shown in HFpEF but the impact of lymphocyte counts on mortality in HFpEF is not 
known.
715
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In contrast to lymphocytes, neutrophils are often increased in HFrEF and show features of 
distinct proinflammatory activation.
716-717
 In a retrospective analysis of patients from the 
Studies Of Left Ventricular Dysfunction (SOLVD), a relative neutrophil elevation posed 
an increasedrisk of all-cause and cardiovascular mortality.
713, 718-719
 However, only scarce 
data are available on the impact of neutrophils on pathophysiology and outcome in HFpEF. 
Also, only limited data arecurrently available on the role of monocytes in HF.  Of note, in 
patients after acute MI high monocyte count was associated with poor recovery of 
LVEF.
400
 However, the impact of monocytes on outcome in stable HF and their role in 
HFpEF is unclear. 
 
5.2. Aims and hypotheses 
 
In this study I aimed to assess possible differences in neutrophils, lymphocytes and 
monocytes between patients with HFrEF and HFpEF and establish the effect of their 
numbers on the risk of death in HF patients.  
 
I hypothesised that: 
1. There are significant differences in neutrophils, lymphocytes and monocytes between 
patients with HFrEF and HFpEF; 
2. Counts of the leucocytes predict the risk of death in patients with HFrEF and HFpEF. 
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5.3. Methods 
5.3.1. Study population 
 
A total number of 1019 patients referred the Cardiology Clinic if the Grodno Regional 
Clinical Hospital in 2008-2009 with HF either with HFrEF (n=856) or with HFpEF 
(n=163) have been included into the study. The diagnosis of HFrEF or HFpEF has been 
established according to the current guidelines of the European Society of Cardiology.
1
 
Exclusion criteria for inclusion in the study were life expectancy less than oneyear due to 
non-cardiac courses (e.g., cancer), and terminal HF (NYHA class IV). All included 
patients were clinically stable and treated (>3 months) before the recruitment, and under 
regular outpatient follow up. 
 
The patients were followed for at least one year with median (inter-quartile range [IQR]) 
follow-up duration of 17 (14-20) months. The endpoint of any-cause death has been 
registered at the end of the period. The study was performed in accordance with 
Declaration of Helsinki and local ethical regulations.  
 
5.3.2. Echocardiography 
 
All subjects underwent routine M-mode, B-mode, and Doppler transthoracic 
echocardiography. Images of parasternal long axis, short axis (at aortic valve level, mitral 
leaflet level, papillary muscle level and apex), apical 4-chamber, apical 5-chamber, apical 
2-chamber and apical 3-chamber views were acquired. The relevant American Society of 
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Echocardiography (ASE) guideline recommendations were used for image acquisition and 
analysis.
646, 648, 720
 LVEF was measured using the modified Simpson’s biplane method.
648
 
The diastolic functional assessment was performed by evaluating E/A ratio, a ratio of early 
and late mitral inflow velocities. 
 
5.3.3. White blood cell count 
 
The white blood cells (neutrophils, lymphocytes, monocytes) were measured in the Central 
laboratory of the Grodno Regional Clinical Hospital using an automatic haematocytometer 
(Micros 60 Horiba, ABX Diagnostics, France). Inter- and intra-assay CVs were <5%. 
 
5.3.4. Statistical analysis 
 
Data are expressed as mean ± standard deviation (SD) for normally distributed variables; 
or as median and IQR for non-normally distributed variables. Comparisons between two 
groups (i.e., patients with EF <50% vs. ≥50%) were performed using T-test (for normally 
distributed parameters) or Mann-Whitney (for non-normally distributed parameters). 
Predictive value of the study parameters for LVEF was assessed using linear regression 
analysis, and factors predictive for death were assessed with logistic regression analysis. 
Predictive value of white blood cells for death was calculated per 1000 granulocytes, 200 
monocytes and 1000 lymphocytes. A p-value of <0.05 was considered statistically 
significant. SPSS 18 (SPSS, Inc, Chicago, Illinois, USA) statistical software was used to 
perform the statistical analyses. 
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5.4. Results 
5.4.1. Demographic and clinical characteristics 
 
The study included 1019 consecutive patients with HF either HFrEF (n=856, age 55 [49-
64], 81% males) or HFpEF (n=163, age 58 [51-65], 56% males) (Table 46). Patients with 
HFrEF had lower body mass index (p=0.017), higher proportion of males (p<0.001), 
patients with atrial fibrillation (p<0.001), subjects with history of previous MI (p=0.002), 
and lover proportion of patients with history of hypertension (p<0.001). As expected 
patients with HFrEF had higher NYHA class than patients with HFpEF (p<0.001). 
 
Patients with HFrEF as compared with patients with HFpEF had significantly higher 
neutrophil counts (p=0.004) and granulocytes percentage (0.018) and significantly lower 
lymphocyte percentage (p=0.004) and platelet numbers (p=0.001)(Table 46). 
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Table 46. Demographic and clinical characteristics of patients with reduced and 
normal ejection fraction 
 EF <50% 
(n=163) 
EF ≥50% 
(n=858) 
p 
Age, years 55 (49-64) 58 (51-65) 0.066 
Male, n (%) 132 (81) 480 (56) <0.001 
Ishaemic aetiology, n (%) 119 (73) 631 (74) 0.89 
NYHA I (%) 36 (22) 654 (76) <0.001 
NYHA II (%) 97 (60) 192 (22)  
NYHA III (%) 30 (18) 12 (1)  
Atrial fibrillation, n (%) 97 (60) 248 (29) <0.001 
Diabetes mellitus, n (%) 8 (5) 82 (9) 0.055 
Hypertension, n (%) 115 (71) 754 (88) <0.001 
BMI, kg/m
2
 27 (25-31) 29 (26-32) 0.017 
History of MI, n (%) 50 (31) 168 (20) 0.002 
Neutrophils, per µL 4140 (3498-5293) 3933 (3247-4760) 0.004 
Neutrophils, % 65 (59-69) 63 (58-68) 0.018 
Monocytes, per µL 208 (80-378) 188 (73-354) 0.48 
Monocytes, % 3.0 (1.0-6.0) 3.0 (1.0-6.0) 0.85 
Lymphocytes, per µL 1936 (1562-2358) 1908 (1567-2277) 0.45 
Lymphocytes, % 29 (24-33) 30 (26-34) 0.004 
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5.4.2. Predictors of left ventricular ejection fraction 
 
Using univariate analysis, significant clinical predictors of reduced LVEF in the whole 
study population were advanced age, male sex, history of hypertension and atrial 
fibrillation (Table 47). Among leukocytes, high neutrophil count and percentage and low 
lymphocyte percentage were associated with reduced LVEF. These parameters remained 
significantly associated with reduced LVEF after adjustment for the clinical predictors 
above (Table 47). 
 
Table 47. Predictive value of the study variables for left ventricular ejection fraction 
Parameter Unadjusted 
R
2
 β p 
Age 0.01 0.09 0.006 
Male sex 0.07 -0.25 <0.001 
Atrial fibrillation 0.04 0.21 <0.001 
Ischaemic aetiology 0.00 0.01 0.66 
Diabetes mellitus 0.00 -0.001 0.98 
Hypertension 0.04 0.20 <0.001 
Body mass index 0.00 0.06 0.072 
Neutrophils, count 0.02 -0.13 <0.001 
Neutrophils, % 0.01 -0.08 0.014 
Monocytes, count 0.00 0.002 0.13 
Monocytes, % 0.00 -0.02 0.46 
Lymphocytes, count 0.00 -0.02 0.59 
Lymphocytes, % 0.01 0.10 0.001 
 Adjusted for age, sex, atrial fibrillation, 
hypertension 
Neutrophils, count 0.14 -0.09 0.003 
Neutrophils, % 0.14 -0.07 0.019 
Monocytes, count 0.13 -0.03 0.33 
Monocytes, % 0.13 -0.02 0.13 
Lymphocytes, count 0.13 0.02 0.56 
Lymphocytes, % 0.14 0.09 0.004 
 
247 
 
5.4.3. Blood cells and mortality 
 
During the follow-up period, 41 deaths (4.02%) occurred (28 deaths in HFpEF and 
13deaths in HFrEF). Using univariate logistic regression analysis, a history of hypertension 
was the only significant clinical predictor for mortality in patients with HFpEF (Table 48). 
Amongst the leukocytes, high monocyte count was the only significant predictor of death 
in HFpEFonunivariate analysis (p=0.01). On multivariate analyses, after adjustment for 
age, LVEF, and hypertension, high monocyte count still significantly predicted death 
(p=0.012). The results in HFpEF indicate a 41% increase in risk of death per rise by every 
200 monocytes (Table 48). Additionally, monocytosis (i.e., monocyte count above 800 
cells/µl) was associated with a 441% increase in risk of death compared to patients with 
normal monocyte levels (i.e., ≤800 per ul, odds ratio 5.41 [95% CI 1.50-19.6], p=0.01, 
R
2
=0.022). We were unable to identify significant predictors for mortality in patients with 
HFrEF among the study parameters (Table 49). 
 
Table 48. Predictors of all cause death in patients with heart failure with preserved 
ejection fraction 
Parameter 
 
Unadjusted 
R
2
 Odds ratio 95% CI p 
Age 0.000 1.01 0.98-1.05 0.52 
Sex 0.014 2.01 0 .88-4.62 0.10 
Ejection fraction 0.006 0.97 0.92-1.03 0.27 
Hypertension 0.021 0.35 0.15-0.85 0.02 
Neutrophils, per 1000 cells 0.008 1.16 0.95-1.41 0.15 
Monocytes, per 200 cells 0.026 1.42 1.09-1.84 0.01 
Lymphocytes, per 1000 cells `0.006 1.40 0.78-2.53 0.27 
 Adjusted for hypertension, age, and ejection fraction 
Monocytes, per 200 cells 0.057 1.41 1.08-1.84 0.012 
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Table 49. Logistic regression analysis for predictors of all cause death in patients with 
heart failure with reduced ejection fraction 
Parameter  
 
Unadjusted 
R
2
 Odds ratio 95% CI p 
Age 0.004 0.99 0.94-1.04 0.59 
Sex 0.002 1.77 0.20-2.96 0.70 
Ejection fraction 0.026 0.96 0.91-1.02 0.31 
Granulocytes, per 1000 cells 0.002 1.06 0.81-1.39 0.69 
Monocytes, per 200 cells 0.001 0.92 0.52-1.62 0.77 
Lymphocytes, per 1000 cells 0.000 0.95 0.42-2.11 0.89 
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5.4. Discussion 
 
This study shows for the first time that high monocyte count is a significant independent 
predictor of mortality in patients with HFpEF. The study also shows significant differences 
between HFpEF and HFrEF in the proportions of leukocytes. 
 
Despite better LV contractility the clinical prognosis in HFpEFis poor and similar to the 
prognosis in HFrEF.
50
 However, the pathophysiology of HFpEF is still poorly 
understoodgiven that this group of patients is rather heterogeneous with leading factors 
driving the symptoms being increased myocardial stiffness, delayed myocardial relaxation, 
and impaired endothelial function.
721
 It is uncertain whether cardiomyocyte dysfunction or 
impaired extracellular matrix properties should be considered as a primary pathogenic 
factor of HFpEF.
722-723
 
 
The observed impact of monocytes on outcome in HFpEF is perhaps not unexpected. 
Monocytes are immune and pro-inflammatory cells with plethora of other biological 
roles.
659-660, 724
 These cells play a key role in the regulation of myocardial extracellular 
matrix turnover.
659
 Moreover, monocytes do contribute to and orchestrate tissue 
remodelling by release of various matrix metalloproteases, cytokines and growth factors.
660
 
It has been previously shown that high monocyte levels were associated with a higher risk 
if future MI in stable CAD and in those with MI, high monocyte numbers were strongly 
associated with increased risk of unfavourable outcomes.
320, 396, 402
 This study expands the 
field by demonstrating of the independent negative impact of monocytosis (i.e., monocyte 
count over 800 per µl) on outcome in patients with HFpEF. 
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In my study, monocytes were not significantly predictive of death inHFrEF. This finding is 
consistent with the increasing appreciation that HFrEF and HFpEF are two different 
clinical entities with different pathogenesis.
50
 Indeed, features of the primary 
cardiomyocyte dysfunction dominate in HFrEF, whilst abnormalities of the cardiac elastic 
properties and pathological changes of the extracellular matrix are perhaps pivotal in 
HFpEF.
50
 
 
In agreement with previous reports, I observed that neutrophil and lymphocytes were 
associated with impairment of LV contractility, but I was unable to establish their 
significant role for the outcome.
707-713, 719
 This may be due to the fact that subjects with 
predominantly mild-to-moderate HF were included in my study in contrast to the 
predominance of moderate-to-severe or acute decompensated HF subjects in most previous 
studies. The present study also shows for the first time that patients with HFrEF have 
significantly higher values of neutrophils and percentage of lymphocytes than subjects 
with HFpEF.  
 
5.5. Limitations 
 
The leukocyte counts were obtained using a routine haematological analysis, which did not 
provide information on specific monocyte and lymphocyte subsets. The assessment of 
functional activity of leukocytes was beyond the scope of the present study. Additionally, 
the death rate was relatively low as the majority of the participants had mild HF and thus, 
these study results may not be transferable to HF patients with higher HYHA classes. 
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5.6. Conclusions 
 
There are significant differences in the numbers of granulocytes and percentage of 
lymphocytes between patients with HFrEF and HFpEF. High granulocyte counts and low 
percentage of lymphocytes are independent predictors of worse LVEF and NYHA status in 
HF.  
 
High monocyte count is a significant independent predictor of death in patients with 
HFpEF. The study results advance the knowledge of the significant differences in the 
pattern of leukocytes between HFpEF and HFrEF. This differential effect of different types 
of leukocytes on LV contractility outcome and mayhelpto better understand the complex 
pathophysiology of this disorder. 
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CHAPTER VI. SUMMARY AND OVERALL CONCLUSIONS 
 
6.1. Thesis summary 
 
This thesisprovides evidence ofsignificant impairment of both micro- and macrovascular 
endothelial function in SAs with HF, which accords with similar previous findings from 
other ethnic groups. In contrast to the measures of endothelial function, parameters of 
arterial stiffness did not differ between SA subjects with HF and matched control groups. 
 
My thesis work demonstrates for the first time that patients with HF also have significantly 
increased levels of both MMPs and PMPs, but only MMPs were independently and 
negatively predictive of LVEF [Chapter III]. In contrast, the work reports for the first time 
significant abnormalities in monocyte-derived CD34+ and KDR+ EPCs in patients with 
systolic HF. The numbers of CD34+ monocytes were 2-fold lower in HF subjects than in 
both control groups with normal LV contractility. Importantly, these abnormalities were 
evident even despite the similar overall monocyte counts among the groups. Counts of 
monocyte-derived EPCs did not correlate with parameters of cardiac geometry and 
function, raising the question of the clinical importance of these cells. However, higher 
VEGF receptor 1 expression on the Mon2 subsets showed some association with lower 
LVEF. 
 
My thesis work highlights for the first time the presence of significant ethnic differences in 
endothelial and blood cellular parameters in patients with systolic HF [Chapter III].  
Whites had better FMD than other ethnic groups, but the differences disappeared after the 
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adjustment for important clinical and demographic co-variables. This analysis suggests that 
ethnicity-related differences in co-morbidities accompanying HF rather than ethnicity itself 
may determine the status of macrovascular endothelial dysfunction. 
 
SAs had more severe impairment of microvascular endothelial function compared to other 
ethnic groups. SA ethnicity was associated with microvascular endothelial dysfunction, 
even after adjustment for age, presence of hypertension and diabetes, blood pressure and 
glucose levels. No significant ethnic difference was seen in PWV. 
 
My thesis work shows for the first time significant ethnic difference in monocyte subsets in 
HF [Chapter III]. The counts and proportion of Mon3, which has been suggested to have 
reparative potential were significantly higher in HF subjects of AC origin. There were also 
significant ethnicity-related differences in monocyte expression of SR-AI among HF 
subjects. These observations accord with better survival of AC subjects with HF, and 
indicate a possible intrinsic protective/reparative potential in this ethnic group. 
 
In contrast to a recent study showing increased Mon2 levels in European patients with HF 
compared with controls, there were no significant HF-related changes in this monocyte 
subset in subjects of SA origin.
425
 Nonetheless, my results indicate significant ethnic 
variations for this subset with white subjects having the highest values, which probably 
explains the discrepancy. 
 
This work shows for the first time the presence of significant differences in neutrophil 
counts and lymphocyte percentage in subjects with HFrEF or HFpEF, thus providing 
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further insight to the possible pathogenic differences between the two conditions [Chapter 
V]. Of importance, the high monocyte count was a significant independent predictor of 
mortality in patients with HFpEF, but not in those with HFrEF. 
 
The thesis also advances the methodological approaches to enumeration and 
characterisation of monocyte subsets and it demonstrates that three human monocyte 
subsets can be reliably discriminated on the basis of their varying expression of CD14, 
CD16 and CCR2[Chapter IV].  
 
The thesis work highlights significant differences in the phenotype and functional activity 
of the monocyte subsets [Chapter IV]. It demonstrates unique characteristics of the 
CD14++CD16+CCR2+ (Mon2) subset featured by attenuated inflammatory properties, 
high production of the anti-inflammatory cytokine IL-10, and maximal of all monocyte 
subsets expression of the angiogenic and reparative markers (e.g., Tie2, CXCR4, CD163, 
VEGF receptors 1 and 2). Of interest this subset was found to be enriched in the bone 
marrow. Together these observations indicate the presence of a reparative potential of this 
subset, which accords with previous observations showing an association between higher 
levels of these cells and better outcome in stoke survivors. The prognostic value of this 
subset in HF is still to be determined. 
 
Additionally my thesis provides new data on the effects of some biological factors on 
monocyte subsets and MPAs [Chapter IV]. For example, it was found that there are 
significant diurnal variations in Mon2 subset with its highest counts seen at 6pm, which 
paralleled maximal CCR2 expression by the subset, which also peaked at 6pm.  
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My thesis work demonstratesa prompt increase in monocyte count and the contrasting 
reduction in MPAs following exercise [Chapter IV]. Although the detailed mechanisms of 
this phenomenon are not entirely clear, it is likely to reflect ability of the exercise to 
facilitate preferential migration to tissues of monocytes aggregated with platelets. This is 
supported by the available data showing the role of platelets in the regulation and 
acceleration of monocyte homing.
700-701
 
 
This work also reveals a significant post-exercise reduction in CD14 expression by 
‘classical’ monocytes, Mon1. Given that CD14 is intimately involved in monocyte 
antibacterial and inflammatory responses the finding might indicate a potential mechanism 
linking beneficial/anti-inflammatory effects of exercise and their immunodepressive 
effects.
26702
 
 
6.2. The study limitations 
The study has a number of limitations which need to be considered during the 
interpretation of the results. The sample size of the ethnic groups is relatively small thus 
leaving a chance for a bias of the statistical tests, particularly given the necessity of 
multiple comparisons aiming to provide a more comprehensive picture of endothelial 
(dys)function and monocyte levels/phenotype. Also the study does not include a control 
group of healthy subjects of White origin, thus making difficult speculations on whether 
the observed ethnic differences are purely HF-related or persist from the premorbid state. 
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Inter-ethnic comparisons are also limited by a single geographic location of the study site, 
which may thus be biased due to the relatively selective nature of migration processes. 
Also inter-ethnic cultural diversity (e.g., reflected by nutritional habits) could affect the 
study results irrespectively of the ethnicity-related genetic background per se. This could 
also be due to possible variations in health behaviours, for example, reliance of medicine 
vs. religious believes, compliance with medications.  
 
Admittedly, majority of the patients with HF from SA and AC origins represents the first 
generation of migrants to the UK with many such subjects derived from less developed 
regions, with suboptimal maternal nutritional access. These prenatal and early postnatal 
differences are likely to lead to some degree of epigenetic changes, which is evident from 
previous data on higher prevalence of cardiovascular risk factors and features of 
endothelial dysfunction in apparently healthy subjects of SA origin as compared to the 
White population (discussed in Chapter 2. Literature review). Accordingly the observed 
ethnicity-associated differences in parameters of endothelial dysfunction and monocyte 
subsets should be considered as a complex effect of genetic, epigenetic, environmental and 
behavioural differences attributed to a particular ethnic group.  
 
6.3. Overall conclusion 
 
Systolic HF in SAs is associated with significant abnormalities of the endothelial function 
and cellular markers of inflammation and repair. A number of significant ethnic 
differences exist in parameters of endothelial function, characteristics of blood monocyte 
subsets and EPCs among HF subjects.  
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The findings further advance knowledge about the role of extracardiac factors in the 
pathogenesis of HF. This is likely to reflect the multiple roles the endothelium is playing in 
the regulation of the circulation. Also it is increasingly recognised that a fine balance 
between detrimental (e.g., excessive inflammation) and reparative factors (e.g., appropriate 
levels and activity of EPCs and ‘reparative’ monocyte subsets). The study finding provide 
further evidence of such dysbalance in HF, which may have specific features in HF 
subjects of different ethnic origin and indicates the presence of significant ethnic 
differences in the pathogenesis of HF. 
 
6.4. Future research and implication for practice 
 
Despite significant advances in the management of chronic HF during the last decades this 
disorder still poses a major threat to public health with a very poor individual outlook. 
Further developments in this field would require even better understanding of the complex 
disease pathology (e.g., involving peripheral vascular abnormalities). Future directions in 
the management of existing HF should perhaps be focused on cardiac repair aiming to 
reverse unfavourable cardiac remodelling and, ideally, to restore impaired myocardial 
contractility.  
 
In the thesis study I show prominent abnormalities of microvascular endothelial function in 
stable HF which are likely to contribute to chronic tissue hypoperfusion, particularly 
during physical activity, when appropriate vasomotor endothelial response is particularly 
important. 
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Accordingly it is tempting to know the impact of impaired microvascular function on 
physical tolerance (e.g., shortness of breath, and fatigue). This should be tested in a clinical 
trial where physical tolerance is objectively measured (e.g., by cardio-pulmonary exercise 
testing).  
 
It is still unknown how the status of microvascular endothelial function affects progression 
(both from the point of view of symptoms and cardiac deterioration) and outcome 
(mortality or need for HF-related hospitalization) in patients with HF. The answers to these 
questions should be obtained in prospective longitudinal studies. 
 
The pathogenic and prognostic roles of microvascular endothelial function should ideally 
be confirmed by specific interventions aiming at the restoration of the microvascular 
endothelium. Admittedly pharmaceutical agents strictly specific to the microvascular 
endothelium are lacking at present. Potential ‘pleiotropic’ benefits of existing medicines 
(such as statins, or inhibitors of the renin-angiotensin-aldosterone system) or exercise 
rehabilitation towards the microvascular endothelium could be difficult to separate from 
other effects of these interventions. However, if prospective clinical trials showed a 
significant and independent pathogenic and prognostic role of the microvascular 
endothelial function in HF it could become a target for future endothelium-specific 
therapies. Obviously such interventions would need to be validated/tested in appropriate 
experimental models prior to their clinical assessment. 
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The clear advantage of the laser Doppler-based method of measurement of microvascular 
endothelial function used in my study is its non-invasiveness and simplicity. It thus may 
become a surrogate marker of generalized (i.e., not only cutaneous) microvascular 
dysfunction. The next step in the exploration of such possibility would be direct 
comparisons of cutaneous laser Doppler-bases tests with (semi)invasive measures of 
microvascular dysfunction in other tissues (e.g., angiography-based methods, or 
contrastechocardiography with dipyridamole test for assessment of myocardial perfusion).  
 
In my study I observed significant ethnic differences in micro- and macrovascular 
endothelial function, and in several parameters associated with reparative potential of 
monocyte subsets and monocyte-derived EPCs. The clinical significance of these findings 
should be confirmed in prospective clinical trials employing different techniques of cardiac 
imaging to evaluate possible changes in cardiac geometry, function, and vascularization. 
These studies should prove or exclude whether the observed ethnicity-related changes in 
the vascular and monocyte parameters are linked to the ethnicity-related differences in the 
disease progression and outcome. If the last hypothesis is correct it would be necessary to 
identify genetic factors and exact molecular mechanisms which drive those ethnicity-
related differences. 
 
This thesis study showed a significant increase in the levels of monocyte-derived 
microparticles in patients with systolic HF where they were significantly associated with 
poor LV contractility. In the light of the emerging evidence suggesting the role of 
circulating microparticles as inter-cellular messengers of biological signals (discussed in 
Chapter II) the pathological and prognostic roles of monocyte-derived microparticles 
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should be explored in prospective studies. In addition to microparticle enumeration, their 
phenotypic characterization and assessment of their contents (e.g., proteins, RNA) should 
be investigated in relation to HF and its progression. The relative simplicity of 
microparticle enumeration makes them potentially attractive prognostic biomarkers. 
The results of my study showed prominent differences between the three monocyte subsets 
in terms of their phenotype, function, and bone-marrow vs. peripheral blood distribution. 
However the exact biological role and potential clinical utility of the minor monocyte 
subsets (i.e., Mon2 and Mon3) are still far from being clear. Different in vitro and in vivo 
experiments need be done to address this. For instance, angiogenic and cardiac reparative 
potential of different monocyte subsets could be explored by their delivery to animal 
models of ischaemic/myocardial damage. The experiments should be designed to be able 
to test (i) the ability of individual monocyte subsets to directly differentiate into functional 
vascular cells or myofibroblasts, (ii) their capacity to augment reparative properties of 
other cardiac and vascular cells, for example via release of angiogenic and growth factors.  
 
Further research is also needed to establish the mutual developmental relationship between 
the monocyte subsets and factors regulating their mobilization to the peripheral blood from 
bone marrow and their homing to tissues. Obtaining data on thein vivo functional role of 
human monocyte subsets is particularly important as there are major differences between 
human and mouse monocyte subsets and direct extrapolation of animal findings to humans 
may be inappropriate. The development and utilization of the novel approaches of non-
invasive imaging able to track human monocyte subsets in vivo would be of great 
advantage for such analysis. 
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Apparently the number of potentially interesting future studies related to the thesis findings 
is not limited to the brief outline above, but the design and details of such analyses should 
probably represent a continuum built on gradually accumulating evidences, hopefully 
supporting clinical the utility of my study results.  
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APPENDICES 
Appendix 1. Standard Operating Procedure 103 ‘Flow-mediated dilation’ 
SOP 103 
Flow Mediated Dilatation (FMD) 
 
Updated by Alena Shantsila November 2009 
 
Background 
Endothelium-dependent vasodilatation of the brachial artery occurs in response to 
increased flow. This response can be assessed using ultrasound (1-3). A blood pressure 
cuff is used to temporally occlude brachial artery. After cuff release, increased blood flow 
down the brachial artery causes nitric oxide (NO) release from the endothelium and 
consequent endothelium-dependent brachial artery vasodilatation. The endothelium-
independent response can be assessed by administration of a systemic NO donor such as 
GTN. Abnormality in FMD have been found in patients at risk of atheroma even before 
evidence of actual atheroma formation, and it is also a predictor of future cardiovascular 
events in hypertension and coronary artery disease (4). Tremendous interest exists in 
determining the clinical utility of brachial artery FMD. It has been hypothesised 
hypothesized that endothelial function may serve as an integrating index of risk factor 
burden and genetic susceptibility, and that endothelial dysfunction may serve as a 
preclinical  marker of cardiovascular disease (5). The technique is particularly well suited 
for study of the earliest stages of atherosclerosis in children and young adults, thus 
providing maximal opportunity for prevention. 
 
It is critical to point that numerous factors affect flow-mediated vascular reactivity, 
including surrounding temperature, food, drugs, sympathetic stimuli, period of menstrual 
circle in women, among others. Therefore, subjects should fast for at least 8 to 12 h before 
the study, and they should be studied in a quiet, temperature-controlled room. All 
vasoactive medications should be withheld for at least four half-lives, if possible. In 
addition, subjects should not exercise, should not ingest substances that might affect FMD 
such as caffeine, high-fat foods and vitamin C or use tobacco for at least 4 to 6 h before the 
study. The investigator should be cognizant of the phase of the subject’s menstrual cycle, 
as it too may affect FMD (6). Vasomotor endothelial function has well demonstrated 
diurnal variations. Accordingly all measurements of FMD within particular study have to 
be perform at uniform time.  
 
FMD assessment in patients with systolic blood pressure above 160 mm Hg has limited 
informativness a should be avoided. Never attempt to do the test when BP 180 mmHg or 
above. 
 
Equipment 
 
You will need: 
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Patient (!) 
Vascular scanner free (for around 45 minutes at least) 
Echo jelly (the tubs are refillable) 
ECG monitoring dots 
Manual sphygmomanometer  
GTN spray 
 
Preparation 
 
a. Allow the subject to rest in the room for about 15 minutes before scanning 
b. Explain details of the procedure and possibility of some discomfort during arm 
compression  
 
3. Slelect the probe on echo machine  
a. Turn on echo machine (switch on the front of the machine, towards the left) 
b. Press ‘patient data’ on the echo machine console (towards the left) and type necessary 
patient details (study ID, age, etc.), then press ’close’ 
c. Place the ECG leads on the patient, connect with ECG cable 
d. Press ‘present/trasducer’ on left side of vertical panel of echo machine console 
e. Select ’L11-3’; then select ‘arterial limb’ 
f. Press ’physio’  then ’next’ on left-side panel  and turn ECG on 
 
4.  Place the Manual sphygmomanometer cuff on the forearm  
 
5. Label the image (using the ‘annotation’ button on the left of vertical panel of the 
console) as ‘baseline’ using  Keybord under cosole.  
 
6. The subject is positioned supine with the arm in a comfortable position for imaging the 
brachial artery. The brachial  artery is imaged above the antecubital fossa in the 
longitudinal plane below the blood pressure cuff. Identify the artery with colour doppler if 
necessary (button marked ‘CFM’ on right panel of echo machine) – arterial flow is 
obviously pulsatile and typically very bright on colour flow (it may be blue or red); once 
identified as arterial, it is easiest to turn colour flow off again in order to see the arterial 
wall clearly. A linear segment with clear anterior and posterior intimal interfaces between 
the lumen and vessel wall is selected for continuous 2D grayscale imaging.  
 
7. Press ‘zoom’ button, choose desirable visualisation of the artery and press ’zoom’ 
buttom again.  
 
8. During image acquisition, anatomic landmarks such as veins and fascial planes are noted 
to help maintain the same image of the artery throughout the study. This makes it much 
easier to be sure you are measuring the same segment in subsequent measurements. It’s 
also worth finding a vessel that is easy to identify because the later scans are time 
dependent and you will be under some pressure to find the same vessel quickly. 
 
9. Freeze the image (button to the right of the console) when you have a clear segment seen 
for several seconds. Scroll backwards and forwards (using the tracker ball) to use the R 
wave of the  ECG cycle so that subsequent readings are taken in the same part of the cycle, 
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and so that the image quality is optimal. Press ‘acquire’ to save the image (allows someone 
else to analyse the image without your measurements being visible); At least 3 cardiac 
cycles should be saved at approximately 30 sec, 1 min, 2 min, 3 min after blood pressure 
cuff decompression. 
 
10. Once the image for analysis is chosen, the boundaries for diameter measurements (the 
lumen-intima or the media-adventitia interfaces) are identified manually with electronic 
calipers or automatically using edgedetection software. Using ‘caliper’ button, measure 5 
readings from leading edge to leading edge of the vessel.  Move the cross cursor to the first 
point, press the white buttom on the left of the trackball once you are happy with position, 
then move to the second area and press the same button again. The machine then displays 
the distance. Select repeat measurement to take 5 readings. Once you have the readings 
save the  image with the readings visible; take the average of the 5 readings as your 
measure. The variability of the diameter measurement is greatest when it is determined 
from a point-to-point measurement of a single frame, and least when there is an average 
derived from multiple diameter measurements determined along a segment of the vessel. 
Different people use different places to measure: the important thing is to be consistent 
between readings and between patients. In the figure, both A and B are acceptable so long 
as the same method is performed in all patients. 
 
 
11. Blood flow is estimated by measuring the peak or time-averaging of the pulsed 
Doppler velocity signal obtained from a midartery sample volume. 
 
12.. Inflate the cuf for at least 20 mm Hg above systolic blood pressure to occlude arterial 
inflow for 5 min.; warn the patient that it will be uncomfortable! Start timing. Keep an eye 
on the pressure in the sphygmomanometer: it may drop a little with time and you will need 
to by pumping more air into the cuff. You can now unfreeze the echo image; delete the 
label with the ‘erase all text’ button to the left of the console. Then label the image 
‘hyperaemia’ or similar in preparation for the next image. 
 
13.. At 5 minutes, deflate the cuff rapidly. A midartery pulsed Doppler signal is obtained 
upon immediate cuff release and no later  than 15 s after cuff deflation to assess hyperemic 
velocity. The ration of blood velocity prior and after the compression serves as a measure 
of the stimulus (sheer stress) applied at the test. It should be similar for all study groups 
analysed. 
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14. Make repeated scans during 3 min. after cuff deflation. It is worthwhile looking for the 
artery soon (immediately) after cuff deflation so that you can be sure to find the artery 
within this time, then holding the probe steady until your 3 min. are reached. Try to 
identify the same segment as you scanned for the first baseline (compare the image you are 
getting with the image displayed on the mac which you sent to echopac), then freeze the 
image and repeat the measurement as before, again using the R wave of the ECG cycle.  
 
15. Wait 15 minutes to allow the effect of the FMD to wear off. (You can use this time to 
gather other information such as history, drug use, or measuring other things such as 
carotid IMT, delete the label with the ‘erase all text’ button to the left of the console. Then 
label the image ‘GTN’ or similar in preparation for the next image.; make sure you are not 
doing anything that might upset vasomotor function though (such as blood pressure, 
venesection). GTN should not be administered to individuals with clinically significant 
bradycardia or hypotension. 
 
16. Repeat blood flow velocity measurement by the pulsed Doppler.. 
 
17. Give 2 puffs of sublingual GTN (warn the patient they may get a mild headache / feel 
dizzy).  
 
18.  Peak vasodilation occurs 3 to 4 min after GTN administration; images should be 
repeatedly recorded during this time,using synchronisation by the R wave of the ECG 
cycle.  
 
19. The acquired images are stored in the buffer and need to be saved on the workstation 
XCelera - press ’end exam’ button on the console. 
 
20. Remove sphygmomanometercuff from the arm, remove  the ECG leads from the 
patient, dicconnect from ECG cabel. Clean jelly off the patient and thank him/her! 
 
21. Clear up the room: tidy up the examination couch, turn off equipment if not going to be 
used shortly. Bear in mind that the equipment is expensive and used by a lot of people. 
 
Potential problems 
 
This technique takes practise – According the current guidelines on FMD assessment it is 
recommended that at least 100 supervised scans and measurements need to be performed 
before independent scanning and reading is attempted; 100 scans per year should be 
performed 
to maintain competency. This recommendation is based in part on criteria for ultrasound 
proficiency established by the Intersocietal Commission for the Accreditation of Vascular 
Laboratories.  
 
It is worth trying quite hard to get a good image, and be scrupulous in technique in trying 
to identify the same segment of artery each time. The second scan (FMD / GTN scan as 
opposed to baseline scans) is a bit pressured as there is a time factor involved. As 
previously mentioned, try to find the relevant segment of artery early to give you more 
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time to look. If you don’t have time to actually measure the vessel diameter before the next 
reading is due, you can measure it later from saved images so don’t worry.  
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Appendix 2. Standard Operating Procedure 107 ‘Measurement of 
microvascular endothelial function’ 
 
Standard Operating Procedure 107 
Measurement of microvascular endothelial function 
 
 
Written by Will Foster and Andrew Blann August 2005 
Updated by Eduard Shantsila and Andrew Blann December 2008 
 
 
Health and Safety / COSHH 
The only major hazard in this procedure is the risk of damage to the retina due to the 
laser. Therefore avoid eye contact. Some subjects may be allergic to Ach & SNP. Some 
may respond adversely to the electrical current. Obtain consent. 
 
The function of large arteries such as the aorta, brachial and femoral can be assessed by 
their dilation response to changes in blood flow (i.e., flow mediated dilatation, FMD). This 
assessment is not possible in the study of small arteries and arterioles, often within 
vascular beds such as the skin. However, the recent development of perfusion imaging can 
assess these small arteries. The present SOP is to enable this assessment. 
 
Introduction 
 
Laser Doppler perfusion imaging is based on four separate technologies  
(a) the Doppler shift phenomenon (change of the wavelength of the moving object 
proportionally the speed of the object, i.e., blood cells),  
(b) the ability of the Laser imaging system to detect this phenomenon,  
(c) perfusion of skin with pharmacologically active drugs (acetylcholine [Ach] and sodium 
nitroprusside [SNP]) that will alter small blood vessels close to the surface of the skin, and  
(d) the electrical delivery of these agents into the skin (ionotophoresis).  
 
Thus the method allows an evaluation of the perfusion of surface tissues (e.g. skin) in real 
time scale. Changes in skin blood flow can be determined in response to various stimuli. 
Vasoactive substances can be used to alter the flow of blood in the skin vessels if delivered 
by an appropriate means. Iontophoresis is a delivery method that uses the charge of a 
charged vasoactive substance to allow it to be driven through the skin using an electric 
current. Sodium nitroprusside is a vasoactive substance with a negative charge that can be 
delivered through the skin to the microcirculation; once it has passed through the skin it 
acts as a nitrate donor and therefore acts directly on the vessel’s smooth muscle to cause 
vasodilatation. Thus it is independent of the endothelium in its vasodilatory action. 
Acetylcholine on the other hand is a positively charged molecule that can similarly be 
delivered to the subcutaneous tissues by iontophoresis but it acts on the endothelium rather 
than on the smooth muscle wall, causing endothelial release of nitric oxide. Thus 
acetylcholine acts in an endothelium-dependent way on the vessel wall to produce 
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vasodilatation. The vasoactive substances are provided close to the skin in a small 
perfusion chamber that also acts as an electrode. A second electrode is required to 
complete the circuit, and this is attached to a nearby section of skin. 
 
1. Test solutions 
Quantities of 2% acetylcholine chloride (Ach) and 0.1% sodium nitroprusside (SNP) [both 
from Sigma-Aldrich] must be prepared in sterile filtered distilled water (Sigma-Aldrich) 
and appropriate volumes (approximately 1ml aliquots) stored in stored top plastic tubes a 
fridge at 4°C up to 1 month. These solutions are transferred from the plastic tubes to the 
iontophoresis chamber with a plastic disposable transfer pipette (stores in preparation room 
and the laboratory). Ensure the reagents are allowed reach room.  
 
2. Patient preparation 
2.1. Use right forearm, in should be clean. 
2.2. Ask the patients to put it on a supportive cloth pad on a table with the participant 
sitting on a chair in a constant room temperature room. Make sure the participant is 
comfortable and the hand is stable. 
2.3. Remove any hair from the forearm gently with a single-use razor. 
2.4. Use a Skin Prep (e.g., Skintact) gently to prepare area of the scans, leave the patient to 
rest for 20 minutes. 
 
3. Preparation of the Laser Doppler Flowmeter, Iontophoresis and Data acquisition  
(Laser Doppler Perfusion and Temperature Monitor DRT4 with Iontophoresis Controller 
Min1-e, Moor Instruments, Moor Instruments, Axminster, Devon, UK). 
 
3.1. To switch on the LD, press the black buttons on the main Laser Doppler block, and on 
Iontophoresis Controller Min1-e, wait for 10 minutes to let the laser warm-up. 
3.2. Put two LD chambers connected to the Iontophoresis controller on the front forearm, 
15 cm apart using single-use sticky rings provided by Moor Instruments. The first chamber 
is placed to the upper forearm, the second to the lower forearm. 
3.3. Connect LD leads to the chambers: Channel 1 to the top chamber, Channel 2 to the 
bottom chamber. 
3.4. Add Ach solution (~1 ml) to the top chamber using a plastic Pasteur pipette; add SNP 
solution (~1 ml) to the bottom chamber in a similar way. 
3.5. Press top blue square button (RUN) on the LD block, make sure there is a good signal 
from both channels, press the same button again. 
3.6. Now the LD will automatically acquire the baseline skin flow for 1 min, following by 
delivery of the electric current for another 1 min, and further following by 10 min of 
recording of post-stimulation signals. 
3.7. The chambers can now be removed, and cleaned, a hand washed. 
 
4. Data Analysis. 
4.1. Use MoorSoft/DRT4 v. 2.0 software installed on your computer. 
4.2. Connect DRT4 to the computer using a grey cable 
4.3. Start the software. 
4.4. Press ‘Download stored data from DRT4’ button on the software panel and indicate a 
folder where the data should be stored. 
4.5. Open a file in the scan data using ‘File’ – ‘Open’. 
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4.6. Use ‘Edit’ – ’Mark’ – ‘Insert’ to put marks at the beginning of the test, beginning of 
the stimulation, the end of the stimulation, the end of the scan. It is very obvious where to 
put them as DRT4 places small arrows to point those at the time of acquisition. 
4.7. Press ‘Analyse’ – ‘New Statistics’ and the measurements on the flow before and after 
the stimulation will be automatically made. 
4.8. Use ‘Analyse’ – ‘New report’ and ‘Print’ options to obtain a hard copy of your results. 
4.9. Put results on the mean flow before and after the stimulation into your database for 
further 
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Appendix 3. Standard Operating Procedure 197 ‘Enumeration of monocytes 
sub-populations by flow cytometry’ 
 
 
 
STANDARD OPERATING PROCEDURE 197 
 
Enumeration of monocytes sub-populations by flow cytometry 
 
ES Heart Failure 
 
N.B. Use of the flow cytometry is forbidden 
Without having been officially trained 
 
Required pre-training 
 
SOPs on venepuncture and on  good clinical practice 
 
SOP 195 – General operation of the flow cytometer 
 
SOP 171 – Operation of the Bayer Advia 
 
Contents 
 
Introduction   Page 1 
 
Materials and suppliers Page 2 
 
Detailed Method  Page 4 
 
Interpretation   Page 7 
 
 
1. Introduction 
 
Monocytes are large mononuclear cells (MNCs) derived from the bone marrow but on 
transit to the tissues where they seem likely to become semi-resident macrophages. 
Traditionally, they have been defined by glass-slide morphology, size, and scatter, but we 
now have the ability to define monocytes by cell surface molecules, using the FACS. For 
example, one sub-population bears CD14, another other bears CD16.  
 
Endothelial progenitor cells (EPCs) are of potential importance in the physiological 
response to endothelial damage. This has led to speculation that the ability to enhance their 
numbers may allow for a novel approach to modulate various disease states. The definition 
of these cells has continued to evolve.  Currently cited markers include CD34, CD133, 
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CD309, VEGFR1 and, notably, CD14.  Importantly, as these cells mature, the cell surface 
markers change. In addition, other cells such as monocytes and tissue resident stem cells 
may cross-differentiate, adding to the complexity of defining this cell population. 
 
This SOP describes enumeration of cells staining for any combination of: 
 
CD34 - widely distributed on stem cells, haematoblasts, progenitor cells etc 
 
VEGFR1. Said to be present specifically on endothelial cells but reported by some to be on 
monocytes   
CD16 – this is an antigen found on the Fc receptors FcγRIIIa and FcγRIIIb. These 
receptors bind to the Fc portion of IgG antibodies. CD16 is present on natural killer cells, 
neutrophil polymorphonuclear leukocytes, monocytes and macrophages. 
 
CD14 – a receptor for LPS present on monocytes, macrophages and neutrophils 
 
This SOP demands a monocyte count, itself derived from the full blood count, from the 
Bayer Advia. 
 
 
2. Materials and Supplier contact details: 
 
Micro-reagents are kept in the fridge behind the door or on nearby shelves. Bulk fluids in 
boxes on other shelves and beneath the benches. 
 
BD “FACS Flow” Running solution [Becton Dickinson, Catalogue No. 342003] 
10L containers. 
 
BD “FACS Clean” Cleaning Solution [Becton Dickinson, Catalogue No. 340345]  
 
3 ml BD Falcon tubes [Becton Dickinson, Catalogue No. 352054] 
 
BD Lysing solution [Becton Dickinson Catalogue No. 349202] 
 
Sterile Phosphate Buffered Saline solution, 0.5L bottles [Invitrogen Ltd, Catalogue No 
20012-068] 
 
CD14 -PE conjugated monoclonal antibody - 100 tests [R&D Systems Europe Ltd, Cat No. 
FAB3832P] 
 
CD16 – Alex-flour 488 conjugated monoclonal antibody - 100 tests [ABD Serotec, 
Cambridge] 
 
CD34 –PerCP conjugated monoclonal antibody - 50 tests [Becton Dickinson, Catalogue 
No. 345803] 
 
VEGF R1-APC conjugated monoclonal antibody - 100 tests [R&D Systems Europe Ltd 
Catalogue No. FAB321A]    
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Clear pipette tips [Alpha Laboratories LimitedCatalogue No FR1250 1250ul Fastrak Refill 
NS]  
 
Yellow pipette tips [[Alpha Laboratories LimitedCatalogue No FR1200 200ul Fastrak 
Refill NS]  
 
 
Remember to dispose of all material thoughtfully.  
 
 
 
 
3. Detailed method 
 
FIRSTLY 
 
 
 
3.1 General Preparation 
 
3.1.1 Lysing solution.   
 
Make from 50ml concentrate 10x FACS Lysing Solution (kept at room temperature). 
Dilute with 450ml distilled water in ½ litre bottle. This solution should not be used if it is 
older than a month (kept at room temperature). 
 
 
3.2 Blood sample preparation 
 
Gently vortex the EDTA or citrate blood sample.  Take 0.1 mL of whole blood with yellow 
tip pipette and add to a 3 mL BD Falcon tube.   
 
Add 10µL each of CD14, CD16, CD34, VEGFR1 fluorochrome labelled antibodies (see 2) 
with a micropipette.  Flush into and out of pipette tip to ensure thoroughly mixed and then 
gently vortex. Incubate in the dark at room temperature for 20 minutes. 
 
Add 2 ml pre-diluted BD lysing/fixing solution (see 3.1.1) with a clear tip using the 1ml 
pipette. Incubate for 10 minutes on bench in the dark. Then centrifuge 300g for 5 minutes. 
 
 
For all WBCC analyses a full blood count (Bayer Advia) must be obtained  
on the same sample of blood that will be used for flow cytometry.  
 
This is essential in order to back-calculate  
monocyte numbers and thus sub-populations to whole blood 
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Decant supernatant and add 3 ml of PBS (good quality PBS in the fridge) solution. Vortex 
gently to resuspend pellet. Then centrifuge once again at 300g for 5 minutes. 
 
Add 0.2 ml of PBS solution and flush into and out of pipette tip, followed by gentle vortex 
to ensure thoroughly mixed. Store sample in dark at 4ºC until ready to be processed (note 
sample must be processed within three days). 
 
 
3.3 Start up procedure [See SOP 195 on General Operation] 
 
Part 1 – restoring reagents and preparation 
 
Switch on Flow Cytometer by pressing the green switch on the right hand side.  The Apple 
Macintosh computer must also be switched on, but only 15 secs after the Flow Cytometer, 
or the link will not be recognized. Open the reagent panel on the left hand side (LHS) by 
pulling the lid towards you. On the left is the sheath fluid reservoir, in the middle are 
switches and tubes, on the right is the waste reservoir. 
 
Carefully unscrew the top of the sheath fluid reservoir and fill with sheath fluid (in large 
box on shelf at head height – use plastic tube) to the level indicated on the top right hand 
corner of the reservoir (little plastic bar). 
 
Carefully disconnect/unscrew the waste container and empty contents down sink with 
plenty of water.  Add approximately 40ml concentrated household bleach along with 360 
ml of distilled water and reconnect container (plastic tubes available). 
 
Pressurise the unit (takes about 20-30 sec) by moving the black toggle switch “Vent 
Valve” switch to the down/front position. It is located at the rear of the middle section 
between the sheath fluid tank and the waste container. 
 
Air must be excluded from the tubing system by flushing it out. Any excess air trapped in 
the sheath filter can, if necessary, be cleared by venting through the bleed tube (the dead-
ended rubber tube with a cap). 
 
Close the drawer 
 
Part 2 - cleaning the machine 
 
Ensure that a 3 ml Falcon tube (labelled 1) approximately 1/3 full of distilled water is 
positioned over the sample injection port (SIP) – a needle sheath - and that the swing arm 
is positioned under this tube.  Press the prime button on the panel.  When the system enters 
“standby” with in 30 seconds then press the “prime” button again. When the standby and 
low buttons comes on again then remove tube 1. We will re-use tube 1 in the shut down 
procedure. 
 
Prepare a second falcon tube (labelled 2) with FACS-clean (should contain about 2750 
microliters so that when inserted on to the sip it doesn’t touch the O ring). This is a smaller 
box on a shelf at above head height and above the bigger box of sheath flow fluid 
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Present tube 2 to the SIP and place support arm underneath it. Press the buttons “run” and 
“high” on the panel at the same time, and run the FACS-clean in falcon tube 2 with 
supporting arm to left or right open for one minute. Then return the supporting arm to 
underneath the tube and “run-high” five minutes.  This process ensures the machine is 
clean prior to running samples and helps minimise blockages.  
 
Return to falcon tube 1 with distilled water. Repeat the above step 9 with this distilled 
water tube. 
 
Press the ‘STANDBY’ and ‘LOW’ button on the system. 
 
The machine is now ready to run samples. 
 
 
 
NB:           FACS COMP may need to be run 
 
 
 
3.3 Running blood samples. 
 
Note. This must be learned from an experienced operator and you must seek scientific staff 
support to clear queries as the intricacies of the Cell Quest software are complex. 
 
Click on the ‘Data 1’ folder on the desk top  
Click on the ‘Monocyte Protocols’ folder. 
Click on the ‘Monocyte Eduard’. 
This will open the CellQuest Pro software with the instrument settings. 
 
Click ‘Connect to Cytometer’, located under the ‘Acquire’ menu. 
 
Under the ‘Cytometer’ menu, click ‘Instrument Settings’.  The window appears 
displaying the compensations and threshold. Change settings by clicking on the open icon 
on the window which displays the folders select ‘Sid’ folder with in the ‘Data 1’ folder and 
click on the ‘Instrument settings’ in this folder. This will update the system settings to the 
preferred settings for the acquisition. Click ‘Set’ on the window and by clicking ‘Done’ 
the windows disappears.  Make sure to click ‘Set’ prior to clicking ‘Done’. 
 
Click the ‘Acquire’ menu once more and click ‘Show browser’.   
 
Click directory-‘Change’ in order to specify the location folder. 
 
Initial user must create new folder by clicking on ‘New folder’ and by entering the title of 
the folder and choose that folder. 
 
Change the custom suffix to the preferred title and number for data and click ‘OK’. 
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Untick the setup box (by clicking on it) in the browser-EPC Acquisition window. Now 
insert your sample and press “RUN” and “HIGH”.  
 
Each sample is now ready to run.  This should be mixed thoroughly and transferred to a 3 
mL BD Falcon tube.  Open swing arm at bottom right of the cytometer and replace the 
Falcon tube with the sample to be run.  Replace the swing arm under the Falcon tube. 
 
Press the buttons ‘Run’ and ‘High’ on the control panel of the cytometer.  
 
Click ‘Acquire’ on the browser menu.  The sample will now run for ~ 2-3 mins.  Cell 
events will be displayed on the screen throughout the process (n.b. the  higher the cell 
density, the more rapidly the cells will be acquired). 
 
Click on ‘Counters’ under the ‘Acquire’ and observe the events per second which varies 
from 500 to 5000 depending on various factors. The objective is to acquire 200,000 events 
for analysis. 
 
Observe the acquisition closely since the system may get blocked (which happens very 
rarely) and the plots may not show any progress and the counters may not show any events 
per second. 
 
Click pause on the acquisition window and replace the sample from the SIP with sterile 
PBS and run for 20/30 seconds minutes (clicking acquire wouldn’t change the results) and 
then continue acquisition with your sample on the sip. If the problem still persists please 
inform the senior scientific staff and seek assistance. 
 
After attaining the target events the analysis stops and the file number changes 
automatically. Click on ‘print’ under the ‘files’. Confirmation window appears again click 
on print. 
 
Vortex your next sample gently. Re-programme the software with a new sample number, 
and repeat the step 11. 
 
If cytometer not ready message appears open the drawer and check the fluids level which 
may need refilling or emptying. The system may run out of Sheath fluid if there are more 
samples. 
 
Be absolutely sure you have downloaded your results on to paper. Keep this paper safe. Do 
not assume the computer will keep the results safe, even if you have directed it to do so. 
Obtain all the raw data (cell numbers) and apply them into the specific spreadsheet you 
have designed for your project. The same spreadsheet should have the WBC results from 
the Advia. 
 
 
3.4 Shut-down procedure   [See SOP 195 on General Operation] 
 
In this section we re-use tubes 1 and 2 with distilled water and FACS clean respectively. 
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Install FACS Clean tube 2 over the SIP needle. Press button ‘High’ and ‘Run’ on the 
panel. Leave the support arm out at 90 degrees for approximately 1 minute.  This cleans 
the outer portion of the aspiration sheath.  The fluid will be rapidly aspirated, so ensure that 
the tube doesn’t empty completely. 
 
Now replace the side arm under the Falcon tube and allow to run for approximately 5 
minutes.  This cleans the inner portion of the aspiration sheath and the FACS machine 
itself. 
 
Repeat steps 2 and 3 with the distilled water tube 1.  Once step 3 is complete, Leave the 
sheath in falcon tube  1 containing distilled water and press ‘STANDBY’. 
 
Open the reservoir draw and depressurize the machine by moving the “Vent Valve” toggle 
switch to the up/rear position.  The machine will hiss as it depressurizes. 
 
Leave the machine on for a further 5 minutes to allow the laser lamp to cool.  Turning the 
machine off prematurely will result in the lamp cracking. 
 
Finally power down the FAC-Scalibur (green button) and Apple Mac. 
 
Clean up ! 
 
Note: * IF THE SYSTEM IS TO BE USED AGAIN ON THE SAME DAY… 
 
LEAVE THE SYSTEM ON STANDBY and then 
 
DEPRESSURISE THE SYSTEM. 
 
 
4. Interpretation of plots 
 
For the first ten or so analyses you will need to have all this explained to you by Dr Blann 
 
Collect your plots from the Advia (Figure 1). Obtain the monocyte count (0.40 x 10
3
/µL = 
0.4 x 10
6
/µL), and the lymphocyte count (1.59 x10
3
/µL = 1.59 x10
6
/mL). Therefore Advia 
defined mononuclear cells (MNCs) = 1.99 x10
6
/mL. Hence the monocytes make up 
0.4/1.99 = 20.1%. Similarly the % MNC population in terms of the entire WBCC 
according to the Advia should be 1.99/6.11 = 32.57%. Remember these numbers.    
 
Now the FACS plots (Figs 2 & 3, but focussing on Fig 2). The top left initial plots show 
the FSC/SSC plot (forward and side scatter, all in black). This is needed to gate the 
presumed monocyte and lymphocyte regions, i.e. = mononuclear cells (MNCs).  
 
Immediately below the figure is a set up data showing the date of the analysis and total 
WBCC events (e.g.200,000). Below this are the number of gated monocytes (e.g. 12,682) 
and number of gated lymphocytes (e.g. 45,445). Sum this to give total number of gated 
MNCs (= 58,127). Note that you can compare the proportion of the Advia defined 
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monocytes/MNCs (20.1%, from para 1 above) with the same data from the FACS 
(12,682/58,127 = 21.8% - note the very good agreement, <10%). 
 
 
1. Gating monocyte subpopulations (Figure 2 as a template) 
 
The central top plot is monocytes by CD14 (horizontal axis) and CD16 (vertical axis), and 
below it are the numbers, the largest e.g. 12,682 is populated from the FSC/SSC window. 
Note the three gates:  
 
Gate 1 is CD14 high CD16-ve. The grid analysis gives 9554 events (75.34%).  
Gate 2 is CD14 high CD16 +ve. By the same token 1354 events = 10.68% 
Gate 3 is CD14 dim CD16 +ve. Ditto 1310 events = 10.33% 
 
You will then need to translate this to meaningful cell biology by converting to cells/ml of 
whole blood, which is why you need the WBCC from the Advia. This section will shortly 
inform additional subanalyses. 
 
2. EPCs from the total MNC population 
 
Next – top right. This is the total MNC population (i.e. all 58,127 events) classified by 
VEGFR1 and CD34 staining. Note the quadrant…. 
 
UL (MNCs VEGFR1+ve/CD34-ve) is 3679 events from 58127 = 6.33% 
UR (MNCs VEGFR1+ve/CD34+ve) 180/58127 = 0.31% = EPCs (?) 
LL (MNCs VEGFR1-ve/CD34-ve) is 53996/58127 = 92.89% 
LR (MNCs VEGFR1-ve/CD34+ve) is 272/58127 = 0.47% 
 
As before, convert to cells/ml using the MNC and WBCC counts from the Advia. N.b. the 
EPC definition here mimics that of the prostate protocol, but in the latter, they were all 
CD45-ve – not here, so beware! 
 
3. Monocyte subanalyses 
 
Bottom left gives 9554 CD14+ve/CD16-ve monocytes from gate 1 analysed by VEGFR1 
and CD34. Check this by looking at the number of events. Observe the quadrants: 
 
UL = VEGFR1+/CD34- : 2732/9554 = 28.6% of all gate 1 monocyte events 
UR = VEGFR1+/CD34+: 101/9554 = 1.06% of all gate 1 monocyte events 
LL = VEGFR1-/CD34- : 6630/9554 = 69.4% of all gate 1 monocyte events 
LR = VEGFR1-/CD34+ : 91/9554 = 0.95% of all gate 1 monocyte events  
 
Exactly what these cells are depends on your thoughts of what CD34 and VEGFR1 are 
found on. Percent of cells is used calculate the absolute of these cells per 1 ml of blood 
using monocyte numbers from the whole blood sample. Example: The Advia says 0.4 x 
10
3
 monocytes/µl = 400,000 cells/mL. As gate 1 = 9554 events from 12,682 monocyte 
events this is 75.34% so there are 400,000 x 75.34% = 301,360 CD14+CD16-ve 
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monocytes/ml. Of these 301,360 cells/ml, 1.06% are additionally VEGFR1+ve/CD34+ve = 
319 cells/mL 
 
The middle plot gives the 1354 CD14+ve/CD16+ve monocytes in gate 2 stained by 
VEGFR1 and by CD34. Observe the quadrants: 
 
UL = VEGFR1+/CD34- : 715/1354 = 52.81% of all gate 2 monocyte events  
UR = VEGFR1+/CD34+: 41/1354 = 3.03% of all gate 2 monocyte events  
LL = VEGFR1-/CD34- : 587/1354 =  43.35% of all gate 2 monocyte events 
LR = VEGFR1-/CD34+: 11/1354 =  0.81% of all gate 2 monocyte events  
 
The bottom right gives analysis of 1310 CD14dim/CD16+ve cells in th3 3
rd
 gated region 
stained by VEGFR1 and by CD34. Observe the quadrants: 
 
UL = VEGFR1+/CD34- : 52/1310 =  3.97% of all gate 3 monocyte events  
UR = VEGFR1+/CD34- : 6/1310 = 0.46% of all gate 3 monocyte events 
LL = VEGFR1-/CD34- : 1145/1310 = 87.4% of gate 3 monocyte events 
LR = VEGFR1-/CD34+ : 107/1310 =  8.17% of gate 3 monocyte events 
 
 
5. Interpretation of results 
 
Exactly what these cells are depends on your thoughts of what CD34, VEGFR1, CD14 and 
CD16 are found on. A word of warningBe not 100% confident of the interpretation of 
your data. Recall that odd CD molecules may be present on cells other then those you 
presume them to be present upon. 
 
 
6. Validation and quality control 
 
The intra-assay reproducibility of the methods was assessed on six samples of blood, one 
set of three from a healthy male and second set of three from a woman with a history of 
renal and ovarian cancer.  
 
Intra-assay coefficients of variation (CV) are derived from the % results of the different 
subpopulations of monocytes. The initial sorting on monocytes into M1, M3 and M3 give a 
mean CV of 4.75% (n=6). This contrasts well with the CV of the monocyte count on the 
Advia of 6.65% (n=2). CVs for the next level of analysis (all monocytes by plus or minus 
VEGFR1/CD34 grouping gives a mean CV of 6.8% (n=8). 
 
CVs of sub-analyses of the M1, M2 and M3 populations according to VEGFR1/CD34 
class were variable. For M1 median (IQ) CV was 8.5% (3.4-20.6), for M2 it was 9.0% 
(6.2-17.8 and for M3 it was 17.9% (4.1 – 23.4%).  
 
However, this pooling smothers a strong mathematic effect of the raw data. Example, a 
clutch of 95%-97%-99% gives a CV of 1%, whereas the same variance of 10%-12%-14% 
gives a CV of 13.6%. Real time examples from this data set are: 
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Results 50%-96% (n=10) - CV = 2.3% 
Results 10%- 39% (n=6) – CV = 6.7% 
Results 2.2% - 9% (n=9) – CV = 13.7% 
Results <2.2% (n=13) – CV = 17.9% 
 
Thus reproducibility is strongly related to percentages, which may be an argument in 
favour of analysing raw data, and also possibly an argument for not analysis data where 
numbers are small as intrinsically CV is likely to be large and the data therefore unreliable.     
 
 
 
SOP 197: Enumeration of monocytes sub-populations by flow cytometry 
 
 
Signed off………………Andrew Blann……………………8
th
 January 2010……….. 
 
 
 
Figures not electronic: F1 Advia printout: F2 FACS printout (see ADB) 
 
Raw analyses available from ADB 
 
280 
 
Appendix 4. Standard Operating Procedure 190 ‘Enumeration of 
microparticles by flow cytometry’. 
 
 
 
STANDARD OPERATING PROCEDURE 190 
 
Enumeration of Microparticles by Flow Cytometry 
 
Eduard Shantsila, Andrew Blann: June 2010 
 
n.b. Use of the flow cytometry is forbidden  
without having been officially trained 
 
Required pre-training 
 
SOP on venepuncture, good clinical practice 
 
SOP 195 – general operation of the flow cytometer 
 
Contents 
 
1. Introduction   Page 1 
 
2. Materials and suppliers  Page 2 
 
3. Detailed Method   Page 4 
 
4. Interpretation and validation Page 6 
 
 
1. Introduction 
 
Cellular microparticles (MP) are submicroscopic fragments resulting from the remodelling 
of plasma membrane in response to numerous conditions, including activation and 
apoptosis [1]. MPs are generally referred to as 0.1 to 1 µm membrane fragments that often 
expose the anionic phospholipids phosphatidylserine and membrane antigens 
representative of their cellular origin. These characteristics discriminate MP from 
exosomes, which are smaller (<0.1 mm), originate from intracellular multivesicular bodies, 
and differ in antigenic composition. 
 
MP have been shown to have prothrombotic irrespectively from their origin (e.g., from 
platelets, leucocytes, endothelial cells, red blood cells). However, presence of certain 
markers (e.g, tissue factor) on MP surface is substantial additional risk of thrombogenesis. 
Flow cytometry allows identifying and enumerating different types of MP on the basis of 
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their size, surface antigen presentation and employing count beads (for absolute count of 
MP number). 
 
This method describes enumeration of: 
 
CD42b (GPIb)+ microparticles for platelet-derived microparticles; 
 
CD144 (VE-cadherin)+ microparticles for endothelial cell-derived microparticles; 
 
CD14+ microparticles for monocyte-derived microparticles 
 
n.b. the SOP may be amended to look at subpopulations of microparticles e.g. those events 
also bearing tissue factor, CD146 or CD34.  
 
2. Materials and Supplier contact details: 
 
 
BD “FACS Flow” Running solution [Becton Dickinson Catalogue No. 342003] 
10L containers.Becton Dickinson (UK) Between Towns Road Cowley Oxford 
,Oxfordshire, OX4 3LY Fax: 01865 781578 
 
BD “FACS Clean” Cleaning Solution [Becton Dickinson Catalogue No. 340345]  
 
BD Falcon tubes [Becton Dickinson, Catalogue No. 352054] 
 
BD Lysing solution [Becton Dickinson Catalogue No. 349202] 
 
Sterile Phosphate Buffered Saline solution, 0.5L bottles [????] 
 
CD144-PE conjugated monoclonal antibody - 100 tests [RD Catalogue No. 
FAD9381P](defines EMPs) 
 
CD14-PerCP conjugated monoclonal antibody - 50 tests [RD Catalogue No. 
FAB3832C](defines PMPs) 
 
CD42b-APC conjugated monoclonal antibody - 100 tests [BD Catalogue No. 
551061](defines MMPs) 
 
CytoCount, Count Control Beads – 17 mL [DakoCytomation, Catalogue No. S2366] 
 
Blue pipette tips [Appleton Woods Catalogue No. HTL160] Appleton Woods Ltd 
Lindon House, Heeley Road Selly Oak, Birmingham B29 6EN Tel 0121 472 7353, Fax 
0121 414 1075. Freefax orderline 0800 387 462 
 
Yellow pipette tips [Appleton Woods Catalogue No. TG701] 
 
 
 
282 
 
3. Detailed method 
 
 
3.1 General Preparation 
 
Peripheral vein blood sample is to be collected with a 21 gauge needle without applying 
hemostasis into sodium citrate Vacutainer tubes (BD Diagnostics) 
 
Platelet-free plasma (PFP) has to be prepared by centrifugations for 15 min at 2860g. 
 
 Aliquots have to be frozen in 1.5-mL tubes (0.5 mL per tube) and stored at -70°C until 
use. 
 
3.2 Sample Preparation 
 
PFP has to be unthawed immediately before sample staining. 
 
Prepare ‘Mastermix’ (MM) of antibodies in the morning of analysis. 
 
Mix 10µL of CD144 and CD14 fluorochrome labelled antibodies and 20µL of CD42b 
antibody in a BD Falcon tube and dilute 360µL of filtered PBS. This amount of antibody 
would be sufficient for 20 samples. Total amount of antibodies should be prepared 
accordingly planned number of samples. 
 
Put 20µL of the MM into BD Falcon tube.  
 
Take 50 µL of thoroughly vortexed PFP with ‘wet tip’ reverse pipetting technique and add 
to the tube above without touching antibodies. 
 
Take 25 µL CytoCount, Count Control Beads with ‘wet tip’ reverse pipetting technique 
and add to the sample above without touching plasma and antibodies. 
 
Gently vortex the sample. Incubate in the dark at room temperature for 10 minutes. 
 
Ad 100 µL of filtered PBS. 
 
The sample is now ready to be used. 
 
 
3.3 Start up procedure [See SOP 195 on General Operation] 
 
Part 1 – restoring reagents and preparation 
 
Switch on Flow Cytometer by pressing the green switch on the right hand side.  The Apple 
Macintosh computer must also be switched on, but only after the Flow Cytometer, or the 
link will not be recognized. Open the reagent panel on the left hand side (LHS) by pulling 
the lid towards you. On the left is the sheath fluid reservoir, in the middle are switches and 
tubes, on the right is the waste reservoir. 
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Carefully unscrew the top of the sheath fluid reservoir and fill with sheath fluid (in large 
box on shelf at head height – use plastic tube) to the level indicated on the top right hand 
corner of the reservoir (little plastic bar). 
 
Carefully disconnect/unscrew the waste container and empty contents down sink with 
plenty of water.  Add approximately 40ml concentrated household bleach along with 360 
ml of distilled water and reconnect container (plastic tubes available). 
 
Pressurise the unit (takes about 20-30 sec) by moving the black toggle switch “Vent 
Valve” switch to the down/front position. It is located at the rear of the middle section 
between the sheath fluid tank and the waste container. 
 
Air must be excluded from the tubing system by flushing it out. Any excess air trapped in 
the sheath filter can, if necessary, be cleared by venting through the bleed tube (the dead-
ended rubber tube with a cap). 
 
Close the draw 
 
Part 2  
 
Ensure that a 3 ml Falcon tube (labelled 1) approximately 1/3 full of distilled water is 
positioned over the sample injection port (SIP) – a needle sheath - and that the swing arm 
is positioned under this tube.  Press the prime button on the panel.  When the system enters 
“standby” then press the “prime” button again. Remove tube 1. We will re-use tube 1 in the 
shut down procedure. 
 
Prepare a second falcon tube (labelled 2) with FACS-clean. This is a smaller box on a shelf 
at above head height and above the bigger box of sheath flow fluid 
 
Present tube 2 to the SIP and place support arm underneath it. Press the buttons “run” and 
“high” on the panel at the same time, and run the FACS-clean in falcon tube 2 with 
supporting arm to left or right open for one minute. Then return the supporting arm to 
underneath the tube and “run-high” five minutes.  This process ensures the machine is 
clean prior to running samples and helps minimise blockages.  
 
Return to falcon tube 1 with distilled water. Repeat the above step 6 with this distilled 
water tube. 
 
The machine is now ready to run samples. 
 
 
3.3 Running Samples. 
 
Note. This must be learned from an experienced operator and you must seek scientific staff 
support to clear queries as the intricacies of the Cell Quest software are complex. 
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Click on CellQuest Pro icon on the desk top to open the CellQuest Pro software with the 
instrument settings. 
 
Click ‘Connect to Cytometer’, located under the ‘Acquisition’ menu. 
 
Under the ‘Cytometer’ menu, click ‘Instrument Settings’.  Change settings to 
‘Microparticles’ Settings, located within the ‘Microparticles’ folder.  Make sure to click 
‘SET’ prior to clicking ‘DONE’. 
 
Click ‘Open’ to open microparticle acquisition protocol from ‘Microparticles' folder. The 
setting are predefined enumerate events positive for CD144, CD14, CD42b and having size 
less 1µm but more ~0.3. 
 
Click the ‘Acquisition menu’ once more and click ‘show browser’.  Enter the file name and 
number for data to be stored under and choose an appropriate location to save data to. 
 
Open swing arm at bottom right of the cytometer and replace the Falcon tube with the 
sample to be run.  Replace the swing arm under the Falcon tube. 
 
Press the buttons run and high on the control panel of the cytometer. Click ‘Acquire’ on 
the browser menu.  The sample will now run for ~ 3 mins.  Absolute number of specific 
microparticle types as,  
 
Number of Cells Counted (e.g. CD42b x CytoCount™ Concentration 
      Number of CytoCount™ Beads Counted x 2 
 
CytoCount™ Concentration is to be taken from the reagent pack. 
2 – represents a ratio in the volumes of plasma and count beads 
 
Obtain all the data and apply in into the specific spreadsheet you have designed for your 
project.  
 
 
3.4 Shut-down procedure   [See SOP 195 on General Operation] 
 
In this section we re-use tubes 1 and 2 with distilled water and FACS clean respectively. 
 
Install FACS Clean tube 2 over the SIP needle. Press button high and run on the panel. 
Leave the support arm out at 90 degrees for approximately 1 minute.  This cleans the outer 
portion of the aspiration sheath.  The fluid will be rapidly aspirated, so ensure that the tube 
doesn’t empty completely. 
 
Now replace the side arm under the Falcon tube and aloe to run for approximately 5 
minutes.  This cleans the inner portion of the aspiration sheath and the FACS machine 
itself. 
 
Repeat steps 2 and 3 with the distilled water tube 1.  Once step 3 is complete, Leave the 
sheath in falcon tube  1 containing distilled water and press STANDBY 
285 
 
 
Open the reservoir draw and depressurize the machine by moving the “Vent Valve” toggle 
switch to the up/rear position.  The machine will hiss as it depressurizes. 
 
Leave the machine on for a further 5 minutes to allow the laser lamp to cool.  Turning the 
machine off prematurely will result in the lamp cracking. 
 
Finally power down the FAC-Scalibur (green button) and Apple Mac. 
 
Clean up! 
 
 
Note: * IF THE SYSTEM IS TO BE USED AGAIN ON THE SAME DAY… 
LEAVE THE SYSTEM ON STANDBY and then 
DEPRESSURISE THE SYSTEM. 
 
 
 
4. Interpretation  
 
Refer to the illustrative figure. It shows three flow cytometer plots.  
 
The left hand plot is the FSC/SSC plot of the sample. The round circle top right are the 
count beads. The region boxed in the bottom right is for microparticles (MPs). 
 
The middle plot is the plot for platelets microparticles (PMPs). The vertical (Y) axis is the 
staining with CD42b for platelets. The horizontal (x) axis is not being used for 
fluorescence but shows the count beads.  
 
Note the cut of lines which define number of PMPs. These have been set by the results of 
the isotype controls. Hence events greater than about 250 arbitrary units are PMPs 
 
The right hand plot is for monocyte (vertical axis, CD14)) and endothelial (horizontal axis, 
CD144) microparticles (MMPs, EMPs).      
 
Also on the plot are the date, the total number of events (e.g. 364,348), and breakdowns of 
the different numbers of events in the different quadrants of the plots.  
 
The plots data is the number of PMPs, EMPs and MMPs per microlitre of plasma. These 
are the numbers you need to add into your spreadsheet.  
 
Typical results are likely to be in the region of….. 
 
4663 PMPs/µL of plasma 
 
2742 EMPs/µL  
 
267 MMPs/ µL 
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Do not be concerned that some numbers fail to add up or match as MP numbers have been 
back calculated from the concentration of the count beads.  
 
The second illustrative plot is of the isotype controls. Note identical layout but much 
smaller numbers (of course, ideally these would be zero). 
 
 
 
Validation 
 
Duplicate agreement was obtained for thoroughly vortexed plasma from the same tube.  
 
Intra-assay coefficients of variation were determined on twelve aliquots of plasma from 
three subjects (i.e. n=4 per assessment). These were analysed in duplicate. Results are 
shown in table 1. n.b. CDs were obtained from unvortexed plasma placed in the different 
tubes 
 
Inter-assay coefficients of variation are to be determined. 
 
 
Table 1 
 
Duplicate agreement and intra-assay CVs 
 
 
 
 
 
 
Duplicate 
agreement 
 
 
Subject A 
CV 
 
Subject B 
CV 
 
Subject C 
CV 
 
Mean 
CV 
 
PMPs 
 
 
4.45% 
 
 
18.9% 
 
12.2% 
 
8.0% 
 
13.0% 
 
EMPs 
 
 
4.02% 
 
 
15.0% 
 
3.3% 
 
9.8% 
 
9.4% 
 
MMPs 
 
 
2.05% 
 
 
15.2% 
 
10.4% 
 
12.7% 
 
12.8% 
 
Mean 
 
 
3.5% 
 
 
16.4% 
 
8.6% 
 
10.2% 
 
11.7% 
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STANDARD OPERATING PROCEDURE 190 
 
Enumeration of Microparticles by Flow Cytometry 
 
 
Signed off………………….…………… …………………… 2010……….. 
 
 
 
 
Figures: Illustrative plot attached. 
 
Raw data analyses available from ADB 
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Appendix 5. Standard operating procedure 201 ‘Monocyte subsets, monocyte-
platelet aggregates by flow cytometry’ 
 
 
 
 
STANDARD OPERATING PROCEDURE 201 
 
MONOCYTE SUBSETS 
 
Monocyte platelet aggregates by flow cytometry 
SOP written by Eduard Shantsila and Andrew Blann 
 
N.B. Use of the flow cytometry is forbidden 
Without having been officially trained 
 
Required pre-training 
 
SOPs on venepuncture and on  good clinical practice 
 
SOP 195 – General operation of the flow cytometer 
 
Contents 
 
Introduction    Page 1 
 
Materials and suppliers  Page 2 
 
Detailed Method   Page 3 
 
Interpretation    Page 8 
 
Validation and quality control Page 9 
 
 
1. Introduction 
 
Monocytes are large mononuclear cells (MNCs) derived from the bone marrow but on 
transit to the tissues where they seem likely to become semi-resident macrophages. 
Traditionally, they have been defined by glass-slide morphology, size, and scatter, but we 
now have the ability to define monocytes by cell surface molecules, using the FACS. For 
example, CD14 is a receptor for LPS present on monocytes, macrophages and neutrophils. 
CD16 is an antigen found on the Fc receptors and is present on natural killer cells, 
neutrophil polymorphonuclear leukocytes, monocytes and macrophages. So leukocytes 
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populations can be further classified by the density of the expression of these markers, for 
example…. 
 
M1 = CD14 strong CD16  negative 
M2 = CD14 strong  CD16 strong 
M3 = CD14 weak CD16 strong 
 
A further characteristic of monocytes in chemotaxis, such as to the chemokine monocyte 
chemoattractant protein-1 (MCP-1), a cytokine involved in monocyte infiltration in 
inflammatory diseases such as rheumatoid arthritis as well as in the inflammatory response 
against tumors. CCR2, short for chemokine (C-C motif) receptor 2, is a chemokine 
receptor for MCP-1 CCR2 has also recently been designated CD192.  
 
Platelets are anucleate fragments of the cytoplasm of the megakaryocyte. They form 
thrombi when self-aggregating but more so in the presence of fibrin. However, platelets 
may also bind to monocytes. Cell surface markers of platelets include CD42a, also known 
as GpIX. It follows that dual labelling of blood with a monocyte marker 
(CD14/CD16/CCR2) and a platelet marker (CD42a) will identify monocyte-platelet 
aggregates (MPAs).  
 
This SOP describes enumeration of monocyte subsets (dependent on expression of CD14, 
CD16 and CCR2) and their participation in the formation of MPAs. And of course you will 
need a platelet count for the project, derived from the full blood count, from the Advia (see 
SOP 171). 
 
2. Materials and Supplier contact details: 
 
Micro-reagents are kept in the fridge behind the door or on nearby shelves. Bulk fluids in 
boxes on other shelves and beneath the benches. 
 
BD “FACS Flow” Running solution [Becton Dickinson (BD), Catalogue No. 342003] 
10L containers. 
 
3 ml BD Falcon tubes [BD Catalogue No. 352054] 
 
BD“FACS Clean” Cleaning Solution [BD Catalogue No. 340345]  
 
BD Lysing solution [BD Catalogue No. 349202] 
 
Sterile Phosphate Buffered Saline solution, 0.5L bottles [Invitrogen Ltd, Catalogue No 
20012-068] 
 
CD14 -PE conjugated monoclonal antibody - 100 tests [BD Catalogue No. 555398] 
 
CD16 – Alex-flour 488 conjugated monoclonal antibody - 100 tests [ABD Serotec, 
Cambridge] 
 
CD42a-PerCP conjugated monoclonal antibody [BD Catalogue No. 340537]  
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CCR2-APC conjugated monoclonal antibody [R&D Systems Europe Ltd, Cat No. 
FAB151A] 
 
[n.b. this combination of  antibodies constitute a Mastermix: See ADB, ES] 
 
Clear pipette tips [Alpha Laboratories LimitedCatalogue No FR1250 1250ul Fastrak Refill 
NS]  
 
Yellow pipette tips [[Alpha Laboratories LimitedCatalogue No FR1200 200ul Fastrak 
Refill NS]  
 
Count beads [BD (Trucount tubes)]. This is a crucial aspect as it will give us the number of 
monocytes/ml of venous blood. The product tube has a statement of the number of beads in 
each tube and so from this you can work out beads/mL. 
 
Remember to dispose of all material thoughtfully.  
 
3. Detailed method 
 
 
3.1 General Preparation 
 
3.1.1 Lysing solution.   
 
Make from 50ml concentrate 10x FACS Lysing Solution (kept at room temperature). 
Dilute with 450ml distilled water in ½ litre bottle. This solution should not be used if it is 
older than a month (kept at room temperature). 
 
 
3.2 Blood sample preparation 
 
Add 12.5µL of Mastermix Absolute Monocyte Count (which includes CD14 2.5 µL, CD16 
2.5µL, CD42a 5µL and CCR2 2.5 µL fluorochrome labelled antibodies) with an electronic 
micropipette.  Just place into the tube below a metal grid without touching the pellet. 
 
Gently vortex the EDTA blood sample.  Take 0.05 mL (=50 µL) of whole blood with 
electronic pipette and add to a Trucount tube.  
 
Do not touch the pellet (this is critical!). Mix the tube gently with the vortex (3 sec). 
Incubate for 15 minutes in the dark, room temperature, shaking with horizontal shaker (set 
at 500 units). Add 0.45 ml (=450 µL) pre-diluted BD FACS Lyse solution (see 3.1.1) with 
a clear tip using the 1ml pipette. Incubate for 15 minutes on shaker as above. 
 
Add 1.5 ml of PBS solution without touching the sample, followed by gentle vortex to 
ensure thoroughly mixed 
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3.3 Start up procedure [See SOP 195 on General Operation] 
 
Part 1 – restoring reagents and preparation 
 
Switch on Flow Cytometer by pressing the green switch on the right hand side.  The Apple 
Macintosh computer must also be switched on, but only 15 secs after the Flow Cytometer, 
or the link will not be recognized. Open the reagent panel on the left hand side (LHS) by 
pulling the lid towards you. On the left is the sheath fluid reservoir, in the middle are 
switches and tubes, and on the right is the waste reservoir. 
 
Carefully unscrew the top of the sheath fluid reservoir and fill with sheath fluid (in large 
box on shelf at head height – use plastic tube) to the level indicated on the top right hand 
corner of the reservoir (little plastic bar). 
 
Carefully disconnect/unscrew the waste container and empty contents down sink with 
plenty of water.  Add approximately 40ml concentrated household bleach along with 360 
ml of distilled water and reconnect container (plastic tubes available). 
 
Pressurise the unit (takes about 20-30 sec) by moving the black toggle switch “Vent 
Valve” switch to the down/front position. It is located at the rear of the middle section 
between the sheath fluid tank and the waste container. 
 
Air must be excluded from the tubing system by flushing it out. Any excess air trapped in 
the sheath filter can, if necessary, be cleared by venting through the bleed tube (the dead-
ended rubber tube with a cap). 
 
Close the drawer 
 
Part 2 - Cleaning the machine 
 
Ensure that a 3 ml Falcon tube (labelled 1) approximately 1/3 full of distilled water is 
positioned over the sample injection port (SIP) – a needle sheath - and that the swing arm 
is positioned under this tube.  Press the prime button on the panel.  When the system enters 
“standby” with in 30 seconds then press the “prime” button again. When the standby and 
low buttons comes on again then remove tube 1. We will re-use tube 1 in the shut down 
procedure. 
 
Prepare a second falcon tube (labelled 2) with FACS-clean (should contain about 2750 
microlitres so that when inserted on to the sip it doesn’t touch the O ring). This is a smaller 
box on a shelf at above head height and above the bigger box of sheath flow fluid 
 
Present tube 2 to the SIP and place support arm underneath it. Press the buttons “run” and 
“high” on the panel at the same time, and run the FACS-clean in falcon tube 2 with 
supporting arm to left or right open for one minute. Then return the supporting arm to 
underneath the tube and “run-high” five minutes.  This process ensures the machine is 
clean prior to running samples and helps minimise blockages.  
 
292 
 
Return to falcon tube 1 with distilled water. Repeat the above step 9 with this distilled 
water tube. 
 
Press the ‘STANDBY’ and ‘LOW’ button on the system. 
 
The machine is now ready to run samples. 
 
 
 
 
 
 
NB:           FACS COMP may need to be run 
 
 
 
 
 
3.4 Running blood samples. 
 
Note. This must be learned from an experienced operator and you must seek scientific staff 
support to clear queries as the intricacies of the Cell Quest software are complex. 
 
Open CellQuest Pro software  
Click ‘File’ – ‘Open’  
Click on the ‘Monocyte Protocols’ folder within ‘Data 1’ folder.  
Click on the ‘Monocyte Absolute Count’. This will open study protocol. 
 
Click ‘Connect to Cytometer’, located under the ‘Acquire’ menu. 
 
Under the ‘Cytometer’ menu, click ‘Instrument Settings’.  The window appears 
displaying the compensations and threshold. Change settings by clicking on the open icon 
on the window which displays the folders select ‘Monocyte Protocols’ folder with in the 
‘Data 1’ folder and click on the ‘Monocyte Absolute Count’ instrument settings in this 
folder. This will update the system settings to the preferred settings for the acquisition. 
Click ‘Set’ on the window and by clicking ‘Done’ the windows disappears.  Make sure to 
click ‘Set’ prior to clicking ‘Done’. 
 
Click the ‘Acquire’ menu once more and click ‘Show browser’.   
 
Click directory-‘Change’ in order to specify the location folder. 
 
Initial user must create new folder by clicking on ‘New folder’ and by entering the title of 
the folder and choose that folder. 
 
Change the custom suffix to the preferred title and number for data and click ‘OK’. 
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Untick the setup box (by clicking on it) in the browser Acquisition window. Now insert 
your sample and press “RUN” and “HIGH”.  
 
Open swing arm at bottom right of the cytometer and replace the Falcon tube with the 
sample to be run.  Replace the swing arm under the Falcon tube. 
 
Press the buttons ‘Run’ and ‘High’ on the control panel of the cytometer.  
 
Click ‘Acquire’ on the browser menu.  The sample will now run for ~ 12 mins.  Cell 
events will be displayed on the screen throughout the process (n.b. the higher the cell 
density, the more rapidly the cells will be acquired). 
 
Click on ‘Counters’ under the ‘Acquire’ and observe the events per second which varies 
from 1000 to 8000 depending on various factors. The objective is to acquire 10,000 count 
beads for analysis. 
 
Observe the acquisition closely since the system may get blocked (which happens very 
rarely) and the plots may not show any progress and the counters may not show any events 
per second. 
 
 
 
Click pause on the acquisition window and replace the sample from the SIP with sterile 
PBS and run for 20/30 seconds minutes (clicking acquire wouldn’t change the results) and 
then continue acquisition with your sample on the SIP. If the problem still persists please 
inform the senior scientific staff and seek assistance. 
 
After attaining the target events the analysis stops and the file number changes 
automatically. Click on ‘print’ under the ‘files’. Confirmation window appears again click 
on print. 
 
Vortex your next sample gently. Re-programme the software with a new sample number, 
and repeat the step 11. 
 
If the cytometer is not ready message appears open the drawer and check the fluids level 
which may need refilling or emptying. The system may run out of Sheath fluid if there are 
more samples. 
 
Be absolutely sure you have downloaded your results on to paper. Keep this paper safe. Do 
not assume the computer will keep the results safe, even if you have directed it to do so. 
Obtain all the raw data (cell numbers) and apply them into the specific spreadsheet you 
have designed for your project. The same spreadsheet should have the WBC and platelet 
count results from the Advia 
 
3.5 Shut-down procedure   [See SOP 195 on General Operation] 
 
In this section we re-use tubes 1 and 2 with distilled water and FACS clean respectively. 
Install FACS Clean tube 2 over the SIP needle. Press button ‘High’ and ‘Run’ on the 
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panel. Leave the support arm out at 90 degrees for approximately 1 minute.  This cleans 
the outer portion of the aspiration sheath.  The fluid will be rapidly aspirated, so ensure that 
the tube doesn’t empty completely. 
 
Now replace the side arm under the Falcon tube and allow it to run for approximately 5 
minutes.  This cleans the inner portion of the aspiration sheath and the FACS machine 
itself. 
 
Repeat steps 2 and 3 with the distilled water tube 1.  Once step 3 is complete, Leave the 
sheath in falcon tube 1 containing distilled water and press ‘STANDBY’. 
 
Open the reservoir draw and depressurize the machine by moving the “Vent Valve” toggle 
switch to the up/rear position.  The machine will hiss as it depressurizes. 
 
Leave the machine on for a further 5 minutes to allow the laser lamp to cool.  Turning the 
machine off prematurely will result in the lamp cracking. 
 
Finally power down the FACScalibur (green button) and Apple Mac, and then clean up! 
 
Note: * IF THE SYSTEM IS TO BE USED AGAIN ON THE SAME DAY… 
 
LEAVE THE SYSTEM ON STANDBY and then 
DEPRESSURISE THE SYSTEM. 
 
4. Interpretation of plots 
 
For the first couple of analyses you will need to have all this explained to you by Dr Blann 
or Dr Shantsila. These numbers refer to the illustrative plot and nine individual plots… 
 
 
TOP THREE PLOTS 
 
The top left initial plots show the FSC/SSC plot (forward and side scatter, all in green). 
This is needed to gate the presumed monocytes. Be generous at this stage, include all 
monocytes. Contamination by granulocytes and lymphocytes will be removed during the 
next stage.  
 
Immediately to the right (i.e. centre) is a plot of the cells stained with CD14 (light blue) 
which further gates the monocytes to separate them from granulocytes. Note a large 
residual proportion of granulocytes at the top of the SSC index. 
 
Top right is plot of CD14/CD16 events (red/brown). Four gates have been drawn to define 
different populations of monocytes. M1 defines CD14strong/CD16-ve, whilst M4 defines 
cells expressing a lot of CD16. The latter will be sub-typed shortly. 
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CENTRE THREE PLOTS 
 
Centre left is a plot of the Count beads (green), which are sampled at a concentration of, 
for example, 50,000 beads/tube. From this you will get monocytes/mL and thus MPAs/mL. 
The CD14-PE horizontal axis is irrelevant. 
 
Centre middle is (green) plot of CD16 versus CD14, which allows you to gate and exclude 
lymphocytes from analysis. Note that pattern is a bit like the upper right box, but with 
CD14-ve/CD16-ve events present. 
 
Centre right is a plot derived from Gate 4. It shows events (cells) that express high and low 
levels of CCR2 according to side scatter. There is a gating line down the middle of this plot 
to give cells staining high and low staining for CCR2. Gate 5 is cells staining weakly for 
CCR2 (=M3) whilst Gate 6 is cells staining strongly for CCR2 (=M2). 
 
 
LOWER THREE PLOTS (all CD42a versus CCR2) 
 
Lower left is a plot of CD42a versus CCR2 on population M1. MPAs are to the right of the 
line  
 
Lower middle is a plot of CD42a versus CCR2 in M2. MPAs are to the right of the line  
 
Lower right is a plot of CD42a versus CCR2 in M3. MPAs are to the right of the line  
 
 
Other numbers on the sheet (1- 12) refer to mathematical analyses, not to plots, as, 
follows…. 
 
5. Interpretation of results (numbers) 
 
This is complicated, so pay attention. There are 12 analyses – the first 4 are raw data: 
 
The total number of events counted and the acquisition date are given top left of the 
numbers section (i.e. 60,964 on 08-Apr-10). 
 
On the far right is number of count beads (9127) used to quantify events to cells/µL 
 
On the left is some maths from the opening plots showing number of total events collected 
in this particular analysis and the proportion that are monocytes. 
 
Below this is the maths from Gates 5 and 6 (SSC and CCR2, middle right plot). So there 
are 667 M2 events and 871 M3 events, giving you relative proportions.  This data is used 
to calculate the absolute count of subsets M2 and M3.  
 
From these analyses numbers 1 – 4 the machine works out for you (given the count bead 
number in analysis 2 i.e. 9127) the percentage and numbers of monocytes and monocyte 
subsets, and these are given as numbers 5 – 12 as follows….  
296 
 
 
Mon is the total number of monocytes per µl, i.e. 582.95 cells/µL. 
Mon 1 is the number of M1 monocytes per µl, i.e. 409.5 cells/µL.  
Mon 2 is the number of M2 monocytes per µl, i.e. 98.23 cells/µL 
Mon 3 is the number of M3 monocytes per µl, i.e. 75.22 cells/µL 
 
The machine has also worked out the % of each subset immediately below. 
 
Next – for MPAs… 
 
MPA is the total number of MPAs per µL, i.e. 102.86 cells/µL 
MPA1 is the total number of MPAs in the M1 population, i.e. 71.29 cells/µL 
MPA2 is the total number of MPAs in the M2 population, i.e. 19.28 cells/µL 
MPA3 is the total number of MPAs in the M3 population, i.e. 12.29 cells/µL 
 
From this you can work out the proportions given a calculator. It follows that since you 
have the platelet count from the Advia, you can also work out how many of the total 
platelet pool are bound to monocytes. But this is for a separate analysis.  
 
 
Conclusion 
 
Using this dataset as a template, the numbers that need to go into your spreadsheet are as 
follows… 
 
Total monocyte count = 582.95 cells/µL 
 
Subsets:  M1 count = 409.50 cells/µL (70.25%) 
M2 count = 98.23 cells/µL (16.85%) 
M3 count = 75.22 cells/µL (12.9%) 
 
Total MPA count = 102.86 cells/µL 
 
Subsets: MPA1 count = 71.29 cells/µL 
  MPA2 count = 19.28 cells/µL 
  MPA3 count = 12.29 cells/µL 
 
Once in the spreadsheet, you can easily do the arithmetic for conversion to % 
 
 
6. Validation and quality control (all work done by a single operator) 
 
Intraobserver and Interobserver coefficients of variation on the validation work 
made by Eduard Shantsila are provided in the thesis 
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SOP 201: Enumeration of monocytes subsets and  
monocyte platelet aggregates by flow cytometry 
 
 
Signed off………………Andrew Blann…………………… 2010……….. 
 
 
 
Figures not electronic: illustrative plot (see ADB): Raw analyses available from ADB 
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Appendix 6. Standard Operating Procedure 206 ‘Intracellular I-Kappa-Kinase 
Beta (IKKβ)’ 
 
 
 
 
STANDARD OPERATING PROCEDURE 202 
 
Intracellular I-Kappa-Kinase Beta (IKKβ) 
 
 
N.B. Use of the flow cytometry is forbidden 
Without having been officially trained 
 
Required pre-training 
 
SOPs on venepuncture and on  good clinical practice 
 
SOP 193 – General operation of the flow cytometer 
 
SOP 171 – Operation of the Bayer Advia 
 
Contents 
 
Introduction   Page 1 
 
Materials and suppliers Page 3 
 
Detailed Method  Page 4 
 
Interpretation and QC  Page 7 
 
Appendices   Page 10 (flow cytometry printout, signalling figure 1) 
 
 
1. Introduction 
 
Nuclear factor κB (NFκB) is a heterodimeric protein composed of different combinations 
of members of the Rel family of transcription factors which are involved mainly in stress-
induced, immune, and inflammatory responses. In addition, these molecules play important 
roles during the regulation of apoptosis, cell proliferation, development of certain 
hemopoietic cells, keratinocytes, and lymphoid organ structures (1).  
 
NFκB can be activated by exposure of cells to lipopolysaccharides (LPS) or inflammatory 
cytokines such as tumour necrosis factor (TNFα) or interleukin (IL)-1, as well as various 
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various growth factors, lymphokines, bacterial and viral infection, and by other 
physiological and non physiological stimuli. The recognition of bacterial and viral products 
by Toll-like receptors on cells of the innate immune system also results in NFκB induction, 
leading to the production of proinflammatory cytokines, matrix metalloproteinases, tissue 
factor, reactive oxidant and nitrogen species and other biologically active substances (1-4). 
 
Inappropriate activation of NFκB has been linked to inflammatory events associated with 
autoimmune arthritis, septic shock, glomerulonephritis, and atherosclerosis. In contrast, 
complete and persistent inhibition of NFκB has been associated with apoptosis, impaired 
immune cell development, and delayed cell growth (5). Critically, NFκB represents one of 
the main transcriptional factors mediating inflammatory responses of monocytes and 
macrophages. The outstanding technical problem with the measurement of NFκB is that 
the resting cytosol form and the activated nuclear form are structurally identical and cannot 
be distinguished by flow cytometry. It can, however, detected in cell lysate with an 
electrophoretic mobility shift assay.    
 
I-kappaB molecules are inhibitors of NFκB transcription factors. The I-kappaB kinase 
(IKK) complex is a phosphorylating enzyme with several subunits. The β subunit is 
involved in transcriptional activation by phosphorylating I-kappaB, a modification that 
triggers its ubiquitination and subsequent degradation in proteolysosomes, enabling the 
passage of (free) NFκB into the nucleus (6). Multiple cytoplasmic and nuclear proteins 
distinct from the NFκB and I-kappaB proteins are phosphorylated by another catalytic 
subunit of the IKK complex (IKKα) which is involed in B lymphocyte maturation. The 
function of a third IKK subunit (IKKγ) is not fully understood  
 
Therefore levels of the IKKβ enzyme are a regulator of NFκB in that high levels of the 
enzyme will lead to the inhibition of I-kappaB and so an increase in the activity of NFκB. 
This is summarised in Figure 1, final page.  
 
Monoclonal antibodies to IKKβ have been developed and can be conjugated to 
flurochromes. The present SOP exploits this technology in that it is designed to quantify 
intra-cellular IKKβ in monocyte subsets, themselves defined by a combination of 
morphology, CD14 and CD16. However, cells must be permeablised to allow the 
conjugated mAbs to enter the cell and thus bind their target 
 
References: 
 
1. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. 
Annu. Rev. Immunol 1996; 14: 649-83. 
2. Pomerantz JL, Baltimore D. Two pathways to NF-KappaB. Mol Cell 2002; 10: 693-5. 
3. D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B (NF-B): an 
emerging theme in anti-inflammatory therapies. Mol Interv. 2002;2:22-35. 
4. Dixit V, Mak TW. NF-KappaB signaling: Many Roads Lead To Madrid. Cell 2002; 111: 
615-9. 
5. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-KappaB 
function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase 
transition. Mol Cell Biol 1999;19: 2690-8. 
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6. Schmid JA, Birbach A. IkappaB kinase beta (IKKbeta/IKK2/IKBKB) - a key molecule 
in signaling to the transcription factor NF-kappaB. Cytokine Growth Fact Rev 2008 
;19:157-65. 
 
 
Legend to figure 1 
 
Intra-nuclear NFκB binds to the promoter region of various ‘proinflammatory’ genes 
Cytoplasmic NFκB may be inhibited by protein I kappa B 
However, if I kappa B is phosphorylated it becomes susceptible to degradation and so will 
not inhibit NFκB  
I kappa B can be phosphorylated by the beta subunit of the enzyme I kappa kinase, i.e. 
IKKβ, which itself needs to be phosphorylated 
IKKβ is phosphorylated by TRAF, a downstream product of intracellular second 
messengers themselves (F) activated by ligand binding of cell surface receptors (G). 
 
2. Materials and Supplier contact details: 
 
Reagents are kept in the fridge behind the door or on nearby shelves. Bulk fluids in boxes 
on other shelves and beneath the benches 
 
BD “Cytofix” Fixation Buffer 100 ml [Becton Dickinson, Catalogue No. 554655] 
 
BD “Cytofix/Cytoperm” Fixation and Permeabilization Solution 125 ml of 1x solution 
[Becton Dickinson, Catalogue No. 554722] 
 
BD “Pharm Lyse” Lysing Buffer 100 ml 10x concentrated [Becton Dickinson, Catalogue 
No. 555899] 
 
BD “Perm/Wash” Buffer 100 ml 10x concentrated [Becton Dickinson, Catalogue No. 
554723] 
 
BD “Pharmingen” Stain Buffer (FBS) Dulbecco’s Phosphate-Buffered Saline (DPBS) 
pH7,4 2% Fetal Bovine Serum 500 ml [Becton Dickinson, Catalogue No. 554656] 
 
BD “FACS Flow” Running solution [Becton Dickinson, Catalogue No. 342003]10L 
containers 
 
BD “FACS Clean” Cleaning Solution [Becton Dickinson, Catalogue No. 340345]  
 
3 ml BD Falcon tubes [Becton Dickinson, Catalogue No. 352054] 
 
Sterile Phosphate Buffered Saline solution, 0.5L bottles [Invitrogen Ltd, Catalogue No 
20012-068] 
 
Mouse Anti Human CD16 Alexa Fluor 488 conjugated monoclonal antibody 100 tests/1ml 
[AbD Serotec, Catalogue No. MCA2537A488] 
 
301 
 
BD Pharmingen PerCP-Cy 5.5 conjugated Mouse Anti Human CD14 monoclonal antibody 
0.2mg/ml - 100 tests/ml [Becton Dickinson, Catalogue No. 550787] 
 
IKKbeta-APC conjugated monoclonal antibody 50µg/ml - 100 tests [Becton Dickinson, 
Catalogue No. 551920] 
 
Clear pipette tips [Alpha Laboratories LimitedCatalogue No FR1250 1250ul Fastrak Refill 
NS]  
 
Yellow pipette tips [[Alpha Laboratories LimitedCatalogue No FR1200 200ul Fastrak 
Refill NS] 
 
Disposable 3 ml Graduated Pastette Steril 20s (500 pipettes) [Alpha Laboratories, 
Catalogue No. LW4114]  
 
 
Remember to dispose of all material thoughtfully.  
 
 
3. Detailed method 
 
FIRSTLY 
 
 
 
3.1 General Preparation 
 
3.1.1 Lysing solution.   
 
Make from 50ml concentrate 10x FACS Lysing Solution (kept at room temperature). 
Dilute with 450ml distilled water in ½ litre bottle. This solution should not be used if it is 
older than a month (kept at room temperature). 
 
 
3.2 Blood sample preparation 
 
3.2.1. Place to a falcon tube: 5µl CD16-AF 488, 2.5µl CD14-PerCP-CY5.5 and add 100µl 
of whole blood sample (collected in an EDTA containing tube). Gently vortex the tube and 
incubate in a dark box for 15 minutes. 
 
 
For all WBCC analyses a full blood count (Bayer Advia) must be obtained  
on the same sample of blood that will be used for flow cytometry.  
 
This is essential in order to back-calculate  
monocyte numbers and thus sub-populations to whole blood 
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3.2.2. Add 2.0 ml ‘PharmLyse’ solution, gently vortex and incubate for 10 minutes in the 
dark box. Spin the tube for 5 minutes at 500g and remove the supernatant by a disposable 
pipette. 
 
3.2.3. Put 2ml of ‘Staining Buffer’ in the tube, gently vortex and spin again for 5 minutes 
at 500g and remove supernatant by disposable pipette. 
 
3.2.4. Add 500µl of ‘Fixation and Permeation’ solution, gently vortex and incubate the 
tube for 20 minutes in the dark box. Spin again for 5 minutes at 500g, remove supernatant 
by a disposable pipette. 
 
3.3.5. Add 2 ml of ‘Perm-Wash’, gently vortex the sample, wait for a10 minutes and spin 
for 5 minutes at 500g. Remove the supernatant by a disposable pipette. 
 
3.3.6. Add 10µl of ‘IKKbeta-APC’ antibody in the sample, gently vortex and incubate 30 
minutes in the dark box. Add 2 ml of ‘Perm-Wash’, spin the tube for 5 minutes at 500g. 
Remove the supernatant by a disposable pipette. 
 
3.3.7. Add 50µl of 4% PFA/PBS, gently vortex and run sample. 
 
 
 
3.3 Start up procedure [See SOP 195 on General Operation] 
 
Part 1 – restoring reagents and preparation 
 
Switch on Flow Cytometer by pressing the green switch on the right hand side.  The Apple 
Macintosh computer must also be switched on, but only 15 secs after the Flow Cytometer, 
or the link will not be recognized. Open the reagent panel on the left hand side (LHS) by 
pulling the lid towards you. On the left is the sheath fluid reservoir, in the middle are 
switches and tubes, on the right is the waste reservoir. 
 
Carefully unscrew the top of the sheath fluid reservoir and fill with sheath fluid (in large 
box on shelf at head height – use plastic tube) to the level indicated on the top right hand 
corner of the reservoir (little plastic bar). 
 
Carefully disconnect/unscrew the waste container and empty contents down sink with 
plenty of water.  Add approximately 40ml concentrated household bleach along with 360 
ml of distilled water and reconnect container (plastic tubes available). 
 
Pressurise the unit (takes about 20-30 sec) by moving the black toggle switch “Vent 
Valve” switch to the down/front position. It is located at the rear of the middle section 
between the sheath fluid tank and the waste container. 
 
Air must be excluded from the tubing system by flushing it out. Any excess air trapped in 
the sheath filter can, if necessary, be cleared by venting through the bleed tube (the dead-
ended rubber tube with a cap). 
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Close the drawer 
 
Part 2 - cleaning the machine 
 
Ensure that a 3 ml Falcon tube (labelled 1) approximately 1/3 full of distilled water is 
positioned over the sample injection port (SIP) – a needle sheath - and that the swing arm 
is positioned under this tube.  Press the prime button on the panel.  When the system enters 
“standby” with in 30 seconds then press the “prime” button again. When the standby and 
low buttons comes on again then remove tube 1. We will re-use tube 1 in the shut down 
procedure. 
 
Prepare a second falcon tube (labelled 2) with FACS-clean (should contain about 2750 
microliters so that when inserted on to the sip it doesn’t touch the O ring). This is a smaller 
box on a shelf at above head height and above the bigger box of sheath flow fluid 
 
Present tube 2 to the SIP and place support arm underneath it. Press the buttons “run” and 
“high” on the panel at the same time, and run the FACS-clean in falcon tube 2 with 
supporting arm to left or right open for one minute. Then return the supporting arm to 
underneath the tube and “run-high” five minutes.  This process ensures the machine is 
clean prior to running samples and helps minimise blockages.  
 
Return to falcon tube 1 with distilled water. Repeat the above step 9 with this distilled 
water tube. 
 
Press the ‘STANDBY’ and ‘LOW’ button on the system. 
 
The machine is now ready to run samples. 
 
 
3.3 Running blood samples. 
 
Note. This must be learned from an experienced operator and you must seek scientific staff 
support to clear queries as the intricacies of the Cell Quest software are complex. 
 
Click on the ‘Data 1’ folder on the desk top  
Click on the ‘Monocyte Protocols’ folder.  
Click on the ‘Monocyte Inset IκKB’. 
This will open the CellQuest Pro software with the instrument settings. 
 
Click ‘Connect to Cytometer’, located under the ‘Acquire’ menu. 
 
Under the ‘Cytometer’ menu, click ‘Instrument Settings’.  The window appears 
displaying the compensations and threshold. Change settings by clicking on the open icon 
on the window which displays the folders select ‘Sid’ folder with in the ‘Data 1’ folder and 
click on the ‘Instrument settings’ in this folder. This will update the system settings to the 
preferred settings for the acquisition. Click ‘Set’ on the window and by clicking ‘Done’ 
the windows disappears.  Make sure to click ‘Set’ prior to clicking ‘Done’. 
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Click the ‘Acquire’ menu once more and click ‘Show browser’.   
 
Click directory-‘Change’ in order to specify the location folder. 
 
Initial user must create new folder by clicking on ‘New folder’ and by entering the title of 
the folder and choose that folder. 
 
Change the custom suffix to the preferred title and number for data and click ‘OK’. 
 
Untick the setup box (by clicking on it) in the browser-EPC Acquisition window. Now 
insert your sample and press “RUN” and “HIGH”.  
 
Each sample is now ready to run.  This should be mixed thoroughly and transferred to a 3 
mL BD Falcon tube.  Open swing arm at bottom right of the cytometer and replace the 
Falcon tube with the sample to be run.  Replace the swing arm under the Falcon tube. 
 
Press the buttons ‘Run’ and ‘High’ on the control panel of the cytometer.  
 
Click ‘Acquire’ on the browser menu.  The sample will now run for ~ 3-4 mins.  Cell 
events will be displayed on the screen throughout the process (n.b. the  higher the cell 
density, the more rapidly the cells will be acquired). 
 
Click on ‘Counters’ under the ‘Acquire’ and observe the events per second which varies 
from 500 to 5000 depending on various factors. The objective is to acquire 400,000 events 
for analysis of NFkB intracellular signalling. 
 
Observe the acquisition closely since the system may get blocked (which happens very 
rarely) and the plots may not show any progress and the counters may not show any events 
per second. 
 
Click pause on the acquisition window and replace the sample from the SIP with sterile 
PBS and run for 20/30 seconds minutes (clicking acquire wouldn’t change the results) and 
then continue acquisition with your sample on the sip. If the problem still persists please 
inform the senior scientific staff and seek assistance. 
 
After attaining the target events the analysis stops and the file number changes 
automatically. Click on ‘print’ under the ‘files’. Confirmation window appears again click 
on print. 
 
Vortex your next sample gently. Re-programme the software with a new sample number, 
and repeat the step 11. 
 
If ‘Cytometer is not ready’ message appears open the drawer and check the fluids level 
which may need refilling or emptying. The system may run out of Sheath fluid if there are 
more samples. 
 
Be absolutely sure you have downloaded your results on to paper. Keep this paper safe. Do 
not assume the computer will keep the results safe, even if you have directed it to do so. 
305 
 
Obtain all the raw data (cell numbers) and apply them into the specific spreadsheet you 
have designed for your project. The same spreadsheet should have the WBC results from 
the Advia. 
 
 
3.4 Shut-down procedure   [See SOP 195 on General Operation] 
 
In this section we re-use tubes 1 and 2 with distilled water and FACS clean respectively. 
 
Install FACS Clean tube 2 over the SIP needle. Press button ‘High’ and ‘Run’ on the 
panel. Leave the support arm out at 90 degrees for approximately 1 minute.  This cleans 
the outer portion of the aspiration sheath.  The fluid will be rapidly aspirated, so ensure that 
the tube doesn’t empty completely. 
 
Now replace the side arm under the Falcon tube and allow to run for approximately 5 
minutes.  This cleans the inner portion of the aspiration sheath and the FACS itself. 
 
Repeat steps 2 and 3 with the distilled water tube 1.  Once step 3 is complete, Leave the 
sheath in falcon tube 1 containing distilled water and press ‘STANDBY’. 
 
Open the reservoir draw and depressurize the machine by moving the “Vent Valve” toggle 
switch to the up/rear position.  The machine will hiss as it depressurizes. 
 
Leave the machine on for a further 5 minutes to allow the laser lamp to cool.  Turning the 
machine off prematurely will result in the lamp cracking. 
 
Finally power down the FAC-Scalibur (green button) and Apple Mac. 
 
Clean up ! 
 
Note: * IF THE SYSTEM IS TO BE USED AGAIN ON THE SAME DAY, LEAVE THE 
SYSTEM ON STANDBY and then DEPRESSURISE THE SYSTEM. 
 
 
4. Interpretation of plots 
 
Refer to page 10 which shows a typical plot. 
 
The first, FSC vs. SSC plot (top left) is set to collect all monocytes in a sample, even if it 
results in some contamination with granulocytes and lymphocytes. 
 
The second plot (ungated SSC vs. CD14-PerCP-Cy5.5, top middle) is for the exclusion of 
granulocytes (large group of events at the middle top part of the plot) from the further 
analysis.  
 
The top right plot (CD16-AF488 vs. CD14-PerCP-Cy5.5) aims to select monocytes only 
(subsets, Mon1, Mon2, Mon3). It represents a gate that includes monocytes on the basis of 
the first plot, excludes granulocytes on the basis of the second plot, and excludes 
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lymphocytes on the basis of the third plot (see point 4 below). The plot allows the selection 
of three monocyte subsets: Mon1 (CD14+/CD16- events), Mon2 (CD14+/CD16+ events) 
and Mon3 (CD14low/CD16+ events).  
 
The left middle plot (events gated from the second plot, CD16-AF488 vs. CD14-PerCP-
Cy5.5) is for the exclusion of lymphocytes and natural killers cells (left side of the plot – 
CD14-negative events). 
 
The three lower range of plots demonstrate the measurement of IKKβ levels in each 
monocyte subset. Monocyte subsets Mon1, Mon2 and Mon3 are gated on three different 
plots with IKKβ on Y-axis and no fluorochrome in channel FL2. Geometric means on Y-
axis of regions M1, M2, and M3 characterise IKKβ expression in Mon1, Mon2 and Mon3 
populations respectively are the key data to be collected.  
 
The units are arbitrary geometric mean fluorescence (GMF). 
 
 
5. Interpretation, validation and quality control 
 
Collect data on the total white blood cell counts and monocyte count (from the Advia). 
This is important because it enables a back calculation to the number of M1, M2 and M3 
monocytes per ml of venous blood. The implications of differences in levels of IKKβ are 
unclear but may relate to levels of NFκB 
 
 
Intra-assay reproducibility =  5.2% 
 
This SOP was assessed in 28
th
 January 2010, blind by BP, on three vacutainers from two 
subjects. 
 
Subject 1 
Levels of IKKβ expression in M1 was 66.28, 72.47 and 76.24  
Mean = 71.67, SD = 4.1, therefore CV = 5.7%   
Levels of IKKβ expression in M2 was 65.6, 74.71 and 73.11  
Mean = 71.14, SD = 4.0, therefore CV = 5.6% 
Levels of IKKβ expression in M1 was 60.47, 63.24 and 63.8  
Mean = 62.5, SD = 2.3, therefore CV = 2.3% 
Mean CV in subject 1 = 4.5% 
Subject 2  
Levels of IKKβ expression in M1 was 77.63, 69.6 and 70.93  
Mean = 72.7, SD = 3.51, therefore CV = 4.8%   
Levels of IKKβ expression in M2 was 80.97, 70.34 and 73.87  
Mean = 75.1, SD = 4.4, therefore CV = 5.9% 
Levels of IKKβ expression in M1 was 79.96, 67.49 and 74.44  
Mean = 74.0, SD = 5.1, therefore CV = 6.9% 
Mean CV in subject 2 = 5.9% 
 
Inter-assay reproducibility = 10.1% 
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This was assessed on six samples of VB from the same healthy (?) 55 year old male over a 
two-month period. 
 
Ikkb in M1 was 59.8, 55.4, 59.4, 71.1, 70.1 and 64.3. Mean = 63.4, SD = 5.8  
So interassay CV = 9.2% 
 
Ikkb in M2 was 63.1, 57.6, 73.7, 74.9, 75.3 and 66.4. Mean = 68.5, SD = 6.6 
        So interassay CV = 9.7% 
 
Ikkb in M3 was 65.3, 54.7, 60.6, 70.7, 78.7 and 68.0. Mean = 68.0, SD = 7.8 
        So interassay CV = 11.4% 
 
Isotype controls 
 
Dr Shantsila generated isotype control data with an IgG1-APC conjugate identified a 
mean expression of IKKβ in M1 cells of 6.6 units, M2 of 6.4 units and in M3 of 6.5 
units.  
 
 
 
SOP 202: I-Kappa-Kinase Beta (IKKβ) staining by flow cytometry 
 
 
 
Signed off………………………………………………………………….. 
 
 
 
Figures (not electronic): F1 Flow cytometry: F2 Signalling pathway. 
 
Raw analyses available from ADB 
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Appendix 7. Standard Operating Procedure 206 ‘Assessment of monocyte 
phagocytic activity by Flow Cytometry’ 
 
 
STANDARD OPERATING PROCEDURE 206 
 
Assessment of monocyte phagocytic activity by Flow Cytometry 
 
SOP developed by Eduard Shantsila Winter 2010/2011 
 
 
N.B. Use of the flow cytometry is forbidden  
Without having been officially trained 
 
Required pre-training 
 
SOPs on venepuncture, good clinical practice 
 
SOP 195 – general operation of the flow cytometer 
 
 
Contents 
 
Introduction and brief method  Page 1 
 
Materials and suppliers   Page 2 
 
Detailed Method    Page 2 
 
Data analysis and validation   Page 5 
 
 
1. Introduction 
 
Monocytes are circulating blood cells participating in innate immunity, inflammatory 
response and phagocytosis. Monocytes include several subsets that can be discriminated on 
the basis of surface expression of CD14 (lipopolysaccharide receptor) and CD16 (Fc 
gamma receptor III). This SOP describes the measurement of the phagocytic activity of: 
 
- CD14+CD16- monocytes (about 85%),  
- CD14+CD16+ monocytes (about 5%) and  
- CD14lowCD16+ monocytes (about 10%). 
 
The phagocytic function is evaluated in whole blood by exposing the heparinized blood 
sample to a conjugate of pHrodo™ E. coli BioParticles®. This conjugate is a novel, no-
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wash fluorogenic reagent that is only weakly fluorogenic when attached to the outer 
surface of the phagocyte but is highly fluorescent in the acidic environment of the 
phagosome upon internalization. This eliminates the wash and quenching steps associated 
with other phagocytosis assay protocols. 
 
Red blood cells are lysed using the proprietary Lysis Buffer A (Component A) and Buffer 
B (Component B) followed by centrifugation and washing. The final cell pellet containing 
white blood cells is resuspended in PBS and is ready for analysis using a flow cytometer. 
The monocytes subsets are distinguished by gating using forward and scatter properties, 
CD14 and CD16 expression. Phagocytic activity of monocyte subsets is determined by 
further gating of individual monocyte subsets and assessment of the amount of 
phagocytised pHrodo™ E. coli BioParticles® particles as the median fluorescent intensity 
(MFI) in the phycoerythrin (PE) channel which lights up in an acid environment.  
 
Brief method 
 
Obtain cells and keep them on ice, bring all reagents to room temperature 
Set up two tubes, add blood to both but only the E coli to one 
Incubate at 37 degree C for 5 mins only 
Add CD14 and CD16 antibodies, back to 37 for 10 minutes 
Lyse red blood cells, wash twice 
Apply to the FACS – voila !  
 
 
2. Materials and Supplier contact details: 
 
BD “FACS Flow” Running solution [Becton Dickinson, Catalogue No. 342003] 
10L containers.  
BD “FACS Clean” Cleaning Solution [Becton Dickinson, Catalogue No. 340345]  
3 ml BD Falcon tubes [Becton Dickinson, Catalogue No. 352054] 
Sterile Phosphate Buffered Saline solution, 0.5L bottles [Invitrogen Ltd, Catalogue No 
20012-068] 
 
pHrodo™ E. coli BioParticles® Phagocytosis Kit for Flow Cytometry [Invitrogen Ltd, Cat 
No. MP10025] 
CD16-Alexa Fluor 488-conjugated monoclonal antibody [AbD Serotec, Oxford, UK, Cat 
No. MCA2537A488] 
CD14 -APC conjugated monoclonal antibody [R&D Systems Europe Ltd, Cat No. 
FAB3832A] 
 
Clear pipette tips [Alpha Laboratories Limited Catalogue No FR1250 1250ul Fastrak Refill 
NS]  
Yellow pipette tips [Alpha Laboratories Limited Catalogue No FR1200 200ul Fastrak 
Refill NS]  
Pipettes required: 2-20ul (grey or white), 40-200 ul (yellow); 200-1000ul (purple) 
 
 
3. Detailed method 
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3.1 General Preparation 
 
3.1.1. Preparing the BioParticles® Solution 
 
3.1.1.1 Add 2.2 mL Buffer B (Component B) to the vial containing the lyophilized product 
to resuspend the pHrodo™ BioParticles® conjugate. This provides sufficient pHrodo™ 
BioParticles® conjugate in a 20 µL aliquot for a 20:1 particle-to-phagocyte ratio. 
 
3.1.1.2 Vortex gently for about 1 minute until all the fluorescent particles are 
homogenously dispersed. 
 
3.1.1.3 Store the pHrodo™ BioParticles® solution on ice for ~10 minutes prior to use. 
3.1.2. Buffers 
 
Bring the Lysis Buffer A (Component A) and Buffer B (Component B) to room 
temperature before use. 
 
3.2 Blood sample preparation 
 
3.2.1. Collect whole blood samples in blood collection tubes containing heparin  
3.2.2. You can collect and store whole blood samples on ice (preferably) or at 4ºC for up to 
1 hour prior to using the blood samples in the phagocytosis assay. Do not use any other 
anticoagulants except heparin for blood collection! 
 
3.3. Performing Phagocytosis Assay 
 
3.3.1. To minimize experimental errors and allow proper interpretation of results, use two 
tubes for each set of experimental samples as outlined in the table below. Each set of 
control tube and experimental tube is incubated at 37ºC.  
3.3.2. Mark two tubes: Tube 1 ‘Sample’ and Tube 2 ‘Control’. 
3.3.3. Take heparinised blood from ice, put on rotator for 20 sec and add 100 µL of whole 
blood into Tube 1 and Tube 2. 
3.3.4. Add 20 µL of pHrodo™ BioParticles® in Tube 1 and 20 µL of PBS in Tube 2. 
3.3.5. Vortex both tube gently and place them into the incubator at 37ºC for 5 min.  
3.3.6. Take the tubes from the incubator, add CD16 and CD14 antibodies (5 µL each), 
vortex for 2-3 sec and put back into the incubator for another 10 min. Be fast with this!!! 
Be precise with timing – it is critical!!! 
3.3.7. Take the tubes from the incubator, add 100 µL Lysis Buffer A (Component A) to 
both tubes, vortex briefly, and incubate at room temperature for 5 minutes. 
3.3.8. Add 1 mL Buffer B to the tubes, vortex briefly, and incubate at room temperature for 
5 minutes. 
3.3.9. Centrifuge the samples at 500 × g for 5 minutes at room temperature. 
3.3.10. Discard the supernatant.  
3.3.11. Resuspend the cell pellets with 1 mL PBS. 
3.3.12. Repeat wash steps 3.3.11 one more time.  
3.3.13. Resuspend the cell pellets in 0.2 mL PBS for flow cytometry analysis. This volume 
should give a high enough cell count for 400-500,000 events in 6 -7 minutes. 
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3.4. Start up procedure [See SOP 195 on General Operation] 
 
- Turn on FC and after few seconds computer. 
- Empty waste (right container) and refill with 360ml distilled water and 40ml bleach 
(ensure no bleach on gloves) 
- Fill machine with left container by FacsFlow to appropriate level (level of indentation) 
- Pressurize 
- Press LOW/PRIME with the arm closed (distilled water in place)- once PRIME light goes 
off press once more 
- Remove distilled water and place ‘top right’ on rack 
- Insert FacsClean tube (2ml of FacsClean) – opened arm 1 minute, closed 5 minutes - then 
remove and place ‘top left’ on rack- set FC on ‘high/run’ 
- Insert a tube with sterile PBS - 1 minute open arm, 5 minutes closed arm 
 
 
3.5. Sample acquisition 
 
- Run FacsComp if you are first user of the flow cytometer during the day 
- Press CellQuest icon 
- ‘FILE’ – ‘Open document’ – ‘Data 1’ – ‘Phagocytosis’ – ‘Phagocytosis’ 
- ACQUIRE – ‘Connect to cytometer’ 
- CYTOMETER – ‘Choose instrument settings’ – ‘Phagocytosis’ – ‘Set’ – ‘Done’ 
- Change appropriate directory to save flow data 
- Change file name 
- Place Tube 1 into cytometer and press ‘Acquire’ (press ‘Acquire’ on top bar, press 
‘Counters’) - once finished, print. Make sure that at least 200 000 events (normally 
400000-500000) with at very least 100 events (at least 400 typically) per each monocyte 
subsets were acquired. Otherwise the is sample is not suitable for analysis. 
Change file name 
- Place Tube 2 into cytometer and press ‘Acquire’ (press ‘Acquire’ on top bar, press 
‘Counters’)  
- Once finished, print a hard paper copy. When back in ASCOT, show it to Dr Blann or Dr 
Shantsila for an explanation. 
 
 
3.6 Shut-down procedure   [See SOP 195 on General Operation] 
 
In this section we re-use tubes 1 and 2 with distilled water and FACS clean respectively. 
 
Install FACS Clean tube 2 over the SIP needle. Press button ‘High’ and ‘Run’ on the 
panel. Leave the support arm out at 90 degrees for approximately 1 minute.  This cleans 
the outer portion of the aspiration sheath.  The fluid will be rapidly aspirated, so ensure that 
the tube doesn’t empty completely. 
 
Now replace the side arm under the Falcon tube and allow to run for ~5 minutes.  This 
cleans the inner portion of the aspiration sheath and the FACS machine itself. 
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Repeat steps 2 and 3 with the distilled water tube 1.  Once step 3 is complete, Leave the 
sheath in falcon tube 1 containing distilled water and press ‘STANDBY’. 
 
Open the reservoir draw and depressurize the machine by moving the “Vent Valve” toggle 
switch to the up/rear position.  The machine will hiss as it depressurizes. 
 
Leave the machine on for a further 5 minutes to allow the laser lamp to cool.  Turning the 
machine off prematurely will result in the lamp cracking. 
 
Finally power down the FAC-Scalibur (green button) and Apple Mac. 
 
Clean up ! 
 
Note: * IF THE SYSTEM IS TO BE USED AGAIN ON THE SAME DAY… 
 
LEAVE THE SYSTEM ON STANDBY and then 
 
DEPRESSURISE THE SYSTEM. 
 
3.6. Data analysis, validation and expected results 
 
Refer to Illustrative plot 1. There are 12 items of plots and data…..  
 
At the top are (left to right) the forward and side scatter, the side scatter and CD14 plot 
(defining monocytes), and the CD14/CD16 plot for the three monocyte subsets. 
 
The middle row is the lymphocyte and NK populations, an acquisition record of the 
proportions of monocyte subsets (and the number of monocytes that are phagocytic), and a 
plot of the cells staining positive or negative for the E-coli induced fluorochrome.  
 
Below these are the plots of MFI according to monocytes subsets M1, M2 and M3. In M1 
and M2 the MFI are 139.49 and 137 arbitrary units respectively. The M3 population 
clearly stains less powerfully (54,74 units) so presumably is not as involved in 
phagocytosis.    
 
Illustrative plot 2 is the same sample processed in the absence of the E coli to stimulate the 
cells. Hence little fluorochrome is activated within the cells. 
 
Intra-assay CVs 
 
This was performed by independently processing three blood samples from the same 
individual. Phagocytic activity of monocyte subsets observed in this healthy volunteer 
were… 
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Population 
 
 
Sample 1 
 
Sample 2 
 
Sample 3 
 
Intra-assay CV 
 
M1 
 
 
155.38 
 
139.49 
 
147.22 
 
5.4% 
 
M2 
 
 
155.38 
 
137.00 
 
138.24 
 
7.1% 
 
M3 
 
 
56.23 
 
54.74 
 
55.73 
 
1.4% 
 
These figures are acceptable.  
 
 
 
SOP 206 Phagocytosis Approved 13
th
 July 2011 
 
Dr A Blann 
 
 
 
 
Appendices: Illustrative plots 1 and 2  
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1. Shantsila E, Bialiuk N, Navitski D, Pyrochkin A, Gill PS, Pyrochkin V,Snezhitskiy V, 
Lip GY. Blood leukocytes in heart failure with preserved ejection fraction: Impact on 
prognosis. Int J Cardiol. 2012 ;155:337-8. PubMed PMID: 22227252. 
 
2. Shantsila E, Wrigley B, Shantsila A, Tapp LD, Blann AD, Gill PS, Lip GY. Ethnic 
differences in macrovascular and microvascular function in systolic heart failure. Circ 
Heart Fail. 2011;4:754-62. PubMed PMID: 21914813. 
 
3. Shantsila E, Wrigley B, Tapp L, Apostolakis S, Montoro-Garcia S, Drayson MT,Lip 
GY. Immunophenotypic characterization of human monocyte subsets: possibleimplications 
for cardiovascular disease pathophysiology. J Thromb Haemost. 2011;9:1056-66. PubMed 
PMID: 21342432. 
 
Literature reviews: 
 
1. Shantsila E, Lip GY, Gill PS. Systolic heart failure in South Asians. Int JClin Pract. 
2011 Dec;65(12):1274-82. PubMed PMID: 22093534. 
 
2. Shantsila E, Kamphuisen PW, Lip GY. Circulating microparticles incardiovascular 
disease: implications for atherogenesis and atherothrombosis. JThromb Haemost. 
2010;8:2358-68. PubMed PMID: 20695980. 
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3. Shantsila E, Lip GY. The role of monocytes in thrombotic disorders. Insightsfrom tissue 
factor, monocyte-platelet aggregates and novel mechanisms. Thromb Haemost. 
2009;102:916-24. PubMed PMID: 19888530. 
 
3. Apostolakis S, Lip GY, Shantsila E. Monocytes in heart failure: relationshipto a 
deteriorating immune overreaction or a desperate attempt for tissue repair? Cardiovasc 
Res. 2010;85:649-60. PubMed PMID:19805399. 
 
4. Shantsila E, Lip GY. The endothelium and thrombotic risk in heart failure. Thromb 
Haemost. 2009;102:185-7. PubMed PMID: 19652866. 
 
5. Shantsila E, Lip GY. Monocytes in acute coronary syndromes. ArteriosclerThromb Vasc 
Biol. 2009;29:1433-8. PubMed PMID: 19229072. 
 
6. Shantsila E, Watson T, Tse HF, Lip GY. New insights on endothelial progenitorcell 
subpopulations and their angiogenic properties. J Am Coll Cardiol. 2008;51:669-71. 
PubMed PMID: 18261687. 
 
7. Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovasculardisorders. 
J Am Coll Cardiol. 2007;49:741-52. PubMed PMID:17306702. 
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angiogenic potential.  ATVB 2011 Scientific Sessions, Chicago, Illinois, 28-30April 2011; 
Abstract P 653:203 
 
Shantsila E, Gill PS, Lip GYH.  Ethnic differences in endothelial function in chronic heart 
failure. Heart Failure 2011. Congress of the Heart Failure Association of the ESC, 
Gothenburg, Sweden, 21-24 May 2011;P1099. 
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failure. Annual Conference of the British Cardiovascular Society, Manchester, UK, 13-15 
June 2011. Heart. 2011; 97 Supplement 1: P 102,  A59. 
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